Catégories
Catégorie : Documents
Catégories
Publications – Buruli
1368488
ulcerans
items
1
0
date
desc
1
262
https://cnrmyrma.fr/wp-content/plugins/zotpress/
%7B%22status%22%3A%22success%22%2C%22updateneeded%22%3Afalse%2C%22instance%22%3A%22zotpress-8adb706ed6da20cb21d35ff55345911c%22%2C%22meta%22%3A%7B%22request_last%22%3A0%2C%22request_next%22%3A0%2C%22used_cache%22%3Atrue%7D%2C%22data%22%3A%5B%7B%22key%22%3A%22T9ZY5DEX%22%2C%22library%22%3A%7B%22id%22%3A1368488%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Phillips%20et%20al.%22%2C%22parsedDate%22%3A%222020-04-18%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EPhillips%2C%20R.%20O.%2C%20Robert%2C%20J.%2C%20Abass%2C%20K.%20M.%2C%20Thompson%2C%20W.%2C%20Sarfo%2C%20F.%20S.%2C%20Wilson%2C%20T.%2C%20Sarpong%2C%20G.%2C%20Gateau%2C%20T.%2C%20Chauty%2C%20A.%2C%20Omollo%2C%20R.%2C%20Ochieng%20Otieno%2C%20M.%2C%20Egondi%2C%20T.%20W.%2C%20Ampadu%2C%20E.%20O.%2C%20Agossadou%2C%20D.%2C%20Marion%2C%20E.%2C%20Ganlonon%2C%20L.%2C%20Wansbrough-Jones%2C%20M.%2C%20Grosset%2C%20J.%2C%20Macdonald%2C%20J.%20M.%2C%20Treadwell%2C%20T.%2C%20Saunderson%2C%20P.%2C%20Paintsil%2C%20A.%2C%20Lehman%2C%20L.%2C%20Frimpong%2C%20M.%2C%20Sarpong%2C%20N.%20F.%2C%20Saizonou%2C%20R.%2C%20Tiendrebeogo%2C%20A.%2C%20Ohene%2C%20S.-A.%2C%20Stienstra%2C%20Y.%2C%20Asiedu%2C%20K.%20B.%2C%20van%20der%20Werf%2C%20T.%20S.%2C%20Osei%20Mireku%2C%20S.%2C%20Abotsi%2C%20J.%2C%20Adu%20Poku%2C%20J.%20K.%2C%20Asamoah-Frimpong%2C%20R.%2C%20Osei-Wusu%2C%20B.%2C%20Sarpong%2C%20E.%2C%20Konadu%2C%20B.%2C%20Opoku%2C%20E.%2C%20Forson%2C%20M.%2C%20Ndogyele%2C%20M.%2C%20Ofori%2C%20E.%2C%20Aboagye%2C%20F.%2C%20Berko%2C%20T.%2C%20Amofa%2C%20G.%2C%20Nsiah%2C%20A.%2C%20Mensah-Bonsu%2C%20J.%2C%20Ofori%20Nyarko%2C%20J.%2C%20Amoako%2C%20Y.%20A.%2C%20Koranteng%20Tannor%2C%20E.%2C%20Boakye-Appiah%2C%20J.%2C%20Dzibordzi%20Loglo%2C%20A.%2C%20Sarpong-Duah%2C%20M.%2C%20Agbavor%2C%20B.%2C%20Ardent%2C%20M.%20F.%2C%20Yamadjako%2C%20A.%2C%20Adanmado%20Gersande%2C%20N.%2C%20Adeye%2C%20A.%2C%20Kindjinou%2C%20M.%2C%20Akpolan%2C%20Kiki%2C%20M.%2C%20Sodjinou%2C%20E.%2C%20Guegnard%2C%20C.%2C%20Klis%2C%20S.-A.%2C%20Velding%2C%20K.%2C%20Omansen%2C%20T.%2C%20Ofori-Adjei%2C%20D.%2C%20Eyangoh%2C%20S.%2C%20Knell%2C%20A.%20and%20Faber%2C%20W.%20%282020%29.%20%3Cb%3ERifampicin%20and%20clarithromycin%20%28extended%20release%29%20versus%20rifampicin%20and%20streptomycin%20for%20limited%20Buruli%20ulcer%20lesions%3A%20a%20randomised%2C%20open-label%2C%20non-inferiority%20phase%203%20trial%3C%5C%2Fb%3E.%20The%20Lancet%20%3Ci%3E395%3C%5C%2Fi%3E%2C%201259%26%23x2013%3B1267%2C%20%3Ca%20target%3D%27_blank%27%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2FS0140-6736%2820%2930047-7%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2FS0140-6736%2820%2930047-7%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Rifampicin%20and%20clarithromycin%20%28extended%20release%29%20versus%20rifampicin%20and%20streptomycin%20for%20limited%20Buruli%20ulcer%20lesions%3A%20a%20randomised%2C%20open-label%2C%20non-inferiority%20phase%203%20trial%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Richard%20O%22%2C%22lastName%22%3A%22Phillips%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%5Cu00e9r%5Cu00f4me%22%2C%22lastName%22%3A%22Robert%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kabiru%20Mohamed%22%2C%22lastName%22%3A%22Abass%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22William%22%2C%22lastName%22%3A%22Thompson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fred%20Stephen%22%2C%22lastName%22%3A%22Sarfo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Tuah%22%2C%22lastName%22%3A%22Wilson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Godfred%22%2C%22lastName%22%3A%22Sarpong%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thierry%22%2C%22lastName%22%3A%22Gateau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Annick%22%2C%22lastName%22%3A%22Chauty%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Raymond%22%2C%22lastName%22%3A%22Omollo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Michael%22%2C%22lastName%22%3A%22Ochieng%20Otieno%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thaddaeus%20W%22%2C%22lastName%22%3A%22Egondi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Edwin%20O%22%2C%22lastName%22%3A%22Ampadu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Didier%22%2C%22lastName%22%3A%22Agossadou%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Estelle%22%2C%22lastName%22%3A%22Marion%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Line%22%2C%22lastName%22%3A%22Ganlonon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mark%22%2C%22lastName%22%3A%22Wansbrough-Jones%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jacques%22%2C%22lastName%22%3A%22Grosset%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22John%20M%22%2C%22lastName%22%3A%22Macdonald%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Terry%22%2C%22lastName%22%3A%22Treadwell%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Paul%22%2C%22lastName%22%3A%22Saunderson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Albert%22%2C%22lastName%22%3A%22Paintsil%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Linda%22%2C%22lastName%22%3A%22Lehman%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Michael%22%2C%22lastName%22%3A%22Frimpong%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nanaa%20Francisca%22%2C%22lastName%22%3A%22Sarpong%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Raoul%22%2C%22lastName%22%3A%22Saizonou%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alexandre%22%2C%22lastName%22%3A%22Tiendrebeogo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sally-Ann%22%2C%22lastName%22%3A%22Ohene%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ymkje%22%2C%22lastName%22%3A%22Stienstra%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kingsley%20B%22%2C%22lastName%22%3A%22Asiedu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Tjip%20S%22%2C%22lastName%22%3A%22van%20der%20Werf%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Samuel%22%2C%22lastName%22%3A%22Osei%20Mireku%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Justice%22%2C%22lastName%22%3A%22Abotsi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Joseph%20Ken%22%2C%22lastName%22%3A%22Adu%20Poku%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Richard%22%2C%22lastName%22%3A%22Asamoah-Frimpong%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bright%22%2C%22lastName%22%3A%22Osei-Wusu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Edward%22%2C%22lastName%22%3A%22Sarpong%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Beatrice%22%2C%22lastName%22%3A%22Konadu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ernest%22%2C%22lastName%22%3A%22Opoku%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mark%22%2C%22lastName%22%3A%22Forson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mathias%22%2C%22lastName%22%3A%22Ndogyele%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Elizabeth%22%2C%22lastName%22%3A%22Ofori%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Felicity%22%2C%22lastName%22%3A%22Aboagye%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thomas%22%2C%22lastName%22%3A%22Berko%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22George%22%2C%22lastName%22%3A%22Amofa%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anastasia%22%2C%22lastName%22%3A%22Nsiah%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Joyce%22%2C%22lastName%22%3A%22Mensah-Bonsu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Joseph%22%2C%22lastName%22%3A%22Ofori%20Nyarko%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yaw%20Ampem%22%2C%22lastName%22%3A%22Amoako%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Elliot%22%2C%22lastName%22%3A%22Koranteng%20Tannor%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Justice%22%2C%22lastName%22%3A%22Boakye-Appiah%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Aloysius%22%2C%22lastName%22%3A%22Dzibordzi%20Loglo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mabel%22%2C%22lastName%22%3A%22Sarpong-Duah%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bernadette%22%2C%22lastName%22%3A%22Agbavor%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marie%20Fran%5Cu00e7oise%22%2C%22lastName%22%3A%22Ardent%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Arnaud%22%2C%22lastName%22%3A%22Yamadjako%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Naomi%22%2C%22lastName%22%3A%22Adanmado%20Gersande%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ambroise%22%2C%22lastName%22%3A%22Adeye%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Martial%22%2C%22lastName%22%3A%22Kindjinou%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22name%22%3A%22Akpolan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Maxime%22%2C%22lastName%22%3A%22Kiki%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Espoir%22%2C%22lastName%22%3A%22Sodjinou%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Cl%5Cu00e9mence%22%2C%22lastName%22%3A%22Guegnard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sandor-Adrian%22%2C%22lastName%22%3A%22Klis%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kristien%22%2C%22lastName%22%3A%22Velding%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Till%22%2C%22lastName%22%3A%22Omansen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22David%22%2C%22lastName%22%3A%22Ofori-Adjei%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sarah%22%2C%22lastName%22%3A%22Eyangoh%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alan%22%2C%22lastName%22%3A%22Knell%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22William%22%2C%22lastName%22%3A%22Faber%22%7D%5D%2C%22abstractNote%22%3A%22Background%5CnBuruli%20ulcer%20is%20a%20neglected%20tropical%20disease%20caused%20by%20Mycobacterium%20ulcerans%20infection%20that%20damages%20the%20skin%20and%20subcutis.%20It%20is%20most%20prevalent%20in%20western%20and%20central%20Africa%20and%20Australia.%20Standard%20antimicrobial%20treatment%20with%20oral%20rifampicin%2010%20mg%5C%2Fkg%20plus%20intramuscular%20streptomycin%2015%20mg%5C%2Fkg%20once%20daily%20for%208%20weeks%20%28RS8%29%20is%20highly%20effective%2C%20but%20streptomycin%20injections%20are%20painful%20and%20potentially%20harmful.%20We%20aimed%20to%20compare%20the%20efficacy%20and%20tolerability%20of%20fully%20oral%20rifampicin%2010%20mg%5C%2Fkg%20plus%20clarithromycin%2015%20mg%5C%2Fkg%20extended%20release%20once%20daily%20for%208%20weeks%20%28RC8%29%20with%20that%20of%20RS8%20for%20treatment%20of%20early%20Buruli%20ulcer%20lesions.%5CnMethods%5CnWe%20did%20an%20open-label%2C%20non-inferiority%2C%20randomised%20%281%3A1%20with%20blocks%20of%20six%29%2C%20multicentre%2C%20phase%203%20clinical%20trial%20comparing%20fully%20oral%20RC8%20with%20RS8%20in%20patients%20with%20early%2C%20limited%20Buruli%20ulcer%20lesions.%20There%20were%20four%20trial%20sites%20in%20hospitals%20in%20Ghana%20%28Agogo%2C%20Tepa%2C%20Nkawie%2C%20Dunkwa%29%20and%20one%20in%20Benin%20%28Pob%5Cu00e8%29.%20Participants%20were%20included%20if%20they%20were%20aged%205%20years%20or%20older%20and%20had%20typical%20Buruli%20ulcer%20with%20no%20more%20than%20one%20lesion%20%28caterories%20I%20and%20II%29%20no%20larger%20than%2010%20cm%20in%20diameter.%20The%20trial%20was%20open%20label%2C%20and%20neither%20the%20investigators%20who%20took%20measurements%20of%20the%20lesions%20nor%20the%20attending%20doctors%20were%20masked%20to%20treatment%20assignment.%20The%20primary%20clinical%20endpoint%20was%20lesion%20healing%20%28ie%2C%20full%20epithelialisation%20or%20stable%20scar%29%20without%20recurrence%20at%2052%20weeks%20after%20start%20of%20antimicrobial%20therapy.%20The%20primary%20endpoint%20and%20safety%20were%20assessed%20in%20the%20intention-to-treat%20population.%20A%20sample%20size%20of%20332%20participants%20was%20calculated%20to%20detect%20inferiority%20of%20RC8%20by%20a%20margin%20of%2012%25.%20This%20study%20was%20registered%20with%20ClinicalTrials.gov%2C%20NCT01659437.%5CnFindings%5CnBetween%20Jan%201%2C%202013%2C%20and%20Dec%2031%2C%202017%2C%20participants%20were%20recruited%20to%20the%20trial.%20We%20stopped%20recruitment%20after%20310%20participants.%20Median%20age%20of%20participants%20was%2014%20years%20%28IQR%2010%5Cu201329%29%20and%20153%20%2852%25%29%20were%20female.%20297%20patients%20had%20PCR-confirmed%20Buruli%20ulcer%3B%20151%20%2851%25%29%20were%20assigned%20to%20RS8%20treatment%2C%20and%20146%20%2849%25%29%20received%20oral%20RC8%20treatment.%20In%20the%20RS8%20group%2C%20lesions%20healed%20in%20144%20%2895%25%2C%2095%25%20CI%2091%20to%2098%29%20of%20151%20patients%2C%20whereas%20lesions%20healed%20in%20140%20%2896%25%2C%2091%20to%2099%29%20of%20146%20patients%20in%20the%20RC8%20group.%20The%20difference%20in%20proportion%2C%20%5Cu22120%5Cu00b75%25%20%28%5Cu20135%5Cu00b72%20to%204%5Cu00b72%29%2C%20was%20not%20significantly%20greater%20than%20zero%20%28p%3D0%5Cu00b759%29%2C%20showing%20that%20RC8%20treatment%20is%20non-inferior%20to%20RS8%20treatment%20for%20lesion%20healing%20at%2052%20weeks.%20Treatment-related%20adverse%20events%20were%20recorded%20in%2020%20%2813%25%29%20patients%20receiving%20RS8%20and%20in%20nine%20%287%25%29%20patients%20receiving%20RC8.%20Most%20adverse%20events%20were%20grade%201%5Cu20132%2C%20but%20one%20%281%25%29%20patient%20receiving%20RS8%20developed%20serious%20ototoxicity%20and%20ended%20treatment%20after%206%20weeks.%20No%20patients%20needed%20surgical%20resection.%20Four%20patients%20%28two%20in%20each%20study%20group%29%20had%20skin%20grafts.%5CnInterpretation%5CnFully%20oral%20RC8%20regimen%20was%20non-inferior%20to%20RS8%20for%20treatment%20of%20early%2C%20limited%20Buruli%20ulcer%20and%20was%20associated%20with%20fewer%20adverse%20events.%20Therefore%2C%20we%20propose%20that%20fully%20oral%20RC8%20should%20be%20the%20preferred%20therapy%20for%20early%2C%20limited%20lesions%20of%20Buruli%20ulcer.%5CnFunding%5CnWHO%20with%20additional%20support%20from%20MAP%20International%2C%20American%20Leprosy%20Missions%2C%20Fondation%20Raoul%20Follereau%20France%2C%20Buruli%20ulcer%20Groningen%20Foundation%2C%20Sanofi-Pasteur%2C%20and%20BuruliVac.%22%2C%22date%22%3A%222020-04-18%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1016%5C%2FS0140-6736%2820%2930047-7%22%2C%22ISSN%22%3A%220140-6736%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fwww.sciencedirect.com%5C%2Fscience%5C%2Farticle%5C%2Fpii%5C%2FS0140673620300477%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222022-03-10T09%3A58%3A39Z%22%7D%7D%2C%7B%22key%22%3A%22SBB4JW6V%22%2C%22library%22%3A%7B%22id%22%3A1368488%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Chauffour%20et%20al.%22%2C%22parsedDate%22%3A%222020%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EChauffour%2C%20A.%2C%20Robert%2C%20J.%2C%20Veziris%2C%20N.%2C%20Aubry%2C%20A.%2C%20Pethe%2C%20K.%20and%20Jarlier%2C%20V.%20%282020%29.%20%3Cb%3ETelacebec%20%28Q203%29-containing%20intermittent%20oral%20regimens%20sterilized%20mice%20infected%20with%20Mycobacterium%20ulcerans%20after%20only%2016%20doses%3C%5C%2Fb%3E.%20PLOS%20Neglected%20Tropical%20Diseases%20%3Ci%3E14%3C%5C%2Fi%3E%2C%20e0007857%2C%20%3Ca%20target%3D%27_blank%27%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1371%5C%2Fjournal.pntd.0007857%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1371%5C%2Fjournal.pntd.0007857%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Telacebec%20%28Q203%29-containing%20intermittent%20oral%20regimens%20sterilized%20mice%20infected%20with%20Mycobacterium%20ulcerans%20after%20only%2016%20doses%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Aur%5Cu00e9lie%22%2C%22lastName%22%3A%22Chauffour%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%5Cu00e9r%5Cu00f4me%22%2C%22lastName%22%3A%22Robert%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nicolas%22%2C%22lastName%22%3A%22Veziris%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alexandra%22%2C%22lastName%22%3A%22Aubry%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kevin%22%2C%22lastName%22%3A%22Pethe%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Vincent%22%2C%22lastName%22%3A%22Jarlier%22%7D%5D%2C%22abstractNote%22%3A%22Buruli%20ulcer%20%28BU%29%2C%20caused%20by%20Mycobacterium%20ulcerans%2C%20is%20currently%20treated%20with%20a%20daily%20combination%20of%20rifampin%20and%20either%20injectable%20streptomycin%20or%20oral%20clarithromycin.%20An%20intermittent%20oral%20regimen%20would%20facilitate%20treatment%20supervision.%20We%20first%20evaluated%20the%20bactericidal%20activity%20of%20newer%20antimicrobials%20against%20M.%20ulcerans%20using%20a%20BU%20animal%20model.%20The%20imidazopyridine%20amine%20telacebec%20%28Q203%29%20exhibited%20high%20bactericidal%20activity%20whereas%20tedizolid%20%28an%20oxazolidinone%20closely%20related%20to%20linezolid%29%2C%20selamectin%20and%20ivermectin%20%28two%20avermectine%20compounds%29%20and%20the%20benzothiazinone%20PBTZ169%20were%20not%20active.%20Consequently%2C%20telacebec%20was%20evaluated%20for%20its%20bactericidal%20and%20sterilizing%20activities%20in%20combined%20intermittent%20regimens.%20Telacebec%20given%20twice%20a%20week%20in%20combination%20with%20a%20long-half-life%20compound%2C%20either%20rifapentine%20or%20bedaquiline%2C%20sterilized%20mouse%20footpads%20in%208%20weeks%2C%20i.e.%20after%20a%20total%20of%20only%2016%20doses%2C%20and%20prevented%20relapse%20during%20a%20period%20of%2020%20weeks%20after%20the%20end%20of%20treatment.%20These%20results%20are%20very%20promising%20for%20future%20intermittent%20oral%20regimens%20which%20would%20greatly%20simplify%20BU%20treatment%20in%20the%20field.%22%2C%22date%22%3A%2231%20ao%5Cu00fbt%202020%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1371%5C%2Fjournal.pntd.0007857%22%2C%22ISSN%22%3A%221935-2735%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fjournals.plos.org%5C%2Fplosntds%5C%2Farticle%3Fid%3D10.1371%5C%2Fjournal.pntd.0007857%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222022-03-10T10%3A50%3A06Z%22%7D%7D%2C%7B%22key%22%3A%22I3MSQAQL%22%2C%22library%22%3A%7B%22id%22%3A1368488%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Scherr%20et%20al.%22%2C%22parsedDate%22%3A%222018-12-18%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EScherr%2C%20N.%2C%20Bieri%2C%20R.%2C%20Thomas%2C%20S.%20S.%2C%20Chauffour%2C%20A.%2C%20Kalia%2C%20N.%20P.%2C%20Schneide%2C%20P.%2C%20Ruf%2C%20M.-T.%2C%20Lamelas%2C%20A.%2C%20Manimekalai%2C%20M.%20S.%20S.%2C%20Gr%26%23xFC%3Bber%2C%20G.%2C%20Ishii%2C%20N.%2C%20Suzuki%2C%20K.%2C%20Tanner%2C%20M.%2C%20Moraski%2C%20G.%20C.%2C%20Miller%2C%20M.%20J.%2C%20Witschel%2C%20M.%2C%20Jarlier%2C%20V.%2C%20Pluschke%2C%20G.%20and%20Pethe%2C%20K.%20%282018%29.%20%3Cb%3ETargeting%20the%20Mycobacterium%20ulcerans%20cytochrome%20bc%201%26%23x202F%3B%3A%20aa%203%20for%20the%20treatment%20of%20Buruli%20ulcer%3C%5C%2Fb%3E.%20Nature%20Communications%20%3Ci%3E9%3C%5C%2Fi%3E%2C%205370%2C%20%3Ca%20target%3D%27_blank%27%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1038%5C%2Fs41467-018-07804-8%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1038%5C%2Fs41467-018-07804-8%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Targeting%20the%20Mycobacterium%20ulcerans%20cytochrome%20bc%201%20%3A%20aa%203%20for%20the%20treatment%20of%20Buruli%20ulcer%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nicole%22%2C%22lastName%22%3A%22Scherr%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Raphael%22%2C%22lastName%22%3A%22Bieri%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sangeeta%20S.%22%2C%22lastName%22%3A%22Thomas%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Aur%5Cu00e9lie%22%2C%22lastName%22%3A%22Chauffour%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nitin%20Pal%22%2C%22lastName%22%3A%22Kalia%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Paul%22%2C%22lastName%22%3A%22Schneide%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marie-Th%5Cu00e9r%5Cu00e8se%22%2C%22lastName%22%3A%22Ruf%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Araceli%22%2C%22lastName%22%3A%22Lamelas%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Malathy%20S.%20S.%22%2C%22lastName%22%3A%22Manimekalai%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gerhard%22%2C%22lastName%22%3A%22Gr%5Cu00fcber%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Norihisa%22%2C%22lastName%22%3A%22Ishii%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Koichi%22%2C%22lastName%22%3A%22Suzuki%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marcel%22%2C%22lastName%22%3A%22Tanner%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Garrett%20C.%22%2C%22lastName%22%3A%22Moraski%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marvin%20J.%22%2C%22lastName%22%3A%22Miller%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Matthias%22%2C%22lastName%22%3A%22Witschel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Vincent%22%2C%22lastName%22%3A%22Jarlier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gerd%22%2C%22lastName%22%3A%22Pluschke%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kevin%22%2C%22lastName%22%3A%22Pethe%22%7D%5D%2C%22abstractNote%22%3A%22Mycobacterium%20ulcerans%20is%20the%20causative%20agent%20of%20Buruli%20ulcer%20%28BU%29.%20Existing%20anti-tubercular%20drugs%20have%20been%20used%20to%20treat%20the%20condition%20with%20varying%20success.%20Here%2C%20the%20authors%20show%20that%20a%20clinical-stage%20drug%20candidate%20for%20tuberculosis%2C%20Q203%2C%20is%20effective%20at%20killing%20M.%20ulcerans%20and%20is%20a%20promising%20therapeutic%20candidate%20for%20BU.%22%2C%22date%22%3A%222018-12-18%22%2C%22language%22%3A%22En%22%2C%22DOI%22%3A%2210.1038%5C%2Fs41467-018-07804-8%22%2C%22ISSN%22%3A%222041-1723%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fwww.nature.com%5C%2Farticles%5C%2Fs41467-018-07804-8%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222019-04-05T14%3A56%3A21Z%22%7D%7D%2C%7B%22key%22%3A%223Z54DDAJ%22%2C%22library%22%3A%7B%22id%22%3A1368488%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Chauffour%20et%20al.%22%2C%22parsedDate%22%3A%222016-10-18%22%2C%22numChildren%22%3A6%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EChauffour%2C%20A.%2C%20Robert%2C%20J.%2C%20Veziris%2C%20N.%2C%20Aubry%2C%20A.%20and%20Jarlier%2C%20V.%20%282016%29.%20%3Cb%3ESterilizing%20Activity%20of%20Fully%20Oral%20Intermittent%20Regimens%20against%20Mycobacterium%20ulcerans%20Infection%20in%20Mice%3C%5C%2Fb%3E.%20PLOS%20Neglected%20Tropical%20Diseases%20%3Ci%3E10%3C%5C%2Fi%3E%2C%20e0005066%2C%20%3Ca%20target%3D%27_blank%27%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1371%5C%2Fjournal.pntd.0005066%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1371%5C%2Fjournal.pntd.0005066%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Sterilizing%20Activity%20of%20Fully%20Oral%20Intermittent%20Regimens%20against%20Mycobacterium%20ulcerans%20Infection%20in%20Mice%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Aur%5Cu00e9lie%22%2C%22lastName%22%3A%22Chauffour%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%5Cu00e9r%5Cu00f4me%22%2C%22lastName%22%3A%22Robert%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nicolas%22%2C%22lastName%22%3A%22Veziris%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alexandra%22%2C%22lastName%22%3A%22Aubry%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Vincent%22%2C%22lastName%22%3A%22Jarlier%22%7D%5D%2C%22abstractNote%22%3A%22Author%20Summary%20Buruli%20ulcer%2C%20caused%20by%20Mycobacterium%20ulcerans%2C%20is%20the%20third%20most%20frequent%20disease%20due%20to%20a%20bacteria%20of%20the%20mycobacteria%20family%2C%20after%20tuberculosis%20and%20leprosy.%20The%20disease%20consists%20of%20a%20cutaneous%20infection%20leading%20to%20skin%20ulcerations%20that%20can%20cause%20severe%20and%20debilitating%20scars.%20It%20occurs%20mostly%20in%20Africa%20where%20access%20to%20healthcare%20is%20still%20difficult.%20Until%20recently%2C%20surgery%20was%20the%20only%20way%20to%20treat%20Buruli%20ulcer.%20Recently%2C%20a%20medical%20treatment%20based%20on%20two%20antibiotics%20%28rifampin%20and%20streptomycin%29%20was%20found%20to%20be%20active%20in%20an%20experimental%20infection%20model%20and%20was%20recommended%20by%20WHO%20in%202004%20for%20humans.%20A%20drawback%20of%20this%20new%20medical%20approach%20is%20a%20long%20and%20daily%20administration%20%282%20months%29%20of%20streptomycin%2C%20an%20aminoglycoside%2C%20which%20requires%20daily%20injections%20and%20can%20have%20secondary%20effects.%20In%20our%20research%2C%20we%20sought%20to%20find%20a%20fully%20oral%20and%20intermittent%20treatment%20to%20facilitate%20the%20management%20of%20the%20patients%20on%20the%20field.%20The%20antibiotics%20combinations%20we%20studied%20were%20efficient%20in%20our%20model%20and%20would%20need%20now%20to%20be%20tested%20on%20the%20field.%22%2C%22date%22%3A%2218%20oct.%202016%22%2C%22language%22%3A%22%22%2C%22DOI%22%3A%2210.1371%5C%2Fjournal.pntd.0005066%22%2C%22ISSN%22%3A%221935-2735%22%2C%22url%22%3A%22http%3A%5C%2F%5C%2Fjournals.plos.org%5C%2Fplosntds%5C%2Farticle%3Fid%3D10.1371%5C%2Fjournal.pntd.0005066%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222022-03-11T23%3A51%3A36Z%22%7D%7D%2C%7B%22key%22%3A%22UQA4EI2T%22%2C%22library%22%3A%7B%22id%22%3A1368488%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Ruf%20et%20al.%22%2C%22parsedDate%22%3A%222012-02-01%22%2C%22numChildren%22%3A3%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3ERuf%2C%20M.-T.%2C%20Sch%26%23xFC%3Btte%2C%20D.%2C%20Chauffour%2C%20A.%2C%20Jarlier%2C%20V.%2C%20Ji%2C%20B.%20and%20Pluschke%2C%20G.%20%282012%29.%20%3Cb%3EChemotherapy-Associated%20Changes%20of%20Histopathological%20Features%20of%20Mycobacterium%20ulcerans%20Lesions%20in%20a%20Buruli%20Ulcer%20Mouse%20Model%3C%5C%2Fb%3E.%20Antimicrob%20Agents%20Chemother%20%3Ci%3E56%3C%5C%2Fi%3E%2C%20687%26%23x2013%3B696%2C%20%3Ca%20target%3D%27_blank%27%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1128%5C%2FAAC.05543-11%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1128%5C%2FAAC.05543-11%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Chemotherapy-Associated%20Changes%20of%20Histopathological%20Features%20of%20Mycobacterium%20ulcerans%20Lesions%20in%20a%20Buruli%20Ulcer%20Mouse%20Model%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marie-Th%5Cu00e9r%5Cu00e8se%22%2C%22lastName%22%3A%22Ruf%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Daniela%22%2C%22lastName%22%3A%22Sch%5Cu00fctte%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Aur%5Cu00e9lie%22%2C%22lastName%22%3A%22Chauffour%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Vincent%22%2C%22lastName%22%3A%22Jarlier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Baohong%22%2C%22lastName%22%3A%22Ji%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gerd%22%2C%22lastName%22%3A%22Pluschke%22%7D%5D%2C%22abstractNote%22%3A%22Combination%20chemotherapy%20with%20rifampin%20and%20streptomycin%20%28RIF-STR%29%20for%208%20weeks%20is%20currently%20recommended%20by%20the%20WHO%20as%20the%20first-line%20treatment%20for%20Mycobacterium%20ulcerans%20infection%20%28Buruli%20ulcer%29.%20To%20gain%20better%20insight%20into%20the%20mode%20of%20action%20of%20these%20antibiotics%20against%20established%20M.%20ulcerans%20infection%20foci%20and%20to%20characterize%20recovery%20of%20local%20immune%20responses%20during%20chemotherapy%2C%20we%20conducted%20a%20detailed%20histopathological%20study%20of%20M.%20ulcerans-infected%20and%20RIF-STR-treated%20mice.%20Mice%20were%20inoculated%20with%20M.%20ulcerans%20in%20the%20footpad%20and%2011%20weeks%20later%20treated%20with%20RIF-STR.%20Development%20of%20lesions%20during%20the%20first%2011%20weeks%20after%20infection%20and%20subsequent%20differences%20in%20disease%20progression%20between%20RIF-STR-treated%20and%20untreated%20mice%20were%20studied.%20Changes%20in%20histopathological%20features%2C%20footpad%20swelling%2C%20and%20number%20of%20CFU%20were%20analyzed.%20After%20inoculation%20with%20M.%20ulcerans%2C%20massive%20infiltrates%20dominated%20by%20polymorphonuclear%20leukocytes%20developed%20at%20the%20inoculation%20site%20but%20did%20not%20prevent%20bacterial%20multiplication.%20Huge%20clusters%20of%20extracellular%20bacteria%20located%20in%20large%20necrotic%20areas%20and%20surrounded%20by%20dead%20leukocytes%20developed%20in%20the%20untreated%20mice.%20Chemotherapy%20with%20RIF-STR%20led%20to%20a%20rapid%20drop%20in%20CFU%20associated%20with%20loss%20of%20solid%20Ziehl-Neelsen%20staining%20of%20acid-fast%20bacilli.%20Development%20of%20B-lymphocyte%20clusters%20and%20of%20macrophage%20accumulations%20surrounding%20the%20mycobacteria%20demonstrated%20the%20resolution%20of%20local%20immune%20suppression.%20Results%20demonstrate%20that%20the%20experimental%20M.%20ulcerans%20mouse%20infection%20model%20will%20be%20a%20valuable%20tool%20to%20investigate%20efficacy%20of%20new%20treatment%20regimens%20and%20of%20candidate%20vaccines.%22%2C%22date%22%3A%2202%5C%2F01%5C%2F2012%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1128%5C%2FAAC.05543-11%22%2C%22ISSN%22%3A%220066-4804%2C%201098-6596%22%2C%22url%22%3A%22http%3A%5C%2F%5C%2Faac.asm.org%5C%2Fcontent%5C%2F56%5C%2F2%5C%2F687%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222016-02-27T14%3A02%3A26Z%22%7D%7D%2C%7B%22key%22%3A%22GX85AMQ9%22%2C%22library%22%3A%7B%22id%22%3A1368488%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Marsollier%20et%20al.%22%2C%22parsedDate%22%3A%222010%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EMarsollier%2C%20L.%2C%20Aubry%2C%20A.%2C%20Carbonnelle%2C%20E.%2C%20Canaan%2C%20S.%2C%20Cambau%2C%20E.%20and%20Herrmann%2C%20J.-L.%20%282010%29.%20%3Cb%3ELes%20Mycobact%26%23xE9%3Brioses%20cutan%26%23xE9%3Bes%20dues%20%26%23xE0%3B%20Mycobacterium%20ulcerans%2C%20Mycobacterium%20marinum%2C%20Mycobacterium%20abscessus%2C%20Mycobacterium%20chelonae%20et%20autres%20mycobact%26%23xE9%3Bries%20non%20tuberculeuses%3C%5C%2Fb%3E%2C%20%3Ci%3EL%26%23x2019%3BEncyclop%26%23xE9%3Bdie%20M%26%23xE9%3Bdico-chirurgicale%3C%5C%2Fi%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22encyclopediaArticle%22%2C%22title%22%3A%22Les%20Mycobact%5Cu00e9rioses%20cutan%5Cu00e9es%20dues%20%5Cu00e0%20Mycobacterium%20ulcerans%2C%20Mycobacterium%20marinum%2C%20Mycobacterium%20abscessus%2C%20Mycobacterium%20chelonae%20et%20autres%20mycobact%5Cu00e9ries%20non%20tuberculeuses%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L%22%2C%22lastName%22%3A%22Marsollier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A%22%2C%22lastName%22%3A%22Aubry%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E%22%2C%22lastName%22%3A%22Carbonnelle%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S%22%2C%22lastName%22%3A%22Canaan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E%22%2C%22lastName%22%3A%22Cambau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J-L%22%2C%22lastName%22%3A%22Herrmann%22%7D%5D%2C%22abstractNote%22%3A%22%22%2C%22encyclopediaTitle%22%3A%22L%27Encyclop%5Cu00e9die%20M%5Cu00e9dico-chirurgicale%22%2C%22date%22%3A%222010%22%2C%22ISBN%22%3A%22%22%2C%22url%22%3A%22%22%2C%22language%22%3A%22%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222016-02-26T17%3A46%3A28Z%22%7D%7D%2C%7B%22key%22%3A%22W54VDTBF%22%2C%22library%22%3A%7B%22id%22%3A1368488%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Ji%20et%20al.%22%2C%22parsedDate%22%3A%222009-07-01%22%2C%22numChildren%22%3A3%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EJi%2C%20B.%2C%20Chauffour%2C%20A.%2C%20Aubry%2C%20A.%2C%20Robert%2C%20J.%2C%20Ibrahim%2C%20M.%20and%20Jarlier%2C%20V.%20%282009%29.%20%3Cb%3EImpacts%20of%20Dosing%20Frequency%20of%20the%20Combination%20Rifampin-Streptomycin%20on%20Its%20Bactericidal%20and%20Sterilizing%20Activities%20against%20Mycobacterium%20ulcerans%20in%20Mice%3C%5C%2Fb%3E.%20Antimicrob%20Agents%20Chemother%20%3Ci%3E53%3C%5C%2Fi%3E%2C%202955%26%23x2013%3B2959%2C%20%3Ca%20target%3D%27_blank%27%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1128%5C%2FAAC.00011-09%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1128%5C%2FAAC.00011-09%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Impacts%20of%20Dosing%20Frequency%20of%20the%20Combination%20Rifampin-Streptomycin%20on%20Its%20Bactericidal%20and%20Sterilizing%20Activities%20against%20Mycobacterium%20ulcerans%20in%20Mice%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Baohong%22%2C%22lastName%22%3A%22Ji%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Aurelie%22%2C%22lastName%22%3A%22Chauffour%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alexandra%22%2C%22lastName%22%3A%22Aubry%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%5Cu00e9r%5Cu00f4me%22%2C%22lastName%22%3A%22Robert%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Murad%22%2C%22lastName%22%3A%22Ibrahim%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Vincent%22%2C%22lastName%22%3A%22Jarlier%22%7D%5D%2C%22abstractNote%22%3A%22Because%20of%20operational%20limitations%2C%20a%20significant%20proportion%20of%20the%20health%20centers%20at%20the%20peripheral%20level%20are%20able%20to%20provide%20treatment%20to%20Buruli%20ulcer%20patients%20with%20the%20combination%20rifampin%20%28rifampicin%29-streptomycin%20%28RIF-STR%29%20only%20five%20times%20weekly%20%285%5C%2F7%29%20instead%20of%20seven%20times%20weekly%20%287%5C%2F7%29%2C%20as%20recommended.%20The%20objective%20of%20this%20experiment%20is%20to%20assess%20the%20impacts%20of%20various%20dosing%20frequencies%20of%20the%20combination%20on%20its%20bactericidal%20and%20sterilizing%20activities%20against%20Mycobacterium%20ulcerans%20in%20mice.%20The%20results%20demonstrate%20that%20the%20bactericidal%20activities%20did%20not%20differ%20significantly%20among%20five%20dosing%20frequencies%20of%20the%20combination%2C%20ranging%20from%20seven%20times%20to%20twice%20weekly%2C%20whereas%20the%20sterilizing%20activities%20differed%20widely.%20RIF-STR%207%5C%2F7%20was%20the%20only%20regimen%20that%20was%20able%20to%20sterilize%20the%20infection%20after%204%20to%208%20weeks%20of%20treatment%3B%20the%20sterilizing%20activities%20associated%20with%20reduced%20dosing%20frequencies%20were%20significantly%20diminished%2C%20and%208%20weeks%20of%205%5C%2F7%20administration%20yielded%20a%20relapse%20rate%20greater%20than%20the%20generally%20accepted%20level%20of%205%25.%20We%20recommend%20that%20the%20duration%20of%20treatment%20with%205%5C%2F7%20administration%20be%20prolonged%20beyond%208%20weeks%20and%20that%20additional%20experiments%20with%20mice%20be%20carried%20out%2C%20with%20sufficient%20statistical%20power%20to%20compare%20the%20relapse%20rates%20of%20M.%20ulcerans%20infection%20between%208%20weeks%20of%207%5C%2F7%20administration%20and%2010%20and%2012%20weeks%20of%205%5C%2F7%20administration%20of%20RIF-STR.%22%2C%22date%22%3A%2207%5C%2F01%5C%2F2009%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1128%5C%2FAAC.00011-09%22%2C%22ISSN%22%3A%220066-4804%2C%201098-6596%22%2C%22url%22%3A%22http%3A%5C%2F%5C%2Faac.asm.org%5C%2Fcontent%5C%2F53%5C%2F7%5C%2F2955%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222013-09-02T21%3A31%3A24Z%22%7D%7D%2C%7B%22key%22%3A%22F9GATMVI%22%2C%22library%22%3A%7B%22id%22%3A1368488%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Ji%20et%20al.%22%2C%22parsedDate%22%3A%222008-06%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EJi%2C%20B.%2C%20Chauffour%2C%20A.%2C%20Robert%2C%20J.%20and%20Jarlier%2C%20V.%20%282008%29.%20%3Cb%3EBactericidal%20and%20Sterilizing%20Activities%20of%20Several%20Orally%20Administered%20Combined%20Regimens%20against%20Mycobacterium%20ulcerans%20in%20Mice%3C%5C%2Fb%3E.%20Antimicrob%20Agents%20Chemother%20%3Ci%3E52%3C%5C%2Fi%3E%2C%201912%26%23x2013%3B1916%2C%20%3Ca%20target%3D%27_blank%27%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1128%5C%2FAAC.00193-08%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1128%5C%2FAAC.00193-08%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Bactericidal%20and%20Sterilizing%20Activities%20of%20Several%20Orally%20Administered%20Combined%20Regimens%20against%20Mycobacterium%20ulcerans%20in%20Mice%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Baohong%22%2C%22lastName%22%3A%22Ji%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Aurelie%22%2C%22lastName%22%3A%22Chauffour%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%5Cu00e9r%5Cu00f4me%22%2C%22lastName%22%3A%22Robert%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Vincent%22%2C%22lastName%22%3A%22Jarlier%22%7D%5D%2C%22abstractNote%22%3A%22Treatment%20with%20rifampin-clarithromycin%20or%20moxifloxacin-clarithromycin%20for%208%20weeks%20displayed%20promising%20bactericidal%20activity%20against%20Mycobacterium%20ulcerans%20in%20mice%3B%20none%20of%20the%20mice%20treated%20with%20rifampin-clarithromycin%20relapsed%2C%20whereas%2059%25%20of%20those%20treated%20with%20moxifloxacin-clarithromycin%20relapsed%20after%20treatment%20was%20stopped.%20The%20bactericidal%20and%20sterilizing%20activities%20of%20the%20five-times-weekly%20%285%5C%2F7%29%20administration%20of%205%20mg%20of%20rifapentine%5C%2Fkg%20of%20body%20weight%2C%20either%20alone%20or%20in%20combination%2C%20were%20virtually%20identical%20to%20those%20of%20the%20corresponding%20regimens%20with%2010%20mg%20of%20rifampin%5C%2Fkg%20of%20body%20weight%3B%20however%2C%20because%20of%20the%20long%20half-life%20of%20rifapentine%2C%20accumulation%20of%20the%20drug%20after%205%5C%2F7%20administration%20is%20a%20concern.%20The%20bactericidal%20activity%20of%2020%20mg%5C%2Fkg%20rifapentine%20in%20monotherapy%20or%2020%20mg%5C%2Fkg%20rifapentine%20in%20combination%20with%20150%20mg%5C%2Fkg%20streptomycin%20or%20200%20mg%5C%2Fkg%20moxifloxacin%20administered%20twice%20weekly%20was%20as%20effective%20as%20the%20corresponding%20regimens%20containing%2010%20mg%5C%2Fkg%20rifampin%20administered%205%5C%2F7%2C%20suggesting%20that%20Buruli%20ulcer%20might%20be%20treated%20with%20intermittently%20administered%20rifapentine-containing%20combinations.%22%2C%22date%22%3A%222008-6%22%2C%22language%22%3A%22%22%2C%22DOI%22%3A%2210.1128%5C%2FAAC.00193-08%22%2C%22ISSN%22%3A%220066-4804%22%2C%22url%22%3A%22http%3A%5C%2F%5C%2Fwww.ncbi.nlm.nih.gov%5C%2Fpmc%5C%2Farticles%5C%2FPMC2415803%5C%2F%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222013-09-09T15%3A50%3A14Z%22%7D%7D%2C%7B%22key%22%3A%22C8BSMNA9%22%2C%22library%22%3A%7B%22id%22%3A1368488%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Ji%20et%20al.%22%2C%22parsedDate%22%3A%222007-10-01%22%2C%22numChildren%22%3A3%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EJi%2C%20B.%2C%20Chauffour%2C%20A.%2C%20Robert%2C%20J.%2C%20Lefran%26%23xE7%3Bois%2C%20S.%20and%20Jarlier%2C%20V.%20%282007%29.%20%3Cb%3EOrally%20Administered%20Combined%20Regimens%20for%20Treatment%20of%20Mycobacterium%20ulcerans%20Infection%20in%20Mice%3C%5C%2Fb%3E.%20Antimicrob%20Agents%20Chemother%20%3Ci%3E51%3C%5C%2Fi%3E%2C%203737%26%23x2013%3B3739%2C%20%3Ca%20target%3D%27_blank%27%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1128%5C%2FAAC.00730-07%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1128%5C%2FAAC.00730-07%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Orally%20Administered%20Combined%20Regimens%20for%20Treatment%20of%20Mycobacterium%20ulcerans%20Infection%20in%20Mice%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Baohong%22%2C%22lastName%22%3A%22Ji%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Aurelie%22%2C%22lastName%22%3A%22Chauffour%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%5Cu00e9r%5Cu00f4me%22%2C%22lastName%22%3A%22Robert%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S%5Cu00e9bastien%22%2C%22lastName%22%3A%22Lefran%5Cu00e7ois%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Vincent%22%2C%22lastName%22%3A%22Jarlier%22%7D%5D%2C%22abstractNote%22%3A%22Eight%20weeks%20of%20treatment%20with%20rifampin-streptomycin%20sterilizes%20Mycobacterium%20ulcerans%20infection%20in%20mice.%20Because%20the%20bactericidal%20activity%20against%20M.%20ulcerans%20of%20the%20combination%20rifampin-moxifloxacin%2C%20rifampin-clarithromycin%2C%20or%20moxifloxacin-clarithromycin%20was%20similar%20to%20that%20of%20rifampin-streptomycin%2C%20these%20combinations%20might%20be%20considered%20as%20alternative%2C%20orally%20administered%20combined%20regimens%20for%20treatment%20of%20Buruli%20ulcer%20in%20humans.%22%2C%22date%22%3A%2210%5C%2F01%5C%2F2007%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1128%5C%2FAAC.00730-07%22%2C%22ISSN%22%3A%220066-4804%2C%201098-6596%22%2C%22url%22%3A%22http%3A%5C%2F%5C%2Faac.asm.org%5C%2Fcontent%5C%2F51%5C%2F10%5C%2F3737%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222013-09-09T16%3A31%3A21Z%22%7D%7D%2C%7B%22key%22%3A%22TMFTEJND%22%2C%22library%22%3A%7B%22id%22%3A1368488%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Lefran%5Cu00e7ois%20et%20al.%22%2C%22parsedDate%22%3A%222007-02-01%22%2C%22numChildren%22%3A3%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3ELefran%26%23xE7%3Bois%2C%20S.%2C%20Robert%2C%20J.%2C%20Chauffour%2C%20A.%2C%20Ji%2C%20B.%20and%20Jarlier%2C%20V.%20%282007%29.%20%3Cb%3ECuring%20Mycobacterium%20ulcerans%20Infection%20in%20Mice%20with%20a%20Combination%20of%20Rifampin-Streptomycin%20or%20Rifampin-Amikacin%3C%5C%2Fb%3E.%20Antimicrob%20Agents%20Chemother%20%3Ci%3E51%3C%5C%2Fi%3E%2C%20645%26%23x2013%3B650%2C%20%3Ca%20target%3D%27_blank%27%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1128%5C%2FAAC.00821-06%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1128%5C%2FAAC.00821-06%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Curing%20Mycobacterium%20ulcerans%20Infection%20in%20Mice%20with%20a%20Combination%20of%20Rifampin-Streptomycin%20or%20Rifampin-Amikacin%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S%5Cu00e9bastien%22%2C%22lastName%22%3A%22Lefran%5Cu00e7ois%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%5Cu00e9r%5Cu00f4me%22%2C%22lastName%22%3A%22Robert%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Aurelie%22%2C%22lastName%22%3A%22Chauffour%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Baohong%22%2C%22lastName%22%3A%22Ji%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Vincent%22%2C%22lastName%22%3A%22Jarlier%22%7D%5D%2C%22abstractNote%22%3A%22The%20curing%20activities%20of%20various%20durations%20of%20treatment%20with%20a%20combination%20of%20rifampin%20%28RIF%29%20and%20either%20streptomycin%20%28STR%29%20or%20amikacin%20%28AMK%29%20in%20murine%20Mycobacterium%20ulcerans%20infection%20were%20compared%20in%20two%20experiments.%20In%20the%20first%20experiment%2C%20treatment%20was%20begun%201%20week%20after%20infection%2C%20when%20the%20inflammatory%20footpad%20lesion%20had%20not%20yet%20occurred%20%28preventive%20model%29%2C%20and%20in%20the%20second%20experiment%2C%20treatment%20was%20begun%206%20weeks%20after%20infection%2C%20when%20inflammatory%20footpad%20lesions%20were%20established%20%28curative%20model%29.%20In%20the%20first%20experiment%2C%204%20weeks%20of%20treatment%20with%20daily%20RIF-STR%20or%20RIF-AMK%20was%20able%20to%20postpone%20the%20occurrence%20of%20footpad%20lesion%20by%2012%20weeks%20%28RIF-STR%29%20or%2017%20weeks%20%28RIF-AMK%29%2C%20thus%20demonstrating%20their%20promising%20bactericidal%20activities%2C%20but%20neither%20treatment%20was%20able%20to%20prevent%20the%20late%20occurrence%20of%20footpad%20lesions.%20In%20the%20second%20experiment%2C%20the%20overall%20cure%20rates%2C%20as%20assessed%20by%20the%20lack%20of%20rebound%20of%20inflammatory%20lesions%20or%20remultiplication%20of%20M.%20ulcerans%2C%20were%20only%2062%25%20after%202%20weeks%20of%20treatment%20with%20RIF%20and%20an%20aminoglycoside%20and%2085%25%20after%204%20weeks%3B%20but%20the%20cure%20rate%20reached%20100%25%20after%208%20or%2012%20weeks%20of%20treatment.%20The%20cure%20rates%20were%20slightly%20higher%20with%20the%20AMK-containing%20combination%20than%20with%20the%20STR-containing%20combination%2C%20but%20the%20difference%20was%20at%20the%20limit%20of%20significance%20%28P%20%3D%200.07%29.%20These%20results%20show%20that%20in%20the%20murine%20model%20of%20Buruli%20ulcer%2C%208%20weeks%20is%20the%20optimal%20duration%20of%20treatment%20with%20a%20combination%20of%20RIF%20and%20an%20aminoglycoside.%22%2C%22date%22%3A%2202%5C%2F01%5C%2F2007%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1128%5C%2FAAC.00821-06%22%2C%22ISSN%22%3A%220066-4804%2C%201098-6596%22%2C%22url%22%3A%22http%3A%5C%2F%5C%2Faac.asm.org%5C%2Fcontent%5C%2F51%5C%2F2%5C%2F645%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222013-09-09T16%3A31%3A14Z%22%7D%7D%2C%7B%22key%22%3A%22MW46EVQT%22%2C%22library%22%3A%7B%22id%22%3A1368488%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Ji%20et%20al.%22%2C%22parsedDate%22%3A%222006-06-01%22%2C%22numChildren%22%3A3%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EJi%2C%20B.%2C%20Lefran%26%23xE7%3Bois%2C%20S.%2C%20Robert%2C%20J.%2C%20Chauffour%2C%20A.%2C%20Truffot%2C%20C.%20and%20Jarlier%2C%20V.%20%282006%29.%20%3Cb%3EIn%20Vitro%20and%20In%20Vivo%20Activities%20of%20Rifampin%2C%20Streptomycin%2C%20Amikacin%2C%20Moxifloxacin%2C%20R207910%2C%20Linezolid%2C%20and%20PA-824%20against%20Mycobacterium%20ulcerans%3C%5C%2Fb%3E.%20Antimicrob%20Agents%20Chemother%20%3Ci%3E50%3C%5C%2Fi%3E%2C%201921%26%23x2013%3B1926%2C%20%3Ca%20target%3D%27_blank%27%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1128%5C%2FAAC.00052-06%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1128%5C%2FAAC.00052-06%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22In%20Vitro%20and%20In%20Vivo%20Activities%20of%20Rifampin%2C%20Streptomycin%2C%20Amikacin%2C%20Moxifloxacin%2C%20R207910%2C%20Linezolid%2C%20and%20PA-824%20against%20Mycobacterium%20ulcerans%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Baohong%22%2C%22lastName%22%3A%22Ji%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S%5Cu00e9bastien%22%2C%22lastName%22%3A%22Lefran%5Cu00e7ois%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%5Cu00e9r%5Cu00f4me%22%2C%22lastName%22%3A%22Robert%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Aurelie%22%2C%22lastName%22%3A%22Chauffour%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Chantal%22%2C%22lastName%22%3A%22Truffot%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Vincent%22%2C%22lastName%22%3A%22Jarlier%22%7D%5D%2C%22abstractNote%22%3A%22Seven%20antimicrobials%20were%20tested%20in%20vitro%20against%2029%20clinical%20isolates%20of%20Mycobacterium%20ulcerans.%20R207910%20demonstrated%20the%20lowest%20MIC50%20and%20MIC90%2C%20followed%20by%20moxifloxacin%20%28MXF%29%2C%20streptomycin%20%28STR%29%2C%20rifampin%20%28RIF%29%2C%20amikacin%20%28AMK%29%2C%20linezolid%20%28LZD%29%2C%20and%20PA-824.%20All%20but%20PA-824%20demonstrated%20an%20MIC90%20significantly%20less%20than%20the%20clinically%20achievable%20peak%20serum%20level.%20Administered%20as%20monotherapy%20to%20mice%2C%20RIF%2C%20STR%2C%20AMK%2C%20MXF%2C%20R207910%2C%20and%20LZD%20demonstrated%20some%20degree%20of%20bactericidal%20activity%2C%20whereas%20PA-824%20failed%20to%20prevent%20mortality%20and%20to%20reduce%20the%20mean%20number%20of%20CFU%20in%20the%20footpads.%20Because%204%20or%208%20weeks%20of%20treatment%20by%20the%20combinations%20RIF-MXF%2C%20RIF-R207910%2C%20and%20RIF-LZD%20displayed%20bactericidal%20effects%20similar%20to%20those%20of%20RIF-STR%20and%20RIF-AMK%2C%20these%20three%20combinations%20might%20be%20considered%20as%20orally%20administered%20combined%20regimens%20for%20treatment%20of%20Buruli%20ulcer.%20Taking%20into%20account%20the%20cost%2C%20potential%20toxicity%2C%20and%20availability%2C%20the%20combination%20RIF-MXF%20appears%20more%20feasible%20for%20application%20in%20the%20field%3B%20additional%20experiments%20with%20mice%20are%20warranted%20to%20define%20further%20its%20activity%20against%20M.%20ulcerans.%20In%20addition%2C%20a%20pilot%20clinical%20trial%20is%20proposed%20to%20test%20the%20efficacy%20of%20RIF-MXF%20for%20treatment%20of%20Buruli%20ulcer.%22%2C%22date%22%3A%2206%5C%2F01%5C%2F2006%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1128%5C%2FAAC.00052-06%22%2C%22ISSN%22%3A%220066-4804%2C%201098-6596%22%2C%22url%22%3A%22http%3A%5C%2F%5C%2Faac.asm.org%5C%2Fcontent%5C%2F50%5C%2F6%5C%2F1921%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222013-09-09T16%3A31%3A05Z%22%7D%7D%2C%7B%22key%22%3A%22RQI3G6BD%22%2C%22library%22%3A%7B%22id%22%3A1368488%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Dega%20et%20al.%22%2C%22parsedDate%22%3A%222002-10-01%22%2C%22numChildren%22%3A3%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EDega%2C%20H.%2C%20Bentoucha%2C%20A.%2C%20Robert%2C%20J.%2C%20Jarlier%2C%20V.%20and%20Grosset%2C%20J.%20%282002%29.%20%3Cb%3EBactericidal%20Activity%20of%20Rifampin-Amikacin%20against%20Mycobacterium%20ulcerans%20in%20Mice%3C%5C%2Fb%3E.%20Antimicrob%20Agents%20Chemother%20%3Ci%3E46%3C%5C%2Fi%3E%2C%203193%26%23x2013%3B3196%2C%20%3Ca%20target%3D%27_blank%27%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1128%5C%2FAAC.46.10.3193-3196.2002%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1128%5C%2FAAC.46.10.3193-3196.2002%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Bactericidal%20Activity%20of%20Rifampin-Amikacin%20against%20Mycobacterium%20ulcerans%20in%20Mice%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Herve%22%2C%22lastName%22%3A%22Dega%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Abdelhalim%22%2C%22lastName%22%3A%22Bentoucha%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%5Cu00e9r%5Cu00f4me%22%2C%22lastName%22%3A%22Robert%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Vincent%22%2C%22lastName%22%3A%22Jarlier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jacques%22%2C%22lastName%22%3A%22Grosset%22%7D%5D%2C%22abstractNote%22%3A%22To%20identify%20the%20most%20active%20curative%20treatment%20of%20Buruli%20ulcer%2C%20two%20regimens%20incorporating%20the%20use%20of%20rifampin%20%28RIF%29%20were%20compared%20with%20the%20use%20of%20RIF%20alone%20in%20a%20mouse%20footpad%20model%20of%20Mycobacterium%20ulcerans%20infection.%20Treatments%20began%20after%20footpad%20swelling%20from%20infection%20and%20continued%20for%2012%20weeks%20with%20five%20doses%20weekly%20of%20one%20of%20the%20following%20regimens%3A%20%28i%29%2010%20mg%20of%20RIF%5C%2Fkg%20alone%3B%20%28ii%29%2010%20mg%20of%20RIF%5C%2Fkg%20and%20100%20mg%20of%20amikacin%20%28AMK%29%5C%2Fkg%3B%20and%20%28iii%29%2010%20mg%20of%20RIF%5C%2Fkg%2C%20100%20mg%20of%20clarithromycin%20%28CLR%29%5C%2Fkg%2C%20and%2050%20mg%20of%20sparfloxacin%20%28SPX%29%5C%2Fkg.%20The%20activity%20of%20each%20regimen%20was%20assessed%20in%20terms%20of%20the%20reduction%20of%20the%20average%20lesion%20index%20and%20acid-fast%20bacillus%20%28AFB%29%20and%20CFU%20counts.%20All%20three%20regimens%20displayed%20various%20degrees%20of%20bactericidal%20activity%20against%20M.%20ulcerans.%20The%20ranking%20of%20bactericidal%20activity%20was%20found%20to%20be%20as%20follows%3A%20RIF-AMK%20%3E%20RIF-CLR-SPX%20%3E%20RIF.%20RIF-AMK%20was%20able%20to%20cure%20M.%20ulcerans-infected%20mice%20and%20prevent%20relapse%2026%20weeks%20after%20completion%20of%20treatment.%20To%20determine%20the%20impact%20of%20different%20rhythms%20of%20administration%20of%20RIF-AMK%20on%20the%20suppression%20of%20M.ulcerans%20growth%2C%20mice%20were%20given%20the%20RIF-AMK%20combination%20for%204%20weeks%20but%20doses%20were%20administered%20either%205%20days%20a%20week%20or%20twice%20or%20once%20weekly.%20After%20completion%20of%20treatment%2C%20the%20mice%20were%20kept%20under%20supervision%20for%2030%20additional%20weeks.%20M.%20ulcerans%20was%20considered%20to%20have%20grown%20in%20the%20footpad%20if%20swelling%20was%20visually%20observed%20and%20harvests%20contained%20more%20than%205%20%5Cu00d7%20105%20AFB%20per%20footpad.%20The%20proportion%20of%20mice%20in%20which%20growth%20of%20M.%20ulcerans%20occurred%2C%20irrespective%20of%20drug%20dosage%2C%20was%20compared%20with%20the%20control%20mice%20to%20determine%20the%20proportion%20of%20M.%20ulcerans%20killed.%20Each%20dosage%20of%20RIF-AMK%20was%20bactericidal%20for%20M.%20ulcerans%20%28P%20%3C%200.001%29%2C%20but%20the%20effect%20was%20significantly%20stronger%20in%20mice%20treated%205%20days%20per%20week.%20The%20promising%20results%20of%20RIF-AMK%20treatment%20in%20M.%20ulcerans-infected%20mice%20support%20the%20clinical%20trial%20that%20is%20currently%20in%20progress%20under%20World%20Health%20Organization%20auspices%20in%20Ghana.%22%2C%22date%22%3A%2210%5C%2F01%5C%2F2002%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1128%5C%2FAAC.46.10.3193-3196.2002%22%2C%22ISSN%22%3A%220066-4804%2C%201098-6596%22%2C%22url%22%3A%22http%3A%5C%2F%5C%2Faac.asm.org%5C%2Fcontent%5C%2F46%5C%2F10%5C%2F3193%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222013-09-09T16%3A30%3A54Z%22%7D%7D%2C%7B%22key%22%3A%226Q4IS636%22%2C%22library%22%3A%7B%22id%22%3A1368488%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Bentoucha%20et%20al.%22%2C%22parsedDate%22%3A%222001-11-01%22%2C%22numChildren%22%3A3%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EBentoucha%2C%20A.%2C%20Robert%2C%20J.%2C%20Dega%2C%20H.%2C%20Lounis%2C%20N.%2C%20Jarlier%2C%20V.%20and%20Grosset%2C%20J.%20%282001%29.%20%3Cb%3EActivities%20of%20New%20Macrolides%20and%20Fluoroquinolones%20against%20Mycobacterium%20ulcerans%20Infection%20in%20Mice%3C%5C%2Fb%3E.%20Antimicrob%20Agents%20Chemother%20%3Ci%3E45%3C%5C%2Fi%3E%2C%203109%26%23x2013%3B3112%2C%20%3Ca%20target%3D%27_blank%27%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1128%5C%2FAAC.45.11.3109-3112.2001%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1128%5C%2FAAC.45.11.3109-3112.2001%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Activities%20of%20New%20Macrolides%20and%20Fluoroquinolones%20against%20Mycobacterium%20ulcerans%20Infection%20in%20Mice%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Abdelhalim%22%2C%22lastName%22%3A%22Bentoucha%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%5Cu00e9r%5Cu00f4me%22%2C%22lastName%22%3A%22Robert%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Herve%22%2C%22lastName%22%3A%22Dega%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nacer%22%2C%22lastName%22%3A%22Lounis%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Vincent%22%2C%22lastName%22%3A%22Jarlier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jacques%22%2C%22lastName%22%3A%22Grosset%22%7D%5D%2C%22abstractNote%22%3A%22Mice%20infected%20in%20the%20left%20hind%20footpad%20with%205%20log10acid-fast%20bacilli%20of%20Mycobacterium%20ulcerans%20were%20divided%20into%20an%20untreated%20control%20group%20and%2017%20treatment%20groups%20that%20received%20one%20of%20the%20following%20regimens%20for%204%20weeks%20%28all%20doses%20in%20milligrams%20per%20kilogram%29%3A%20100%20mg%20of%20azithromycin%20%28AZM%29%2C%20100%20mg%20of%20clarithromycin%20%28CLR%29%2C%20or%2050%20mg%20of%20AZM%20for%20a%20duration%20of%205%20days%20a%20week%20%28daily%29%2C%20three%20times%20a%20week%2C%20or%20once%20weekly.%20In%20addition%2C%20the%20following%20regimens%20were%20administered%20daily%3A%20100%20mg%20of%20telithromycin%20%28TLM%29%2C%20sparfloxacin%20%28SPX%29%2C%20or%20moxifloxacin%20%28MOX%29%3B%20200%20mg%20of%20levofloxacin%20%28LVX%29%3B%20100%20mg%20of%20streptomycin%20%28STR%29%20or%20amikacin%20%28AMK%29%3B%2010%20mg%20of%20rifampin%20%28RIF%29%3B%20and%20the%20combination%20of%2010%20mg%20of%20RIF%20and%20100%20mg%20of%20AMK%20%28RIF%2BAMK%29.%20After%20completion%20of%20treatment%2C%20mice%20were%20observed%20for%2030%20weeks.%20The%20effectiveness%20of%20treatment%20regimens%20was%20assessed%20in%20terms%20of%20the%20delay%20in%20median%20time%20to%20footpad%20swelling%20in%20treated%20mice%20compared%20with%20that%20in%20the%20untreated%20controls.%20Clear-cut%20bactericidal%20activity%2C%20i.e.%2C%20an%20observed%20delay%20in%20footpad%20swelling%20that%20exceeded%20the%20period%20of%20treatment%2C%20was%20observed%20in%20the%20STR-%2C%20AMK-%2C%20and%20RIF%2BAMK-treated%20mice.%20However%2C%20all%20mice%20treated%20with%20either%20AMK%20or%20STR%20alone%20had%20swollen%20footpads%20before%20the%20end%20of%20the%2030-week%20observation%20period%2C%20suggesting%20regrowth%20of%20M.%20ulcerans.%20In%20contrast%2C%2050%25%20of%20the%20mice%20treated%20with%20the%20RIF%2BAMK%20combination%20exhibited%20no%20lesion%20even%20after%2030%20weeks%2C%20suggesting%20cure.%20The%20remaining%20regimens%20could%20be%20assigned%20to%20one%20of%20three%20groups%3A%20%28i%29%20no%20activity%20%2850%20mg%20of%20AZM%2C%20100%20mg%20of%20AZM%20thrice%20weekly%2C%20TLM%2C%20and%20LVX%29%3B%20%28ii%29%20bacteriostatic%20activity%2C%20i.e.%2C%20a%20delay%20in%20footpad%20swelling%20shorter%20than%20the%204-week%20treatment%20duration%20%28100%20mg%20of%20AZM%20daily%20or%20once%20weekly%2C%20CLR%20thrice%20or%20once%20weekly%2C%20and%20MOX%29%3B%20or%20%28iii%29%20weak%20bactericidal%20activity%20%28CLR%20daily%20and%20SPX%29.%20The%20RIF%2BAMK%20combination%20and%20possibly%20RIF%2BSTR%20warrant%20further%20study%20for%20the%20treatment%20of%20M.%20ulceransinfection%20in%20humans.%22%2C%22date%22%3A%2211%5C%2F01%5C%2F2001%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1128%5C%2FAAC.45.11.3109-3112.2001%22%2C%22ISSN%22%3A%220066-4804%2C%201098-6596%22%2C%22url%22%3A%22http%3A%5C%2F%5C%2Faac.asm.org%5C%2Fcontent%5C%2F45%5C%2F11%5C%2F3109%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222013-09-09T16%3A30%3A45Z%22%7D%7D%2C%7B%22key%22%3A%22ADCZWI6K%22%2C%22library%22%3A%7B%22id%22%3A1368488%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Dega%20et%20al.%22%2C%22parsedDate%22%3A%222000-09-01%22%2C%22numChildren%22%3A3%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EDega%2C%20H.%2C%20Robert%2C%20J.%2C%20Bonnafous%2C%20P.%2C%20Jarlier%2C%20V.%20and%20Grosset%2C%20J.%20%282000%29.%20%3Cb%3EActivities%20of%20Several%20Antimicrobials%20againstMycobacterium%20ulcerans%20Infection%20in%20Mice%3C%5C%2Fb%3E.%20Antimicrob%20Agents%20Chemother%20%3Ci%3E44%3C%5C%2Fi%3E%2C%202367%26%23x2013%3B2372%2C%20%3Ca%20target%3D%27_blank%27%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1128%5C%2FAAC.44.9.2367-2372.2000%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1128%5C%2FAAC.44.9.2367-2372.2000%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Activities%20of%20Several%20Antimicrobials%20againstMycobacterium%20ulcerans%20Infection%20in%20Mice%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Herve%22%2C%22lastName%22%3A%22Dega%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%5Cu00e9r%5Cu00f4me%22%2C%22lastName%22%3A%22Robert%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pascale%22%2C%22lastName%22%3A%22Bonnafous%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Vincent%22%2C%22lastName%22%3A%22Jarlier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jacques%22%2C%22lastName%22%3A%22Grosset%22%7D%5D%2C%22abstractNote%22%3A%22Mycobacterium%20ulcerans%20inoculated%20into%20the%20footpads%20of%20mice%20at%206%20%5Cu00d7%20103%20CFU%20was%20shown%20to%20have%20a%20generation%20time%20of%206.5%20days%20when%20estimated%20from%20weekly%20changes%20in%20microscopic%20counts%20of%20acid-fast%20bacilli%20%28AFB%29%20and%207.5%20days%20when%20calculated%20from%20actual%20CFU%20enumerated%20on%20Lowenstein-Jensen%20egg%20medium%20incubated%20at%2032%5Cu00b0C.%20Footpads%20became%20swollen%20at%20week%2010%20%28W10%29%20after%20infection%2C%20and%20all%20infected%20control%20mice%20were%20dead%20at%20W15%20after%20infection.%20Daily%20%285%20days%5C%2Fweek%29%20treatment%20with%20100%20mg%20of%20clarithromycin%20%28CLR%29%5C%2Fkg%20of%20body%20weight%20beginning%20the%20day%20after%20infection%20prevented%20swelling%20of%20footpads%20at%20W10.%20When%20initiation%20of%20treatment%20was%20delayed%20until%20obvious%20footpad%20swelling%20was%20observed%2C%20there%20was%20a%20reduction%20in%20both%20the%20increase%20in%20AFB%20counts%20and%20deterioration%20of%20swollen%20footpads%20and%20also%20a%20prolonged%20survival%20of%20the%20mice%20to%20W18.%20Mice%20infected%20in%20the%20hind%20footpads%20with%205%20%5Cu00d7%20105%20CFU%20of%20M.%20ulcerans%20were%20divided%20into%20an%20untreated%20control%20group%20and%20six%20treatment%20groups%20that%20received%20one%20of%20the%20following%20therapies%20for%208%20weeks%3A%20100%20mg%20of%20CLR%5C%2Fkg%2C%2025%20mg%20of%20minocycline%20%28MIN%29%5C%2Fkg%2C%2050%20mg%20of%20sparfloxacin%20%28SPX%29%5C%2Fkg%2C%2010%20mg%20of%20rifampin%20%28RIF%29%5C%2Fkg%2C%2010%20mg%20of%20rifabutin%20%28RBT%29%5C%2Fkg%2C%20or%20100%20mg%20of%20amikacin%20%28AMK%29%5C%2Fkg.%20After%20completion%20of%20therapy%2C%20treated%20animals%20were%20observed%20for%20an%20additional%2017%20weeks.%20All%20control%20mice%20and%20mice%20treated%20with%20CLR%2C%20MIN%2C%20or%20SPX%20exhibited%20swollen%20footpads%20during%20the%20observation%20period.%20In%20contrast%2C%20of%20those%20animals%20treated%20with%20RIF%2C%20RBT%2C%20or%20AMK%2C%20none%20had%20footpad%20swelling%20and%20all%20inoculated%20cultures%20done%20after%20the%20W17%20observation%20remained%20negative.%20These%20results%20suggest%20that%20RIF%2C%20RBT%2C%20and%20AMK%20may%20be%20effective%20in%20the%20treatment%20of%20human%20infection%20with%20M.%20ulcerans.%22%2C%22date%22%3A%2209%5C%2F01%5C%2F2000%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1128%5C%2FAAC.44.9.2367-2372.2000%22%2C%22ISSN%22%3A%220066-4804%2C%201098-6596%22%2C%22url%22%3A%22http%3A%5C%2F%5C%2Faac.asm.org%5C%2Fcontent%5C%2F44%5C%2F9%5C%2F2367%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222013-09-09T16%3A30%3A34Z%22%7D%7D%5D%7D
Phillips, R. O., Robert, J., Abass, K. M., Thompson, W., Sarfo, F. S., Wilson, T., Sarpong, G., Gateau, T., Chauty, A., Omollo, R., Ochieng Otieno, M., Egondi, T. W., Ampadu, E. O., Agossadou, D., Marion, E., Ganlonon, L., Wansbrough-Jones, M., Grosset, J., Macdonald, J. M., Treadwell, T., Saunderson, P., Paintsil, A., Lehman, L., Frimpong, M., Sarpong, N. F., Saizonou, R., Tiendrebeogo, A., Ohene, S.-A., Stienstra, Y., Asiedu, K. B., van der Werf, T. S., Osei Mireku, S., Abotsi, J., Adu Poku, J. K., Asamoah-Frimpong, R., Osei-Wusu, B., Sarpong, E., Konadu, B., Opoku, E., Forson, M., Ndogyele, M., Ofori, E., Aboagye, F., Berko, T., Amofa, G., Nsiah, A., Mensah-Bonsu, J., Ofori Nyarko, J., Amoako, Y. A., Koranteng Tannor, E., Boakye-Appiah, J., Dzibordzi Loglo, A., Sarpong-Duah, M., Agbavor, B., Ardent, M. F., Yamadjako, A., Adanmado Gersande, N., Adeye, A., Kindjinou, M., Akpolan, Kiki, M., Sodjinou, E., Guegnard, C., Klis, S.-A., Velding, K., Omansen, T., Ofori-Adjei, D., Eyangoh, S., Knell, A. and Faber, W. (2020). Rifampicin and clarithromycin (extended release) versus rifampicin and streptomycin for limited Buruli ulcer lesions: a randomised, open-label, non-inferiority phase 3 trial. The Lancet 395, 1259–1267, http://doi.org/10.1016/S0140-6736(20)30047-7.
Chauffour, A., Robert, J., Veziris, N., Aubry, A., Pethe, K. and Jarlier, V. (2020). Telacebec (Q203)-containing intermittent oral regimens sterilized mice infected with Mycobacterium ulcerans after only 16 doses. PLOS Neglected Tropical Diseases 14, e0007857, http://doi.org/10.1371/journal.pntd.0007857.
Scherr, N., Bieri, R., Thomas, S. S., Chauffour, A., Kalia, N. P., Schneide, P., Ruf, M.-T., Lamelas, A., Manimekalai, M. S. S., Grüber, G., Ishii, N., Suzuki, K., Tanner, M., Moraski, G. C., Miller, M. J., Witschel, M., Jarlier, V., Pluschke, G. and Pethe, K. (2018). Targeting the Mycobacterium ulcerans cytochrome bc 1 : aa 3 for the treatment of Buruli ulcer. Nature Communications 9, 5370, http://doi.org/10.1038/s41467-018-07804-8.
Chauffour, A., Robert, J., Veziris, N., Aubry, A. and Jarlier, V. (2016). Sterilizing Activity of Fully Oral Intermittent Regimens against Mycobacterium ulcerans Infection in Mice. PLOS Neglected Tropical Diseases 10, e0005066, http://doi.org/10.1371/journal.pntd.0005066.
Ruf, M.-T., Schütte, D., Chauffour, A., Jarlier, V., Ji, B. and Pluschke, G. (2012). Chemotherapy-Associated Changes of Histopathological Features of Mycobacterium ulcerans Lesions in a Buruli Ulcer Mouse Model. Antimicrob Agents Chemother 56, 687–696, http://doi.org/10.1128/AAC.05543-11.
Marsollier, L., Aubry, A., Carbonnelle, E., Canaan, S., Cambau, E. and Herrmann, J.-L. (2010). Les Mycobactérioses cutanées dues à Mycobacterium ulcerans, Mycobacterium marinum, Mycobacterium abscessus, Mycobacterium chelonae et autres mycobactéries non tuberculeuses, L’Encyclopédie Médico-chirurgicale.
Ji, B., Chauffour, A., Aubry, A., Robert, J., Ibrahim, M. and Jarlier, V. (2009). Impacts of Dosing Frequency of the Combination Rifampin-Streptomycin on Its Bactericidal and Sterilizing Activities against Mycobacterium ulcerans in Mice. Antimicrob Agents Chemother 53, 2955–2959, http://doi.org/10.1128/AAC.00011-09.
Ji, B., Chauffour, A., Robert, J. and Jarlier, V. (2008). Bactericidal and Sterilizing Activities of Several Orally Administered Combined Regimens against Mycobacterium ulcerans in Mice. Antimicrob Agents Chemother 52, 1912–1916, http://doi.org/10.1128/AAC.00193-08.
Ji, B., Chauffour, A., Robert, J., Lefrançois, S. and Jarlier, V. (2007). Orally Administered Combined Regimens for Treatment of Mycobacterium ulcerans Infection in Mice. Antimicrob Agents Chemother 51, 3737–3739, http://doi.org/10.1128/AAC.00730-07.
Lefrançois, S., Robert, J., Chauffour, A., Ji, B. and Jarlier, V. (2007). Curing Mycobacterium ulcerans Infection in Mice with a Combination of Rifampin-Streptomycin or Rifampin-Amikacin. Antimicrob Agents Chemother 51, 645–650, http://doi.org/10.1128/AAC.00821-06.
Ji, B., Lefrançois, S., Robert, J., Chauffour, A., Truffot, C. and Jarlier, V. (2006). In Vitro and In Vivo Activities of Rifampin, Streptomycin, Amikacin, Moxifloxacin, R207910, Linezolid, and PA-824 against Mycobacterium ulcerans. Antimicrob Agents Chemother 50, 1921–1926, http://doi.org/10.1128/AAC.00052-06.
Dega, H., Bentoucha, A., Robert, J., Jarlier, V. and Grosset, J. (2002). Bactericidal Activity of Rifampin-Amikacin against Mycobacterium ulcerans in Mice. Antimicrob Agents Chemother 46, 3193–3196, http://doi.org/10.1128/AAC.46.10.3193-3196.2002.
Bentoucha, A., Robert, J., Dega, H., Lounis, N., Jarlier, V. and Grosset, J. (2001). Activities of New Macrolides and Fluoroquinolones against Mycobacterium ulcerans Infection in Mice. Antimicrob Agents Chemother 45, 3109–3112, http://doi.org/10.1128/AAC.45.11.3109-3112.2001.
Dega, H., Robert, J., Bonnafous, P., Jarlier, V. and Grosset, J. (2000). Activities of Several Antimicrobials againstMycobacterium ulcerans Infection in Mice. Antimicrob Agents Chemother 44, 2367–2372, http://doi.org/10.1128/AAC.44.9.2367-2372.2000.
Catégories
Publications – Tuberculose
Seules les publications les plus récentes sont présentées – Pour voir plus de publications aller à la page de recherche : toutes les publications
Only the most recent publications are displayed – to see more, go to the search page : all publications
1368488
tuberculosis
items
1
0
date
desc
1
245
https://cnrmyrma.fr/wp-content/plugins/zotpress/
%7B%22status%22%3A%22success%22%2C%22updateneeded%22%3Afalse%2C%22instance%22%3A%22zotpress-f621288fa4e5ae2006872a3f8b16c8ea%22%2C%22meta%22%3A%7B%22request_last%22%3A200%2C%22request_next%22%3A50%2C%22used_cache%22%3Atrue%7D%2C%22data%22%3A%5B%7B%22key%22%3A%222HSDN9QD%22%2C%22library%22%3A%7B%22id%22%3A1368488%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Veziris%20et%20al.%22%2C%22parsedDate%22%3A%222024-03-19%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EVeziris%2C%20N.%2C%20Aubry%2C%20A.%2C%20Bonnet%2C%20I.%2C%20Petersen%2C%20T.%2C%20Poignon%2C%20C.%2C%20Gyd%26%23xE9%3B%2C%20E.%2C%20Guglielmetti%2C%20L.%20and%20Robert%2C%20J.%20%282024%29.%20%3Cb%3EActualit%26%23xE9%3Bs%20sur%20la%20tuberculose%20%26%23xE0%3B%20bacilles%20multir%26%23xE9%3Bsistants%20aux%20antibiotiques%20et%20ses%20nouveaux%20traitements%3C%5C%2Fb%3E.%20Bull%20%26%23xC9%3Bpid%20Hebdo%20127%26%23x2013%3B131%2C%20URL%3A%20%3Ca%20target%3D%27_blank%27%20href%3D%27http%3A%5C%2F%5C%2Fbeh.santepubliquefrance.fr%5C%2Fbeh%5C%2F2024%5C%2F6-7%5C%2F2024_6-7_4.html%27%3Ehttp%3A%5C%2F%5C%2Fbeh.santepubliquefrance.fr%5C%2Fbeh%5C%2F2024%5C%2F6-7%5C%2F2024_6-7_4.html%3C%5C%2Fa%3E%20%5BAccessed%20March%202024%5D.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Actualit%5Cu00e9s%20sur%20la%20tuberculose%20%5Cu00e0%20bacilles%20multir%5Cu00e9sistants%20aux%20antibiotiques%20et%20ses%20nouveaux%20traitements%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22N%22%2C%22lastName%22%3A%22Veziris%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A%22%2C%22lastName%22%3A%22Aubry%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22I%22%2C%22lastName%22%3A%22Bonnet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22T%22%2C%22lastName%22%3A%22Petersen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C%22%2C%22lastName%22%3A%22Poignon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E%22%2C%22lastName%22%3A%22Gyd%5Cu00e9%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L%22%2C%22lastName%22%3A%22Guglielmetti%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%22%2C%22lastName%22%3A%22Robert%22%7D%5D%2C%22abstractNote%22%3A%22%22%2C%22date%22%3A%222024-03-19%22%2C%22language%22%3A%22French%22%2C%22DOI%22%3A%22%22%2C%22ISSN%22%3A%22%22%2C%22url%22%3A%22http%3A%5C%2F%5C%2Fbeh.santepubliquefrance.fr%5C%2Fbeh%5C%2F2024%5C%2F6-7%5C%2F2024_6-7_4.html%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222024-03-19T17%3A03%3A50Z%22%7D%7D%2C%7B%22key%22%3A%22TGPHGG7Y%22%2C%22library%22%3A%7B%22id%22%3A1368488%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Maitre%20et%20al.%22%2C%22parsedDate%22%3A%222024%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EMaitre%2C%20T.%2C%20Baulard%2C%20A.%2C%20Aubry%2C%20A.%20and%20Veziris%2C%20N.%20%282024%29.%20%3Cb%3EOptimizing%20the%20use%20of%20current%20antituberculosis%20drugs%20to%20overcome%20drug%20resistance%20in%20Mycobacterium%20tuberculosis%3C%5C%2Fb%3E.%20Infectious%20Diseases%20Now%20%3Ci%3E54%3C%5C%2Fi%3E%2C%20104807%2C%20%3Ca%20target%3D%27_blank%27%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.idnow.2023.104807%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.idnow.2023.104807%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Optimizing%20the%20use%20of%20current%20antituberculosis%20drugs%20to%20overcome%20drug%20resistance%20in%20Mycobacterium%20tuberculosis%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thomas%22%2C%22lastName%22%3A%22Maitre%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alain%22%2C%22lastName%22%3A%22Baulard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alexandra%22%2C%22lastName%22%3A%22Aubry%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nicolas%22%2C%22lastName%22%3A%22Veziris%22%7D%5D%2C%22abstractNote%22%3A%22%22%2C%22date%22%3A%2202%5C%2F2024%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1016%5C%2Fj.idnow.2023.104807%22%2C%22ISSN%22%3A%2226669919%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Flinkinghub.elsevier.com%5C%2Fretrieve%5C%2Fpii%5C%2FS2666991923001690%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222023-11-13T09%3A44%3A03Z%22%7D%7D%2C%7B%22key%22%3A%22V2XSRDIF%22%2C%22library%22%3A%7B%22id%22%3A1368488%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Maitre%20et%20al.%22%2C%22parsedDate%22%3A%222024%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EMaitre%2C%20T.%2C%20Guglielmetti%2C%20L.%2C%20Robert%2C%20J.%2C%20Aubry%2C%20A.%20and%20Veziris%2C%20N.%20%282024%29.%20%3Cb%3EAvanc%26%23xE9%3Bes%20dans%20l%26%23x2019%3Bantibioth%26%23xE9%3Brapie%20de%20la%20tuberculose%3C%5C%2Fb%3E.%20Rev%20Prat%20%3Ci%3E74%3C%5C%2Fi%3E%2C%20239%26%23x2013%3B244.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Avanc%5Cu00e9es%20dans%20l%5Cu2019antibioth%5Cu00e9rapie%20de%20la%20tuberculose%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22T%22%2C%22lastName%22%3A%22Maitre%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L%22%2C%22lastName%22%3A%22Guglielmetti%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%22%2C%22lastName%22%3A%22Robert%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A%22%2C%22lastName%22%3A%22Aubry%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22N%22%2C%22lastName%22%3A%22Veziris%22%7D%5D%2C%22abstractNote%22%3A%22%22%2C%22date%22%3A%222024%22%2C%22language%22%3A%22%22%2C%22DOI%22%3A%22%22%2C%22ISSN%22%3A%22%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222024-03-19T17%3A06%3A35Z%22%7D%7D%2C%7B%22key%22%3A%22WVC2IXYE%22%2C%22library%22%3A%7B%22id%22%3A1368488%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Campbell%20et%20al.%22%2C%22parsedDate%22%3A%222023-12-22%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3ECampbell%2C%20J.%20R.%2C%20Brode%2C%20S.%20K.%2C%20Barry%2C%20P.%2C%20Bastos%2C%20M.%20L.%2C%20Bonnet%2C%20M.%2C%20Guglielmetti%2C%20L.%2C%20Kempker%2C%20R.%2C%20Klimuk%2C%20D.%2C%20Labor%26%23xED%3Bn%2C%20R.%20L.%2C%20Milanov%2C%20V.%2C%20Singla%2C%20R.%2C%20Skrahina%2C%20A.%2C%20Trajman%2C%20A.%2C%20Van%20Der%20Werf%2C%20T.%20S.%2C%20Viiklepp%2C%20P.%20and%20Menzies%2C%20D.%20%282023%29.%20%3Cb%3EAssociation%20of%20indicators%20of%20extensive%20disease%20and%20rifampin-resistant%20tuberculosis%20treatment%20outcomes%3A%20an%20individual%20participant%20data%20meta-analysis%3C%5C%2Fb%3E.%20Thorax%20thorax-2023-220249%2C%20%3Ca%20target%3D%27_blank%27%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1136%5C%2Fthorax-2023-220249%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1136%5C%2Fthorax-2023-220249%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Association%20of%20indicators%20of%20extensive%20disease%20and%20rifampin-resistant%20tuberculosis%20treatment%20outcomes%3A%20an%20individual%20participant%20data%20meta-analysis%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jonathon%20R%22%2C%22lastName%22%3A%22Campbell%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sarah%20K%22%2C%22lastName%22%3A%22Brode%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pennan%22%2C%22lastName%22%3A%22Barry%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mayara%20Lisboa%22%2C%22lastName%22%3A%22Bastos%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Maryline%22%2C%22lastName%22%3A%22Bonnet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lorenzo%22%2C%22lastName%22%3A%22Guglielmetti%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Russell%22%2C%22lastName%22%3A%22Kempker%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Dzmitry%22%2C%22lastName%22%3A%22Klimuk%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Rafael%20Laniado%22%2C%22lastName%22%3A%22Labor%5Cu00edn%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Vladimir%22%2C%22lastName%22%3A%22Milanov%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Rupak%22%2C%22lastName%22%3A%22Singla%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alena%22%2C%22lastName%22%3A%22Skrahina%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anete%22%2C%22lastName%22%3A%22Trajman%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Tjip%20S%22%2C%22lastName%22%3A%22Van%20Der%20Werf%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Piret%22%2C%22lastName%22%3A%22Viiklepp%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Dick%22%2C%22lastName%22%3A%22Menzies%22%7D%5D%2C%22abstractNote%22%3A%22Background%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Indicators%20of%20extensive%20disease%5Cu2014acid%20fast%20bacilli%20%28AFB%29%20smear%20positivity%20and%20lung%20cavitation%5Cu2014have%20been%20inconsistently%20associated%20with%20clinical%20rifampin-resistant%5C%2Fmultidrug-resistant%20tuberculosis%20%28RR%5C%2FMDR-TB%29%20outcomes.%20We%20evaluated%20the%20association%20of%20these%20indicators%20with%20end-of-treatment%20outcomes.%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Methods%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20We%20did%20an%20individual%20participant%20data%20meta-analysis%20of%20people%20treated%20for%20RR%5C%2FMDR-TB%20with%20longer%20regimens%20with%20documented%20AFB%20smear%20and%20chest%20radiography%20findings.%20We%20compared%20people%20AFB%20smear-negative%20without%20cavities%20to%20people%3A%20%281%29%20smear-negative%20with%20lung%20cavities%3B%20%282%29%20smear-positive%20without%20lung%20cavities%20and%20%283%29%20AFB%20smear-positive%20with%20lung%20cavities.%20Using%20multivariable%20logistic%20regression%20accounting%20for%20demographic%2C%20treatment%20and%20clinical%20factors%2C%20we%20calculated%20adjusted%20ORs%20%28aOR%29%20for%20any%20unfavourable%20outcome%20%28death%2C%20lost%20to%20follow-up%2C%20failure%5C%2Frecurrence%29%2C%20and%20mortality%20and%20treatment%20failure%5C%2Frecurrence%20alone.%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Results%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20We%20included%205596%20participants%3B%20included%20participants%20significantly%20differed%20from%20excluded%20participants.%20Overall%2C%20774%20%2813.8%25%29%20were%20AFB%20smear-negative%20without%20cavities%2C%20647%20%2811.6%25%29%20only%20had%20cavities%2C%201424%20%2825.4%25%29%20were%20AFB%20smear-positive%20alone%20and%202751%20%2849.2%25%29%20were%20AFB%20smear-positive%20with%20cavities.%20The%20median%20age%20was%2037%20years%20%28IQR%3A%2028%5Cu201347%29%2C%203580%20%2864%25%29%20were%20male%20and%20686%20%2812.5%25%29%20had%20HIV.%20Compared%20with%20participants%20AFB%20smear-negative%20without%20cavities%2C%20aOR%20%2895%25%20CI%29%20for%20any%20unfavourable%20outcome%20was%201.0%20%280.8%20to%201.4%29%20for%20participants%20smear-negative%20with%20lung%20cavities%2C%201.2%20%280.9%20to%201.5%29%20if%20smear-positive%20without%20cavities%20and%201.6%20%281.3%20to%202.0%29%20if%20AFB%20smear-positive%20with%20lung%20cavities.%20Odds%20were%20only%20significantly%20increased%20for%20mortality%20%281.5%2C%2095%25%20CI%201.1%20to%202.1%29%20and%20failure%5C%2Frecurrence%20%282.2%2C%2095%25%20CI%201.5%20to%203.3%29%20among%20participants%20AFB%20smear-positive%20with%20lung%20cavities.%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Conclusion%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Only%20the%20combination%20of%20AFB%20smear-positivity%20and%20lung%20cavitation%20was%20associated%20with%20unfavourable%20outcomes%2C%20suggesting%20they%20may%20benefit%20from%20stronger%20regimens.%22%2C%22date%22%3A%222023-12-22%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1136%5C%2Fthorax-2023-220249%22%2C%22ISSN%22%3A%220040-6376%2C%201468-3296%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fthorax.bmj.com%5C%2Flookup%5C%2Fdoi%5C%2F10.1136%5C%2Fthorax-2023-220249%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222023-12-31T15%3A24%3A42Z%22%7D%7D%2C%7B%22key%22%3A%22AYT74SVL%22%2C%22library%22%3A%7B%22id%22%3A1368488%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Du%20Cros%20et%20al.%22%2C%22parsedDate%22%3A%222023-12-01%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EDu%20Cros%2C%20P.%2C%20Greig%2C%20J.%2C%20Alffenaar%2C%20J.-W.%20C.%2C%20Cross%2C%20G.%20B.%2C%20Cousins%2C%20C.%2C%20Berry%2C%20C.%2C%20Khan%2C%20U.%2C%20Phillips%2C%20P.%20P.%20J.%2C%20Vel%26%23xE1%3Bsquez%2C%20G.%20E.%2C%20Furin%2C%20J.%2C%20Spigelman%2C%20M.%2C%20Denholm%2C%20J.%20T.%2C%20Thi%2C%20S.%20S.%2C%20Tiberi%2C%20S.%2C%20Huang%2C%20G.%20K.%20L.%2C%20Marks%2C%20G.%20B.%2C%20Turkova%2C%20A.%2C%20Guglielmetti%2C%20L.%2C%20Chew%2C%20K.%20L.%2C%20Nguyen%2C%20H.%20T.%2C%20Ong%2C%20C.%20W.%20M.%2C%20Brigden%2C%20G.%2C%20Singh%2C%20K.%20P.%2C%20Motta%2C%20I.%2C%20Lange%2C%20C.%2C%20Seddon%2C%20J.%20A.%2C%20Nyang%26%23x2019%3Bwa%2C%20B.-T.%2C%20Maug%2C%20A.%20K.%20J.%2C%20Gler%2C%20M.%20T.%2C%20Dooley%2C%20K.%20E.%2C%20Quelapio%2C%20M.%2C%20Tsogt%2C%20B.%2C%20Menzies%2C%20D.%2C%20Cox%2C%20V.%2C%20Upton%2C%20C.%20M.%2C%20Skrahina%2C%20A.%2C%20McKenna%2C%20L.%2C%20Horsburgh%2C%20C.%20R.%2C%20Dheda%2C%20K.%20and%20Marais%2C%20B.%20J.%20%282023%29.%20%3Cb%3EStandards%20for%20clinical%20trials%20for%20treating%20TB%3C%5C%2Fb%3E.%20int%20j%20tuberc%20lung%20dis%20%3Ci%3E27%3C%5C%2Fi%3E%2C%20885%26%23x2013%3B898%2C%20%3Ca%20target%3D%27_blank%27%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.5588%5C%2Fijtld.23.0341%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.5588%5C%2Fijtld.23.0341%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Standards%20for%20clinical%20trials%20for%20treating%20TB%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P.%22%2C%22lastName%22%3A%22Du%20Cros%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%22%2C%22lastName%22%3A%22Greig%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.-W.%20C.%22%2C%22lastName%22%3A%22Alffenaar%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22G.%20B.%22%2C%22lastName%22%3A%22Cross%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%22%2C%22lastName%22%3A%22Cousins%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%22%2C%22lastName%22%3A%22Berry%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22U.%22%2C%22lastName%22%3A%22Khan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P.%20P.%20J.%22%2C%22lastName%22%3A%22Phillips%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22G.%20E.%22%2C%22lastName%22%3A%22Vel%5Cu00e1squez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%22%2C%22lastName%22%3A%22Furin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Spigelman%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%20T.%22%2C%22lastName%22%3A%22Denholm%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%20S.%22%2C%22lastName%22%3A%22Thi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%22%2C%22lastName%22%3A%22Tiberi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22G.%20K.%20L.%22%2C%22lastName%22%3A%22Huang%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22G.%20B.%22%2C%22lastName%22%3A%22Marks%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Turkova%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L.%22%2C%22lastName%22%3A%22Guglielmetti%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22K.%20L.%22%2C%22lastName%22%3A%22Chew%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22H.%20T.%22%2C%22lastName%22%3A%22Nguyen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%20W.%20M.%22%2C%22lastName%22%3A%22Ong%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22G.%22%2C%22lastName%22%3A%22Brigden%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22K.%20P.%22%2C%22lastName%22%3A%22Singh%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22I.%22%2C%22lastName%22%3A%22Motta%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%22%2C%22lastName%22%3A%22Lange%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%20A.%22%2C%22lastName%22%3A%22Seddon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22B-T.%22%2C%22lastName%22%3A%22Nyang%5Cu2019wa%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%20K.%20J.%22%2C%22lastName%22%3A%22Maug%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%20T.%22%2C%22lastName%22%3A%22Gler%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22K.%20E.%22%2C%22lastName%22%3A%22Dooley%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Quelapio%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22B.%22%2C%22lastName%22%3A%22Tsogt%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22D.%22%2C%22lastName%22%3A%22Menzies%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22V.%22%2C%22lastName%22%3A%22Cox%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%20M.%22%2C%22lastName%22%3A%22Upton%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Skrahina%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L.%22%2C%22lastName%22%3A%22McKenna%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%20R.%22%2C%22lastName%22%3A%22Horsburgh%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22K.%22%2C%22lastName%22%3A%22Dheda%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22B.%20J.%22%2C%22lastName%22%3A%22Marais%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%3A%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20The%20value%2C%20speed%20of%20completion%20and%20robustness%20of%20the%20evidence%20generated%20by%20TB%20treatment%20trials%20could%20be%20improved%20by%20implementing%20standards%20for%20best%20practice.%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20METHODS%3A%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20A%20global%20panel%20of%20experts%20participated%20in%20a%20Delphi%20process%2C%20using%20a%207-point%20Likert%20scale%20%5Cn%20to%20score%20and%20revise%20draft%20standards%20until%20consensus%20was%20reached.%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20RESULTS%3A%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Eleven%20standards%20were%20defined%3A%20Standard%201%2C%20high%20quality%20data%20on%20TB%20regimens%20are%20essential%20to%20inform%20clinical%20and%20programmatic%20management%3B%20Standard%202%2C%20the%20research%20questions%20addressed%20by%20TB%20trials%20should%20be%20%5Cn%20relevant%20to%20affected%20communities%2C%20who%20should%20be%20included%20in%20all%20trial%20stages%3B%20Standard%203%2C%20trials%20should%20make%20every%20effort%20to%20be%20as%20inclusive%20as%20possible%3B%20Standard%204%2C%20the%20most%20efficient%20trial%20designs%20should%20be%20considered%20to%20improve%20the%20evidence%20base%20as%20quickly%20and%20cost%20effectively%20as%20possible%2C%20%5Cn%20without%20compromising%20quality%3B%20Standard%205%2C%20trial%20governance%20should%20be%20in%20line%20with%20accepted%20good%20clinical%20practice%3B%20Standard%206%2C%20trials%20should%20investigate%20and%20report%20strategies%20that%20promote%20optimal%20engagement%20in%20care%3B%20Standard%207%2C%20where%20possible%2C%20TB%20trials%20should%20include%20pharmacokinetic%20and%20pharmacodynamic%20%5Cn%20components%3B%20Standard%208%2C%20outcomes%20should%20include%20frequency%20of%20disease%20recurrence%20and%20post-treatment%20sequelae%3B%20Standard%209%2C%20TB%20trials%20should%20aim%20to%20harmonise%20key%20outcomes%20and%20data%20structures%20across%20studies%3B%20Standard%2010%2C%20TB%20trials%20should%20include%20biobanking%3B%20Standard%2011%2C%20treatment%20trials%20should%20%5Cn%20invest%20in%20capacity%20strengthening%20of%20local%20trial%20and%20TB%20programme%20staff.%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20CONCLUSION%3A%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20These%20standards%20should%20improve%20the%20efficiency%20and%20effectiveness%20of%20evidence%20generation%2C%20as%20well%20as%20the%20translation%20of%20research%20into%20policy%20and%20practice.%22%2C%22date%22%3A%222023-12-01%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.5588%5C%2Fijtld.23.0341%22%2C%22ISSN%22%3A%221027-3719%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fwww.ingentaconnect.com%5C%2Fcontent%5C%2F10.5588%5C%2Fijtld.23.0341%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222023-12-31T15%3A25%3A09Z%22%7D%7D%2C%7B%22key%22%3A%22NLTQM49X%22%2C%22library%22%3A%7B%22id%22%3A1368488%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Patil%20et%20al.%22%2C%22parsedDate%22%3A%222023-11-30%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EPatil%2C%20S.%20B.%2C%20Tamirat%2C%20M.%2C%20Khazhidinov%2C%20K.%2C%20Ardizzoni%2C%20E.%2C%20Atger%2C%20M.%2C%20Austin%2C%20A.%2C%20Baudin%2C%20E.%2C%20Bekhit%2C%20M.%2C%20Bektasov%2C%20S.%2C%20Berikova%2C%20E.%2C%20Bonnet%2C%20M.%2C%20Caboclo%2C%20R.%2C%20Chaudhry%2C%20M.%2C%20Chavan%2C%20V.%2C%20Cloez%2C%20S.%2C%20Coit%2C%20J.%2C%20Coutisson%2C%20S.%2C%20Dakenova%2C%20Z.%2C%20De%20Jong%2C%20B.%20C.%2C%20Delifer%2C%20C.%2C%20Demaisons%2C%20S.%2C%20Do%2C%20J.%20M.%2C%20Dos%20Santos%20Tozzi%2C%20D.%2C%20Ducher%2C%20V.%2C%20Ferlazzo%2C%20G.%2C%20Gouillou%2C%20M.%2C%20Khan%2C%20U.%2C%20Kunda%2C%20M.%2C%20Lachenal%2C%20N.%2C%20LaHood%2C%20A.%20N.%2C%20Lecca%2C%20L.%2C%20Mazmanian%2C%20M.%2C%20McIlleron%2C%20H.%2C%20Moreau%2C%20M.%2C%20Moschioni%2C%20M.%2C%20Nahid%2C%20P.%2C%20Osso%2C%20E.%2C%20Oyewusi%2C%20L.%2C%20Panda%2C%20S.%2C%20P%26%23xE2%3Bquet%2C%20A.%2C%20Thuong%20Huu%2C%20P.%2C%20Pichon%2C%20L.%2C%20Rich%2C%20M.%20L.%2C%20Rupasinghe%2C%20P.%2C%20Salahuddin%2C%20N.%2C%20Sanchez%20Garavito%2C%20E.%2C%20Seung%2C%20K.%20J.%2C%20Vel%26%23xE1%3Bsquez%2C%20G.%20E.%2C%20Vallet%2C%20M.%2C%20Varaine%2C%20F.%2C%20Yuya-Septoh%2C%20F.%20J.%2C%20Mitnick%2C%20C.%20D.%20and%20Guglielmetti%2C%20L.%20%282023%29.%20%3Cb%3EEvaluating%20newly%20approved%20drugs%20in%20combination%20regimens%20for%20multidrug-resistant%20tuberculosis%20with%20fluoroquinolone%20resistance%20%28endTB-Q%29%3A%20study%20protocol%20for%20a%20multi-country%20randomized%20controlled%20trial%3C%5C%2Fb%3E.%20Trials%20%3Ci%3E24%3C%5C%2Fi%3E%2C%20773%2C%20%3Ca%20target%3D%27_blank%27%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1186%5C%2Fs13063-023-07701-6%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1186%5C%2Fs13063-023-07701-6%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Evaluating%20newly%20approved%20drugs%20in%20combination%20regimens%20for%20multidrug-resistant%20tuberculosis%20with%20fluoroquinolone%20resistance%20%28endTB-Q%29%3A%20study%20protocol%20for%20a%20multi-country%20randomized%20controlled%20trial%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%20B.%22%2C%22lastName%22%3A%22Patil%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Tamirat%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22K.%22%2C%22lastName%22%3A%22Khazhidinov%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E.%22%2C%22lastName%22%3A%22Ardizzoni%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Atger%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Austin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E.%22%2C%22lastName%22%3A%22Baudin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Bekhit%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%22%2C%22lastName%22%3A%22Bektasov%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E.%22%2C%22lastName%22%3A%22Berikova%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Bonnet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R.%22%2C%22lastName%22%3A%22Caboclo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Chaudhry%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22V.%22%2C%22lastName%22%3A%22Chavan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%22%2C%22lastName%22%3A%22Cloez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%22%2C%22lastName%22%3A%22Coit%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%22%2C%22lastName%22%3A%22Coutisson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Z.%22%2C%22lastName%22%3A%22Dakenova%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22B.%20C.%22%2C%22lastName%22%3A%22De%20Jong%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%22%2C%22lastName%22%3A%22Delifer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%22%2C%22lastName%22%3A%22Demaisons%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%20M.%22%2C%22lastName%22%3A%22Do%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22D.%22%2C%22lastName%22%3A%22Dos%20Santos%20Tozzi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22V.%22%2C%22lastName%22%3A%22Ducher%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22G.%22%2C%22lastName%22%3A%22Ferlazzo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Gouillou%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22U.%22%2C%22lastName%22%3A%22Khan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Kunda%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22N.%22%2C%22lastName%22%3A%22Lachenal%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%20N.%22%2C%22lastName%22%3A%22LaHood%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L.%22%2C%22lastName%22%3A%22Lecca%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Mazmanian%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22H.%22%2C%22lastName%22%3A%22McIlleron%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Moreau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Moschioni%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P.%22%2C%22lastName%22%3A%22Nahid%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E.%22%2C%22lastName%22%3A%22Osso%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L.%22%2C%22lastName%22%3A%22Oyewusi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%22%2C%22lastName%22%3A%22Panda%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22P%5Cu00e2quet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P.%22%2C%22lastName%22%3A%22Thuong%20Huu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L.%22%2C%22lastName%22%3A%22Pichon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%20L.%22%2C%22lastName%22%3A%22Rich%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P.%22%2C%22lastName%22%3A%22Rupasinghe%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22N.%22%2C%22lastName%22%3A%22Salahuddin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E.%22%2C%22lastName%22%3A%22Sanchez%20Garavito%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22K.%20J.%22%2C%22lastName%22%3A%22Seung%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22G.%20E.%22%2C%22lastName%22%3A%22Vel%5Cu00e1squez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Vallet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22F.%22%2C%22lastName%22%3A%22Varaine%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22F.%20J.%22%2C%22lastName%22%3A%22Yuya-Septoh%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%20D.%22%2C%22lastName%22%3A%22Mitnick%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L.%22%2C%22lastName%22%3A%22Guglielmetti%22%7D%5D%2C%22abstractNote%22%3A%22Abstract%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Background%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Treatment%20for%20fluoroquinolone-resistant%20multidrug-resistant%5C%2Frifampicin-resistant%20tuberculosis%20%28pre-XDR%20TB%29%20often%20lasts%20longer%20than%20treatment%20for%20less%20resistant%20strains%2C%20yields%20worse%20efficacy%20results%2C%20and%20causes%20substantial%20toxicity.%20The%20newer%20anti-tuberculosis%20drugs%2C%20bedaquiline%20and%20delamanid%2C%20and%20repurposed%20drugs%20clofazimine%20and%20linezolid%2C%20show%20great%20promise%20for%20combination%20in%20shorter%2C%20less-toxic%2C%20and%20effective%20regimens.%20To%20date%2C%20there%20has%20been%20no%20randomized%2C%20internally%20and%20concurrently%20controlled%20trial%20of%20a%20shorter%2C%20all-oral%20regimen%20comprising%20these%20newer%20and%20repurposed%20drugs%20sufficiently%20powered%20to%20produce%20results%20for%20pre-XDR%20TB%20patients.%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Methods%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20endTB-Q%20is%20a%20phase%20III%2C%20multi-country%2C%20randomized%2C%20controlled%2C%20parallel%2C%20open-label%20clinical%20trial%20evaluating%20the%20efficacy%20and%20safety%20of%20a%20treatment%20strategy%20for%20patients%20with%20pre-XDR%20TB.%20Study%20participants%20are%20randomized%202%3A1%20to%20experimental%20or%20control%20arms%2C%20respectively.%20The%20experimental%20arm%20contains%20bedaquiline%2C%20linezolid%2C%20clofazimine%2C%20and%20delamanid.%20The%20control%20comprises%20the%20contemporaneous%20WHO%20standard%20of%20care%20for%20pre-XDR%20TB.%20Experimental%20arm%20duration%20is%20determined%20by%20a%20composite%20of%20smear%20microscopy%20and%20chest%20radiographic%20imaging%20at%20baseline%20and%20re-evaluated%20at%206%5Cu00a0months%20using%20sputum%20culture%20results%3A%20participants%20with%20less%20extensive%20disease%20receive%206%5Cu00a0months%20and%20participants%20with%20more%20extensive%20disease%20receive%209%5Cu00a0months%20of%20treatment.%20Randomization%20is%20stratified%20by%20country%20and%20by%20participant%20extent-of-TB-disease%20phenotype%20defined%20according%20to%20screening%5C%2Fbaseline%20characteristics.%20Study%20participation%20lasts%20up%20to%20104%5Cu00a0weeks%20post%20randomization.%20The%20primary%20objective%20is%20to%20assess%20whether%20the%20efficacy%20of%20experimental%20regimens%20at%2073%5Cu00a0weeks%20is%20non-inferior%20to%20that%20of%20the%20control.%20A%20sample%20size%20of%20324%20participants%20across%202%20arms%20affords%20at%20least%2080%25%20power%20to%20show%20the%20non-inferiority%2C%20with%20a%20one-sided%20alpha%20of%200.025%20and%20a%20non-inferiority%20margin%20of%2012%25%2C%20against%20the%20control%20in%20both%20modified%20intention-to-treat%20and%20per-protocol%20populations.%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Discussion%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20This%20internally%20controlled%20study%20of%20shortened%20treatment%20for%20pre-XDR%20TB%20will%20provide%20urgently%20needed%20data%20and%20evidence%20for%20clinical%20and%20policy%20decision-making%20around%20the%20treatment%20of%20pre-XDR%20TB%20with%20a%20four-drug%2C%20all-oral%2C%20shortened%20regimen.%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Trial%20registration%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20ClinicalTrials.Gov%20NCT03896685.%20Registered%20on%201%20April%202018%3B%20the%20record%20was%20last%20updated%20for%20study%20protocol%20version%204.3%20on%2017%20March%202023.%22%2C%22date%22%3A%222023-11-30%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1186%5C%2Fs13063-023-07701-6%22%2C%22ISSN%22%3A%221745-6215%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Ftrialsjournal.biomedcentral.com%5C%2Farticles%5C%2F10.1186%5C%2Fs13063-023-07701-6%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222023-12-31T15%3A25%3A49Z%22%7D%7D%2C%7B%22key%22%3A%229EZSBXQY%22%2C%22library%22%3A%7B%22id%22%3A1368488%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Sahal%20et%20al.%22%2C%22parsedDate%22%3A%222023-10-12%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3ESahal%2C%20M.%20R.%2C%20Senelle%2C%20G.%2C%20La%2C%20K.%2C%20Panda%2C%20T.%20W.%2C%20Taura%2C%20D.%20W.%2C%20Guyeux%2C%20C.%2C%20Cambau%2C%20E.%20and%20Sola%2C%20C.%20%282023%29.%20%3Cb%3EMycobacterium%20tuberculosis%20complex%20drug-resistance%2C%20phylogenetics%2C%20and%20evolution%20in%20Nigeria%3A%20Comparison%20with%20Ghana%20and%20Cameroon%3C%5C%2Fb%3E%20Ed.%20Rayner%2C%20S.%20PLoS%20Negl%20Trop%20Dis%20%3Ci%3E17%3C%5C%2Fi%3E%2C%20e0011619%2C%20%3Ca%20target%3D%27_blank%27%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1371%5C%2Fjournal.pntd.0011619%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1371%5C%2Fjournal.pntd.0011619%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Mycobacterium%20tuberculosis%20complex%20drug-resistance%2C%20phylogenetics%2C%20and%20evolution%20in%20Nigeria%3A%20Comparison%20with%20Ghana%20and%20Cameroon%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Muhammed%20Rabiu%22%2C%22lastName%22%3A%22Sahal%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gaetan%22%2C%22lastName%22%3A%22Senelle%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kevin%22%2C%22lastName%22%3A%22La%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Tukur%20Wada%22%2C%22lastName%22%3A%22Panda%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Dalha%20Wada%22%2C%22lastName%22%3A%22Taura%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christophe%22%2C%22lastName%22%3A%22Guyeux%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Emmanuelle%22%2C%22lastName%22%3A%22Cambau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christophe%22%2C%22lastName%22%3A%22Sola%22%7D%2C%7B%22creatorType%22%3A%22editor%22%2C%22firstName%22%3A%22Simon%22%2C%22lastName%22%3A%22Rayner%22%7D%5D%2C%22abstractNote%22%3A%22In%20this%20article%2C%20we%20provide%20an%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20in-depth%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20analysis%20on%20the%20drug-resistance%20phenotypic%20characteristics%20of%20a%20cohort%20of%20325%20tuberculosis%20and%20characterize%20by%20Whole%20Genome%20Sequencing%2024%20isolates%20from%20Nigeria%20belonging%20to%20L4%2C%20L5%20and%20L6.%20Our%20results%20suggest%20an%20alarming%20rate%20of%20drug-resistance%20of%20the%20L4.6.2.2%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Mycobacterium%20tuberculosis%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20complex%20%28MTBC%29%20lineage%20and%20a%20high%20diversity%20of%20L5.%20We%20compiled%20these%20new%20Sequence%20Read%20Archives%20%28SRAs%29%20to%20previously%20published%20ones%20from%20available%20Bioprojects%20run%20in%20Nigeria.%20We%20performed%20RAxML%20phylogenetic%20reconstructions%20of%20larger%20samples%20that%20include%20public%20NCBI%20SRAs%20from%20some%20neighboring%20countries%20%28Cameroon%2C%20Ghana%29.%20To%20confront%20phylogenetic%20reconstruction%20to%20metadata%2C%20we%20used%20a%20new%20proprietary%20database%20named%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20TB-Annotator%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20.%20We%20show%20that%20L5%20genomes%20in%20Northern%20Nigeria%20belong%20to%20new%20clades%20as%20the%20ones%20described%20until%20now%20and%20allow%20an%20update%20of%20the%20taxonomy%20of%20L5.%20In%20addition%2C%20we%20describe%20the%20L4.6.2.2%20lineage%20in%20Nigeria%2C%20Cameroon%20and%20Ghana.%20We%20provide%20computations%20on%20the%20likely%20divergence%20time%20of%20L4.6.2.2%20and%20suggest%20a%20new%20hypothesis%20concerning%20its%20origin.%20Finally%20we%20provide%20a%20short%20overview%20on%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20M%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20.%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20bovis%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20diversity%20in%20Nigeria.%20This%20study%20constitutes%20a%20baseline%20knowledge%20on%20the%20global%20genomic%20diversity%2C%20phylogeography%20and%20phylodynamics%20of%20MTBC%20in%20Nigeria%2C%20as%20well%20as%20on%20the%20natural%20history%20of%20this%20largely%20ignored%20but%20densely%20populated%20country%20of%20Africa.%20These%20results%20highlight%20the%20need%20of%20sequencing%20additional%20MTBC%20genomes%20in%20Nigeria%20and%20more%20generally%20in%20West-Africa%2C%20both%20for%20public%20health%20and%20for%20academic%20reasons.%20The%20likelihood%20of%20replacement%20of%20L5-L6%20by%20L4.6.2.2%20isolates%2C%20leave%20potentially%20little%20time%20to%20gather%20historical%20knowledge%20informative%20on%20the%20ancient%20history%20of%20tuberculosis%20in%20West-Africa.%22%2C%22date%22%3A%222023-10-12%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1371%5C%2Fjournal.pntd.0011619%22%2C%22ISSN%22%3A%221935-2735%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fdx.plos.org%5C%2F10.1371%5C%2Fjournal.pntd.0011619%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222023-12-31T15%3A29%3A26Z%22%7D%7D%2C%7B%22key%22%3A%22CUDV3QRA%22%2C%22library%22%3A%7B%22id%22%3A1368488%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22G%5Cu00fcnther%20et%20al.%22%2C%22parsedDate%22%3A%222023-05-01%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EG%26%23xFC%3Bnther%2C%20G.%2C%20Guglielmetti%2C%20L.%2C%20Leu%2C%20C.%2C%20van%20Leth%2C%20F.%20and%20Lange%2C%20C.%20%282023%29.%20%3Cb%3ERelative%20cost%20of%20multidrug-resistant%20TB%20medicines%20in%20Europe%3C%5C%2Fb%3E.%20The%20International%20Journal%20of%20Tuberculosis%20and%20Lung%20Disease%20%3Ci%3E27%3C%5C%2Fi%3E%2C%20341%26%23x2013%3B344%2C%20%3Ca%20target%3D%27_blank%27%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.5588%5C%2Fijtld.23.0026%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.5588%5C%2Fijtld.23.0026%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Relative%20cost%20of%20multidrug-resistant%20TB%20medicines%20in%20Europe%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22G.%22%2C%22lastName%22%3A%22G%5Cu00fcnther%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L.%22%2C%22lastName%22%3A%22Guglielmetti%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%22%2C%22lastName%22%3A%22Leu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22F.%22%2C%22lastName%22%3A%22van%20Leth%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%22%2C%22lastName%22%3A%22Lange%22%7D%5D%2C%22abstractNote%22%3A%22%22%2C%22date%22%3A%222023-05-01%22%2C%22language%22%3A%22%22%2C%22DOI%22%3A%2210.5588%5C%2Fijtld.23.0026%22%2C%22ISSN%22%3A%22%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222023-06-28T12%3A40%3A51Z%22%7D%7D%2C%7B%22key%22%3A%22CPD8NT5H%22%2C%22library%22%3A%7B%22id%22%3A1368488%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Campbell%20et%20al.%22%2C%22parsedDate%22%3A%222023-04-01%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3ECampbell%2C%20J.%20R.%2C%20Chan%2C%20E.%20D.%2C%20Anderson%2C%20L.%20F.%2C%20Bonnet%2C%20M.%2C%20Brode%2C%20S.%20K.%2C%20Cegielski%2C%20J.%20P.%2C%20Guglielmetti%2C%20L.%2C%20Singla%2C%20R.%2C%20Fox%2C%20G.%20J.%2C%20Skrahina%2C%20A.%2C%20Rodrigues%2C%20D.%2C%20Kuksa%2C%20L.%2C%20Viiklepp%2C%20P.%20and%20Menzies%2C%20D.%20%282023%29.%20%3Cb%3EAssociation%20of%20smoking%20and%20alcohol%20use%20with%20rifampin-resistant%20TB%20treatment%20outcomes%3C%5C%2Fb%3E.%20The%20International%20Journal%20of%20Tuberculosis%20and%20Lung%20Disease%20%3Ci%3E27%3C%5C%2Fi%3E%2C%20338%26%23x2013%3B340%2C%20%3Ca%20target%3D%27_blank%27%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.5588%5C%2Fijtld.22.0678%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.5588%5C%2Fijtld.22.0678%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Association%20of%20smoking%20and%20alcohol%20use%20with%20rifampin-resistant%20TB%20treatment%20outcomes%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%20R.%22%2C%22lastName%22%3A%22Campbell%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E.%20D.%22%2C%22lastName%22%3A%22Chan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L.%20F.%22%2C%22lastName%22%3A%22Anderson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Bonnet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%20K.%22%2C%22lastName%22%3A%22Brode%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%20P.%22%2C%22lastName%22%3A%22Cegielski%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L.%22%2C%22lastName%22%3A%22Guglielmetti%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R.%22%2C%22lastName%22%3A%22Singla%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22G.%20J.%22%2C%22lastName%22%3A%22Fox%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Skrahina%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22D.%22%2C%22lastName%22%3A%22Rodrigues%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L.%22%2C%22lastName%22%3A%22Kuksa%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P.%22%2C%22lastName%22%3A%22Viiklepp%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22D.%22%2C%22lastName%22%3A%22Menzies%22%7D%5D%2C%22abstractNote%22%3A%22%22%2C%22date%22%3A%222023-04-01%22%2C%22language%22%3A%22%22%2C%22DOI%22%3A%2210.5588%5C%2Fijtld.22.0678%22%2C%22ISSN%22%3A%22%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222023-06-28T12%3A41%3A04Z%22%7D%7D%2C%7B%22key%22%3A%22WNCRMSUT%22%2C%22library%22%3A%7B%22id%22%3A1368488%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Guthmann%20et%20al.%22%2C%22parsedDate%22%3A%222023-03-23%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EGuthmann%2C%20J.-P.%2C%20Fraisse%2C%20P.%2C%20Bonnet%2C%20I.%20and%20Robert%2C%20J.%20%282023%29.%20%3Cb%3EActive%20tuberculosis%20screening%20among%20the%20displaced%20population%20fleeing%20Ukraine%2C%20France%2C%20February%20to%20October%202022%3C%5C%2Fb%3E.%20Eurosurveillance%20%3Ci%3E28%3C%5C%2Fi%3E%2C%20%3Ca%20target%3D%27_blank%27%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.2807%5C%2F1560-7917.ES.2023.28.12.2300155%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.2807%5C%2F1560-7917.ES.2023.28.12.2300155%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Active%20tuberculosis%20screening%20among%20the%20displaced%20population%20fleeing%20Ukraine%2C%20France%2C%20February%20to%20October%202022%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Paul%22%2C%22lastName%22%3A%22Guthmann%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Philippe%22%2C%22lastName%22%3A%22Fraisse%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Isabelle%22%2C%22lastName%22%3A%22Bonnet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%5Cu00e9r%5Cu00f4me%22%2C%22lastName%22%3A%22Robert%22%7D%5D%2C%22abstractNote%22%3A%22Persons%20fleeing%20Ukraine%20since%20February%202022%20have%20potentially%20higher%20risk%20of%20tuberculosis%20%28TB%29%20vs%20all%20European%20Union%20countries.%20Interest%20of%20active%20TB%20screening%20among%20this%20population%20is%20debated%20and%20not%20widely%20adopted.%20In%20this%20screening%20intervention%20by%20a%20network%20of%20TB%20centres%20in%20France%2C%20the%20number%20needed%20to%20screen%20%28NNS%29%20was%20862%20to%20find%20one%20case.%20This%20experience%20shows%20that%20this%20strategy%20may%20be%20relevant%20for%20TB%20control%20in%20situations%20of%20massive%20displacement%2C%20similar%20to%20that%20following%20the%20Russian%20invasion.%22%2C%22date%22%3A%222023-03-23%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.2807%5C%2F1560-7917.ES.2023.28.12.2300155%22%2C%22ISSN%22%3A%221560-7917%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fwww.eurosurveillance.org%5C%2Fcontent%5C%2F10.2807%5C%2F1560-7917.ES.2023.28.12.2300155%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222023-03-27T15%3A02%3A22Z%22%7D%7D%2C%7B%22key%22%3A%22UJGH7XG2%22%2C%22library%22%3A%7B%22id%22%3A1368488%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Aubry%20and%20Veziris%22%2C%22parsedDate%22%3A%222023-03-01%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EAubry%2C%20A.%20and%20Veziris%2C%20N.%20%282023%29.%20%3Cb%3ELa%20tuberculose%2C%20l%26%23x2019%3Bune%20des%20plus%20anciennes%20maladies%20infectieuses%26%23x202F%3B%3A%20quelles%20avanc%26%23xE9%3Bes%20r%26%23xE9%3Bcentes%20majeures%26%23x202F%3B%3F%3C%5C%2Fb%3E%20Med%20Sci%20%28Paris%29%20%3Ci%3E39%3C%5C%2Fi%3E%2C%20203%26%23x2013%3B204%2C%20%3Ca%20target%3D%27_blank%27%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1051%5C%2Fmedsci%5C%2F2023054%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1051%5C%2Fmedsci%5C%2F2023054%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22La%20tuberculose%2C%20l%5Cu2019une%20des%20plus%20anciennes%20maladies%20infectieuses%20%3A%20quelles%20avanc%5Cu00e9es%20r%5Cu00e9centes%20majeures%20%3F%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alexandra%22%2C%22lastName%22%3A%22Aubry%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nicolas%22%2C%22lastName%22%3A%22Veziris%22%7D%5D%2C%22abstractNote%22%3A%22m%26eacute%3Bdecine%5C%2Fsciences%20%28M%5C%2FS%29%2C%20revue%20internationale%20dans%20le%20domaine%20de%20la%20recherche%20biologique%2C%20m%26eacute%3Bdicale%20et%20en%20sant%26eacute%3B%22%2C%22date%22%3A%222023%5C%2F03%5C%2F01%22%2C%22language%22%3A%22fr%22%2C%22DOI%22%3A%2210.1051%5C%2Fmedsci%5C%2F2023054%22%2C%22ISSN%22%3A%220767-0974%2C%201958-5381%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fwww.medecinesciences.org%5C%2Farticles%5C%2Fmedsci%5C%2Fabs%5C%2F2023%5C%2F03%5C%2Fmsc230068%5C%2Fmsc230068.html%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222023-06-28T12%3A27%3A00Z%22%7D%7D%2C%7B%22key%22%3A%22GXEAIVT5%22%2C%22library%22%3A%7B%22id%22%3A1368488%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Masini%20et%20al.%22%2C%22parsedDate%22%3A%222023-03%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EMasini%2C%20T.%2C%20Furin%2C%20J.%2C%20Udwadia%2C%20Z.%20and%20Guglielmetti%2C%20L.%20%282023%29.%20%3Cb%3EOptimal%20management%20of%20drug-resistant%20tuberculosis%3A%20Can%20India%20lead%20the%20way%3F%3C%5C%2Fb%3E%20Indian%20Journal%20of%20Medical%20Research%20%3Ci%3E157%3C%5C%2Fi%3E%2C%20220%2C%20%3Ca%20target%3D%27_blank%27%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.4103%5C%2Fijmr.ijmr_300_23%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.4103%5C%2Fijmr.ijmr_300_23%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Optimal%20management%20of%20drug-resistant%20tuberculosis%3A%20Can%20India%20lead%20the%20way%3F%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Tiziana%22%2C%22lastName%22%3A%22Masini%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jennifer%22%2C%22lastName%22%3A%22Furin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Zarir%22%2C%22lastName%22%3A%22Udwadia%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lorenzo%22%2C%22lastName%22%3A%22Guglielmetti%22%7D%5D%2C%22abstractNote%22%3A%22An%20abstract%20is%20unavailable.%22%2C%22date%22%3A%22Feb-Mar%202023%22%2C%22language%22%3A%22en-US%22%2C%22DOI%22%3A%2210.4103%5C%2Fijmr.ijmr_300_23%22%2C%22ISSN%22%3A%220971-5916%20%28Print%29%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fjournals.lww.com%5C%2Fijmr%5C%2FFulltext%5C%2F2023%5C%2F02000%5C%2FOptimal_management_of_drug_resistant_tuberculosis_.17.aspx%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222023-06-28T12%3A40%3A38Z%22%7D%7D%2C%7B%22key%22%3A%22Q5BS6SYV%22%2C%22library%22%3A%7B%22id%22%3A1368488%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Dom%5Cu00ednguez%20et%20al.%22%2C%22parsedDate%22%3A%222023-02-28%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EDom%26%23xED%3Bnguez%2C%20Jos%26%23xE9%3B%2C%20Boeree%2C%20M.%20J.%2C%20Cambau%2C%20E.%2C%20Chesov%2C%20D.%2C%20Conradie%2C%20F.%2C%20Cox%2C%20V.%2C%20Dheda%2C%20K.%2C%20Dudnyk%2C%20A.%2C%20Farhat%2C%20M.%20R.%2C%20Gagneux%2C%20S.%2C%20Grobusch%2C%20M.%20P.%2C%20Gr%26%23xF6%3Bschel%2C%20M.%20I.%2C%20Guglielmetti%2C%20L.%2C%20Kontsevaya%2C%20I.%2C%20Lange%2C%20B.%2C%20van%20Leth%2C%20F.%2C%20Lienhardt%2C%20C.%2C%20Mandalakas%2C%20Anna%20M%2C%20Maurer%2C%20F.%20P.%2C%20Merker%2C%20M.%2C%20Miotto%2C%20P.%2C%20Molina-Moya%2C%20B.%2C%20Morel%2C%20F.%2C%20Niemann%2C%20S.%2C%20Veziris%2C%20N.%2C%20Whitelaw%2C%20A.%2C%20Horsburgh%2C%20Charles%20R%2C%20Lange%2C%20C.%2C%20Dom%26%23xED%3Bnguez%2C%20Jose%2C%20Boeree%2C%20M.%20J.%2C%20Cambau%2C%20E.%2C%20Chesov%2C%20D.%2C%20Conradie%2C%20F.%2C%20Cox%2C%20V.%2C%20Dheda%2C%20K.%2C%20Dudnyk%2C%20A.%2C%20Farhat%2C%20M.%20R.%2C%20Gagneux%2C%20S.%2C%20Grobusch%2C%20M.%20P.%2C%20Gr%26%23xF6%3Bschel%2C%20M.%20I.%2C%20Guglielmetti%2C%20L.%2C%20Kontsevaya%2C%20I.%2C%20Lange%2C%20B.%2C%20van%20Leth%2C%20F.%2C%20Lienhardt%2C%20C.%2C%20Mandalakas%2C%20Anna%20Maria%2C%20Maurer%2C%20F.%2C%20Merker%2C%20M.%2C%20Miotto%2C%20P.%2C%20Molina-Moya%2C%20B.%2C%20Morel%2C%20F.%2C%20Niemann%2C%20S.%2C%20Veziris%2C%20N.%2C%20Whitelaw%2C%20A.%2C%20Horsburgh%2C%20Charles%20Robert%20and%20Lange%2C%20C.%20%282023%29.%20%3Cb%3EClinical%20implications%20of%20molecular%20drug%20resistance%20testing%20for%20Mycobacterium%20tuberculosis%3A%20a%202023%20TBnet%5C%2FRESIST-TB%20consensus%20statement%3C%5C%2Fb%3E.%20The%20Lancet%20Infectious%20Diseases%2C%20%3Ca%20target%3D%27_blank%27%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2FS1473-3099%2822%2900875-1%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2FS1473-3099%2822%2900875-1%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Clinical%20implications%20of%20molecular%20drug%20resistance%20testing%20for%20Mycobacterium%20tuberculosis%3A%20a%202023%20TBnet%5C%2FRESIST-TB%20consensus%20statement%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jos%5Cu00e9%22%2C%22lastName%22%3A%22Dom%5Cu00ednguez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Martin%20J%22%2C%22lastName%22%3A%22Boeree%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Emmanuelle%22%2C%22lastName%22%3A%22Cambau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Dumitru%22%2C%22lastName%22%3A%22Chesov%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Francesca%22%2C%22lastName%22%3A%22Conradie%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Vivian%22%2C%22lastName%22%3A%22Cox%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Keertan%22%2C%22lastName%22%3A%22Dheda%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Andrii%22%2C%22lastName%22%3A%22Dudnyk%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Maha%20R%22%2C%22lastName%22%3A%22Farhat%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sebastien%22%2C%22lastName%22%3A%22Gagneux%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Martin%20P%22%2C%22lastName%22%3A%22Grobusch%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Matthias%20I%22%2C%22lastName%22%3A%22Gr%5Cu00f6schel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lorenzo%22%2C%22lastName%22%3A%22Guglielmetti%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Irina%22%2C%22lastName%22%3A%22Kontsevaya%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Berit%22%2C%22lastName%22%3A%22Lange%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Frank%22%2C%22lastName%22%3A%22van%20Leth%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christian%22%2C%22lastName%22%3A%22Lienhardt%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anna%20M%22%2C%22lastName%22%3A%22Mandalakas%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Florian%20P%22%2C%22lastName%22%3A%22Maurer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Matthias%22%2C%22lastName%22%3A%22Merker%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Paolo%22%2C%22lastName%22%3A%22Miotto%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Barbara%22%2C%22lastName%22%3A%22Molina-Moya%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Florence%22%2C%22lastName%22%3A%22Morel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Stefan%22%2C%22lastName%22%3A%22Niemann%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nicolas%22%2C%22lastName%22%3A%22Veziris%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Andrew%22%2C%22lastName%22%3A%22Whitelaw%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Charles%20R%22%2C%22lastName%22%3A%22Horsburgh%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christoph%22%2C%22lastName%22%3A%22Lange%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jose%22%2C%22lastName%22%3A%22Dom%5Cu00ednguez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Martin%20J.%22%2C%22lastName%22%3A%22Boeree%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Emmanuelle%22%2C%22lastName%22%3A%22Cambau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Dumitru%22%2C%22lastName%22%3A%22Chesov%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Francesca%22%2C%22lastName%22%3A%22Conradie%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Vivian%22%2C%22lastName%22%3A%22Cox%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Keertan%22%2C%22lastName%22%3A%22Dheda%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Andrii%22%2C%22lastName%22%3A%22Dudnyk%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Maha%20R.%22%2C%22lastName%22%3A%22Farhat%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sebastien%22%2C%22lastName%22%3A%22Gagneux%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Martin%20P.%22%2C%22lastName%22%3A%22Grobusch%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Matthias%20I.%22%2C%22lastName%22%3A%22Gr%5Cu00f6schel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lorenzo%22%2C%22lastName%22%3A%22Guglielmetti%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Irina%22%2C%22lastName%22%3A%22Kontsevaya%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Berit%22%2C%22lastName%22%3A%22Lange%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Frank%22%2C%22lastName%22%3A%22van%20Leth%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christian%22%2C%22lastName%22%3A%22Lienhardt%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anna%20Maria%22%2C%22lastName%22%3A%22Mandalakas%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Florian%22%2C%22lastName%22%3A%22Maurer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Matthias%22%2C%22lastName%22%3A%22Merker%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Paolo%22%2C%22lastName%22%3A%22Miotto%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Barbara%22%2C%22lastName%22%3A%22Molina-Moya%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Florence%22%2C%22lastName%22%3A%22Morel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Stefan%22%2C%22lastName%22%3A%22Niemann%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nicolas%22%2C%22lastName%22%3A%22Veziris%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Andrew%22%2C%22lastName%22%3A%22Whitelaw%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Charles%20Robert%22%2C%22lastName%22%3A%22Horsburgh%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christoph%22%2C%22lastName%22%3A%22Lange%22%7D%5D%2C%22abstractNote%22%3A%22Drug-resistant%20tuberculosis%20is%20a%20substantial%20health-care%20concern%20worldwide.%20Despite%20culture-based%20methods%20being%20considered%20the%20gold%20standard%20for%20drug%20susceptibility%20testing%2C%20molecular%20methods%20provide%20rapid%20information%20about%20the%20Mycobacterium%20tuberculosis%20mutations%20associated%20with%20resistance%20to%20anti-tuberculosis%20drugs.%20This%20consensus%20document%20was%20developed%20on%20the%20basis%20of%20a%20comprehensive%20literature%20search%2C%20by%20the%20TBnet%20and%20RESIST-TB%20networks%2C%20about%20reporting%20standards%20for%20the%20clinical%20use%20of%20molecular%20drug%20susceptibility%20testing.%20Review%20and%20the%20search%20for%20evidence%20included%20hand-searching%20journals%20and%20searching%20electronic%20databases.%20The%20panel%20identified%20studies%20that%20linked%20mutations%20in%20genomic%20regions%20of%20M%20tuberculosis%20with%20treatment%20outcome%20data.%20Implementation%20of%20molecular%20testing%20for%20the%20prediction%20of%20drug%20resistance%20in%20M%20tuberculosis%20is%20key.%20Detection%20of%20mutations%20in%20clinical%20isolates%20has%20implications%20for%20the%20clinical%20management%20of%20patients%20with%20multidrug-resistant%20or%20rifampicin-resistant%20tuberculosis%2C%20especially%20in%20situations%20when%20phenotypic%20drug%20susceptibility%20testing%20is%20not%20available.%20A%20multidisciplinary%20team%20including%20clinicians%2C%20microbiologists%2C%20and%20laboratory%20scientists%20reached%20a%20consensus%20on%20key%20questions%20relevant%20to%20molecular%20prediction%20of%20drug%20susceptibility%20or%20resistance%20to%20M%20tuberculosis%2C%20and%20their%20implications%20for%20clinical%20practice.%20This%20consensus%20document%20should%20help%20clinicians%20in%20the%20management%20of%20patients%20with%20tuberculosis%2C%20providing%20guidance%20for%20the%20design%20of%20treatment%20regimens%20and%20optimising%20outcomes.%22%2C%22date%22%3A%222023-02-28%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1016%5C%2FS1473-3099%2822%2900875-1%22%2C%22ISSN%22%3A%221473-3099%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fwww.sciencedirect.com%5C%2Fscience%5C%2Farticle%5C%2Fpii%5C%2FS1473309922008751%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222023-03-10T14%3A55%3A36Z%22%7D%7D%2C%7B%22key%22%3A%22CVEKMV76%22%2C%22library%22%3A%7B%22id%22%3A1368488%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Barbier%20et%20al.%22%2C%22parsedDate%22%3A%222023-02-01%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EBarbier%2C%20E.%2C%20Fouchet%2C%20T.%2C%20Hartmann%2C%20A.%2C%20Cambau%2C%20E.%2C%20Mougari%2C%20F.%2C%20Dubois%2C%20C.%2C%20Lubetzki%2C%20M.%20and%20Rochelet%2C%20M.%20%282023%29.%20%3Cb%3ERapid%20electrochemical%20detection%20of%20Mycobacterium%20tuberculosis%20in%20sputum%20by%20measuring%20Ag85%20activity%20with%20disposable%20carbon%20sensors%3C%5C%2Fb%3E.%20Talanta%20%3Ci%3E253%3C%5C%2Fi%3E%2C%20123927%2C%20%3Ca%20target%3D%27_blank%27%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.talanta.2022.123927%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.talanta.2022.123927%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Rapid%20electrochemical%20detection%20of%20Mycobacterium%20tuberculosis%20in%20sputum%20by%20measuring%20Ag85%20activity%20with%20disposable%20carbon%20sensors%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Elodie%22%2C%22lastName%22%3A%22Barbier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Th%5Cu00e9o%22%2C%22lastName%22%3A%22Fouchet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alain%22%2C%22lastName%22%3A%22Hartmann%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Emmanuelle%22%2C%22lastName%22%3A%22Cambau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Faiza%22%2C%22lastName%22%3A%22Mougari%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Cl%5Cu00e9ment%22%2C%22lastName%22%3A%22Dubois%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Maurice%22%2C%22lastName%22%3A%22Lubetzki%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Murielle%22%2C%22lastName%22%3A%22Rochelet%22%7D%5D%2C%22abstractNote%22%3A%22An%20electrochemical%20assay%20for%20the%20detection%20of%20the%20enzymatic%20activity%20of%20the%20antigen%2085%20%28Ag85%29%20tuberculosis%20%28TB%29%20biomarker%20was%20developed%20and%20evaluated%20for%20the%20qualitative%20detection%20of%20Mycobacterium%20tuberculosis%20in%20decontaminated%20sputum.%20For%20this%20purpose%2C%20the%20electroactive%20properties%20of%20both%20synthetic%20p-aminophenyl-6-O-octanoyl-3-d-glucopyranoside%20%28p-APOG%29%20substrate%20and%20p-aminophenyl-6-3-d-glucopyranoside%20%28p-APG%29%20product%20released%20after%20the%20removal%20of%20the%20octanoyl%20fatty%20acid%20by%20the%20Ag85%20were%20investigated%20with%20disposable%20carbon%20screen-printed%20electrodes%20by%20cyclic%20voltammetry.%20Since%20specific%20anodic%20responses%20were%20obtained%20for%20the%20p-APOG%20substrate%20and%20the%20p-APG%20product%2C%20the%20intensity%20of%20the%20oxidation%20peak%20of%20the%20p-APG%20%28E%5Cu00a0%3D%5Cu00a0%2B%200.35%5Cu00a0V%20vs.%20Ag%5C%2FAgCl%29%20was%20selected%20as%20the%20analytical%20response%20for%20the%20detection%20of%20the%20Ag85%20acyltransferase%20activity.%20Once%20the%20proof%20of%20concept%20of%20the%20Ag85%20electrochemical%20assay%20was%20validated%20with%20a%20commercially-available%20Ag85B%20protein%2C%20its%20specificity%20was%20further%20assessed%20by%20analyzing%20pure%20cultures%20of%20various%20bacteria%20including%20tuberculous%20and%20non-tuberculous%20mycobacteria%20as%20well%20as%20different%20species%20found%20in%20patients%27%20sputum.%20Finally%2C%20with%20a%20specificity%20of%2078%25%20and%20a%20sensitivity%20of%2089%25%2C%20the%20method%20was%20successfully%20compared%20to%20microscopy%20and%20culture%20routine%20tests%20for%20TB%20testing%20in%2036%20frozen%20fluidized%20and%20decontaminated%20sputum.%20This%20suggests%20that%20owing%20to%20its%20convenience%2C%20rapidity%2C%20low-cost%20and%20portability%2C%20the%20reported%20Ag85%20electrochemical%20assay%20is%20a%20promising%20tool%20to%20screen%20patients%20for%20TB.%22%2C%22date%22%3A%222023-02-01%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1016%5C%2Fj.talanta.2022.123927%22%2C%22ISSN%22%3A%220039-9140%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fwww.sciencedirect.com%5C%2Fscience%5C%2Farticle%5C%2Fpii%5C%2FS0039914022007238%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222022-12-28T16%3A13%3A06Z%22%7D%7D%2C%7B%22key%22%3A%226W5JQ546%22%2C%22library%22%3A%7B%22id%22%3A1368488%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Khan%20and%20Guglielmetti%22%2C%22parsedDate%22%3A%222023-01-01%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EKhan%2C%20U.%20and%20Guglielmetti%2C%20L.%20%282023%29.%20%3Cb%3ETailored%20TPT%20for%20drug-resistant%20TB%20-%20promoting%20equity%20and%20access%20to%20optimal%20care%3C%5C%2Fb%3E.%20Int%20J%20Tuberc%20Lung%20Dis%20%3Ci%3E27%3C%5C%2Fi%3E%2C%2089b%26%23x2013%3B890%2C%20%3Ca%20target%3D%27_blank%27%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.5588%5C%2Fijtld.22.0538%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.5588%5C%2Fijtld.22.0538%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Tailored%20TPT%20for%20drug-resistant%20TB%20-%20promoting%20equity%20and%20access%20to%20optimal%20care%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22U.%22%2C%22lastName%22%3A%22Khan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L.%22%2C%22lastName%22%3A%22Guglielmetti%22%7D%5D%2C%22abstractNote%22%3A%22%22%2C%22date%22%3A%222023-01-01%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.5588%5C%2Fijtld.22.0538%22%2C%22ISSN%22%3A%221815-7920%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222023-03-10T14%3A58%3A55Z%22%7D%7D%2C%7B%22key%22%3A%2227ERGIBY%22%2C%22library%22%3A%7B%22id%22%3A1368488%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22G%5Cu00fcnther%20et%20al.%22%2C%22parsedDate%22%3A%222023-01-01%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EG%26%23xFC%3Bnther%2C%20G.%2C%20Guglielmetti%2C%20L.%2C%20Leu%2C%20C.%2C%20Lange%2C%20C.%2C%20van%20Leth%2C%20F.%2C%20Hasan%20Hafizi%2C%20Khachatryan%2C%20N.%2C%20Aroyan%2C%20H.%2C%20Kabasakalyan%2C%20E.%2C%20Knappik%2C%20M.%2C%20Skrahina%2C%20A.%2C%20Klimuk%2C%20D.%2C%20Nikolenka%2C%20A.%2C%20Muylle%2C%20I.%2C%20Milanov%2C%20V.%2C%20Velkovska%2C%20D.%2C%20Tarinska%2C%20N.%2C%20Bachiyska%2C%20E.%2C%20Jankovic%2C%20M.%2C%20Pieridou%2C%20D.%2C%20Adamide%2C%20T.%2C%20Nicolaou%2C%20N.%2C%20Vasakova%2C%20M.%2C%20Sukholytka%2C%20M.%2C%20Kopeck%26%23xE0%3B%2C%20E.%2C%20Folkvardsen%2C%20D.%20B.%2C%20Svensson%2C%20E.%2C%20Danilovits%2C%20M.%2C%20Kummik%2C%20T.%2C%20Vasankari%2C%20T.%2C%20Fr%26%23xE9%3Bchet-Jachym%2C%20M.%2C%20Nahmiash%2C%20A.%2C%20Togonidze%2C%20T.%2C%20Avaliani%2C%20Z.%2C%20Kinkladze%2C%20I.%2C%20Aspindzelashvili%2C%20R.%2C%20Bichashvili%2C%20T.%2C%20Losaberidze%2C%20G.%2C%20Merabishvili%2C%20T.%2C%20Kalsdorf%2C%20B.%2C%20Manika%2C%20K.%2C%20Tsiakitzis%2C%20K.%2C%20Bakos%2C%20A.%2C%20%26%23xC6%3Bgisd%26%23xF3%3Bttir%2C%20T.%20R.%2C%20Michelsen%2C%20G.%20S.%2C%20Karlsd%26%23xF3%3Bttir%2C%20K.%2C%20McLaughlin%2C%20A.-M.%2C%20Fitzgibbon%2C%20M.%2C%20Chemtob%2C%20D.%2C%20Codecasa%2C%20L.%20R.%2C%20Ferrarese%2C%20M.%2C%20Torri%2C%20S.%2C%20Gjocaj%2C%20M.%2C%20Kuksa%2C%20L.%2C%20Davidaviciene%2C%20E.%2C%20Wirtz%2C%20G.%2C%20Perrin%2C%20M.%2C%20Asciak%2C%20A.%20P.%2C%20Chesov%2C%20D.%2C%20de%20Lange%2C%20W.%2C%20Akkerman%2C%20O.%2C%20Poposka%2C%20B.%20I.%2C%20Mack%2C%20U.%2C%20Jensenius%2C%20M.%2C%20Kvalvik%2C%20L.%2C%20Mengshoel%2C%20A.%20T.%2C%20Kruczak%2C%20K.%2C%20Duarte%2C%20R.%2C%20Ribeiro%2C%20N.%2C%20Ibraim%2C%20E.%2C%20Kaluzhenina%2C%20A.%2C%20Barkanova%2C%20O.%2C%20Pesut%2C%20D.%2C%20Solovic%2C%20I.%2C%20Svetina%2C%20P.%2C%20Souza-Galv%26%23xE3%3Bo%2C%20M.-L.%20de%2C%20Millet%2C%20J.-P.%2C%20Casas%2C%20X.%2C%20Vives%2C%20M.%2C%20Bruchfeld%2C%20J.%2C%20Dalemo%2C%20P.%2C%20Jonsson%2C%20J.%2C%20Aeschbacher%2C%20K.%2C%20Keller%2C%20P.%2C%20%26%23xD6%3Bzkara%2C%20S.%2C%20Tiberi%2C%20S.%2C%20Chen%2C%20C.%2C%20Terleeva%2C%20Y.%20and%20Dudnyk%2C%20A.%20%282023%29.%20%3Cb%3EAvailability%20and%20costs%20of%20medicines%20for%20the%20treatment%20of%20tuberculosis%20in%20Europe%3C%5C%2Fb%3E.%20Clinical%20Microbiology%20and%20Infection%20%3Ci%3E29%3C%5C%2Fi%3E%2C%2077%26%23x2013%3B84%2C%20%3Ca%20target%3D%27_blank%27%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.cmi.2022.07.026%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.cmi.2022.07.026%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Availability%20and%20costs%20of%20medicines%20for%20the%20treatment%20of%20tuberculosis%20in%20Europe%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gunar%22%2C%22lastName%22%3A%22G%5Cu00fcnther%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lorenzo%22%2C%22lastName%22%3A%22Guglielmetti%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Claude%22%2C%22lastName%22%3A%22Leu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christoph%22%2C%22lastName%22%3A%22Lange%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Frank%22%2C%22lastName%22%3A%22van%20Leth%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22name%22%3A%22Hasan%20Hafizi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Naira%22%2C%22lastName%22%3A%22Khachatryan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Harut%22%2C%22lastName%22%3A%22Aroyan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eduard%22%2C%22lastName%22%3A%22Kabasakalyan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Michael%22%2C%22lastName%22%3A%22Knappik%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alena%22%2C%22lastName%22%3A%22Skrahina%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Dzmitry%22%2C%22lastName%22%3A%22Klimuk%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alena%22%2C%22lastName%22%3A%22Nikolenka%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Inge%22%2C%22lastName%22%3A%22Muylle%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Vladimir%22%2C%22lastName%22%3A%22Milanov%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Desislava%22%2C%22lastName%22%3A%22Velkovska%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Neli%22%2C%22lastName%22%3A%22Tarinska%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Elizabeta%22%2C%22lastName%22%3A%22Bachiyska%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mateja%22%2C%22lastName%22%3A%22Jankovic%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Despo%22%2C%22lastName%22%3A%22Pieridou%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Tonia%22%2C%22lastName%22%3A%22Adamide%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nicos%22%2C%22lastName%22%3A%22Nicolaou%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Martina%22%2C%22lastName%22%3A%22Vasakova%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mariia%22%2C%22lastName%22%3A%22Sukholytka%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Emilia%22%2C%22lastName%22%3A%22Kopeck%5Cu00e0%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Dorte%20Bek%22%2C%22lastName%22%3A%22Folkvardsen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Erik%22%2C%22lastName%22%3A%22Svensson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Manfred%22%2C%22lastName%22%3A%22Danilovits%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Tiina%22%2C%22lastName%22%3A%22Kummik%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Tuula%22%2C%22lastName%22%3A%22Vasankari%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mathilde%22%2C%22lastName%22%3A%22Fr%5Cu00e9chet-Jachym%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Audrey%22%2C%22lastName%22%3A%22Nahmiash%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Tamar%22%2C%22lastName%22%3A%22Togonidze%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Zaza%22%2C%22lastName%22%3A%22Avaliani%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Inga%22%2C%22lastName%22%3A%22Kinkladze%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Rusudan%22%2C%22lastName%22%3A%22Aspindzelashvili%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Teona%22%2C%22lastName%22%3A%22Bichashvili%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gulnazi%22%2C%22lastName%22%3A%22Losaberidze%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Tsitsino%22%2C%22lastName%22%3A%22Merabishvili%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Barbara%22%2C%22lastName%22%3A%22Kalsdorf%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Katerina%22%2C%22lastName%22%3A%22Manika%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Karyofyllis%22%2C%22lastName%22%3A%22Tsiakitzis%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Agnes%22%2C%22lastName%22%3A%22Bakos%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Tinna%20R%5Cu00e1n%22%2C%22lastName%22%3A%22%5Cu00c6gisd%5Cu00f3ttir%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gu%5Cu00f0r%5Cu00fan%20Svanhv%5Cu00edt%22%2C%22lastName%22%3A%22Michelsen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Krist%5Cu00edn%22%2C%22lastName%22%3A%22Karlsd%5Cu00f3ttir%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anne-Marie%22%2C%22lastName%22%3A%22McLaughlin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Margaret%22%2C%22lastName%22%3A%22Fitzgibbon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Daniel%22%2C%22lastName%22%3A%22Chemtob%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Luigi%20R.%22%2C%22lastName%22%3A%22Codecasa%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Maurizio%22%2C%22lastName%22%3A%22Ferrarese%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Stefania%22%2C%22lastName%22%3A%22Torri%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Majlinda%22%2C%22lastName%22%3A%22Gjocaj%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Liga%22%2C%22lastName%22%3A%22Kuksa%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Edita%22%2C%22lastName%22%3A%22Davidaviciene%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gil%22%2C%22lastName%22%3A%22Wirtz%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Monique%22%2C%22lastName%22%3A%22Perrin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Analita%20Pace%22%2C%22lastName%22%3A%22Asciak%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Dumitri%22%2C%22lastName%22%3A%22Chesov%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Wiel%22%2C%22lastName%22%3A%22de%20Lange%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Onno%22%2C%22lastName%22%3A%22Akkerman%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Biljana%20Ilievska%22%2C%22lastName%22%3A%22Poposka%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ulrich%22%2C%22lastName%22%3A%22Mack%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mogens%22%2C%22lastName%22%3A%22Jensenius%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lajla%22%2C%22lastName%22%3A%22Kvalvik%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anne%20Torunn%22%2C%22lastName%22%3A%22Mengshoel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Katarzyna%22%2C%22lastName%22%3A%22Kruczak%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Raquel%22%2C%22lastName%22%3A%22Duarte%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nadine%22%2C%22lastName%22%3A%22Ribeiro%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Elmira%22%2C%22lastName%22%3A%22Ibraim%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anna%22%2C%22lastName%22%3A%22Kaluzhenina%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Olga%22%2C%22lastName%22%3A%22Barkanova%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Dragica%22%2C%22lastName%22%3A%22Pesut%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ivan%22%2C%22lastName%22%3A%22Solovic%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Petra%22%2C%22lastName%22%3A%22Svetina%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Maria-Luiza%20de%22%2C%22lastName%22%3A%22Souza-Galv%5Cu00e3o%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Joan-Pau%22%2C%22lastName%22%3A%22Millet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Xavi%22%2C%22lastName%22%3A%22Casas%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Montserrat%22%2C%22lastName%22%3A%22Vives%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Judith%22%2C%22lastName%22%3A%22Bruchfeld%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Paulina%22%2C%22lastName%22%3A%22Dalemo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jerker%22%2C%22lastName%22%3A%22Jonsson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Katrin%22%2C%22lastName%22%3A%22Aeschbacher%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Peter%22%2C%22lastName%22%3A%22Keller%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Seref%22%2C%22lastName%22%3A%22%5Cu00d6zkara%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Simon%22%2C%22lastName%22%3A%22Tiberi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christabelle%22%2C%22lastName%22%3A%22Chen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yana%22%2C%22lastName%22%3A%22Terleeva%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Andrii%22%2C%22lastName%22%3A%22Dudnyk%22%7D%5D%2C%22abstractNote%22%3A%22Objectives%5CnTo%20evaluate%20the%20access%20to%20comprehensive%20diagnostics%20and%20novel%20antituberculosis%20medicines%20in%20European%20countries.%5CnMethods%5CnWe%20investigated%20the%20access%20to%20genotypic%20and%20phenotypic%20Mycobacterium%20tuberculosis%20drug%20susceptibility%20testing%20and%20the%20availability%20of%20antituberculosis%20drugs%20and%20calculated%20the%20cost%20of%20drugs%20and%20treatment%20regimens%20at%20major%20tuberculosis%20treatment%20centres%20in%20countries%20of%20the%20WHO%20European%20region%20where%20rates%20of%20drug-resistant%20tuberculosis%20are%20the%20highest%20among%20all%20WHO%20regions.%20Results%20were%20stratified%20by%20middle-income%20and%20high-income%20countries.%5CnResults%5CnOverall%2C%2043%20treatment%20centres%20from%2043%20countries%20participated%20in%20the%20study.%20For%20WHO%20group%20A%20drugs%2C%20the%20frequency%20of%20countries%20with%20the%20availability%20of%20phenotypic%20drug%20susceptibility%20testing%20was%20as%20follows%3A%20%28a%29%2075%25%20%2830%5C%2F40%29%20for%20levofloxacin%2C%20%28b%29%2082%25%20%2833%5C%2F40%29%20for%20moxifloxacin%2C%20%28c%29%2048%25%20%2819%5C%2F40%29%20for%20bedaquiline%2C%20and%20%28d%29%2072%25%20%2829%5C%2F40%29%20for%20linezolid.%20Overall%2C%20of%20the%2043%20countries%2C%2036%20%2884%25%29%20and%2024%20%2856%25%29%20countries%20had%20access%20to%20bedaquiline%20and%20delamanid%2C%20respectively%2C%20whereas%20only%206%20%2814%25%29%20countries%20had%20access%20to%20rifapentine.%20The%20treatment%20of%20patients%20with%20extensively%20drug-resistant%20tuberculosis%20with%20a%20regimen%20including%20a%20carbapenem%20was%20available%20only%20in%2017%20%2840%25%29%20of%20the%2043%20countries.%20The%20median%20cost%20of%20regimens%20for%20drug-susceptible%20tuberculosis%2C%20multidrug-resistant%5C%2Frifampicin-resistant%20tuberculosis%20%28shorter%20regimen%2C%20including%20bedaquiline%20for%206%5Cu00a0months%29%2C%20and%20extensively%20drug-resistant%20tuberculosis%20%28including%20bedaquiline%2C%20delamanid%2C%20and%20a%20carbapenem%29%20were%20%5Cu20ac44%20%28minimum%5Cu2013maximum%2C%20%5Cu20ac15%5Cu2013152%29%2C%20%5Cu20ac764%20%28minimum%5Cu2013maximum%2C%20%5Cu20ac542%5Cu201315152%29%2C%20and%20%5Cu20ac8709%20%28minimum%5Cu2013maximum%2C%20%5Cu20ac7965%5Cu201311759%29%20in%20middle-income%20countries%20%28n%5Cu00a0%3D%5Cu00a012%29%20and%20%5Cu20ac280%20%28minimum%5Cu2013maximum%2C%20%5Cu20ac78%5Cu20131084%29%2C%20%5Cu20ac29765%20%28minimum%5Cu2013maximum%2C%20%5Cu20ac11116%5Cu201340584%29%2C%20and%20%5Cu20ac217591%20%28minimum%5Cu2013maximum%2C%20%5Cu20ac82827%5Cu2013320146%29%20in%20high-income%20countries%20%28n%5Cu00a0%3D%5Cu00a029%29%2C%20respectively.%5CnDiscussion%5CnIn%20countries%20of%20the%20WHO%20European%20region%2C%20there%20is%20a%20widespread%20lack%20of%20drug%20susceptibility%20testing%20capacity%20to%20new%20and%20repurposed%20antituberculosis%20drugs%2C%20lack%20of%20access%20to%20essential%20medications%20in%20several%20countries%2C%20and%20a%20high%20cost%20for%20the%20treatment%20of%20drug-resistant%20tuberculosis.%22%2C%22date%22%3A%222023-01-01%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1016%5C%2Fj.cmi.2022.07.026%22%2C%22ISSN%22%3A%221198-743X%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fwww.sciencedirect.com%5C%2Fscience%5C%2Farticle%5C%2Fpii%5C%2FS1198743X22003949%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222022-12-28T16%3A07%3A09Z%22%7D%7D%2C%7B%22key%22%3A%22KW8CU9JI%22%2C%22library%22%3A%7B%22id%22%3A1368488%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Senelle%20et%20al.%22%2C%22parsedDate%22%3A%222023%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3ESenelle%2C%20G.%2C%20Sahal%2C%20M.%20R.%2C%20La%2C%20K.%2C%20Billard-Pomares%2C%20T.%2C%20Marin%2C%20J.%2C%20Mougari%2C%20F.%2C%20Bridier-Nahmias%2C%20A.%2C%20Carbonnelle%2C%20E.%2C%20Cambau%2C%20E.%2C%20Refr%26%23xE9%3Bgier%2C%20G.%2C%20Guyeux%2C%20C.%20and%20Sola%2C%20C.%20%282023%29.%20%3Cb%3ETowards%20the%20reconstruction%20of%20a%20global%20TB%20history%20using%20a%20new%20pipeline%20%26%23x201C%3BTB-Annotator%5C%22%3C%5C%2Fb%3E.%20Tuberculosis%20%3Ci%3E143%3C%5C%2Fi%3E%2C%20102376%2C%20%3Ca%20target%3D%27_blank%27%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.tube.2023.102376%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.tube.2023.102376%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Towards%20the%20reconstruction%20of%20a%20global%20TB%20history%20using%20a%20new%20pipeline%20%5Cu201cTB-Annotator%5C%22%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gaetan%22%2C%22lastName%22%3A%22Senelle%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Muhammed%20Rabiu%22%2C%22lastName%22%3A%22Sahal%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kevin%22%2C%22lastName%22%3A%22La%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Typhaine%22%2C%22lastName%22%3A%22Billard-Pomares%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Julie%22%2C%22lastName%22%3A%22Marin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Faiza%22%2C%22lastName%22%3A%22Mougari%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Antoine%22%2C%22lastName%22%3A%22Bridier-Nahmias%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Etienne%22%2C%22lastName%22%3A%22Carbonnelle%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Emmanuelle%22%2C%22lastName%22%3A%22Cambau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Guislaine%22%2C%22lastName%22%3A%22Refr%5Cu00e9gier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christophe%22%2C%22lastName%22%3A%22Guyeux%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christophe%22%2C%22lastName%22%3A%22Sola%22%7D%5D%2C%22abstractNote%22%3A%22%22%2C%22date%22%3A%2212%5C%2F2023%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1016%5C%2Fj.tube.2023.102376%22%2C%22ISSN%22%3A%2214729792%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Flinkinghub.elsevier.com%5C%2Fretrieve%5C%2Fpii%5C%2FS1472979223000744%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222023-12-31T15%3A27%3A25Z%22%7D%7D%2C%7B%22key%22%3A%22KN8HXK6R%22%2C%22library%22%3A%7B%22id%22%3A1368488%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Motta%20et%20al.%22%2C%22parsedDate%22%3A%222023%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EMotta%2C%20I.%2C%20Boeree%2C%20M.%2C%20Chesov%2C%20D.%2C%20Dheda%2C%20K.%2C%20G%26%23xFC%3Bnther%2C%20G.%2C%20Horsburgh%2C%20C.%20R.%2C%20Kherabi%2C%20Y.%2C%20Lange%2C%20C.%2C%20Lienhardt%2C%20C.%2C%20McIlleron%2C%20H.%20M.%2C%20Paton%2C%20N.%20I.%2C%20Stagg%2C%20H.%20R.%2C%20Thwaites%2C%20G.%2C%20Udwadia%2C%20Z.%2C%20Van%20Crevel%2C%20R.%2C%20Vel%26%23xE1%3Bsquez%2C%20G.%20E.%2C%20Wilkinson%2C%20R.%20J.%2C%20Guglielmetti%2C%20L.%2C%20Motta%2C%20I.%2C%20Kherabi%2C%20Y.%2C%20Van%20Crevel%2C%20R.%20and%20Guglielmetti%2C%20L.%20%282023%29.%20%3Cb%3ERecent%20advances%20in%20the%20treatment%20of%20tuberculosis%3C%5C%2Fb%3E.%20Clinical%20Microbiology%20and%20Infection%20S1198743X23003397%2C%20%3Ca%20target%3D%27_blank%27%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.cmi.2023.07.013%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.cmi.2023.07.013%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Recent%20advances%20in%20the%20treatment%20of%20tuberculosis%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ilaria%22%2C%22lastName%22%3A%22Motta%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Martin%22%2C%22lastName%22%3A%22Boeree%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Dumitru%22%2C%22lastName%22%3A%22Chesov%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Keertan%22%2C%22lastName%22%3A%22Dheda%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gunar%22%2C%22lastName%22%3A%22G%5Cu00fcnther%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Charles%20Robert%22%2C%22lastName%22%3A%22Horsburgh%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yousra%22%2C%22lastName%22%3A%22Kherabi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christoph%22%2C%22lastName%22%3A%22Lange%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christian%22%2C%22lastName%22%3A%22Lienhardt%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Helen%20M.%22%2C%22lastName%22%3A%22McIlleron%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nicholas%20I.%22%2C%22lastName%22%3A%22Paton%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Helen%20R.%22%2C%22lastName%22%3A%22Stagg%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Guy%22%2C%22lastName%22%3A%22Thwaites%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Zarir%22%2C%22lastName%22%3A%22Udwadia%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Reinout%22%2C%22lastName%22%3A%22Van%20Crevel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gustavo%20E.%22%2C%22lastName%22%3A%22Vel%5Cu00e1squez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Robert%20J.%22%2C%22lastName%22%3A%22Wilkinson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lorenzo%22%2C%22lastName%22%3A%22Guglielmetti%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ilaria%22%2C%22lastName%22%3A%22Motta%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yousra%22%2C%22lastName%22%3A%22Kherabi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Reinout%22%2C%22lastName%22%3A%22Van%20Crevel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lorenzo%22%2C%22lastName%22%3A%22Guglielmetti%22%7D%5D%2C%22abstractNote%22%3A%22%22%2C%22date%22%3A%227%5C%2F2023%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1016%5C%2Fj.cmi.2023.07.013%22%2C%22ISSN%22%3A%221198743X%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Flinkinghub.elsevier.com%5C%2Fretrieve%5C%2Fpii%5C%2FS1198743X23003397%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222023-11-13T15%3A55%3A06Z%22%7D%7D%2C%7B%22key%22%3A%22A2TD2VUD%22%2C%22library%22%3A%7B%22id%22%3A1368488%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Holmgaard%20et%20al.%22%2C%22parsedDate%22%3A%222022-11-04%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EHolmgaard%2C%20F.%20B.%2C%20Guglielmetti%2C%20L.%2C%20Lillebaek%2C%20T.%2C%20Andersen%2C%20%26%23xC5%3B.%20B.%2C%20Wejse%2C%20C.%20and%20Dahl%2C%20V.%20N.%20%282022%29.%20%3Cb%3EEfficacy%20and%20tolerability%20of%20concomitant%20use%20of%20bedaquiline%20and%20delamanid%20for%20multidrug-%20and%20extensively%20drug-resistant%20tuberculosis%3A%20a%20systematic%20review%20and%20meta-analysis%3C%5C%2Fb%3E.%20Clin%20Infect%20Dis%20ciac876%2C%20%3Ca%20target%3D%27_blank%27%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1093%5C%2Fcid%5C%2Fciac876%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1093%5C%2Fcid%5C%2Fciac876%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Efficacy%20and%20tolerability%20of%20concomitant%20use%20of%20bedaquiline%20and%20delamanid%20for%20multidrug-%20and%20extensively%20drug-resistant%20tuberculosis%3A%20a%20systematic%20review%20and%20meta-analysis%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Freja%20Breth%22%2C%22lastName%22%3A%22Holmgaard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lorenzo%22%2C%22lastName%22%3A%22Guglielmetti%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Troels%22%2C%22lastName%22%3A%22Lillebaek%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22%5Cu00c5se%20Bengaard%22%2C%22lastName%22%3A%22Andersen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christian%22%2C%22lastName%22%3A%22Wejse%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Victor%20Naestholt%22%2C%22lastName%22%3A%22Dahl%22%7D%5D%2C%22abstractNote%22%3A%22The%20introduction%20of%20two%20novel%20drugs%2C%20bedaquiline%20and%20delamanid%2C%20has%20given%20hope%20for%20better%20and%20shorter%20treatments%20of%20drug-resistant%20tuberculosis.%20A%20systematic%20review%20was%20conducted%20to%20evaluate%20the%20efficacy%20and%20safety%20of%20concomitant%20bedaquiline%20and%20delamanid%20administration.%20Pooled%20estimates%20of%20WHO-defined%20favorable%20treatment%20outcome%20and%20significant%20QTc-interval%20prolongation%20%28QTc%20%5Cu2265500%5Cu2005ms%20or%20%5Cu226560%5Cu2005ms%20increase%20from%20baseline%29%20were%20calculated%20using%20a%20random%20effects%20model.%20Thirteen%20studies%20including%20a%20total%20of%201031%20individuals%20with%20multidrug-resistant%5C%2Frifampicin-resistant%20tuberculosis%20who%20received%20bedaquiline%20and%20delamanid%20were%20included.%20The%20pooled%20estimate%20of%20favorable%20treatment%20outcome%20was%2073.1%25%20%2895%25CI%3A%2064.3-81.8%29.%20Sputum%20culture%20conversion%20at%20six%20months%20ranged%20from%2061-95%25.%20Overall%2C%20the%20pooled%20proportion%20of%20QTc-prolongation%20was%207.8%25%20%2895%25CI%3A%204.1-11.6%29%20and%20few%20cardiac%20events%20were%20reported%20%280.8%25%2C%20n%5Cu2009%3D%5Cu20096%5C%2F798%29.%20Rates%20of%20sputum%20culture%20conversion%20and%20favorable%20treatment%20outcome%20were%20high%20in%20patients%20treated%20concomitantly%20with%20bedaquiline%20and%20delamanid%2C%20and%20the%20treatment%20seemed%20tolerable%20with%20low%20rates%20of%20clinically%20significant%20cardiac%20toxicity.%22%2C%22date%22%3A%222022-11-04%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1093%5C%2Fcid%5C%2Fciac876%22%2C%22ISSN%22%3A%221537-6591%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222023-03-10T14%3A59%3A47Z%22%7D%7D%2C%7B%22key%22%3A%228NJBYM8Z%22%2C%22library%22%3A%7B%22id%22%3A1368488%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Wetzstein%20et%20al.%22%2C%22parsedDate%22%3A%222022-10-01%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EWetzstein%2C%20N.%2C%20Drummer%2C%20A.-P.%2C%20Bockey%2C%20A.%2C%20Herrmann%2C%20E.%2C%20K%26%23xFC%3Bpper-Tetzel%2C%20C.%20P.%2C%20Graf%2C%20C.%2C%20Koch%2C%20B.%2C%20Goetsch%2C%20U.%2C%20Vehreschild%2C%20M.%20J.%20G.%20T.%2C%20Guglielmetti%2C%20L.%2C%20Lange%2C%20B.%2C%20Wichelhaus%2C%20T.%20A.%20and%20Stephan%2C%20C.%20%282022%29.%20%3Cb%3EOccurrence%20of%20extrapulmonary%20tuberculosis%20is%20associated%20with%20geographical%20origin%3A%20spatial%20characteristics%20of%20the%20Frankfurt%20TB%20cohort%202013%26%23x2013%3B2018%3C%5C%2Fb%3E.%20Infection%2C%20%3Ca%20target%3D%27_blank%27%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1007%5C%2Fs15010-022-01921-9%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1007%5C%2Fs15010-022-01921-9%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Occurrence%20of%20extrapulmonary%20tuberculosis%20is%20associated%20with%20geographical%20origin%3A%20spatial%20characteristics%20of%20the%20Frankfurt%20TB%20cohort%202013%5Cu20132018%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nils%22%2C%22lastName%22%3A%22Wetzstein%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alena-Pauline%22%2C%22lastName%22%3A%22Drummer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Annabelle%22%2C%22lastName%22%3A%22Bockey%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eva%22%2C%22lastName%22%3A%22Herrmann%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Claus%20Philippe%22%2C%22lastName%22%3A%22K%5Cu00fcpper-Tetzel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christiana%22%2C%22lastName%22%3A%22Graf%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Benjamin%22%2C%22lastName%22%3A%22Koch%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Udo%22%2C%22lastName%22%3A%22Goetsch%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Maria%20J.%20G.%20T.%22%2C%22lastName%22%3A%22Vehreschild%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lorenzo%22%2C%22lastName%22%3A%22Guglielmetti%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Berit%22%2C%22lastName%22%3A%22Lange%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thomas%20A.%22%2C%22lastName%22%3A%22Wichelhaus%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christoph%22%2C%22lastName%22%3A%22Stephan%22%7D%5D%2C%22abstractNote%22%3A%22Tuberculosis%20%28TB%29%20is%20caused%20by%20M.%20tuberculosis%20complex%20%28MTB%29%20and%20pulmonary%20tuberculosis%20%28PTB%29%20is%20its%20classical%20manifestation.%20However%2C%20in%20some%20regions%20of%20the%20world%2C%20extrapulmonary%20TB%20%28EPTB%29%20seems%20to%20be%20more%20frequent.%22%2C%22date%22%3A%222022-10-01%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1007%5C%2Fs15010-022-01921-9%22%2C%22ISSN%22%3A%221439-0973%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1007%5C%2Fs15010-022-01921-9%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222022-12-28T16%3A07%3A36Z%22%7D%7D%2C%7B%22key%22%3A%22JXJYY2QR%22%2C%22library%22%3A%7B%22id%22%3A1368488%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Kherabi%20et%20al.%22%2C%22parsedDate%22%3A%222022-10%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EKherabi%2C%20Y.%2C%20Tunesi%2C%20S.%2C%20Kay%2C%20A.%20and%20Guglielmetti%2C%20L.%20%282022%29.%20%3Cb%3EPreventive%20Therapy%20for%20Contacts%20of%20Drug-Resistant%20Tuberculosis%3C%5C%2Fb%3E.%20Pathogens%20%3Ci%3E11%3C%5C%2Fi%3E%2C%201189%2C%20%3Ca%20target%3D%27_blank%27%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.3390%5C%2Fpathogens11101189%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.3390%5C%2Fpathogens11101189%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Preventive%20Therapy%20for%20Contacts%20of%20Drug-Resistant%20Tuberculosis%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yousra%22%2C%22lastName%22%3A%22Kherabi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Simone%22%2C%22lastName%22%3A%22Tunesi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alexander%22%2C%22lastName%22%3A%22Kay%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lorenzo%22%2C%22lastName%22%3A%22Guglielmetti%22%7D%5D%2C%22abstractNote%22%3A%22Preventing%20the%20progression%20of%20a%20drug-resistant%20tuberculosis%20%28DR-TB%29%20infection%20to%20disease%20is%20an%20important%20pillar%20of%20the%20DR-TB%20elimination%20strategy.%20International%20guidelines%20have%20recently%20proposed%20fluoroquinolones%20for%20tuberculosis%20preventive%20therapy%20%28TPT%29%20in%20DR-TB%20contacts%2C%20although%20the%20available%20evidence%20is%20low%20quality.%20The%20pooled%20data%20from%20small%20observational%20studies%20suggest%20that%20a%20fluoroquinolone-based%20TPT%20is%20safe%2C%20effective%20and%20cost-effective%20as%20a%20preventive%20treatment%20in%20DR-TB%20contacts.%20Three%20clinical%20trials%20are%20currently%20ongoing%20to%20generate%20higher%20quality%20evidence%20on%20the%20efficacy%20of%20levofloxacin%20and%20delamanid%20as%20a%20DR-TB%20preventive%20therapy.%20Additional%20evidence%20is%20also%20needed%2C%20regarding%20TPT%20treatment%20in%20fluoroquinolone-resistant-TB%20contacts%2C%20patient%20and%20health%20care%20worker%20perceptions%20on%20DR-TB%20preventive%20therapy%20for%20contacts%2C%20and%20the%20service%20delivery%20models%20to%20increase%20DR-TPT%20access.%20This%20state-of-the-art%20review%20presents%20the%20current%20literature%20on%20TPT%20for%20contacts%20of%20DR-TB%20cases%2C%20focusing%20on%20the%20available%20evidence%20and%20international%20guidelines.%22%2C%22date%22%3A%222022%5C%2F10%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.3390%5C%2Fpathogens11101189%22%2C%22ISSN%22%3A%222076-0817%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fwww.mdpi.com%5C%2F2076-0817%5C%2F11%5C%2F10%5C%2F1189%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222022-12-28T16%3A07%3A55Z%22%7D%7D%2C%7B%22key%22%3A%224ND3DBVZ%22%2C%22library%22%3A%7B%22id%22%3A1368488%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Khan%20and%20Guglielmetti%22%2C%22parsedDate%22%3A%222022-09-01%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EKhan%2C%20U.%20and%20Guglielmetti%2C%20L.%20%282022%29.%20%3Cb%3EEvidence%20and%20ethical%20considerations%20for%20the%20treatment%20of%20contacts%20exposed%20to%20drug-resistant%20TB%3C%5C%2Fb%3E.%20The%20International%20Journal%20of%20Tuberculosis%20and%20Lung%20Disease%20%3Ci%3E26%3C%5C%2Fi%3E%2C%20900%26%23x2013%3B901%2C%20%3Ca%20target%3D%27_blank%27%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.5588%5C%2Fijtld.22.0328%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.5588%5C%2Fijtld.22.0328%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Evidence%20and%20ethical%20considerations%20for%20the%20treatment%20of%20contacts%20exposed%20to%20drug-resistant%20TB%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22U.%22%2C%22lastName%22%3A%22Khan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L.%22%2C%22lastName%22%3A%22Guglielmetti%22%7D%5D%2C%22abstractNote%22%3A%22%22%2C%22date%22%3A%222022-09-01%22%2C%22language%22%3A%22%22%2C%22DOI%22%3A%2210.5588%5C%2Fijtld.22.0328%22%2C%22ISSN%22%3A%22%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222023-04-26T13%3A17%3A52Z%22%7D%7D%2C%7B%22key%22%3A%22YKWPDBTM%22%2C%22library%22%3A%7B%22id%22%3A1368488%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Kherabi%20et%20al.%22%2C%22parsedDate%22%3A%222022-09%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EKherabi%2C%20Y.%2C%20Fr%26%23xE9%3Bchet-Jachym%2C%20M.%2C%20Rioux%2C%20C.%2C%20Yazdanpanah%2C%20Y.%2C%20M%26%23xE9%3Bcha%26%23xEF%3B%2C%20F.%2C%20Pourcher%2C%20V.%2C%20Robert%2C%20J.%20and%20Guglielmetti%2C%20L.%20%282022%29.%20%3Cb%3ERevised%20Definitions%20of%20Tuberculosis%20Resistance%20and%20Treatment%20Outcomes%2C%20France%2C%202006%26%23x2013%3B2019%3C%5C%2Fb%3E.%20Emerg%20Infect%20Dis%20%3Ci%3E28%3C%5C%2Fi%3E%2C%201796%26%23x2013%3B1804%2C%20%3Ca%20target%3D%27_blank%27%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.3201%5C%2Feid2809.220458%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.3201%5C%2Feid2809.220458%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Revised%20Definitions%20of%20Tuberculosis%20Resistance%20and%20Treatment%20Outcomes%2C%20France%2C%202006%5Cu20132019%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yousra%22%2C%22lastName%22%3A%22Kherabi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mathilde%22%2C%22lastName%22%3A%22Fr%5Cu00e9chet-Jachym%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christophe%22%2C%22lastName%22%3A%22Rioux%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yazdan%22%2C%22lastName%22%3A%22Yazdanpanah%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fr%5Cu00e9d%5Cu00e9ric%22%2C%22lastName%22%3A%22M%5Cu00e9cha%5Cu00ef%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Val%5Cu00e9rie%22%2C%22lastName%22%3A%22Pourcher%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%5Cu00e9r%5Cu00f4me%22%2C%22lastName%22%3A%22Robert%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lorenzo%22%2C%22lastName%22%3A%22Guglielmetti%22%7D%5D%2C%22abstractNote%22%3A%22Definitions%20of%20resistance%20in%20multidrug-resistant%20tuberculosis%20%28MDR%20TB%29%20and%20extensively%20drug-resistant%20tuberculosis%20%28XDR%20TB%29%20have%20been%20updated.%20Pre%5Cu2013XDR%20TB%2C%20defined%20as%20MDR%20TB%20with%20additional%20resistance%20to%20fluoroquinolones%2C%20and%20XDR%20TB%2C%20with%20additional%20resistance%20to%20bedaquiline%20or%20linezolid%2C%20are%20frequently%20associated%20with%20treatment%20failure%20and%20toxicity.%20We%20retrospectively%20determined%20the%20effects%20of%20pre-XDR%5C%2FXDR%20TB%20resistance%20on%20outcomes%20and%20safety%20of%20MDR%20TB%20treatment%20in%20France.%20The%20study%20included%20298%20patients%20treated%20for%20MDR%20TB%20at%203%20reference%20centers%20during%202006%5Cu20132019.%20Of%20those%2C%20205%20%2868.8%25%29%20cases%20were%20fluoroquinolone-susceptible%20MDR%20TB%20and%2093%20%2831.2%25%29%20were%20pre-XDR%5C%2FXDR%20TB.%20Compared%20with%20fluoroquinolone-susceptible%20MDR%20TB%2C%20pre-XDR%5C%2FXDR%20TB%20was%20associated%20with%20more%20cavitary%20lung%20lesions%20and%20bilateral%20disease%20and%20required%20longer%20treatment.%20Overall%2C%20202%20patients%20%2867.8%25%29%20had%20favorable%20treatment%20outcomes%2C%20with%20no%20significant%20difference%20between%20pre-XDR%5C%2FXDR%20TB%20%2867.7%25%29%20and%20fluoroquinolone-susceptible%20MDR%20TB%20%2867.8%25%3B%20p%20%3D%200.99%29.%20Pre-XDR%5C%2FXDR%20TB%20was%20not%20associated%20with%20higher%20risk%20for%20serious%20adverse%20events.%22%2C%22date%22%3A%222022-9%22%2C%22language%22%3A%22%22%2C%22DOI%22%3A%2210.3201%5C%2Feid2809.220458%22%2C%22ISSN%22%3A%221080-6040%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fwww.ncbi.nlm.nih.gov%5C%2Fpmc%5C%2Farticles%5C%2FPMC9423894%5C%2F%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222022-09-23T13%3A14%3A59Z%22%7D%7D%2C%7B%22key%22%3A%2232L5JEUW%22%2C%22library%22%3A%7B%22id%22%3A1368488%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22De%20Castro%20et%20al.%22%2C%22parsedDate%22%3A%222022-08-01%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EDe%20Castro%2C%20N.%2C%20Mecha%26%23xEF%3B%2C%20F.%2C%20Bachelet%2C%20D.%2C%20Canestri%2C%20A.%2C%20Joly%2C%20V.%2C%20Vandenhende%2C%20M.%2C%20Boutoille%2C%20D.%2C%20Kerjouan%2C%20M.%2C%20Veziris%2C%20N.%2C%20Molina%2C%20J.%20M.%2C%20Grall%2C%20N.%2C%20Tattevin%2C%20P.%2C%20Laou%26%23xE9%3Bnan%2C%20C.%2C%20Yazdanpanah%2C%20Y.%20and%20for%20the%20FAST%20TB%20Study%20Group%20%282022%29.%20%3Cb%3ETreatment%20With%20a%20Three-Drug%20Regimen%20for%20Pulmonary%20Tuberculosis%20Based%20on%20Rapid%20Molecular%20Detection%20of%20Isoniazid%20Resistance%3A%20A%20Noninferiority%20Randomized%20Trial%20%28FAST-TB%29%3C%5C%2Fb%3E.%20Open%20Forum%20Infectious%20Diseases%20%3Ci%3E9%3C%5C%2Fi%3E%2C%20ofac353%2C%20%3Ca%20target%3D%27_blank%27%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1093%5C%2Fofid%5C%2Fofac353%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1093%5C%2Fofid%5C%2Fofac353%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Treatment%20With%20a%20Three-Drug%20Regimen%20for%20Pulmonary%20Tuberculosis%20Based%20on%20Rapid%20Molecular%20Detection%20of%20Isoniazid%20Resistance%3A%20A%20Noninferiority%20Randomized%20Trial%20%28FAST-TB%29%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22N%22%2C%22lastName%22%3A%22De%20Castro%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22F%22%2C%22lastName%22%3A%22Mecha%5Cu00ef%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22D%22%2C%22lastName%22%3A%22Bachelet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A%22%2C%22lastName%22%3A%22Canestri%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22V%22%2C%22lastName%22%3A%22Joly%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M%22%2C%22lastName%22%3A%22Vandenhende%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22D%22%2C%22lastName%22%3A%22Boutoille%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M%22%2C%22lastName%22%3A%22Kerjouan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22N%22%2C%22lastName%22%3A%22Veziris%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%20M%22%2C%22lastName%22%3A%22Molina%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22N%22%2C%22lastName%22%3A%22Grall%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P%22%2C%22lastName%22%3A%22Tattevin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C%22%2C%22lastName%22%3A%22Laou%5Cu00e9nan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Y%22%2C%22lastName%22%3A%22Yazdanpanah%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22name%22%3A%22for%20the%20FAST%20TB%20Study%20Group%22%7D%5D%2C%22abstractNote%22%3A%22The%20rationale%20behind%20the%20use%20of%20ethambutol%20in%20the%20standard%20tuberculosis%20treatment%20is%20to%20prevent%20the%20emergence%20of%20resistance%20to%20rifampicin%20in%20case%20of%20primary%20resistance%20to%20isoniazid.%20We%20evaluated%20whether%20early%20detection%20of%20isoniazid%20resistance%20using%20molecular%20testing%20allows%20the%20use%20an%20ethambutol-free%20regimen.FAST-TB%2C%20a%20phase%204%2C%20French%2C%20multicenter%2C%20open-label%2C%20non-inferiority%20trial%2C%20compared%202%20strategies%3A%20%281%29%20polymerase%20chain%20reaction%20%28PCR%29-based%20detection%20of%20isoniazid%20and%20rifampicin%20resistance%20at%20baseline%20using%20Genotype%20MTBDRplus%20version%202.0%20followed%20by%20ethambutol%20discontinuation%20if%20no%20resistance%20was%20detected%20%28PCR%20arm%29%20and%20%282%29%20a%20standard%204-drug%20combination%2C%20pending%20phenotypic%20drug-susceptibility%20results%20%28C%20arm%29.%20Adult%20patients%20with%20smear-positive%20pulmonary%20tuberculosis%20were%20enrolled.%20The%20primary%20endpoint%20was%20the%20proportion%20of%20patients%20with%20treatment%20success%20defined%20as%20bacteriological%20or%20clinical%20cure%20at%20the%20end%20of%20treatment.%20A%20non-inferiority%20margin%20of%2010%25%20was%20used.Two%20hundred%20three%20patients%20were%20randomized%2C%20104%20in%20the%20PCR%20arm%20and%2099%20in%20the%20C%20arm%3A%2026.6%25%20were%20female%2C%20median%20age%20was%2037%20%28interquartile%20range%2C%2028%5Cu201351%29%20years%2C%2072.4%25%20were%20born%20in%20Africa%2C%20and%205.4%25%20were%20infected%20with%20human%20immunodeficiency%20virus.%20Chest%20x-ray%20showed%20cavities%20in%2064.5%25%20of%20the%20cases.%20Overall%2C%20169%20patients%20met%20criteria%20of%20treatment%20success%3A%2087%20of%20104%20%2883.7%25%29%20in%20the%20PCR%20arm%20and%2082%20of%2099%20%2882.8%25%29%20in%20the%20C%20arm%20with%20a%20difference%20of%20%2B0.8%25%20%2890%25%20confidence%20interval%2C%20%5Cu22127.9%20to%209.6%29%2C%20meeting%20the%20noninferiority%20criteria%20in%20the%20intention-to-treat%20population%20%28P%5Cu2009%3D%5Cu2009.02%29.In%20a%20setting%20with%20low%20prevalence%20of%20primary%20isoniazid%20resistance%2C%20a%203-drug%20combination%20with%20isoniazid%2C%20rifampicin%2C%20and%20pyrazinamide%2C%20based%20on%20rapid%20detection%20of%20isoniazid%20resistance%20using%20molecular%20testing%2C%20was%20noninferior%20to%20starting%20the%20recommended%204-drug%20regimen.%22%2C%22date%22%3A%222022-08-01%22%2C%22language%22%3A%22%22%2C%22DOI%22%3A%2210.1093%5C%2Fofid%5C%2Fofac353%22%2C%22ISSN%22%3A%222328-8957%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1093%5C%2Fofid%5C%2Fofac353%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222022-09-23T13%3A20%3A00Z%22%7D%7D%2C%7B%22key%22%3A%224KRX87K9%22%2C%22library%22%3A%7B%22id%22%3A1368488%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Kraef%20et%20al.%22%2C%22parsedDate%22%3A%222022-07-05%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EKraef%2C%20C.%2C%20Lindquist%2C%20E.%2C%20Svensson%2C%20E.%20and%20Cambau%2C%20E.%20%282022%29.%20%3Cb%3EDiagnostic%20toolkit%20for%20tuberculosis%3A%20should%20we%20include%20urine%20lipoarabinomannan%20%28LAM%29%20detection%20in%20the%20WHO%20European%20Region%3F%3C%5C%2Fb%3E%20Clinical%20Microbiology%20and%20Infection%2C%20%3Ca%20target%3D%27_blank%27%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.cmi.2022.06.022%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.cmi.2022.06.022%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Diagnostic%20toolkit%20for%20tuberculosis%3A%20should%20we%20include%20urine%20lipoarabinomannan%20%28LAM%29%20detection%20in%20the%20WHO%20European%20Region%3F%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christian%22%2C%22lastName%22%3A%22Kraef%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Emilia%22%2C%22lastName%22%3A%22Lindquist%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Erik%22%2C%22lastName%22%3A%22Svensson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Emmanuelle%22%2C%22lastName%22%3A%22Cambau%22%7D%5D%2C%22abstractNote%22%3A%22%22%2C%22date%22%3A%222022-07-05%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1016%5C%2Fj.cmi.2022.06.022%22%2C%22ISSN%22%3A%221198-743X%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fwww.sciencedirect.com%5C%2Fscience%5C%2Farticle%5C%2Fpii%5C%2FS1198743X22003366%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222022-09-23T13%3A28%3A42Z%22%7D%7D%2C%7B%22key%22%3A%22PF5DMFLC%22%2C%22library%22%3A%7B%22id%22%3A1368488%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Bachir%20et%20al.%22%2C%22parsedDate%22%3A%222022-07-01%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EBachir%2C%20M.%2C%20Guglielmetti%2C%20L.%2C%20Tunesi%2C%20S.%2C%20Billard-Pomares%2C%20T.%2C%20Chiesi%2C%20S.%2C%20Jaffr%26%23xE9%3B%2C%20J.%2C%20Langris%2C%20H.%2C%20Pourcher%2C%20V.%2C%20Schramm%2C%20F.%2C%20Lema%26%23xEE%3Btre%2C%20N.%20and%20Robert%2C%20J.%20%282022%29.%20%3Cb%3EMolecular%20detection%20of%20isoniazid%20monoresistance%20improves%20tuberculosis%20treatment%3A%20A%20retrospective%20cohort%20in%20France%3C%5C%2Fb%3E.%20Journal%20of%20Infection%20%3Ci%3E85%3C%5C%2Fi%3E%2C%2024%26%23x2013%3B30%2C%20%3Ca%20target%3D%27_blank%27%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.jinf.2022.05.017%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.jinf.2022.05.017%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Molecular%20detection%20of%20isoniazid%20monoresistance%20improves%20tuberculosis%20treatment%3A%20A%20retrospective%20cohort%20in%20France%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marwa%22%2C%22lastName%22%3A%22Bachir%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lorenzo%22%2C%22lastName%22%3A%22Guglielmetti%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Simone%22%2C%22lastName%22%3A%22Tunesi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Typhaine%22%2C%22lastName%22%3A%22Billard-Pomares%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sheila%22%2C%22lastName%22%3A%22Chiesi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%5Cu00e9r%5Cu00e9my%22%2C%22lastName%22%3A%22Jaffr%5Cu00e9%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Hugo%22%2C%22lastName%22%3A%22Langris%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Val%5Cu00e9rie%22%2C%22lastName%22%3A%22Pourcher%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fr%5Cu00e9d%5Cu00e9ric%22%2C%22lastName%22%3A%22Schramm%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nadine%22%2C%22lastName%22%3A%22Lema%5Cu00eetre%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%5Cu00e9r%5Cu00f4me%22%2C%22lastName%22%3A%22Robert%22%7D%5D%2C%22abstractNote%22%3A%22Objectives%5CnIsoniazid-monoresistant%20tuberculosis%20%28HR-TB%29%20requires%20early%20diagnosis%20and%20adapted%20treatment%20to%20achieve%20optimal%20outcomes.%20The%20primary%20aim%20of%20the%20study%20was%20to%20assess%20the%20impact%20of%20the%20implementation%20of%20rapid%20diagnostic%20tests%20on%20HR-TB%20treatment%20in%20France.%5CnMethods%5CnWe%20designed%20a%20retrospective%20multicentre%20study%20including%20consecutive%20HR-TB%20patients%20diagnosed%20in%202016%20and%202017.%20Implementation%20of%20a%20molecular%20assay%20detecting%20isoniazid%20resistance%20directly%20on%20a%20clinical%20sample%20was%20recorded.%20The%20association%20between%20early%20implementation%20of%20such%20assays%20and%20adequate%20treatment%20was%20assessed%20by%20a%20multivariable%20Cox%20proportional%20hazards%20model.%5CnResults%5CnOverall%2C%2099%20HR-TB%20patients%20were%20included%20from%2020%20University%20Hospitals.%20Among%20all%20smear-positive%20HR-TB%20patients%2C%20only%2026%25%20beneficiated%20from%20early%20molecular%20HR%20detection.%20This%20detection%20was%20independently%20associated%20with%20shorter%20time%20to%20adequate%20treatment%20%28HR%5Cu00a0%3D%5Cu00a02.0%20%5B1.1%5Cu20133.8%5D%2C%20p%5Cu00a0%3D%5Cu00a00.03%29.%5CnConclusion%5CnIn%20our%20study%2C%20molecular%20detection%20of%20HR%20on%20an%20initial%20sample%20was%20independently%20associated%20with%20earlier%20treatment%20adaptation.%22%2C%22date%22%3A%222022-07-01%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1016%5C%2Fj.jinf.2022.05.017%22%2C%22ISSN%22%3A%220163-4453%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fwww.sciencedirect.com%5C%2Fscience%5C%2Farticle%5C%2Fpii%5C%2FS0163445322003061%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222022-07-06T13%3A19%3A23Z%22%7D%7D%2C%7B%22key%22%3A%22VG5PNGPC%22%2C%22library%22%3A%7B%22id%22%3A1368488%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Maitre%20et%20al.%22%2C%22parsedDate%22%3A%222022-07%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EMaitre%2C%20T.%2C%20Morel%2C%20F.%2C%20Brossier%2C%20F.%2C%20Sougakoff%2C%20W.%2C%20Jaffre%2C%20J.%2C%20Cheng%2C%20S.%2C%20Veziris%2C%20N.%2C%20Aubry%2C%20A.%20and%20on%20behalf%20of%20the%20NRC-MyRMA%20%282022%29.%20%3Cb%3EHow%20a%20PCR%20Sequencing%20Strategy%20Can%20Bring%20New%20Data%20to%20Improve%20the%20Diagnosis%20of%20Ethionamide%20Resistance%3C%5C%2Fb%3E.%20Microorganisms%20%3Ci%3E10%3C%5C%2Fi%3E%2C%201436%2C%20%3Ca%20target%3D%27_blank%27%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.3390%5C%2Fmicroorganisms10071436%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.3390%5C%2Fmicroorganisms10071436%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22How%20a%20PCR%20Sequencing%20Strategy%20Can%20Bring%20New%20Data%20to%20Improve%20the%20Diagnosis%20of%20Ethionamide%20Resistance%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thomas%22%2C%22lastName%22%3A%22Maitre%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Florence%22%2C%22lastName%22%3A%22Morel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Florence%22%2C%22lastName%22%3A%22Brossier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Wladimir%22%2C%22lastName%22%3A%22Sougakoff%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%5Cu00e9remy%22%2C%22lastName%22%3A%22Jaffre%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sokleaph%22%2C%22lastName%22%3A%22Cheng%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nicolas%22%2C%22lastName%22%3A%22Veziris%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alexandra%22%2C%22lastName%22%3A%22Aubry%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22name%22%3A%22on%20behalf%20of%20the%20NRC-MyRMA%22%7D%5D%2C%22abstractNote%22%3A%22Ethionamide%20%28ETH%29%20is%20a%20second-line%20antituberculosis%20drug.%20ETH%20resistance%20%28ETH-R%29%20is%20mainly%20related%20to%20the%20mutations%20of%20the%20monooxygenase-activating%20ETH%20%28EthA%29%2C%20the%20ETH%20target%20%28InhA%29%2C%20and%20the%20inhA%20promoter.%20Nonetheless%2C%20diagnosing%20ETH-R%20is%20still%20challenging.%20We%20assessed%20the%20strategy%20used%20for%20detecting%20ETH-R%20at%20the%20French%20National%20Reference%20Center%20for%20Mycobacteria%20in%20497%20MDR-TB%20isolates%20received%20from%202008%20to%202016.%20The%20genotypic%20ETH%5Cu2019s%20resistance%20detection%20was%20performed%20by%20sequencing%20ethA%2C%20ethR%2C%20the%20ethA-ethR%20intergenic%20region%2C%20and%20the%20inhA%20promoter%20in%20the%20497%20multidrug-resistant%20isolates%2C%20whereas%20the%20phenotypic%20ETH%20susceptibility%20testing%20%28PST%29%20was%20performed%20using%20the%20reference%20proportion%20method.%20Mutations%20were%20found%20in%20up%20to%2076%25%20of%20the%20387%20resistant%20isolates%20and%20in%20up%20to%2028%25%20of%20the%20110%20susceptible%20isolates.%20Our%20results%20do%20not%20support%20the%20role%20of%20ethR%20mutations%20in%20ETH%20resistance.%20Altogether%2C%20the%20positive%20predictive%20value%20of%20our%20genotypic%20strategy%20to%20diagnose%20ETH-R%20was%20improved%20when%20only%20considering%20the%20variants%20included%20in%20the%20WHO%20catalogue%20and%20in%20other%20databases%2C%20such%20as%20TB-Profiler.%20Therefore%2C%20our%20work%20will%20help%20to%20update%20the%20list%20of%20mutations%20that%20could%20be%20graded%20as%20being%20associated%20with%20resistance%20to%20improve%20ETH-R%20diagnosis.%22%2C%22date%22%3A%222022%5C%2F7%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.3390%5C%2Fmicroorganisms10071436%22%2C%22ISSN%22%3A%222076-2607%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fwww.mdpi.com%5C%2F2076-2607%5C%2F10%5C%2F7%5C%2F1436%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222022-09-23T13%3A18%3A47Z%22%7D%7D%2C%7B%22key%22%3A%22S6JQ4XIX%22%2C%22library%22%3A%7B%22id%22%3A1368488%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Eimer%20et%20al.%22%2C%22parsedDate%22%3A%222022-06-19%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EEimer%2C%20J.%2C%20Fr%26%23xE9%3Bchet-Jachym%2C%20M.%2C%20Le%20D%26%23xFB%3B%2C%20D.%2C%20Caumes%2C%20E.%2C%20El-Helali%2C%20N.%2C%20Marigot-Outtandy%2C%20D.%2C%20Mechai%2C%20F.%2C%20Peytavin%2C%20G.%2C%20Pourcher%2C%20V.%2C%20Rioux%2C%20C.%2C%20Yazdanpanah%2C%20Y.%2C%20Robert%2C%20J.%2C%20Guglielmetti%2C%20L.%20and%20for%20the%20LZDM%20group%20%282022%29.%20%3Cb%3EIncreased%20linezolid%20plasma%20concentrations%20are%20associated%20with%20the%20development%20of%20severe%20toxicity%20in%20MDR-TB%20treatment.%3C%5C%2Fb%3E%20Clinical%20Infectious%20Diseases%20ciac485%2C%20%3Ca%20target%3D%27_blank%27%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1093%5C%2Fcid%5C%2Fciac485%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1093%5C%2Fcid%5C%2Fciac485%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Increased%20linezolid%20plasma%20concentrations%20are%20associated%20with%20the%20development%20of%20severe%20toxicity%20in%20MDR-TB%20treatment.%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Johannes%22%2C%22lastName%22%3A%22Eimer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mathilde%22%2C%22lastName%22%3A%22Fr%5Cu00e9chet-Jachym%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Damien%22%2C%22lastName%22%3A%22Le%20D%5Cu00fb%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eric%22%2C%22lastName%22%3A%22Caumes%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Najoua%22%2C%22lastName%22%3A%22El-Helali%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Dhiba%22%2C%22lastName%22%3A%22Marigot-Outtandy%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fr%5Cu00e9d%5Cu00e9ric%22%2C%22lastName%22%3A%22Mechai%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gilles%22%2C%22lastName%22%3A%22Peytavin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Val%5Cu00e9rie%22%2C%22lastName%22%3A%22Pourcher%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christophe%22%2C%22lastName%22%3A%22Rioux%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yazdan%22%2C%22lastName%22%3A%22Yazdanpanah%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%5Cu00e9r%5Cu00f4me%22%2C%22lastName%22%3A%22Robert%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lorenzo%22%2C%22lastName%22%3A%22Guglielmetti%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22name%22%3A%22for%20the%20LZDM%20group%22%7D%5D%2C%22abstractNote%22%3A%22Treatment%20of%20multidrug-resistant%20tuberculosis%20%28MDR-TB%29%20with%20linezolid%20is%20characterized%20by%20high%20rates%20of%20adverse%20events.%20Evidence%20on%20therapeutic%20drug%20monitoring%20to%20predict%20drug%20toxicity%20is%20scarce.%20This%20study%20aimed%20to%20evaluate%20the%20association%20of%20linezolid%20trough%20concentrations%20with%20severe%20toxicity.We%20retrospectively%20assessed%20consecutive%20patients%20started%20on%20linezolid%20for%20MDR-TB%20between%202011%20and%202017.%20The%20primary%20outcome%20was%20severe%20mitochondrial%20toxicity%20%28SMT%29%20due%20to%20linezolid%2C%20defined%20as%20neurotoxicity%20or%20myelotoxicity%20leading%20to%20drug%20discontinuation.%20The%20impact%20of%20plasma%20linezolid%20trough%20concentrations%20%26gt%3B2%5Cu2005mg%5C%2FL%20was%20assessed%20in%20multivariate%20Cox%20proportional%20hazards%20models%20including%20time-varying%20covariates.SMT%20occurred%20in%2057%20of%20146%20included%20patients%20%2839%25%29%20at%20an%20incidence%20rate%20of%200.38%20per%20person-year%20%2895%25CI%200.30-0.49%29.%20A%20maximum%20linezolid%20trough%20concentration%20%26gt%3B2%5Cu2005mg%5C%2FL%20was%20detected%20in%2052%20patients%20%2835.6%25%29%2C%20while%20the%20mean%20trough%20concentration%20was%20%26gt%3B2%5Cu2005mg%5C%2FL%20in%2022%20%2815%25%29.%20The%20adjusted%20hazard%20ratio%20for%20SMT%20was%202.35%20%2895%25CI%201.26%5Cu20134.38%2C%20p%5Cu2009%3D%5Cu20090.01%29%20in%20patients%20with%20a%20mean%20trough%20concentration%20%26gt%3B2%5Cu2005mg%5C%2FL%20and%202.63%20%2895%25CI%201.55%5Cu20134.47%2C%20p%5Cu2009%26lt%3B%5Cu20090.01%29%20for%20SMT%20after%20the%20first%20detection%20of%20a%20trough%20concentration%20%26gt%3B2%5Cu2005mg%5C%2FL.%20In%20an%20exploratory%20analysis%2C%20higher%20maximum%20trough%20concentrations%20were%20dose-dependently%20associated%20with%20toxicity%2C%20while%20lowering%20of%20elevated%20trough%20concentrations%20did%20not%20restore%20baseline%20risk.Linezolid%20trough%20concentrations%20%26gt%3B2%5Cu2005mg%5C%2FL%20are%20strongly%20associated%20with%20the%20development%20of%20severe%20treatment-emergent%20toxicity%20in%20patients%20treated%20for%20MDR-TB.%20Pending%20further%20prospective%20evidence%2C%20an%20individual%20risk-benefit%20assessment%20on%20the%20continuation%20of%20linezolid%20treatment%20is%20warranted%20in%20any%20patient%20with%20trough%20concentrations%20above%202%5Cu2005mg%5C%2FL.%22%2C%22date%22%3A%222022-06-19%22%2C%22language%22%3A%22%22%2C%22DOI%22%3A%2210.1093%5C%2Fcid%5C%2Fciac485%22%2C%22ISSN%22%3A%221058-4838%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1093%5C%2Fcid%5C%2Fciac485%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222022-07-08T13%3A02%3A02Z%22%7D%7D%2C%7B%22key%22%3A%22HUBVTWEL%22%2C%22library%22%3A%7B%22id%22%3A1368488%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Bonnet%20et%20al.%22%2C%22parsedDate%22%3A%222022-06-14%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EBonnet%2C%20I.%2C%20Haddad%2C%20E.%2C%20Guglielmetti%2C%20L.%2C%20B%26%23xE9%3Bmer%2C%20P.%2C%20Bernard%2C%20L.%2C%20Bourgoin%2C%20A.%2C%20Brault%2C%20R.%2C%20Catho%2C%20G.%2C%20Caumes%2C%20E.%2C%20Escaut%2C%20L.%2C%20Fourniols%2C%20E.%2C%20Fr%26%23xE9%3Bchet-Jachym%2C%20M.%2C%20Gaudart%2C%20A.%2C%20Guillot%2C%20H.%2C%20Lafon-Desmurs%2C%20B.%2C%20Lanoix%2C%20J.-P.%2C%20Lanotte%2C%20P.%2C%20Lemaignen%2C%20A.%2C%20Lemaire%2C%20B.%2C%20Lemaitre%2C%20N.%2C%20Michau%2C%20C.%2C%20Morand%2C%20P.%2C%20Mougari%2C%20F.%2C%20Marigot-Outtandy%2C%20D.%2C%20Patrat-Delon%2C%20S.%2C%20Perpoint%2C%20T.%2C%20Piau%2C%20C.%2C%20Pourcher%2C%20V.%2C%20Zarrouk%2C%20V.%2C%20Zeller%2C%20V.%2C%20Veziris%2C%20N.%2C%20Jaur%26%23xE9%3Bguiberry%2C%20S.%20and%20Aubry%2C%20A.%20%282022%29.%20%3Cb%3EClinical%20Features%20and%20Outcome%20of%20Multidrug-Resistant%20Osteoarticular%20Tuberculosis%3A%20A%2012-Year%20Case%20Series%20from%20France%3C%5C%2Fb%3E.%20Microorganisms%20%3Ci%3E10%3C%5C%2Fi%3E%2C%201215%2C%20%3Ca%20target%3D%27_blank%27%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.3390%5C%2Fmicroorganisms10061215%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.3390%5C%2Fmicroorganisms10061215%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Clinical%20Features%20and%20Outcome%20of%20Multidrug-Resistant%20Osteoarticular%20Tuberculosis%3A%20A%2012-Year%20Case%20Series%20from%20France%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Isabelle%22%2C%22lastName%22%3A%22Bonnet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Elie%22%2C%22lastName%22%3A%22Haddad%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lorenzo%22%2C%22lastName%22%3A%22Guglielmetti%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pascale%22%2C%22lastName%22%3A%22B%5Cu00e9mer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Louis%22%2C%22lastName%22%3A%22Bernard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anne%22%2C%22lastName%22%3A%22Bourgoin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Rachel%22%2C%22lastName%22%3A%22Brault%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gaud%22%2C%22lastName%22%3A%22Catho%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eric%22%2C%22lastName%22%3A%22Caumes%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L%5Cu00e9lia%22%2C%22lastName%22%3A%22Escaut%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eric%22%2C%22lastName%22%3A%22Fourniols%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mathilde%22%2C%22lastName%22%3A%22Fr%5Cu00e9chet-Jachym%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alice%22%2C%22lastName%22%3A%22Gaudart%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22H%5Cu00e9l%5Cu00e8ne%22%2C%22lastName%22%3A%22Guillot%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Barth%5Cu00e9l%5Cu00e9my%22%2C%22lastName%22%3A%22Lafon-Desmurs%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Philippe%22%2C%22lastName%22%3A%22Lanoix%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Philippe%22%2C%22lastName%22%3A%22Lanotte%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Adrien%22%2C%22lastName%22%3A%22Lemaignen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22B%5Cu00e9n%5Cu00e9dicte%22%2C%22lastName%22%3A%22Lemaire%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nadine%22%2C%22lastName%22%3A%22Lemaitre%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christophe%22%2C%22lastName%22%3A%22Michau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Philippe%22%2C%22lastName%22%3A%22Morand%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Faiza%22%2C%22lastName%22%3A%22Mougari%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Dhiba%22%2C%22lastName%22%3A%22Marigot-Outtandy%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sol%5Cu00e8ne%22%2C%22lastName%22%3A%22Patrat-Delon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thomas%22%2C%22lastName%22%3A%22Perpoint%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Caroline%22%2C%22lastName%22%3A%22Piau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Val%5Cu00e9rie%22%2C%22lastName%22%3A%22Pourcher%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Virginie%22%2C%22lastName%22%3A%22Zarrouk%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Val%5Cu00e9rie%22%2C%22lastName%22%3A%22Zeller%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nicolas%22%2C%22lastName%22%3A%22Veziris%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22St%5Cu00e9phane%22%2C%22lastName%22%3A%22Jaur%5Cu00e9guiberry%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alexandra%22%2C%22lastName%22%3A%22Aubry%22%7D%5D%2C%22abstractNote%22%3A%22The%20optimal%20treatment%20for%20osteoarticular%20infection%20due%20to%20multidrug-resistant%20tuberculosis%20strains%20%28MDR-OATB%29%20remains%20unclear.%20This%20study%20aims%20to%20evaluate%20the%20diagnosis%2C%20management%20and%20outcome%20of%20MDR-OATB%20in%20France.%20We%20present%20a%20case%20series%20of%20MDR-OATB%20patients%20reviewed%20at%20the%20French%20National%20Reference%20Center%20for%20Mycobacteria%20between%202007%20and%202018.%20Medical%20history%20and%20clinical%2C%20microbiological%2C%20treatment%20and%20outcome%20data%20were%20collected.%20Twenty-three%20MDR-OATB%20cases%20were%20reported%2C%20representing%203%25%20of%20all%20concurrent%20MDR-TB%20cases%20in%20France.%20Overall%2C%2017%20were%20male%2C%20and%20the%20median%20age%20was%2032%20years.%20Six%20patients%20were%20previously%20treated%20for%20TB%2C%20including%20four%20with%20first-line%20drugs.%20The%20most%20frequently%20affected%20site%20was%20the%20spine%20%28n%20%3D%2016%29.%20Bone%20and%20joint%20surgery%20were%20required%20in%2012%20patients.%20Twenty-one%20patients%20%2891%25%29%20successfully%20completed%20the%20treatment%20with%20a%20regimen%20containing%20a%20mean%20of%20four%20drugs%20%28range%2C%202%5Cu20136%29%20for%20a%20mean%20duration%20of%2020%20months%20%28range%2C%2013%5Cu201327%29.%20Overall%2C%20high%20rates%20of%20treatment%20success%20were%20achieved%20following%20WHO%20MDR-TB%20treatment%20guidelines%20and%20individualized%20patient%20management%20recommendations%20by%20the%20French%20National%20TB%20Consilium.%20However%2C%20the%20optimal%20combination%20of%20drugs%2C%20duration%20of%20treatment%20and%20role%20of%20surgery%20in%20the%20management%20of%20MDR-OATB%20remains%20to%20be%20determined.%22%2C%22date%22%3A%222022-6-14%22%2C%22language%22%3A%22%22%2C%22DOI%22%3A%2210.3390%5C%2Fmicroorganisms10061215%22%2C%22ISSN%22%3A%222076-2607%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fwww.ncbi.nlm.nih.gov%5C%2Fpmc%5C%2Farticles%5C%2FPMC9229793%5C%2F%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222022-06-29T14%3A21%3A11Z%22%7D%7D%2C%7B%22key%22%3A%22NH7XCKNV%22%2C%22library%22%3A%7B%22id%22%3A1368488%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Guglielmetti%20et%20al.%22%2C%22parsedDate%22%3A%222022-05-01%22%2C%22numChildren%22%3A3%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EGuglielmetti%2C%20L.%2C%20G%26%23xFC%3Bnther%2C%20G.%2C%20Leu%2C%20C.%2C%20Cirillo%2C%20D.%2C%20Duarte%2C%20R.%2C%20Garcia-Basteiro%2C%20A.%20L.%2C%20Goletti%2C%20D.%2C%20Jankovic%2C%20M.%2C%20Kuksa%2C%20L.%2C%20Maurer%2C%20F.%20P.%2C%20M%26%23xE9%3Bcha%26%23xEF%3B%2C%20F.%2C%20Tiberi%2C%20S.%2C%20Leth%2C%20F.%20van%2C%20Veziris%2C%20N.%20and%20Lange%2C%20C.%20%282022%29.%20%3Cb%3ERifapentine%20access%20in%20Europe%3A%20growing%20concerns%20over%20key%20tuberculosis%20treatment%20component%3C%5C%2Fb%3E.%20European%20Respiratory%20Journal%20%3Ci%3E59%3C%5C%2Fi%3E%2C%20%3Ca%20target%3D%27_blank%27%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1183%5C%2F13993003.00388-2022%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1183%5C%2F13993003.00388-2022%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Rifapentine%20access%20in%20Europe%3A%20growing%20concerns%20over%20key%20tuberculosis%20treatment%20component%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lorenzo%22%2C%22lastName%22%3A%22Guglielmetti%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gunar%22%2C%22lastName%22%3A%22G%5Cu00fcnther%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Claude%22%2C%22lastName%22%3A%22Leu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Daniela%22%2C%22lastName%22%3A%22Cirillo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Raquel%22%2C%22lastName%22%3A%22Duarte%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alberto%20L.%22%2C%22lastName%22%3A%22Garcia-Basteiro%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Delia%22%2C%22lastName%22%3A%22Goletti%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mateja%22%2C%22lastName%22%3A%22Jankovic%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Liga%22%2C%22lastName%22%3A%22Kuksa%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Florian%20P.%22%2C%22lastName%22%3A%22Maurer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fr%5Cu00e9d%5Cu00e9ric%22%2C%22lastName%22%3A%22M%5Cu00e9cha%5Cu00ef%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Simon%22%2C%22lastName%22%3A%22Tiberi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Frank%20van%22%2C%22lastName%22%3A%22Leth%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nicolas%22%2C%22lastName%22%3A%22Veziris%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christoph%22%2C%22lastName%22%3A%22Lange%22%7D%5D%2C%22abstractNote%22%3A%22Tweetable%20abstract%20%40ERSpublications%5Cnclick%20to%20tweetLack%20of%20access%20to%20rifapentine%20in%20Europe%20denies%20patients%20optimal%20care%20for%20active%20tuberculosis%20and%20latent%20tuberculosis%20infection%2C%20and%20deprives%20healthcare%20providers%20of%20adequate%20tools%20to%20pursue%20tuberculosis%20control%20and%20elimination%20https%3A%5C%2F%5C%2Fbit.ly%5C%2F3jz85eh%22%2C%22date%22%3A%222022%5C%2F05%5C%2F01%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1183%5C%2F13993003.00388-2022%22%2C%22ISSN%22%3A%220903-1936%2C%201399-3003%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Ferj.ersjournals.com%5C%2Fcontent%5C%2F59%5C%2F5%5C%2F2200388%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222022-06-29T14%3A23%3A00Z%22%7D%7D%2C%7B%22key%22%3A%22DP27S3F7%22%2C%22library%22%3A%7B%22id%22%3A1368488%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Le%20Ray%20et%20al.%22%2C%22parsedDate%22%3A%222022-05%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3ELe%20Ray%2C%20L.%20F.%2C%20Aubry%2C%20A.%2C%20Sougakoff%2C%20W.%2C%20Revest%2C%20M.%2C%20Robert%2C%20J.%2C%20Bonnet%2C%20I.%2C%20Veziris%2C%20N.%20and%20Morel%2C%20F.%20%282022%29.%20%3Cb%3EatpE%20Mutation%20in%20Mycobacterium%20tuberculosis%20Not%20Always%20Predictive%20of%20Bedaquiline%20Treatment%20Failure%3C%5C%2Fb%3E.%20Emerg%20Infect%20Dis%20%3Ci%3E28%3C%5C%2Fi%3E%2C%201062%26%23x2013%3B1064%2C%20%3Ca%20target%3D%27_blank%27%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.3201%5C%2Feid2805.212517%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.3201%5C%2Feid2805.212517%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22atpE%20Mutation%20in%20Mycobacterium%20tuberculosis%20Not%20Always%20Predictive%20of%20Bedaquiline%20Treatment%20Failure%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laure%20Fournier%22%2C%22lastName%22%3A%22Le%20Ray%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alexandra%22%2C%22lastName%22%3A%22Aubry%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Wladimir%22%2C%22lastName%22%3A%22Sougakoff%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Matthieu%22%2C%22lastName%22%3A%22Revest%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%5Cu00e9r%5Cu00f4me%22%2C%22lastName%22%3A%22Robert%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Isabelle%22%2C%22lastName%22%3A%22Bonnet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nicolas%22%2C%22lastName%22%3A%22Veziris%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Florence%22%2C%22lastName%22%3A%22Morel%22%7D%5D%2C%22abstractNote%22%3A%22We%20report%20the%20emergence%20of%20an%20atpE%20mutation%20in%20a%20clinical%20Mycobacterium%20tuberculosis%20strain.%20Genotypic%20and%20phenotypic%20bedaquiline%20susceptibility%20testing%20displayed%20variable%20results%20over%20time%20and%20ultimately%20were%20not%20predictive%20of%20treatment%20outcome.%20This%20observation%20highlights%20the%20limits%20of%20current%20genotypic%20and%20phenotypic%20methods%20for%20detection%20of%20bedaquiline%20resistance.%22%2C%22date%22%3A%222022-5%22%2C%22language%22%3A%22%22%2C%22DOI%22%3A%2210.3201%5C%2Feid2805.212517%22%2C%22ISSN%22%3A%221080-6040%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fwww.ncbi.nlm.nih.gov%5C%2Fpmc%5C%2Farticles%5C%2FPMC9045433%5C%2F%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222022-07-06T13%3A29%3A33Z%22%7D%7D%2C%7B%22key%22%3A%22QDAG4PLL%22%2C%22library%22%3A%7B%22id%22%3A1368488%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Group%20et%20al.%22%2C%22parsedDate%22%3A%222022-04-01%22%2C%22numChildren%22%3A3%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EGroup%2C%20A.%20S.%20T.%2C%20Georghiou%2C%20S.%20B.%2C%20Rodwell%2C%20T.%20C.%2C%20Korobitsyn%2C%20A.%2C%20Abbadi%2C%20S.%20H.%2C%20Ajbani%2C%20K.%2C%20Alffenaar%2C%20J.-W.%2C%20Alland%2C%20D.%2C%20Alvarez%2C%20N.%2C%20Andres%2C%20S.%2C%20Ardizzoni%2C%20E.%2C%20Aubry%2C%20A.%2C%20Baldan%2C%20R.%2C%20Ballif%2C%20M.%2C%20Barilar%2C%20I.%2C%20B%26%23xF6%3Bttger%2C%20E.%20C.%2C%20Chakravorty%2C%20S.%2C%20Claxton%2C%20P.%20M.%2C%20Cirillo%2C%20D.%20M.%2C%20Comas%2C%20I.%2C%20Coulter%2C%20C.%2C%20Denkinger%2C%20C.%20M.%2C%20Derendinger%2C%20B.%2C%20Desmond%2C%20E.%20P.%2C%20Steenwinkel%2C%20J.%20E.%20M.%20de%2C%20Dheda%2C%20K.%2C%20Diacon%2C%20A.%20H.%2C%20Dolinger%2C%20D.%20L.%2C%20Dooley%2C%20K.%20E.%2C%20Egger%2C%20M.%2C%20Ehsani%2C%20S.%2C%20Farhat%2C%20M.%20R.%2C%20Fattorini%2C%20L.%2C%20Finci%2C%20I.%2C%20Ray%2C%20L.%20F.%20L.%2C%20Furi%26%23xF3%3B%2C%20V.%2C%20Groenheit%2C%20R.%2C%20Gumbo%2C%20T.%2C%20Heysell%2C%20S.%20K.%2C%20Hillemann%2C%20D.%2C%20Hoffmann%2C%20H.%2C%20Hsueh%2C%20P.-R.%2C%20Hu%2C%20Y.%2C%20Huang%2C%20H.%2C%20Hussain%2C%20A.%2C%20Ismail%2C%20F.%2C%20Izumi%2C%20K.%2C%20Jagielski%2C%20T.%2C%20Johnson%2C%20J.%20L.%2C%20Kambli%2C%20P.%2C%20Kaniga%2C%20K.%2C%20Karunaratne%2C%20G.%20H.%20R.%20E.%2C%20Sharma%2C%20M.%20K.%2C%20Keller%2C%20P.%20M.%2C%20Kelly%2C%20E.%20C.%2C%20Kholina%2C%20M.%2C%20Kohli%2C%20M.%2C%20Kranzer%2C%20K.%2C%20Laurenson%2C%20I.%20F.%2C%20Limberis%2C%20J.%2C%20Lin%2C%20S.-Y.%20G.%2C%20Liu%2C%20Y.%2C%20L%26%23xF3%3Bpez-Gav%26%23xED%3Bn%2C%20A.%2C%20Lyander%2C%20A.%2C%20Machado%2C%20D.%2C%20Martinez%2C%20E.%2C%20Masood%2C%20F.%2C%20Mitarai%2C%20S.%2C%20Mvelase%2C%20N.%20R.%2C%20Niemann%2C%20S.%2C%20Nikolayevskyy%2C%20V.%2C%20Maurer%2C%20F.%20P.%2C%20Merker%2C%20M.%2C%20Miotto%2C%20P.%2C%20Omar%2C%20S.%20V.%2C%20Otto-Knapp%2C%20R.%2C%20Palaci%2C%20M.%2C%20Guti%26%23xE9%3Brrez%2C%20J.%20J.%20P.%2C%20Peacock%2C%20S.%20J.%2C%20Peloquin%2C%20C.%20A.%2C%20Perera%2C%20J.%2C%20Pierre-Audigier%2C%20C.%2C%20Pholwat%2C%20S.%2C%20Posey%2C%20J.%20E.%2C%20Prammananan%2C%20T.%2C%20Rigouts%2C%20L.%2C%20Robledo%2C%20J.%2C%20Rockwood%2C%20N.%2C%20Rodrigues%2C%20C.%2C%20Salfinger%2C%20M.%2C%20Schechter%2C%20M.%20C.%2C%20Seifert%2C%20M.%2C%20Sengstake%2C%20S.%2C%20Shinnick%2C%20T.%2C%20Shubladze%2C%20N.%2C%20Sintchenko%2C%20V.%2C%20Sirgel%2C%20F.%2C%20Somasundaram%2C%20S.%2C%20Sterling%2C%20T.%20R.%2C%20Spitaleri%2C%20A.%2C%20Streicher%2C%20E.%2C%20Supply%2C%20P.%2C%20Svensson%2C%20E.%2C%20Tagliani%2C%20E.%2C%20Tahseen%2C%20S.%2C%20Takaki%2C%20A.%2C%20Theron%2C%20G.%2C%20Torrea%2C%20G.%2C%20Deun%2C%20A.%20V.%2C%20Ingen%2C%20J.%20van%2C%20Rie%2C%20A.%20V.%2C%20Soolingen%2C%20D.%20van%2C%20Jr%2C%20R.%20V.%2C%20Venter%2C%20A.%2C%20Veziris%2C%20N.%2C%20Villellas%2C%20C.%2C%20Viveiros%2C%20M.%2C%20Warren%2C%20R.%2C%20Wen%2C%20S.%2C%20Werngren%2C%20J.%2C%20Wilkinson%2C%20R.%20J.%2C%20Yang%2C%20C.%2C%20Y%26%23x131%3Blmaz%2C%20F.%20F.%2C%20Zhang%2C%20T.%2C%20Zimenkov%2C%20D.%2C%20Ismail%2C%20N.%2C%20K%26%23xF6%3Bser%2C%20C.%20U.%20and%20Sch%26%23xF6%3Bn%2C%20T.%20%282022%29.%20%3Cb%3EUpdating%20the%20approaches%20to%20define%20susceptibility%20and%20resistance%20to%20anti-tuberculosis%20agents%3A%20implications%20for%20diagnosis%20and%20treatment%3C%5C%2Fb%3E.%20European%20Respiratory%20Journal%20%3Ci%3E59%3C%5C%2Fi%3E%2C%20%3Ca%20target%3D%27_blank%27%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1183%5C%2F13993003.00166-2022%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1183%5C%2F13993003.00166-2022%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Updating%20the%20approaches%20to%20define%20susceptibility%20and%20resistance%20to%20anti-tuberculosis%20agents%3A%20implications%20for%20diagnosis%20and%20treatment%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Antimycobacterial%20Susceptibility%20Testing%22%2C%22lastName%22%3A%22Group%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sophia%20B.%22%2C%22lastName%22%3A%22Georghiou%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Timothy%20C.%22%2C%22lastName%22%3A%22Rodwell%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alexei%22%2C%22lastName%22%3A%22Korobitsyn%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Said%20H.%22%2C%22lastName%22%3A%22Abbadi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kanchan%22%2C%22lastName%22%3A%22Ajbani%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jan-Willem%22%2C%22lastName%22%3A%22Alffenaar%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22David%22%2C%22lastName%22%3A%22Alland%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nataly%22%2C%22lastName%22%3A%22Alvarez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S%5Cu00f6nke%22%2C%22lastName%22%3A%22Andres%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Elisa%22%2C%22lastName%22%3A%22Ardizzoni%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alexandra%22%2C%22lastName%22%3A%22Aubry%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Rossella%22%2C%22lastName%22%3A%22Baldan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marie%22%2C%22lastName%22%3A%22Ballif%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ivan%22%2C%22lastName%22%3A%22Barilar%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Erik%20C.%22%2C%22lastName%22%3A%22B%5Cu00f6ttger%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Soumitesh%22%2C%22lastName%22%3A%22Chakravorty%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pauline%20M.%22%2C%22lastName%22%3A%22Claxton%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Daniela%20M.%22%2C%22lastName%22%3A%22Cirillo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22I%5Cu00f1aki%22%2C%22lastName%22%3A%22Comas%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Chris%22%2C%22lastName%22%3A%22Coulter%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Claudia%20M.%22%2C%22lastName%22%3A%22Denkinger%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Brigitta%22%2C%22lastName%22%3A%22Derendinger%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Edward%20P.%22%2C%22lastName%22%3A%22Desmond%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jurriaan%20E.%20M.%20de%22%2C%22lastName%22%3A%22Steenwinkel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Keertan%22%2C%22lastName%22%3A%22Dheda%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Andreas%20H.%22%2C%22lastName%22%3A%22Diacon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22David%20L.%22%2C%22lastName%22%3A%22Dolinger%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kelly%20E.%22%2C%22lastName%22%3A%22Dooley%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Matthias%22%2C%22lastName%22%3A%22Egger%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Soudeh%22%2C%22lastName%22%3A%22Ehsani%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Maha%20R.%22%2C%22lastName%22%3A%22Farhat%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lanfranco%22%2C%22lastName%22%3A%22Fattorini%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Iris%22%2C%22lastName%22%3A%22Finci%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laure%20Fournier%20Le%22%2C%22lastName%22%3A%22Ray%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Victoria%22%2C%22lastName%22%3A%22Furi%5Cu00f3%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ramona%22%2C%22lastName%22%3A%22Groenheit%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Tawanda%22%2C%22lastName%22%3A%22Gumbo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Scott%20K.%22%2C%22lastName%22%3A%22Heysell%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Doris%22%2C%22lastName%22%3A%22Hillemann%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Harald%22%2C%22lastName%22%3A%22Hoffmann%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Po-Ren%22%2C%22lastName%22%3A%22Hsueh%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yi%22%2C%22lastName%22%3A%22Hu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Hairong%22%2C%22lastName%22%3A%22Huang%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alamdar%22%2C%22lastName%22%3A%22Hussain%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Farzana%22%2C%22lastName%22%3A%22Ismail%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kiyohiko%22%2C%22lastName%22%3A%22Izumi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Tomasz%22%2C%22lastName%22%3A%22Jagielski%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22John%20L.%22%2C%22lastName%22%3A%22Johnson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Priti%22%2C%22lastName%22%3A%22Kambli%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kon%5Cu00e9%22%2C%22lastName%22%3A%22Kaniga%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22G.%20H.%20R.%20Eranga%22%2C%22lastName%22%3A%22Karunaratne%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Meenu%20Kaushal%22%2C%22lastName%22%3A%22Sharma%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Peter%20M.%22%2C%22lastName%22%3A%22Keller%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ellis%20C.%22%2C%22lastName%22%3A%22Kelly%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Margarita%22%2C%22lastName%22%3A%22Kholina%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mikashmi%22%2C%22lastName%22%3A%22Kohli%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Katharina%22%2C%22lastName%22%3A%22Kranzer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ian%20F.%22%2C%22lastName%22%3A%22Laurenson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jason%22%2C%22lastName%22%3A%22Limberis%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.-Y.%20Grace%22%2C%22lastName%22%3A%22Lin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yongge%22%2C%22lastName%22%3A%22Liu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alexandre%22%2C%22lastName%22%3A%22L%5Cu00f3pez-Gav%5Cu00edn%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anna%22%2C%22lastName%22%3A%22Lyander%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Diana%22%2C%22lastName%22%3A%22Machado%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Elena%22%2C%22lastName%22%3A%22Martinez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Faisal%22%2C%22lastName%22%3A%22Masood%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Satoshi%22%2C%22lastName%22%3A%22Mitarai%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nomonde%20R.%22%2C%22lastName%22%3A%22Mvelase%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Stefan%22%2C%22lastName%22%3A%22Niemann%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Vladyslav%22%2C%22lastName%22%3A%22Nikolayevskyy%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Florian%20P.%22%2C%22lastName%22%3A%22Maurer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Matthias%22%2C%22lastName%22%3A%22Merker%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Paolo%22%2C%22lastName%22%3A%22Miotto%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Shaheed%20V.%22%2C%22lastName%22%3A%22Omar%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ralf%22%2C%22lastName%22%3A%22Otto-Knapp%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mois%5Cu00e9s%22%2C%22lastName%22%3A%22Palaci%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Juan%20Jos%5Cu00e9%20Palacios%22%2C%22lastName%22%3A%22Guti%5Cu00e9rrez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sharon%20J.%22%2C%22lastName%22%3A%22Peacock%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Charles%20A.%22%2C%22lastName%22%3A%22Peloquin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jennifer%22%2C%22lastName%22%3A%22Perera%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Catherine%22%2C%22lastName%22%3A%22Pierre-Audigier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Suporn%22%2C%22lastName%22%3A%22Pholwat%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22James%20E.%22%2C%22lastName%22%3A%22Posey%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Therdsak%22%2C%22lastName%22%3A%22Prammananan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Leen%22%2C%22lastName%22%3A%22Rigouts%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jaime%22%2C%22lastName%22%3A%22Robledo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Neesha%22%2C%22lastName%22%3A%22Rockwood%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Camilla%22%2C%22lastName%22%3A%22Rodrigues%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Max%22%2C%22lastName%22%3A%22Salfinger%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marcos%20C.%22%2C%22lastName%22%3A%22Schechter%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marva%22%2C%22lastName%22%3A%22Seifert%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sarah%22%2C%22lastName%22%3A%22Sengstake%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thomas%22%2C%22lastName%22%3A%22Shinnick%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Natalia%22%2C%22lastName%22%3A%22Shubladze%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Vitali%22%2C%22lastName%22%3A%22Sintchenko%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Frederick%22%2C%22lastName%22%3A%22Sirgel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sulochana%22%2C%22lastName%22%3A%22Somasundaram%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Timothy%20R.%22%2C%22lastName%22%3A%22Sterling%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Andrea%22%2C%22lastName%22%3A%22Spitaleri%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Elizabeth%22%2C%22lastName%22%3A%22Streicher%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Philip%22%2C%22lastName%22%3A%22Supply%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Erik%22%2C%22lastName%22%3A%22Svensson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Elisa%22%2C%22lastName%22%3A%22Tagliani%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sabira%22%2C%22lastName%22%3A%22Tahseen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Akiko%22%2C%22lastName%22%3A%22Takaki%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Grant%22%2C%22lastName%22%3A%22Theron%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gabriela%22%2C%22lastName%22%3A%22Torrea%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Armand%20Van%22%2C%22lastName%22%3A%22Deun%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jakko%20van%22%2C%22lastName%22%3A%22Ingen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Annelies%20Van%22%2C%22lastName%22%3A%22Rie%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Dick%20van%22%2C%22lastName%22%3A%22Soolingen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Roger%20Vargas%22%2C%22lastName%22%3A%22Jr%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Amour%22%2C%22lastName%22%3A%22Venter%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nicolas%22%2C%22lastName%22%3A%22Veziris%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Cristina%22%2C%22lastName%22%3A%22Villellas%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Miguel%22%2C%22lastName%22%3A%22Viveiros%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Robin%22%2C%22lastName%22%3A%22Warren%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Shu%27an%22%2C%22lastName%22%3A%22Wen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jim%22%2C%22lastName%22%3A%22Werngren%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Robert%20J.%22%2C%22lastName%22%3A%22Wilkinson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Caie%22%2C%22lastName%22%3A%22Yang%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22F.%20Ferda%22%2C%22lastName%22%3A%22Y%5Cu0131lmaz%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Tingting%22%2C%22lastName%22%3A%22Zhang%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Danila%22%2C%22lastName%22%3A%22Zimenkov%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nazir%22%2C%22lastName%22%3A%22Ismail%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Claudio%20U.%22%2C%22lastName%22%3A%22K%5Cu00f6ser%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thomas%22%2C%22lastName%22%3A%22Sch%5Cu00f6n%22%7D%5D%2C%22abstractNote%22%3A%22Tweetable%20abstract%20%40ERSpublications%5Cnclick%20to%20tweetInappropriately%20high%20breakpoints%20have%20resulted%20in%20systematic%20false-susceptible%20AST%20results%20to%20anti-TB%20drugs.%20MIC%2C%20PK%5C%2FPD%20and%20clinical%20outcome%20data%20should%20be%20combined%20when%20setting%20breakpoints%20to%20minimise%20the%20emergence%20and%20spread%20of%20antimicrobial%20resistance.%20https%3A%5C%2F%5C%2Fbit.ly%5C%2F3i43wb6%22%2C%22date%22%3A%222022%5C%2F04%5C%2F01%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1183%5C%2F13993003.00166-2022%22%2C%22ISSN%22%3A%220903-1936%2C%201399-3003%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Ferj.ersjournals.com%5C%2Fcontent%5C%2F59%5C%2F4%5C%2F2200166%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222022-06-29T14%3A23%3A32Z%22%7D%7D%2C%7B%22key%22%3A%22EDWVUW7S%22%2C%22library%22%3A%7B%22id%22%3A1368488%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Tunesi%20et%20al.%22%2C%22parsedDate%22%3A%222022-03-07%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3ETunesi%2C%20S.%2C%20D%26%23xFB%3B%2C%20D.%20L.%2C%20Gualano%2C%20G.%2C%20Millet%2C%20J.-P.%2C%20Skrahin%2C%20A.%2C%20Bothamley%2C%20G.%2C%20Casas%2C%20X.%2C%20Goletti%2C%20D.%2C%20Lange%2C%20C.%2C%20Musso%2C%20M.%2C%20Palmieri%2C%20F.%2C%20Pourcher%2C%20V.%2C%20Rioux%2C%20C.%2C%20Skrahina%2C%20A.%2C%20Veziris%2C%20N.%2C%20Viatushka%2C%20D.%2C%20Jachym-Fr%26%23xE9%3Bchet%2C%20M.%20and%20Guglielmetti%2C%20L.%20%282022%29.%20%3Cb%3ECo-administration%20of%20treatment%20for%20rifampicin-resistant%20TB%20and%20chronic%20HCV%20infection%3A%20a%20TBnet%20and%20ESGMYC%20study%3C%5C%2Fb%3E.%20Journal%20of%20Infection%2C%20%3Ca%20target%3D%27_blank%27%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.jinf.2022.03.004%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.jinf.2022.03.004%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Co-administration%20of%20treatment%20for%20rifampicin-resistant%20TB%20and%20chronic%20HCV%20infection%3A%20a%20TBnet%20and%20ESGMYC%20study%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Simone%22%2C%22lastName%22%3A%22Tunesi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Damien%20Le%22%2C%22lastName%22%3A%22D%5Cu00fb%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gina%22%2C%22lastName%22%3A%22Gualano%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Joan-Pau%22%2C%22lastName%22%3A%22Millet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Aliaksandr%22%2C%22lastName%22%3A%22Skrahin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Graham%22%2C%22lastName%22%3A%22Bothamley%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Xavier%22%2C%22lastName%22%3A%22Casas%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Delia%22%2C%22lastName%22%3A%22Goletti%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christoph%22%2C%22lastName%22%3A%22Lange%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Maria%22%2C%22lastName%22%3A%22Musso%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fabrizio%22%2C%22lastName%22%3A%22Palmieri%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Val%5Cu00e9rie%22%2C%22lastName%22%3A%22Pourcher%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christophe%22%2C%22lastName%22%3A%22Rioux%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alena%22%2C%22lastName%22%3A%22Skrahina%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nicolas%22%2C%22lastName%22%3A%22Veziris%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Dzmitry%22%2C%22lastName%22%3A%22Viatushka%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mathilde%22%2C%22lastName%22%3A%22Jachym-Fr%5Cu00e9chet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lorenzo%22%2C%22lastName%22%3A%22Guglielmetti%22%7D%5D%2C%22abstractNote%22%3A%22%22%2C%22date%22%3A%222022-03-07%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1016%5C%2Fj.jinf.2022.03.004%22%2C%22ISSN%22%3A%220163-4453%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fwww.sciencedirect.com%5C%2Fscience%5C%2Farticle%5C%2Fpii%5C%2FS016344532200130X%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222022-03-16T14%3A21%3A35Z%22%7D%7D%2C%7B%22key%22%3A%22M3NEXJYZ%22%2C%22library%22%3A%7B%22id%22%3A1368488%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Migliori%20et%20al.%22%2C%22parsedDate%22%3A%222022-03%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EMigliori%2C%20G.%20B.%2C%20Wu%2C%20S.%20J.%2C%20Matteelli%2C%20A.%2C%20Zenner%2C%20D.%2C%20Goletti%2C%20D.%2C%20Ahmedov%2C%20S.%2C%20Al-Abri%2C%20S.%2C%20Allen%2C%20D.%20M.%2C%20Balcells%2C%20M.%20E.%2C%20Garcia-Basteiro%2C%20A.%20L.%2C%20Cambau%2C%20E.%2C%20Chaisson%2C%20R.%20E.%2C%20Chee%2C%20C.%20B.%20E.%2C%20Dalcolmo%2C%20M.%20P.%2C%20Denholm%2C%20J.%20T.%2C%20Erkens%2C%20C.%2C%20Esposito%2C%20S.%2C%20Farnia%2C%20P.%2C%20Friedland%2C%20J.%20S.%2C%20Graham%2C%20S.%2C%20Hamada%2C%20Y.%2C%20Harries%2C%20A.%20D.%2C%20Kay%2C%20A.%20W.%2C%20Kritski%2C%20A.%2C%20Manga%2C%20S.%2C%20Marais%2C%20B.%20J.%2C%20Menzies%2C%20D.%2C%20Ng%2C%20D.%2C%20Petrone%2C%20L.%2C%20Rendon%2C%20A.%2C%20Silva%2C%20D.%20R.%2C%20Schaaf%2C%20H.%20S.%2C%20Skrahina%2C%20A.%2C%20Sotgiu%2C%20G.%2C%20Thwaites%2C%20G.%2C%20Tiberi%2C%20S.%2C%20Tukvadze%2C%20N.%2C%20Zellweger%2C%20J.-P.%2C%20D%26%23x2019%3BAmbrosio%2C%20L.%2C%20Centis%2C%20R.%20and%20Ong%2C%20C.%20W.%20M.%20%282022%29.%20%3Cb%3EClinical%20standards%20for%20the%20diagnosis%2C%20treatment%20and%20prevention%20of%20TB%20infection%3C%5C%2Fb%3E.%20Int%20J%20Tuberc%20Lung%20Dis%20%3Ci%3E26%3C%5C%2Fi%3E%2C%20190%26%23x2013%3B205%2C%20%3Ca%20target%3D%27_blank%27%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.5588%5C%2Fijtld.21.0753%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.5588%5C%2Fijtld.21.0753%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Clinical%20standards%20for%20the%20diagnosis%2C%20treatment%20and%20prevention%20of%20TB%20infection%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22G.%20B.%22%2C%22lastName%22%3A%22Migliori%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%20J.%22%2C%22lastName%22%3A%22Wu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Matteelli%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22D.%22%2C%22lastName%22%3A%22Zenner%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22D.%22%2C%22lastName%22%3A%22Goletti%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%22%2C%22lastName%22%3A%22Ahmedov%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%22%2C%22lastName%22%3A%22Al-Abri%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22D.%20M.%22%2C%22lastName%22%3A%22Allen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%20E.%22%2C%22lastName%22%3A%22Balcells%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%20L.%22%2C%22lastName%22%3A%22Garcia-Basteiro%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E.%22%2C%22lastName%22%3A%22Cambau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R.%20E.%22%2C%22lastName%22%3A%22Chaisson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%20B.%20E.%22%2C%22lastName%22%3A%22Chee%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%20P.%22%2C%22lastName%22%3A%22Dalcolmo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%20T.%22%2C%22lastName%22%3A%22Denholm%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%22%2C%22lastName%22%3A%22Erkens%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%22%2C%22lastName%22%3A%22Esposito%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P.%22%2C%22lastName%22%3A%22Farnia%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%20S.%22%2C%22lastName%22%3A%22Friedland%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%22%2C%22lastName%22%3A%22Graham%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Y.%22%2C%22lastName%22%3A%22Hamada%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%20D.%22%2C%22lastName%22%3A%22Harries%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%20W.%22%2C%22lastName%22%3A%22Kay%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Kritski%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%22%2C%22lastName%22%3A%22Manga%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22B.%20J.%22%2C%22lastName%22%3A%22Marais%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22D.%22%2C%22lastName%22%3A%22Menzies%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22D.%22%2C%22lastName%22%3A%22Ng%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L.%22%2C%22lastName%22%3A%22Petrone%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Rendon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22D.%20R.%22%2C%22lastName%22%3A%22Silva%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22H.%20S.%22%2C%22lastName%22%3A%22Schaaf%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Skrahina%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22G.%22%2C%22lastName%22%3A%22Sotgiu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22G.%22%2C%22lastName%22%3A%22Thwaites%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%22%2C%22lastName%22%3A%22Tiberi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22N.%22%2C%22lastName%22%3A%22Tukvadze%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.-P.%22%2C%22lastName%22%3A%22Zellweger%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L.%22%2C%22lastName%22%3A%22D%5Cu2019Ambrosio%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R.%22%2C%22lastName%22%3A%22Centis%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%20W.%20M.%22%2C%22lastName%22%3A%22Ong%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%3A%5CnTuberculosis%20%28TB%29%20preventive%20therapy%20%28TPT%29%20decreases%20the%20risk%20of%20developing%20TB%20disease%20and%20its%20associated%20morbidity%20and%20mortality.%20The%20aim%20of%20these%20clinical%20standards%20is%20to%20guide%20the%20assessment%2C%20management%20of%20TB%20infection%20%28TBI%29%20and%20implementation%20of%20TPT.%5Cn%5CnMETHODS%3A%5CnA%20panel%20of%20global%20experts%20in%20the%20field%20of%20TB%20care%20was%20identified%3B%2041%20participated%20in%20a%20Delphi%20process.%20A%205-point%20Likert%20scale%20was%20used%20to%20score%20the%20initial%20standards.%20After%20rounds%20of%20revision%2C%20the%20document%20was%20approved%20with%20100%25%20agreement.%5Cn%5CnRESULTS%3A%5CnEight%20clinical%20standards%20were%20defined%3A%20Standard%201%2C%20all%20individuals%20belonging%20to%20at-risk%20groups%20for%20TB%20should%20undergo%20testing%20for%20TBI%3B%20Standard%202%2C%20all%20individual%20candidates%20for%20TPT%20%28including%20caregivers%20of%20children%29%20should%20undergo%20a%20counselling%5C%2Fhealth%20education%20session%3B%20Standard%203%2C%20testing%20for%20TBI%3A%20timing%20and%20test%20of%20choice%20should%20be%20optimised%3B%20Standard%204%2C%20TB%20disease%20should%20be%20excluded%20prior%20to%20initiation%20of%20TPT%3B%20Standard%205%2C%20all%20candidates%20for%20TPT%20should%20undergo%20a%20set%20of%20baseline%20examinations%3B%20Standard%206%2C%20all%20individuals%20initiating%20TPT%20should%20receive%20one%20of%20the%20recommended%20regimens%3B%20Standard%207%2C%20all%20individuals%20who%20have%20started%20TPT%20should%20be%20monitored%3B%20Standard%208%2C%20a%20TBI%20screening%20and%20testing%20register%20should%20be%20kept%20to%20inform%20the%20cascade%20of%20care.%5Cn%5CnCONCLUSION%3A%5CnThis%20is%20the%20first%20consensus-based%20set%20of%20Clinical%20Standards%20for%20TBI.%20This%20document%20guides%20clinicians%2C%20programme%20managers%20and%20public%20health%20officers%20in%20planning%20and%20implementing%20adequate%20measures%20to%20assess%20and%20manage%20TBI.%22%2C%22date%22%3A%222022-3%22%2C%22language%22%3A%22%22%2C%22DOI%22%3A%2210.5588%5C%2Fijtld.21.0753%22%2C%22ISSN%22%3A%221027-3719%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fwww.ncbi.nlm.nih.gov%5C%2Fpmc%5C%2Farticles%5C%2FPMC8886963%5C%2F%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222022-05-26T21%3A18%3A54Z%22%7D%7D%2C%7B%22key%22%3A%22MY9BQ8HY%22%2C%22library%22%3A%7B%22id%22%3A1368488%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Guyeux%20et%20al.%22%2C%22parsedDate%22%3A%222022%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EGuyeux%2C%20C.%2C%20Senelle%2C%20G.%2C%20Refr%26%23xE9%3Bgier%2C%20G.%2C%20Bretelle-Establet%2C%20F.%2C%20Cambau%2C%20E.%20and%20Sola%2C%20C.%20%282022%29.%20%3Cb%3EConnection%20between%20two%20historical%20tuberculosis%20outbreak%20sites%20in%20Japan%2C%20Honshu%2C%20by%20a%20new%20ancestral%20Mycobacterium%20tuberculosis%20L2%20sublineage%3C%5C%2Fb%3E.%20Epidemiology%20%26amp%3B%20Infection%20%3Ci%3E150%3C%5C%2Fi%3E%2C%20%3Ca%20target%3D%27_blank%27%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1017%5C%2FS0950268822000048%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1017%5C%2FS0950268822000048%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Connection%20between%20two%20historical%20tuberculosis%20outbreak%20sites%20in%20Japan%2C%20Honshu%2C%20by%20a%20new%20ancestral%20Mycobacterium%20tuberculosis%20L2%20sublineage%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christophe%22%2C%22lastName%22%3A%22Guyeux%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gaetan%22%2C%22lastName%22%3A%22Senelle%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Guislaine%22%2C%22lastName%22%3A%22Refr%5Cu00e9gier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Florence%22%2C%22lastName%22%3A%22Bretelle-Establet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Emmanuelle%22%2C%22lastName%22%3A%22Cambau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christophe%22%2C%22lastName%22%3A%22Sola%22%7D%5D%2C%22abstractNote%22%3A%22By%20gathering%20680%20publicly%20available%20Sequence%20Read%20Archives%20from%20isolates%20of%20Mycobacterium%20tuberculosis%20complex%20%28MTBC%29%20including%20190%20belonging%20to%20the%20lineage%202%20Beijing%2C%20and%20using%20an%20in-house%20bioinformatical%20pipeline%2C%20the%20TB-Annotator%2C%20that%20analyses%20more%20than%2050%20000%20characters%2C%20we%20describe%20herein%20a%20new%20L2%20sublineage%20from%2020%20isolates%20found%20in%20the%20Tochigi%20province%2C%20%28Japan%29%2C%20that%20we%20designate%20as%20asia%20ancestral%205%20%28AAnc5%29.%20These%20isolates%20harbour%20a%20number%20of%20specific%20criteria%20%2842%20SNPs%29%20and%20their%20intra-cluster%20pairwise%20distance%20suggests%20historical%20and%20not%20epidemiological%20transmission.%20These%20isolates%20harbour%20a%20mutation%20in%20rpoC%2C%20and%20do%20not%20fulfil%2C%20any%20of%20the%20modern%20Beijing%20lineage%20criteria%2C%20nor%20any%20of%20the%20other%20ancestral%20Beijing%20lineages%20described%20so%20far.%20Asia%20ancestral%205%20isolates%20do%20not%20possess%20mutT2%2058%20and%20ogt%2012%20characteristics%20of%20modern%20Beijing%2C%20but%20possess%20ancestral%20Beijing%20SNPs%20characteristics.%20By%20looking%20into%20the%20literature%2C%20we%20found%20a%20reference%20isolate%20ID381%2C%20described%20in%20Kobe%20and%20Osaka%20belonging%20to%20the%20%5Cu2018G3%5Cu2019%20group%2C%20sharing%2036%20out%20of%20the%2042%20specific%20SNPs%20found%20in%20AAnc5.%20We%20also%20assessed%20the%20intermediate%20position%20of%20the%20asia%20ancestral%204%20%28AAnc4%29%20sublineage%20recently%20described%20in%20Thailand%20and%20propose%20an%20improved%20classification%20of%20the%20L2%20that%20now%20includes%20AAnc4%20and%20AAnc5.%20By%20increasing%20the%20recruitment%20into%20TB-Annotator%20to%20around%203000%20genomes%20%28including%20642%20belonging%20to%20L2%29%2C%20we%20confirmed%20our%20results%20and%20discovered%20additional%20historical%20ancestral%20L2%20branches%20that%20remain%20to%20be%20investigated%20in%20more%20detail.%20We%20also%20present%2C%20in%20addition%2C%20some%20anthropological%20and%20historical%20data%20from%20Chinese%20and%20Japan%20history%20of%20tuberculosis%2C%20as%20well%20as%20from%20Korea%2C%20that%20could%20support%20our%20results%20on%20L2%20evolution.%20This%20study%20shows%20that%20the%20reconstruction%20of%20the%20early%20history%20of%20tuberculosis%20in%20Asia%20is%20likely%20to%20reveal%20complex%20patterns%20since%20its%20emergence.%22%2C%22date%22%3A%222022%5C%2Fed%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1017%5C%2FS0950268822000048%22%2C%22ISSN%22%3A%220950-2688%2C%201469-4409%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fwww.cambridge.org%5C%2Fcore%5C%2Fjournals%5C%2Fepidemiology-and-infection%5C%2Farticle%5C%2Fconnection-between-two-historical-tuberculosis-outbreak-sites-in-japan-honshu-by-a-new-ancestral-mycobacterium-tuberculosis-l2-sublineage%5C%2F79482A3DD638BB99618B2CCDAA4EBC56%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222022-05-26T21%3A18%3A03Z%22%7D%7D%2C%7B%22key%22%3A%22JN9GMQY9%22%2C%22library%22%3A%7B%22id%22%3A1368488%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Nyang%5Cu2019wa%20et%20al.%22%2C%22parsedDate%22%3A%222021-12%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3ENyang%26%23x2019%3Bwa%2C%20B.%20T.%2C%20LaHood%2C%20A.%20N.%2C%20Mitnick%2C%20C.%20D.%20and%20Guglielmetti%2C%20L.%20%282021%29.%20%3Cb%3ETB%20research%20requires%20strong%20protections%2C%20innovation%2C%20and%20increased%20funding%20in%20response%20to%20COVID-19%3C%5C%2Fb%3E.%20Trials%20%3Ci%3E22%3C%5C%2Fi%3E%2C%201%26%23x2013%3B3%2C%20%3Ca%20target%3D%27_blank%27%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1186%5C%2Fs13063-021-05331-4%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1186%5C%2Fs13063-021-05331-4%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22TB%20research%20requires%20strong%20protections%2C%20innovation%2C%20and%20increased%20funding%20in%20response%20to%20COVID-19%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22B.%20T.%22%2C%22lastName%22%3A%22Nyang%5Cu2019wa%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%20N.%22%2C%22lastName%22%3A%22LaHood%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%20D.%22%2C%22lastName%22%3A%22Mitnick%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L.%22%2C%22lastName%22%3A%22Guglielmetti%22%7D%5D%2C%22abstractNote%22%3A%22%22%2C%22date%22%3A%222021%5C%2F12%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1186%5C%2Fs13063-021-05331-4%22%2C%22ISSN%22%3A%221745-6215%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Ftrialsjournal.biomedcentral.com%5C%2Farticles%5C%2F10.1186%5C%2Fs13063-021-05331-4%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222022-02-25T15%3A32%3A53Z%22%7D%7D%2C%7B%22key%22%3A%22WSG27KUJ%22%2C%22library%22%3A%7B%22id%22%3A1368488%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Bonnet%20et%20al.%22%2C%22parsedDate%22%3A%222021-10-29%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EBonnet%2C%20I.%2C%20Enouf%2C%20V.%2C%20Morel%2C%20F.%2C%20Ok%2C%20V.%2C%20Jaffr%26%23xE9%3B%2C%20J.%2C%20Jarlier%2C%20V.%2C%20Aubry%2C%20A.%2C%20Robert%2C%20J.%20and%20Sougakoff%2C%20W.%20%282021%29.%20%3Cb%3EA%20Comprehensive%20Evaluation%20of%20GeneLEAD%20VIII%20DNA%20Platform%20Combined%20to%20Deeplex%20Myc-TB%26%23xAE%3B%20Assay%20to%20Detect%20in%208%20Days%20Drug%20Resistance%20to%2013%20Antituberculous%20Drugs%20and%20Transmission%20of%20Mycobacterium%20tuberculosis%20Complex%20Directly%20From%20Clinical%20Samples%3C%5C%2Fb%3E.%20Front%20Cell%20Infect%20Microbiol%20%3Ci%3E11%3C%5C%2Fi%3E%2C%20707244%2C%20%3Ca%20target%3D%27_blank%27%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.3389%5C%2Ffcimb.2021.707244%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.3389%5C%2Ffcimb.2021.707244%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22A%20Comprehensive%20Evaluation%20of%20GeneLEAD%20VIII%20DNA%20Platform%20Combined%20to%20Deeplex%20Myc-TB%5Cu00ae%20Assay%20to%20Detect%20in%208%20Days%20Drug%20Resistance%20to%2013%20Antituberculous%20Drugs%20and%20Transmission%20of%20Mycobacterium%20tuberculosis%20Complex%20Directly%20From%20Clinical%20Samples%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Isabelle%22%2C%22lastName%22%3A%22Bonnet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Vincent%22%2C%22lastName%22%3A%22Enouf%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Florence%22%2C%22lastName%22%3A%22Morel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Vichita%22%2C%22lastName%22%3A%22Ok%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%5Cu00e9r%5Cu00e9my%22%2C%22lastName%22%3A%22Jaffr%5Cu00e9%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Vincent%22%2C%22lastName%22%3A%22Jarlier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alexandra%22%2C%22lastName%22%3A%22Aubry%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%5Cu00e9r%5Cu00f4me%22%2C%22lastName%22%3A%22Robert%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Wladimir%22%2C%22lastName%22%3A%22Sougakoff%22%7D%5D%2C%22abstractNote%22%3A%22The%20GeneLEAD%20VIII%20%28Diagenode%2C%20Belgium%29%20is%20a%20new%2C%20fully%20automated%2C%20sample-to-result%20precision%20instrument%20for%20the%20extraction%20of%20DNA%20and%20PCR%20detection%20of%20Mycobacterium%20tuberculosis%20complex%20%28MTBC%29%20directly%20from%20clinical%20samples.%20The%20Deeplex%20Myc-TB%5Cu00ae%20assay%20%28Genoscreen%2C%20France%29%20is%20a%20diagnostic%20kit%20based%20on%20the%20deep%20sequencing%20of%20a%2024-plexed%20amplicon%20mix%20allowing%20simultaneously%20the%20detection%20of%20resistance%20to%2013%20antituberculous%20%28antiTB%29%20drugs%20and%20the%20determination%20of%20spoligotype.%20We%20evaluated%20the%20performance%20of%20a%20strategy%20combining%20the%20both%20mentioned%20tools%20to%20detect%20directly%20from%20clinical%20samples%2C%20in%208%20days%2C%20MTBC%20and%20its%20resistance%20to%2013%20antiTB%20drugs%2C%20and%20identify%20potential%20transmission%20of%20strains%20from%20patient-to-patient.%20Using%20this%20approach%2C%20we%20screened%20112%20clinical%20samples%20%2865%20smear-negative%29%20and%2094%20MTBC%20cultured%20strains.%20The%20sensitivity%20and%20the%20specificity%20of%20the%20GeneLEAD%5C%2FDeeplex%20Myc-TB%20approach%20for%20MTBC%20detection%20were%2079.3%25%20and%20100%25%2C%20respectively.%20One%20hundred%20forty%20successful%20Deeplex%20Myc-TB%20results%20were%20obtained%20for%2046%20clinical%20samples%20and%2094%20strains%2C%20a%20total%20of%2085.4%25%20of%20which%20had%20a%20Deeplex%20Myc-TB%20susceptibility%20and%20resistance%20prediction%20consistent%20with%20phenotypic%20drug%20susceptibility%20testing%20%28DST%29.%20Importantly%2C%20the%20Deeplex%20Myc-TB%20assay%20was%20able%20to%20detect%20100%25%20of%20the%20multidrug-resistant%20%28MDR%29%20MTBC%20tested.%20The%20lowest%20concordance%20rates%20were%20for%20pyrazinamide%2C%20ethambutol%2C%20streptomycin%2C%20and%20ethionamide%20%2884.5%25%2C%2081.5%25%2C%2073%25%2C%20and%2055%25%2C%20respectively%29%20for%20which%20the%20determination%20of%20susceptibility%20or%20resistance%20is%20generally%20difficult%20with%20current%20tools.%20One%20of%20the%20main%20difficulties%20of%20Deeplex%20Myc-TB%20is%20to%20interpret%20the%20non-synonymous%20uncharacterized%20variants%20that%20can%20represent%20up%20to%2030%25%20of%20the%20detected%20single%20nucleotide%20variants.%20We%20observed%20a%20good%20level%20of%20concordance%20between%20Deeplex%20Myc-TB-spoligotyping%20and%20MIRU-VNTR%20despite%20a%20lower%20discriminatory%20power%20for%20spoligotyping.%20The%20median%20time%20to%20obtain%20complete%20results%20from%20clinical%20samples%20was%208%20days%20%28IQR%207%5Cu201313%29%20provided%20a%20high-throughput%20NGS%20sequencing%20platform%20was%20available.%20Our%20results%20highlight%20that%20the%20GeneLEAD%5C%2FDeeplex%20Myc-TB%20approach%20could%20be%20a%20breakthrough%20in%20rapid%20diagnosis%20of%20MDR%20TB%20in%20routine%20practice.%22%2C%22date%22%3A%222021-10-29%22%2C%22language%22%3A%22%22%2C%22DOI%22%3A%2210.3389%5C%2Ffcimb.2021.707244%22%2C%22ISSN%22%3A%222235-2988%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fwww.ncbi.nlm.nih.gov%5C%2Fpmc%5C%2Farticles%5C%2FPMC8586210%5C%2F%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222022-03-16T23%3A11%3A13Z%22%7D%7D%2C%7B%22key%22%3A%22WIAN9XI8%22%2C%22library%22%3A%7B%22id%22%3A1368488%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Guglielmetti%20et%20al.%22%2C%22parsedDate%22%3A%222021-09-25%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EGuglielmetti%2C%20L.%2C%20Ardizzoni%2C%20E.%2C%20Atger%2C%20M.%2C%20Baudin%2C%20E.%2C%20Berikova%2C%20E.%2C%20Bonnet%2C%20M.%2C%20Chang%2C%20E.%2C%20Cloez%2C%20S.%2C%20Coit%2C%20J.%20M.%2C%20Cox%2C%20V.%2C%20de%20Jong%2C%20B.%20C.%2C%20Delifer%2C%20C.%2C%20Do%2C%20J.%20M.%2C%20Tozzi%2C%20D.%20D.%20S.%2C%20Ducher%2C%20V.%2C%20Ferlazzo%2C%20G.%2C%20Gouillou%2C%20M.%2C%20Khan%2C%20A.%2C%20Khan%2C%20U.%2C%20Lachenal%2C%20N.%2C%20LaHood%2C%20A.%20N.%2C%20Lecca%2C%20L.%2C%20Mazmanian%2C%20M.%2C%20McIlleron%2C%20H.%2C%20Moschioni%2C%20M.%2C%20O%26%23x2019%3BBrien%2C%20K.%2C%20Okunbor%2C%20O.%2C%20Oyewusi%2C%20L.%2C%20Panda%2C%20S.%2C%20Patil%2C%20S.%20B.%2C%20Phillips%2C%20P.%20P.%20J.%2C%20Pichon%2C%20L.%2C%20Rupasinghe%2C%20P.%2C%20Rich%2C%20M.%20L.%2C%20Saluhuddin%2C%20N.%2C%20Seung%2C%20K.%20J.%2C%20Tamirat%2C%20M.%2C%20Trippa%2C%20L.%2C%20Cellamare%2C%20M.%2C%20Vel%26%23xE1%3Bsquez%2C%20G.%20E.%2C%20Wasserman%2C%20S.%2C%20Zimetbaum%2C%20P.%20J.%2C%20Varaine%2C%20F.%20and%20Mitnick%2C%20C.%20D.%20%282021%29.%20%3Cb%3EEvaluating%20newly%20approved%20drugs%20for%20multidrug-resistant%20tuberculosis%20%28endTB%29%3A%20study%20protocol%20for%20an%20adaptive%2C%20multi-country%20randomized%20controlled%20trial%3C%5C%2Fb%3E.%20Trials%20%3Ci%3E22%3C%5C%2Fi%3E%2C%20651%2C%20%3Ca%20target%3D%27_blank%27%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1186%5C%2Fs13063-021-05491-3%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1186%5C%2Fs13063-021-05491-3%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Evaluating%20newly%20approved%20drugs%20for%20multidrug-resistant%20tuberculosis%20%28endTB%29%3A%20study%20protocol%20for%20an%20adaptive%2C%20multi-country%20randomized%20controlled%20trial%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L.%22%2C%22lastName%22%3A%22Guglielmetti%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E.%22%2C%22lastName%22%3A%22Ardizzoni%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Atger%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E.%22%2C%22lastName%22%3A%22Baudin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E.%22%2C%22lastName%22%3A%22Berikova%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Bonnet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E.%22%2C%22lastName%22%3A%22Chang%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%22%2C%22lastName%22%3A%22Cloez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%20M.%22%2C%22lastName%22%3A%22Coit%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22V.%22%2C%22lastName%22%3A%22Cox%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22B.%20C.%22%2C%22lastName%22%3A%22de%20Jong%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%22%2C%22lastName%22%3A%22Delifer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%20M.%22%2C%22lastName%22%3A%22Do%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22D.%20Dos%20Santos%22%2C%22lastName%22%3A%22Tozzi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22V.%22%2C%22lastName%22%3A%22Ducher%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22G.%22%2C%22lastName%22%3A%22Ferlazzo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Gouillou%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Khan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22U.%22%2C%22lastName%22%3A%22Khan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22N.%22%2C%22lastName%22%3A%22Lachenal%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%20N.%22%2C%22lastName%22%3A%22LaHood%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L.%22%2C%22lastName%22%3A%22Lecca%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Mazmanian%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22H.%22%2C%22lastName%22%3A%22McIlleron%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Moschioni%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22K.%22%2C%22lastName%22%3A%22O%5Cu2019Brien%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22O.%22%2C%22lastName%22%3A%22Okunbor%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L.%22%2C%22lastName%22%3A%22Oyewusi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%22%2C%22lastName%22%3A%22Panda%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%20B.%22%2C%22lastName%22%3A%22Patil%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P.%20P.%20J.%22%2C%22lastName%22%3A%22Phillips%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L.%22%2C%22lastName%22%3A%22Pichon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P.%22%2C%22lastName%22%3A%22Rupasinghe%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%20L.%22%2C%22lastName%22%3A%22Rich%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22N.%22%2C%22lastName%22%3A%22Saluhuddin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22K.%20J.%22%2C%22lastName%22%3A%22Seung%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Tamirat%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L.%22%2C%22lastName%22%3A%22Trippa%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Cellamare%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22G.%20E.%22%2C%22lastName%22%3A%22Vel%5Cu00e1squez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%22%2C%22lastName%22%3A%22Wasserman%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P.%20J.%22%2C%22lastName%22%3A%22Zimetbaum%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22F.%22%2C%22lastName%22%3A%22Varaine%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%20D.%22%2C%22lastName%22%3A%22Mitnick%22%7D%5D%2C%22abstractNote%22%3A%22Background%5CnTreatment%20of%20multidrug-%5Cu00a0and%20rifampin-resistant%20tuberculosis%20%28MDR%5C%2FRR-TB%29%20is%20expensive%2C%20labour-intensive%2C%20and%20associated%20with%20substantial%20adverse%20events%20and%20poor%20outcomes.%20While%20most%20MDR%5C%2FRR-TB%20patients%20do%20not%20receive%20treatment%2C%20many%20who%20do%20are%20treated%20for%2018%20months%20or%20more.%20A%20shorter%20all-oral%20regimen%20is%20currently%20recommended%20for%20only%20a%20sub-set%20of%20MDR%5C%2FRR-TB.%20Its%20use%20is%20only%20conditionally%20recommended%20because%20of%20very%20low-quality%20evidence%20underpinning%20the%20recommendation.%20Novel%20combinations%20of%20newer%20and%20repurposed%20drugs%20bring%20hope%20in%20the%20fight%20against%20MDR%5C%2FRR-TB%2C%20but%20their%20use%20has%20not%20been%20optimized%20in%20all-oral%2C%20shorter%20regimens.%20This%20has%20greatly%20limited%20their%20impact%20on%20the%20burden%20of%20disease.%20There%20is%2C%20therefore%2C%20dire%20need%20for%20high-quality%20evidence%20on%20the%20performance%20of%20new%2C%20shortened%2C%20injectable-sparing%20regimens%20for%20MDR-TB%20which%20can%20be%20adapted%20to%20individual%20patients%20and%20different%20settings.%5Cn%5CnMethods%5CnendTB%20is%20a%20phase%20III%2C%20pragmatic%2C%20multi-country%2C%20adaptive%2C%20randomized%2C%20controlled%2C%20parallel%2C%20open-label%20clinical%20trial%20evaluating%20the%20efficacy%20and%20safety%20of%20shorter%20treatment%20regimens%20containing%20new%20drugs%20for%20patients%20with%20fluoroquinolone-susceptible%2C%20rifampin-resistant%20tuberculosis.%20Study%20participants%20are%20randomized%20to%20either%20the%20control%20arm%2C%20based%20on%20the%20current%20standard%20of%20care%20for%20MDR%5C%2FRR-TB%2C%20or%20to%20one%20of%20five%2039-week%20multi-drug%20regimens%20containing%20newly%20approved%20and%20repurposed%20drugs.%20Study%20participation%20in%20all%20arms%20lasts%20at%20least%2073%20and%20up%20to%20104%20weeks%20post-randomization.%20Randomization%20is%20response-adapted%20using%20interim%20Bayesian%20analysis%20of%20efficacy%20endpoints.%20The%20primary%20objective%20is%20to%20assess%20whether%20the%20efficacy%20of%20experimental%20regimens%20at%2073%20weeks%20is%20non-inferior%20to%20that%20of%20the%20control.%20A%20sample%20size%20of%20750%20patients%20across%206%20arms%20affords%20at%20least%2080%25%20power%20to%20detect%20the%20non-inferiority%20of%20at%20least%201%20%28and%20up%20to%203%29%20experimental%20regimens%2C%20with%20a%20one-sided%20alpha%20of%200.025%20and%20a%20non-inferiority%20margin%20of%2012%25%2C%20against%20the%20control%20in%20both%20modified%20intention-to-treat%20and%20per%20protocol%20populations.%5Cn%5CnDiscussion%5CnThe%20lack%20of%20a%20safe%20and%20effective%20regimen%20that%20can%20be%20used%20in%20all%20patients%20is%20a%20major%20obstacle%20to%20delivering%20appropriate%20treatment%20to%20all%20patients%20with%20active%20MDR%5C%2FRR-TB.%20Identifying%20multiple%20shorter%2C%20safe%2C%20and%20effective%20regimens%20has%20the%20potential%20to%20greatly%20reduce%20the%20burden%20of%20this%20deadly%20disease%20worldwide.%5Cn%5CnTrial%20registration%5CnClinicalTrials.gov%20Identifier%20NCT02754765.%20Registered%20on%2028%20April%202016%3B%20the%20record%20was%20last%20updated%20for%20study%20protocol%20version%203.3%2C%20on%2027%20August%202019.%22%2C%22date%22%3A%222021-9-25%22%2C%22language%22%3A%22%22%2C%22DOI%22%3A%2210.1186%5C%2Fs13063-021-05491-3%22%2C%22ISSN%22%3A%221745-6215%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fwww.ncbi.nlm.nih.gov%5C%2Fpmc%5C%2Farticles%5C%2FPMC8465691%5C%2F%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222022-03-16T14%3A16%3A40Z%22%7D%7D%2C%7B%22key%22%3A%22BXKAYDV2%22%2C%22library%22%3A%7B%22id%22%3A1368488%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Roelens%20et%20al.%22%2C%22parsedDate%22%3A%222021-09-15%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3ERoelens%2C%20M.%2C%20Battista%20Migliori%2C%20G.%2C%20Rozanova%2C%20L.%2C%20Estill%2C%20J.%2C%20Campbell%2C%20J.%20R.%2C%20Cegielski%2C%20J.%20P.%2C%20Tiberi%2C%20S.%2C%20Palmero%2C%20D.%2C%20Fox%2C%20G.%20J.%2C%20Guglielmetti%2C%20L.%2C%20Sotgiu%2C%20G.%2C%20Brust%2C%20J.%20C.%20M.%2C%20Bang%2C%20D.%2C%20Lienhardt%2C%20C.%2C%20Lange%2C%20C.%2C%20Menzies%2C%20D.%2C%20Keiser%2C%20O.%20and%20Raviglione%2C%20M.%20%282021%29.%20%3Cb%3EEvidence-based%20Definition%20for%20Extensively%20Drug-Resistant%20Tuberculosis%3C%5C%2Fb%3E.%20Am%20J%20Respir%20Crit%20Care%20Med%20%3Ci%3E204%3C%5C%2Fi%3E%2C%20713%26%23x2013%3B722%2C%20%3Ca%20target%3D%27_blank%27%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1164%5C%2Frccm.202009-3527OC%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1164%5C%2Frccm.202009-3527OC%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Evidence-based%20Definition%20for%20Extensively%20Drug-Resistant%20Tuberculosis%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Maroussia%22%2C%22lastName%22%3A%22Roelens%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Giovanni%22%2C%22lastName%22%3A%22Battista%20Migliori%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Liudmila%22%2C%22lastName%22%3A%22Rozanova%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Janne%22%2C%22lastName%22%3A%22Estill%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jonathon%20R.%22%2C%22lastName%22%3A%22Campbell%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%20Peter%22%2C%22lastName%22%3A%22Cegielski%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Simon%22%2C%22lastName%22%3A%22Tiberi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Domingo%22%2C%22lastName%22%3A%22Palmero%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Greg%20J.%22%2C%22lastName%22%3A%22Fox%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lorenzo%22%2C%22lastName%22%3A%22Guglielmetti%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Giovanni%22%2C%22lastName%22%3A%22Sotgiu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22James%20C.%20M.%22%2C%22lastName%22%3A%22Brust%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Didi%22%2C%22lastName%22%3A%22Bang%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christian%22%2C%22lastName%22%3A%22Lienhardt%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christoph%22%2C%22lastName%22%3A%22Lange%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Dick%22%2C%22lastName%22%3A%22Menzies%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Olivia%22%2C%22lastName%22%3A%22Keiser%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mario%22%2C%22lastName%22%3A%22Raviglione%22%7D%5D%2C%22abstractNote%22%3A%22Rationale%3A%20Until%202020%2C%20extensively%20drug-resistant%20tuberculosis%20%28XDR-TB%29%20was%20defined%20as%20TB%20with%20resistance%20to%20rifampicin%20and%20isoniazid%20%28multidrug-resistant%20TB%20%5BMDR-TB%5D%29%2C%20any%20fluoroquinolone%20%28FQ%29%2C%20and%20any%20second-line%20injectable%20drug%20%28SLID%29.%20In%202019%2C%20the%20World%20Health%20Organization%20issued%20new%20recommendations%20for%20treating%20patients%20with%20drug-resistant%20TB%2C%20substantially%20limiting%20the%20role%20of%20SLIDs%20in%20MDR-TB%20treatment%20and%20thus%20putting%20the%20definition%20of%20XDR-TB%20into%20question.%5Cn%5CnObjectives%3A%20To%20propose%20an%20up-to-date%20definition%20for%20XDR-TB.%5Cn%5CnMethods%3A%20We%20used%20a%20large%20data%20set%20to%20assess%20treatment%20outcomes%20for%20patients%20with%20MDR-TB%20exposed%20to%20any%20type%20of%20longer%20regimen.%20We%20included%20patients%20with%20bacteriologically%20confirmed%20MDR-TB%20and%20known%20FQ%20and%20SLID%20resistance%20results.%20We%20performed%20logistic%20regression%20to%20estimate%20the%20adjusted%20odds%20ratios%20%28aORs%29%20for%20an%20unfavorable%20treatment%20outcome%20%28failure%2C%20relapse%2C%20death%2C%20loss%20to%20follow-up%29%2C%20and%20estimates%20were%20stratified%20by%20the%20resistance%20pattern%20%28FQ%20and%5C%2For%20SLID%29%20and%20group%20A%20drug%20use%20%28moxifloxacin%5C%2Flevofloxacin%2C%20linezolid%2C%20and%5C%2For%20bedaquiline%29.%5Cn%5CnMeasurements%20and%20Main%20Results%3A%20We%20included%2011%2C666%20patients%20with%20MDR-TB%3B%204%2C653%20%2839.9%25%29%20had%20an%20unfavorable%20treatment%20outcome.%20Resistance%20to%20FQs%20increased%20the%20odds%20of%20an%20unfavorable%20treatment%20outcome%20%28aOR%2C%201.91%3B%2095%25%20confidence%20interval%20%5BCI%5D%2C%201.63%5Cu20132.23%29.%20Administration%20of%20bedaquiline%20and%5C%2For%20linezolid%20improved%20treatment%20outcomes%20regardless%20of%20resistance%20to%20FQs%20and%5C%2For%20SLIDs.%20Among%20patients%20with%20XDR-TB%2C%20compared%20with%20persons%20receiving%20no%20group%20A%20drug%2C%20aORs%20for%20an%20unfavorable%20outcome%20were%200.37%20%2895%25%20CI%2C%200.20%5Cu20130.69%29%20with%20linezolid%20only%2C%200.40%20%2895%25%20CI%2C%200.21%5Cu20130.77%29%20with%20bedaquiline%20only%2C%20and%200.21%20%2895%25%20CI%2C%200.12%5Cu20130.38%29%20with%20both.%5Cn%5CnConclusions%3A%20Our%20study%20supports%20a%20new%20definition%20of%20XDR-TB%20as%20MDR-TB%20and%20additional%20resistance%20to%20FQ%20plus%20bedaquiline%20and%5C%2For%20linezolid%20and%20helps%20assess%20the%20adequacy%20of%20this%20definition%20for%20surveillance%20and%20treatment%20choice.%22%2C%22date%22%3A%222021-09-15%22%2C%22language%22%3A%22%22%2C%22DOI%22%3A%2210.1164%5C%2Frccm.202009-3527OC%22%2C%22ISSN%22%3A%221073-449X%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fwww.atsjournals.org%5C%2Fdoi%5C%2F10.1164%5C%2Frccm.202009-3527OC%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222022-02-25T15%3A32%3A03Z%22%7D%7D%2C%7B%22key%22%3A%22M3AU88AV%22%2C%22library%22%3A%7B%22id%22%3A1368488%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Veziris%20et%20al.%22%2C%22parsedDate%22%3A%222021-08-01%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EVeziris%2C%20N.%2C%20Bonnet%2C%20I.%2C%20Morel%2C%20F.%2C%20Guglielmetti%2C%20L.%2C%20Maitre%2C%20T.%2C%20Ray%2C%20L.%20F.%20L.%2C%20Sougakoff%2C%20W.%2C%20Robert%2C%20J.%20and%20Aubry%2C%20A.%20%282021%29.%20%3Cb%3EImpact%20of%20the%20revised%20definition%20of%20extensively%20drug-resistant%20tuberculosis%3C%5C%2Fb%3E.%20European%20Respiratory%20Journal%20%3Ci%3E58%3C%5C%2Fi%3E%2C%20%3Ca%20target%3D%27_blank%27%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1183%5C%2F13993003.00641-2021%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1183%5C%2F13993003.00641-2021%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Impact%20of%20the%20revised%20definition%20of%20extensively%20drug-resistant%20tuberculosis%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nicolas%22%2C%22lastName%22%3A%22Veziris%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Isabelle%22%2C%22lastName%22%3A%22Bonnet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Florence%22%2C%22lastName%22%3A%22Morel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lorenzo%22%2C%22lastName%22%3A%22Guglielmetti%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thomas%22%2C%22lastName%22%3A%22Maitre%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laure%20Fournier%20Le%22%2C%22lastName%22%3A%22Ray%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Wladimir%22%2C%22lastName%22%3A%22Sougakoff%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%5Cu00e9r%5Cu00f4me%22%2C%22lastName%22%3A%22Robert%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alexandra%22%2C%22lastName%22%3A%22Aubry%22%7D%5D%2C%22abstractNote%22%3A%22Extract%5CnRecently%2C%20the%20World%20Health%20Organization%20%28WHO%29%20has%20released%20a%20revised%20definition%20of%20extensively%20drug-resistant%20%28XDR%29%20tuberculosis%20%28TB%29%20that%20should%20be%20used%20for%20clinical%20and%20surveillance%20purposes%20starting%20from%201%20January%2C%202021%20%5B1%2C%202%5D.%20The%20previous%20definition%20of%20XDR-TB%20was%20TB%20that%20is%20resistant%20to%20any%20fluoroquinolone%20%28levofloxacin%20and%5C%2For%20moxifloxacin%29%20and%20to%20at%20least%20one%20of%20three%20second-line%20injectable%20drugs%20%28SLIs%3A%20capreomycin%2C%20kanamycin%20and%20amikacin%29%2C%20in%20addition%20to%20multidrug%20resistance.%20The%20revised%20definition%20is%3A%20TB%20caused%20by%20Mycobacterium%20tuberculosis%20strains%20that%20fulfil%20the%20definition%20of%20MDR%5C%2FRR-TB%20and%20which%20are%20also%20resistant%20to%20any%20fluoroquinolone%20and%20at%20least%20one%20additional%20group%20A%20drug.%20WHO%20group%20A%20drugs%20currently%20include%20fluoroquinolones%20%28levofloxacin%20or%20moxifloxacin%29%2C%20linezolid%20and%20bedaquiline.%20In%20addition%2C%20pre-XDR-TB%20is%20now%20a%20WHO-endorsed%20definition%2C%20identified%20as%20MDR%5C%2FRR-TB%20with%20any%20fluoroquinolone%20resistance.%20Although%20the%20previous%20definition%20of%20XDR-TB%20has%20proved%20to%20be%20predictive%20of%20poor%20treatment%20outcome%20%5B3%5D%2C%20the%202020%20update%20appears%20in%20line%20with%20recent%20changes%20of%20treatment%20regimens%20given%2C%20i.e.%20less%20frequent%20use%20of%20SLI%20in%20favour%20of%20the%20potent%20oral%20drugs%2C%20bedaquiline%20and%20linezolid.%20Moreover%2C%20a%20large%20meta-analysis%20failed%20to%20show%20an%20association%20between%20mortality%20reduction%20and%20SLI%20use%2C%20whereas%20this%20association%20was%20shown%20for%20bedaquiline%20and%20linezolid%20%5B4%5D.%20In%20this%20study%2C%20we%20aimed%20to%20measure%20retrospectively%20the%20impact%20of%20the%20revised%20definition%20on%20the%20epidemiology%20of%20XDR-TB%20in%20France.%5CnTweetable%20abstract%20%40ERSpublications%5Cnclick%20to%20tweetThe%20revised%20WHO%20definition%20of%20XDR-TB%20decreases%20the%20number%20of%20TB%20cases%20classified%20as%20such%2C%20and%20allows%20better%20focus%20on%20the%20most%20difficult%20to%20treat%20cases%20of%20TB%20https%3A%5C%2F%5C%2Fbit.ly%5C%2F3tgaXQA%22%2C%22date%22%3A%222021%5C%2F08%5C%2F01%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1183%5C%2F13993003.00641-2021%22%2C%22ISSN%22%3A%220903-1936%2C%201399-3003%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Ferj.ersjournals.com%5C%2Fcontent%5C%2F58%5C%2F2%5C%2F2100641%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222022-02-25T15%3A29%3A34Z%22%7D%7D%2C%7B%22key%22%3A%22Z9XZJ6DC%22%2C%22library%22%3A%7B%22id%22%3A1368488%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Starshinova%20et%20al.%22%2C%22parsedDate%22%3A%222021-07-01%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EStarshinova%2C%20A.%2C%20Guglielmetti%2C%20L.%2C%20Rzhepishevska%2C%20O.%2C%20Ekaterincheva%2C%20O.%2C%20Zinchenko%2C%20Yu.%20and%20Kudlay%2C%20D.%20%282021%29.%20%3Cb%3EDiagnostics%20and%20management%20of%20tuberculosis%20and%20COVID-19%20in%20a%20patient%20with%20pneumothorax%20%28clinical%20case%29%3C%5C%2Fb%3E.%20J%20Clin%20Tuberc%20Other%20Mycobact%20Dis%20%3Ci%3E24%3C%5C%2Fi%3E%2C%20100259%2C%20%3Ca%20target%3D%27_blank%27%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.jctube.2021.100259%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.jctube.2021.100259%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Diagnostics%20and%20management%20of%20tuberculosis%20and%20COVID-19%20in%20a%20patient%20with%20pneumothorax%20%28clinical%20case%29%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Starshinova%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L.%22%2C%22lastName%22%3A%22Guglielmetti%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22O.%22%2C%22lastName%22%3A%22Rzhepishevska%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22O.%22%2C%22lastName%22%3A%22Ekaterincheva%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yu.%22%2C%22lastName%22%3A%22Zinchenko%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22D.%22%2C%22lastName%22%3A%22Kudlay%22%7D%5D%2C%22abstractNote%22%3A%22The%20spread%20of%20COVID-19%20in%20countries%20with%20high%20and%20medium%20incidence%20of%20tuberculosis%20has%20led%20to%20an%20increased%20risk%20of%20COVID-19%20and%20tuberculosis%20co-infection%2C%20introducing%20new%20diagnostic%20and%20therapeutic%20challenges%20for%20the%20clinician.%20Hereby%20we%20describe%20a%20first%20case%20where%20tuberculosis%20and%20COVID-19%20were%20diagnosed%20concomitantly%20in%20a%20Russian%20patient%20with%20pneumothorax.%20We%20discuss%20the%20challenges%20associated%20with%20the%20diagnosis%20and%20treatment%20of%20tuberculosis%20during%20the%20COVID-19%20pandemic.%22%2C%22date%22%3A%222021-7-01%22%2C%22language%22%3A%22%22%2C%22DOI%22%3A%2210.1016%5C%2Fj.jctube.2021.100259%22%2C%22ISSN%22%3A%222405-5794%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fwww.ncbi.nlm.nih.gov%5C%2Fpmc%5C%2Farticles%5C%2FPMC8245665%5C%2F%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222022-03-19T16%3A25%3A28Z%22%7D%7D%2C%7B%22key%22%3A%22DKDYEURY%22%2C%22library%22%3A%7B%22id%22%3A1368488%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Ok%20et%20al.%22%2C%22parsedDate%22%3A%222021-07%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EOk%2C%20V.%2C%20Aubry%2C%20A.%2C%20Morel%2C%20F.%2C%20Bonnet%2C%20I.%2C%20Robert%2C%20J.%20and%20Sougakoff%2C%20W.%20%282021%29.%20%3Cb%3ERapid%20Molecular%20Diagnosis%20of%20Tuberculosis%20and%20Its%20Resistance%20to%20Rifampicin%20and%20Isoniazid%20with%20Automated%20MDR%5C%2FMTB%20ELITe%20MGB%26%23xAE%3B%20Assay%3C%5C%2Fb%3E.%20Antibiotics%20%3Ci%3E10%3C%5C%2Fi%3E%2C%20797%2C%20%3Ca%20target%3D%27_blank%27%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.3390%5C%2Fantibiotics10070797%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.3390%5C%2Fantibiotics10070797%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Rapid%20Molecular%20Diagnosis%20of%20Tuberculosis%20and%20Its%20Resistance%20to%20Rifampicin%20and%20Isoniazid%20with%20Automated%20MDR%5C%2FMTB%20ELITe%20MGB%5Cu00ae%20Assay%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Vichita%22%2C%22lastName%22%3A%22Ok%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alexandra%22%2C%22lastName%22%3A%22Aubry%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Florence%22%2C%22lastName%22%3A%22Morel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Isabelle%22%2C%22lastName%22%3A%22Bonnet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%5Cu00e9r%5Cu00f4me%22%2C%22lastName%22%3A%22Robert%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Wladimir%22%2C%22lastName%22%3A%22Sougakoff%22%7D%5D%2C%22abstractNote%22%3A%22The%20MDR%5C%2FMTB%20ELITe%20MGB%5Cu00ae%20kit%20%28ELITech%29%20carried%20on%20the%20ELITe%20InGenius%5Cu00ae%20platform%20is%20a%20new%20real-time%20PCR%20assay%20allowing%20automated%20extraction%20and%20detection%20of%20DNA%20of%20the%20Mycobacterium%20tuberculosis%20complex%20%28MTB%29%20and%20mutations%20in%20the%20rpoB%20and%20katG%20genes%20and%20inhA%20promoter%20region%20%28pro-inhA%29%20associated%20to%20resistance%20to%20rifampicin%20and%20isoniazid%2C%20the%20two%20markers%20of%20multidrug-resistant%20TB%20%28MDR%29.%20We%20assessed%20the%20performances%20of%20the%20test%20on%20a%20collection%20of%20strains%20%28n%20%3D%2054%29%20and%20a%20set%20of%20clinical%20samples%20%28n%20%3D%20242%29%20from%20routine%20practice%2C%20comparatively%20to%20TB%20diagnosis%20and%20genotypic%20drug%20susceptibility%20testing%20%28gDST%29%20as%20references.%20Regarding%20the%20242%20clinical%20samples%2C%20the%20sensitivity%20and%20specificity%20of%20MTB%20detection%20by%20ELITe%20were%2090.9%25%20and%2097.5%25%2C%20respectively.%20For%20the%20detection%20of%20resistance-conferring%20mutations%20on%20positive%20clinical%20samples%2C%20we%20observed%20perfect%20agreement%20with%20gDST%20for%20katG%20and%20pro-inhA%20%28%5Cu03ba%20%3D%201.0%29%20and%20two%20discordant%20results%20for%20rpoB%20%28%5Cu03ba%20%3D%200.82%29.%20Considering%20the%2054%20cultured%20strains%2C%20very%20good%20agreement%20with%20gDST%20was%20observed%20for%20the%20detection%20of%20the%2025%20distinct%20mutations%20in%20rpoB%2C%20katG%2C%20and%20pro-inhA%2C%20%28%5Cu03ba%20%3D%200.95%2C%200.88%2C%20and%200.95%2C%20respectively%29.%20In%20conclusion%2C%20the%20automated%20MDR%5C%2FMTB%20ELITe%20MGB%5Cu00ae%20assay%20shows%20great%20promise%20and%20appears%20to%20be%20a%20valuable%20tool%20for%20rapid%20detection%20of%20pre-MDR-%20and%20MDR-TB%20directly%20from%20clinical%20specimens.%22%2C%22date%22%3A%222021%5C%2F7%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.3390%5C%2Fantibiotics10070797%22%2C%22ISSN%22%3A%222079-6382%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fwww.mdpi.com%5C%2F2079-6382%5C%2F10%5C%2F7%5C%2F797%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222022-02-25T15%3A27%3A59Z%22%7D%7D%2C%7B%22key%22%3A%22N2BKBBDI%22%2C%22library%22%3A%7B%22id%22%3A1368488%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Hewison%20and%20Guglielmetti%22%2C%22parsedDate%22%3A%222021-07%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EHewison%2C%20C.%20and%20Guglielmetti%2C%20L.%20%282021%29.%20%3Cb%3ECardiac%20safety%20of%20multidrug-resistant%20tuberculosis%20treatment%3A%20moving%20towards%20individualised%20monitoring%3C%5C%2Fb%3E.%20Lancet%20Infect%20Dis%20%3Ci%3E21%3C%5C%2Fi%3E%2C%20894%26%23x2013%3B895%2C%20%3Ca%20target%3D%27_blank%27%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2FS1473-3099%2820%2930836-7%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2FS1473-3099%2820%2930836-7%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Cardiac%20safety%20of%20multidrug-resistant%20tuberculosis%20treatment%3A%20moving%20towards%20individualised%20monitoring%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Catherine%22%2C%22lastName%22%3A%22Hewison%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lorenzo%22%2C%22lastName%22%3A%22Guglielmetti%22%7D%5D%2C%22abstractNote%22%3A%22%22%2C%22date%22%3A%222021-07%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1016%5C%2FS1473-3099%2820%2930836-7%22%2C%22ISSN%22%3A%221474-4457%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222022-02-25T15%3A33%3A56Z%22%7D%7D%2C%7B%22key%22%3A%22D6F5BYLH%22%2C%22library%22%3A%7B%22id%22%3A1368488%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Guglielmetti%20and%20Varaine%22%2C%22parsedDate%22%3A%222021-06-01%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EGuglielmetti%2C%20L.%20and%20Varaine%2C%20F.%20%282021%29.%20%3Cb%3EThe%20coming-of-age%20of%20bedaquiline%3A%20a%20tale%20with%20an%20open%20ending%3C%5C%2Fb%3E.%20European%20Respiratory%20Journal%20%3Ci%3E57%3C%5C%2Fi%3E%2C%20%3Ca%20target%3D%27_blank%27%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1183%5C%2F13993003.00066-2021%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1183%5C%2F13993003.00066-2021%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22The%20coming-of-age%20of%20bedaquiline%3A%20a%20tale%20with%20an%20open%20ending%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lorenzo%22%2C%22lastName%22%3A%22Guglielmetti%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Francis%22%2C%22lastName%22%3A%22Varaine%22%7D%5D%2C%22abstractNote%22%3A%22Extract%5CnBedaquiline%20can%20probably%20be%20considered%20the%20biggest%20breakthrough%20in%20tuberculosis%20drug%20development%20of%20the%20past%20decades.%20The%20first%20compound%20of%20a%20new%20anti-tuberculosis%20drug%20class%2C%20diarylquinolines%2C%20bedaquiline%20binds%20the%20mycobacterial%20ATP%20synthase%2C%20inducing%20major%20conformational%20changes%20and%20ultimately%20impacting%20the%20bacterial%20respiration%20pathway%20%5B1%2C%202%5D.%20After%20being%20developed%20in%202005%20%5B3%5D%2C%20bedaquiline%20showed%20promising%20results%20in%20phase%20II%20trials%20%5B4%2C%205%5D%2C%20and%20was%20granted%20accelerated%20approval%20in%202012%20by%20the%20US%20Food%20and%20Drug%20Administration%20%28FDA%29%20and%20conditional%20approval%20in%202014%20by%20the%20European%20Medicines%20Agency.%20In%20the%20following%20years%2C%20the%20access%20to%20bedaquiline%20has%20progressively%20increased%2C%20from%20compassionate%20to%20programmatic%20use%20%5B6%2C%207%5D%2C%20although%20at%20an%20insufficient%20pace.%20Between%20July%202015%20and%20December%202019%2C%2051%20098%20patients%20received%20bedaquiline%20worldwide%3A%20although%20remarkable%2C%20this%20figure%20only%20represents%2011%25%20of%20those%20who%20are%20estimated%20to%20need%20it%20according%20to%20the%20most%20recent%20recommendations%20by%20the%20World%20Health%20Organization%20%28WHO%29%20%5B8%5D.%5CnTweetable%20abstract%20%40ERSpublications%5Cnclick%20to%20tweetFuture%20strategic%20choices%20in%20the%20clinical%20development%20of%20bedaquiline%20should%20be%20guided%20by%20the%20need%20to%20generate%20high-quality%20evidence%20and%20ultimately%20improve%20outcomes%20of%20tuberculosis%20treatment%2C%20while%20preventing%20the%20emergence%20of%20drug%20resistance%20https%3A%5C%2F%5C%2Fbit.ly%5C%2F3iAOCZr%22%2C%22date%22%3A%222021%5C%2F06%5C%2F01%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1183%5C%2F13993003.00066-2021%22%2C%22ISSN%22%3A%220903-1936%2C%201399-3003%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Ferj.ersjournals.com%5C%2Fcontent%5C%2F57%5C%2F6%5C%2F2100066%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222022-02-25T15%3A28%3A43Z%22%7D%7D%2C%7B%22key%22%3A%2295VRF8CW%22%2C%22library%22%3A%7B%22id%22%3A1368488%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22World%20Health%20Organisation%22%2C%22parsedDate%22%3A%222021-05-02%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EWorld%20Health%20Organisation%20%282021%29.%20Technical%20Report%20on%20critical%20concentrations%20for%20drug%20susceptibility%20testing%20of%20isoniazid%20and%20the%20rifamycins%20%28rifampicin%2C%20rifabutin%20and%20rifapentine%29%2C%20WHO%2C%20Geneva%2C%20URL%3A%20%3Ca%20target%3D%27_blank%27%20href%3D%27https%3A%5C%2F%5C%2Fwww.who.int%5C%2Fpublications%5C%2Fi%5C%2Fitem%5C%2Ftechnical-report-on-critical-concentrations-for-drugsusceptibility-testing-of-isoniazid-and-therifamycins-%28rifampicin-rifabutin-and-rifapentine%29%27%3Ehttps%3A%5C%2F%5C%2Fwww.who.int%5C%2Fpublications%5C%2Fi%5C%2Fitem%5C%2Ftechnical-report-on-critical-concentrations-for-drugsusceptibility-testing-of-isoniazid-and-therifamycins-%28rifampicin-rifabutin-and-rifapentine%29%3C%5C%2Fa%3E%20%5BAccessed%20March%202022%5D.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22report%22%2C%22title%22%3A%22Technical%20Report%20on%20critical%20concentrations%20for%20drug%20susceptibility%20testing%20of%20isoniazid%20and%20the%20rifamycins%20%28rifampicin%2C%20rifabutin%20and%20rifapentine%29%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22%22%2C%22lastName%22%3A%22World%20Health%20Organisation%22%7D%5D%2C%22abstractNote%22%3A%22%22%2C%22reportNumber%22%3A%22978-92-4-001728-3%22%2C%22reportType%22%3A%22%22%2C%22institution%22%3A%22WHO%22%2C%22date%22%3A%2205%5C%2F02%5C%2F2021%22%2C%22language%22%3A%22Anglais%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fwww.who.int%5C%2Fpublications%5C%2Fi%5C%2Fitem%5C%2Ftechnical-report-on-critical-concentrations-for-drugsusceptibility-testing-of-isoniazid-and-therifamycins-%28rifampicin-rifabutin-and-rifapentine%29%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222022-03-16T23%3A20%3A09Z%22%7D%7D%2C%7B%22key%22%3A%22I4RV4A3G%22%2C%22library%22%3A%7B%22id%22%3A1368488%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Maitre%20et%20al.%22%2C%22parsedDate%22%3A%222021-04-01%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EMaitre%2C%20T.%2C%20Guglielmetti%2C%20L.%20and%20Veziris%2C%20N.%20%282021%29.%20%3Cb%3EDefining%20optimal%20fluoroquinolone%20exposure%20against%20Mycobacterium%20tuberculosis%3A%20contribution%20of%20murine%20studies%3C%5C%2Fb%3E.%20European%20Respiratory%20Journal%20%3Ci%3E57%3C%5C%2Fi%3E%2C%20%3Ca%20target%3D%27_blank%27%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1183%5C%2F13993003.04315-2020%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1183%5C%2F13993003.04315-2020%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Defining%20optimal%20fluoroquinolone%20exposure%20against%20Mycobacterium%20tuberculosis%3A%20contribution%20of%20murine%20studies%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thomas%22%2C%22lastName%22%3A%22Maitre%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lorenzo%22%2C%22lastName%22%3A%22Guglielmetti%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nicolas%22%2C%22lastName%22%3A%22Veziris%22%7D%5D%2C%22abstractNote%22%3A%22Extract%5CnWe%20read%20with%20interest%20the%20research%20letter%20published%20by%20Davies%20Forsman%20et%20al.%20%5B1%5D%20in%20the%20European%20Respiratory%20Journal.%20The%20authors%20determined%20the%20proportion%20of%20multidrug-resistant%20tuberculosis%20patients%20treated%20with%20moxifloxacin%20or%20levofloxacin%20who%20attained%20an%20optimal%20exposure%20for%20these%20drugs.%20The%20target%20exposure%20corresponded%20to%20the%20area%20under%20the%20curve%20%28AUC0%5Cu201324h%29%5C%2Fminimal%20inhibitory%20concentration%20%28MIC%29%20ratio%20generating%20the%20optimal%20bactericidal%20activity.%20The%20authors%20based%20their%20calculations%20on%20the%20AUC0%5Cu201324h%5C%2FMIC%20ratio%20measured%20in%20a%20preclinical%20model%20called%20Hollow%20Fiber%20System%20%28HFS%29%2C%20an%20in%20vitro%20model%20used%20to%20assess%20anti-tuberculosis%20activity%20of%20candidate%20drugs.%20Based%20on%20this%20model%2C%20they%20reported%20that%20the%20target%20ratio%20was%20reached%20in%20only%20half%20of%20patients%20receiving%20moxifloxacin%2C%20and%20in%20none%20of%20those%20receiving%20levofloxacin.%5CnTweetable%20abstract%20%40ERSpublications%5Cnclick%20to%20tweetThe%20proportion%20of%20TB%20patients%20attaining%20the%20fluoroquinolone%20target%20exposure%2C%20as%20defined%20by%20in%20vitro%20models%2C%20is%20very%20low%20in%20clinical%20practice%3B%20however%2C%20it%20would%20be%20even%20smaller%20if%20the%20target%20AUC%5C%2FMIC%20ratios%20were%20calculated%20in%20murine%20models%20of%20tuberculosis%20https%3A%5C%2F%5C%2Fbit.ly%5C%2F2Wg8K8H%22%2C%22date%22%3A%222021%5C%2F04%5C%2F01%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1183%5C%2F13993003.04315-2020%22%2C%22ISSN%22%3A%220903-1936%2C%201399-3003%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Ferj.ersjournals.com%5C%2Fcontent%5C%2F57%5C%2F4%5C%2F2004315%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222022-02-25T15%3A29%3A12Z%22%7D%7D%2C%7B%22key%22%3A%22UG9CJEM5%22%2C%22library%22%3A%7B%22id%22%3A1368488%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Mohamed%20et%20al.%22%2C%22parsedDate%22%3A%222021-03-01%22%2C%22numChildren%22%3A3%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EMohamed%2C%20S.%2C%20K%26%23xF6%3Bser%2C%20C.%20U.%2C%20Salfinger%2C%20M.%2C%20Sougakoff%2C%20W.%20and%20Heysell%2C%20S.%20K.%20%282021%29.%20%3Cb%3ETargeted%20next-generation%20sequencing%3A%20a%20Swiss%20army%20knife%20for%20mycobacterial%20diagnostics%3F%3C%5C%2Fb%3E%20European%20Respiratory%20Journal%20%3Ci%3E57%3C%5C%2Fi%3E%2C%20%3Ca%20target%3D%27_blank%27%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1183%5C%2F13993003.04077-2020%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1183%5C%2F13993003.04077-2020%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Targeted%20next-generation%20sequencing%3A%20a%20Swiss%20army%20knife%20for%20mycobacterial%20diagnostics%3F%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sagal%22%2C%22lastName%22%3A%22Mohamed%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Claudio%20U.%22%2C%22lastName%22%3A%22K%5Cu00f6ser%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Max%22%2C%22lastName%22%3A%22Salfinger%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Wladimir%22%2C%22lastName%22%3A%22Sougakoff%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Scott%20K.%22%2C%22lastName%22%3A%22Heysell%22%7D%5D%2C%22abstractNote%22%3A%22Tweetable%20abstract%20%40ERSpublications%5Cnclick%20to%20tweetLike%20a%20multifunctional%20Swiss%20army%20knife%2C%20Deeplex%20offers%20unprecedented%20versatility%20directly%20from%20the%20clinical%20sample%20and%20represents%20a%20welcome%20addition%20to%20the%20diagnostic%20and%20epidemiological%20toolbox%20https%3A%5C%2F%5C%2Fbit.ly%5C%2F38s6ukF%22%2C%22date%22%3A%222021%5C%2F03%5C%2F01%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1183%5C%2F13993003.04077-2020%22%2C%22ISSN%22%3A%220903-1936%2C%201399-3003%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Ferj.ersjournals.com%5C%2Fcontent%5C%2F57%5C%2F3%5C%2F2004077%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222022-02-25T15%3A27%3A49Z%22%7D%7D%2C%7B%22key%22%3A%225JB2PK4Y%22%2C%22library%22%3A%7B%22id%22%3A1368488%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Sch%5Cu00f6n%20et%20al.%22%2C%22parsedDate%22%3A%222021-02-01%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3ESch%26%23xF6%3Bn%2C%20T.%2C%20Werngren%2C%20J.%2C%20Machado%2C%20D.%2C%20Borroni%2C%20E.%2C%20Wijkander%2C%20M.%2C%20Lina%2C%20G.%2C%20Mouton%2C%20J.%2C%20Matuschek%2C%20E.%2C%20Kahlmeter%2C%20G.%2C%20Giske%2C%20C.%2C%20Santin%2C%20M.%2C%20Cirillo%2C%20D.%20M.%2C%20Viveiros%2C%20M.%20and%20Cambau%2C%20E.%20%282021%29.%20%3Cb%3EMulticentre%20testing%20of%20the%20EUCAST%20broth%20microdilution%20reference%20method%20for%20MIC%20determination%20on%20Mycobacterium%20tuberculosis%3C%5C%2Fb%3E.%20Clinical%20Microbiology%20and%20Infection%20%3Ci%3E27%3C%5C%2Fi%3E%2C%20288.e1-288.e4%2C%20%3Ca%20target%3D%27_blank%27%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.cmi.2020.10.019%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.cmi.2020.10.019%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Multicentre%20testing%20of%20the%20EUCAST%20broth%20microdilution%20reference%20method%20for%20MIC%20determination%20on%20Mycobacterium%20tuberculosis%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thomas%22%2C%22lastName%22%3A%22Sch%5Cu00f6n%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jim%22%2C%22lastName%22%3A%22Werngren%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Diana%22%2C%22lastName%22%3A%22Machado%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Emanuele%22%2C%22lastName%22%3A%22Borroni%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Maria%22%2C%22lastName%22%3A%22Wijkander%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gerard%22%2C%22lastName%22%3A%22Lina%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Johan%22%2C%22lastName%22%3A%22Mouton%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Erika%22%2C%22lastName%22%3A%22Matuschek%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gunnar%22%2C%22lastName%22%3A%22Kahlmeter%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christian%22%2C%22lastName%22%3A%22Giske%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Miguel%22%2C%22lastName%22%3A%22Santin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Daniela%20Maria%22%2C%22lastName%22%3A%22Cirillo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Miguel%22%2C%22lastName%22%3A%22Viveiros%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Emmanuelle%22%2C%22lastName%22%3A%22Cambau%22%7D%5D%2C%22abstractNote%22%3A%22%22%2C%22date%22%3A%222021-02-01%22%2C%22language%22%3A%22English%22%2C%22DOI%22%3A%2210.1016%5C%2Fj.cmi.2020.10.019%22%2C%22ISSN%22%3A%221198-743X%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fwww.clinicalmicrobiologyandinfection.com%5C%2Farticle%5C%2FS1198-743X%2820%2930650-9%5C%2Ffulltext%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222022-03-10T10%3A52%3A38Z%22%7D%7D%2C%7B%22key%22%3A%22DJJVGF34%22%2C%22library%22%3A%7B%22id%22%3A1368488%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Molina%5Cu2010Moya%20et%20al.%22%2C%22parsedDate%22%3A%222021-02-01%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EMolina%26%23x2010%3BMoya%2C%20B.%2C%20Guglielmetti%2C%20L.%2C%20Bothamley%2C%20G.%2C%20van%20Leth%2C%20F.%2C%20Lange%2C%20C.%2C%20Dominguez%2C%20J.%20and%20TBnet%20Study%20Group%20%282021%29.%20%3Cb%3EUse%20and%20impact%20of%20molecular%20methods%20for%20detecting%20drug%26%23x2010%3Bresistant%20TB%3C%5C%2Fb%3E.%20The%20International%20Journal%20of%20Tuberculosis%20and%20Lung%20Disease%20%3Ci%3E25%3C%5C%2Fi%3E%2C%20157%26%23x2013%3B159%2C%20%3Ca%20target%3D%27_blank%27%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.5588%5C%2Fijtld.20.0527%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.5588%5C%2Fijtld.20.0527%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Use%20and%20impact%20of%20molecular%20methods%20for%20detecting%20drug%5Cu2010resistant%20TB%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22B.%22%2C%22lastName%22%3A%22Molina%5Cu2010Moya%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L.%22%2C%22lastName%22%3A%22Guglielmetti%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22G.%22%2C%22lastName%22%3A%22Bothamley%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22F.%22%2C%22lastName%22%3A%22van%20Leth%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%22%2C%22lastName%22%3A%22Lange%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22%2C%20J.%22%2C%22lastName%22%3A%22Dominguez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22name%22%3A%22TBnet%20Study%20Group%22%7D%5D%2C%22abstractNote%22%3A%22%22%2C%22date%22%3A%222021-02-01%22%2C%22language%22%3A%22%22%2C%22DOI%22%3A%2210.5588%5C%2Fijtld.20.0527%22%2C%22ISSN%22%3A%22%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222022-02-25T15%3A33%3A13Z%22%7D%7D%2C%7B%22key%22%3A%228AV5ZLZK%22%2C%22library%22%3A%7B%22id%22%3A1368488%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Calin%20et%20al.%22%2C%22parsedDate%22%3A%222021-01-06%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3ECalin%2C%20R.%2C%20Belkacem%2C%20A.%2C%20Caraux-Paz%2C%20P.%2C%20Wagner%2C%20M.%2C%20Guillot%2C%20H.%2C%20Veziris%2C%20N.%2C%20Jaureguiberry%2C%20S.%2C%20Caumes%2C%20E.%2C%20Patey%2C%20O.%20and%20Pourcher%2C%20V.%20%282021%29.%20%3Cb%3EAbdominal%20Tuberculosis%3A%20Experience%20from%20Two%20Tertiary-Care%20Hospitals%20in%20the%20Paris%20Region%3C%5C%2Fb%3E.%20The%20American%20Journal%20of%20Tropical%20Medicine%20and%20Hygiene%20%3Ci%3E104%3C%5C%2Fi%3E%2C%20223%26%23x2013%3B228%2C%20%3Ca%20target%3D%27_blank%27%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.4269%5C%2Fajtmh.20-0023%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.4269%5C%2Fajtmh.20-0023%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Abdominal%20Tuberculosis%3A%20Experience%20from%20Two%20Tertiary-Care%20Hospitals%20in%20the%20Paris%20Region%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ruxandra%22%2C%22lastName%22%3A%22Calin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anna%22%2C%22lastName%22%3A%22Belkacem%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pauline%22%2C%22lastName%22%3A%22Caraux-Paz%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mathilde%22%2C%22lastName%22%3A%22Wagner%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22H%5Cu00e9%5Cu00e8ne%22%2C%22lastName%22%3A%22Guillot%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nicolas%22%2C%22lastName%22%3A%22Veziris%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22St%5Cu00e9phane%22%2C%22lastName%22%3A%22Jaureguiberry%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eric%22%2C%22lastName%22%3A%22Caumes%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Olivier%22%2C%22lastName%22%3A%22Patey%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Val%5Cu00e9rie%22%2C%22lastName%22%3A%22Pourcher%22%7D%5D%2C%22abstractNote%22%3A%22ABSTRACT%20Abdominal%20tuberculosis%20%28ATB%29%20is%20uncommon%20and%20not%20very%20well%20known%20by%20clinicians.%20We%20describe%20the%20characteristics%2C%20evolution%2C%20and%20treatment%20of%20patients%20with%20ATB%20in%20two%20large%20hospitals%20in%20the%20Paris%20region.%20We%20reviewed%20all%20records%20of%20patients%20treated%20for%20ATB%2C%20from%20January%2001%2C%202010%20to%20December%2001%2C%202016%2C%20diagnosed%20by%20bacteriological%20and%5C%2For%20histological%20methods%20or%20highly%20suspected%20because%20of%20clinical%5C%2Fradiological%20features.%20We%20included%2080%20patients%2C%20with%20a%20median%20%28IQR%29%20age%20of%2039%20%2829%5Cu201350%29%20years%2C%20with%2056.2%25%20being%20males.%20Among%20them%2C%2063.7%25%20had%20African%20origins%2C%2015%25%20Asian%2C%20and%2011.2%25%20European.%20Twenty-nine%20had%20a%20cause%20of%20immunosuppression%20%28n%20%3D%2021%20HIV%20infection%29.%20The%20main%20abdominal%20localizations%20were%20lymph%20nodes%20%2872.5%25%29%2C%20peritoneum%20%2862.5%25%29%2C%20and%20solid%20organs%20%2825%25%29.%20Extra-abdominal%20localizations%20were%20recorded%20in%2065%20%2881.2%25%29%20patients.%20Tuberculosis%20was%20proven%20bacteriologically%20in%2071%25%2C%20histologically%20in%2050%25%2C%20and%20solely%20clinical%5C%2Fradiological%20in%2010%25%20of%20cases.%20Patients%20received%20standard%20therapy%20for%20a%20median%20duration%20of%209%20months%2C%20with%20a%20favorable%20outcome.%20Corticosteroid%20therapy%20was%20used%20in%2015%20cases%2C%20either%20for%20paradoxical%20reaction%20or%20to%20prevent%20complications.%20Abdominal%20TB%20was%20mainly%20represented%20by%20lymphatic%20and%20peritoneal%20localizations%2C%20proven%20bacteriologically%2C%20and%20associated%20with%20extra-abdominal%20localizations%20in%20most%20cases.%20The%20use%20of%20steroids%20remains%20controversial%2C%20but%20it%20does%20not%20seem%20systematically%20needed%20in%20case%20of%20abdominal%20involvement.%22%2C%22date%22%3A%222021%5C%2F01%5C%2F06%22%2C%22language%22%3A%22EN%22%2C%22DOI%22%3A%2210.4269%5C%2Fajtmh.20-0023%22%2C%22ISSN%22%3A%220002-9637%2C%201476-1645%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fwww.ajtmh.org%5C%2Fview%5C%2Fjournals%5C%2Ftpmd%5C%2F104%5C%2F1%5C%2Farticle-p223.xml%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222022-02-25T15%3A29%3A00Z%22%7D%7D%5D%7D
Veziris, N., Aubry, A., Bonnet, I., Petersen, T., Poignon, C., Gydé, E., Guglielmetti, L. and Robert, J. (2024). Actualités sur la tuberculose à bacilles multirésistants aux antibiotiques et ses nouveaux traitements. Bull Épid Hebdo 127–131, URL: http://beh.santepubliquefrance.fr/beh/2024/6-7/2024_6-7_4.html [Accessed March 2024].
Maitre, T., Baulard, A., Aubry, A. and Veziris, N. (2024). Optimizing the use of current antituberculosis drugs to overcome drug resistance in Mycobacterium tuberculosis. Infectious Diseases Now 54, 104807, http://doi.org/10.1016/j.idnow.2023.104807.
Maitre, T., Guglielmetti, L., Robert, J., Aubry, A. and Veziris, N. (2024). Avancées dans l’antibiothérapie de la tuberculose. Rev Prat 74, 239–244.
Campbell, J. R., Brode, S. K., Barry, P., Bastos, M. L., Bonnet, M., Guglielmetti, L., Kempker, R., Klimuk, D., Laborín, R. L., Milanov, V., Singla, R., Skrahina, A., Trajman, A., Van Der Werf, T. S., Viiklepp, P. and Menzies, D. (2023). Association of indicators of extensive disease and rifampin-resistant tuberculosis treatment outcomes: an individual participant data meta-analysis. Thorax thorax-2023-220249, http://doi.org/10.1136/thorax-2023-220249.
Du Cros, P., Greig, J., Alffenaar, J.-W. C., Cross, G. B., Cousins, C., Berry, C., Khan, U., Phillips, P. P. J., Velásquez, G. E., Furin, J., Spigelman, M., Denholm, J. T., Thi, S. S., Tiberi, S., Huang, G. K. L., Marks, G. B., Turkova, A., Guglielmetti, L., Chew, K. L., Nguyen, H. T., Ong, C. W. M., Brigden, G., Singh, K. P., Motta, I., Lange, C., Seddon, J. A., Nyang’wa, B.-T., Maug, A. K. J., Gler, M. T., Dooley, K. E., Quelapio, M., Tsogt, B., Menzies, D., Cox, V., Upton, C. M., Skrahina, A., McKenna, L., Horsburgh, C. R., Dheda, K. and Marais, B. J. (2023). Standards for clinical trials for treating TB. int j tuberc lung dis 27, 885–898, http://doi.org/10.5588/ijtld.23.0341.
Patil, S. B., Tamirat, M., Khazhidinov, K., Ardizzoni, E., Atger, M., Austin, A., Baudin, E., Bekhit, M., Bektasov, S., Berikova, E., Bonnet, M., Caboclo, R., Chaudhry, M., Chavan, V., Cloez, S., Coit, J., Coutisson, S., Dakenova, Z., De Jong, B. C., Delifer, C., Demaisons, S., Do, J. M., Dos Santos Tozzi, D., Ducher, V., Ferlazzo, G., Gouillou, M., Khan, U., Kunda, M., Lachenal, N., LaHood, A. N., Lecca, L., Mazmanian, M., McIlleron, H., Moreau, M., Moschioni, M., Nahid, P., Osso, E., Oyewusi, L., Panda, S., Pâquet, A., Thuong Huu, P., Pichon, L., Rich, M. L., Rupasinghe, P., Salahuddin, N., Sanchez Garavito, E., Seung, K. J., Velásquez, G. E., Vallet, M., Varaine, F., Yuya-Septoh, F. J., Mitnick, C. D. and Guglielmetti, L. (2023). Evaluating newly approved drugs in combination regimens for multidrug-resistant tuberculosis with fluoroquinolone resistance (endTB-Q): study protocol for a multi-country randomized controlled trial. Trials 24, 773, http://doi.org/10.1186/s13063-023-07701-6.
Sahal, M. R., Senelle, G., La, K., Panda, T. W., Taura, D. W., Guyeux, C., Cambau, E. and Sola, C. (2023). Mycobacterium tuberculosis complex drug-resistance, phylogenetics, and evolution in Nigeria: Comparison with Ghana and Cameroon Ed. Rayner, S. PLoS Negl Trop Dis 17, e0011619, http://doi.org/10.1371/journal.pntd.0011619.
Günther, G., Guglielmetti, L., Leu, C., van Leth, F. and Lange, C. (2023). Relative cost of multidrug-resistant TB medicines in Europe. The International Journal of Tuberculosis and Lung Disease 27, 341–344, http://doi.org/10.5588/ijtld.23.0026.
Campbell, J. R., Chan, E. D., Anderson, L. F., Bonnet, M., Brode, S. K., Cegielski, J. P., Guglielmetti, L., Singla, R., Fox, G. J., Skrahina, A., Rodrigues, D., Kuksa, L., Viiklepp, P. and Menzies, D. (2023). Association of smoking and alcohol use with rifampin-resistant TB treatment outcomes. The International Journal of Tuberculosis and Lung Disease 27, 338–340, http://doi.org/10.5588/ijtld.22.0678.
Guthmann, J.-P., Fraisse, P., Bonnet, I. and Robert, J. (2023). Active tuberculosis screening among the displaced population fleeing Ukraine, France, February to October 2022. Eurosurveillance 28, http://doi.org/10.2807/1560-7917.ES.2023.28.12.2300155.
Aubry, A. and Veziris, N. (2023). La tuberculose, l’une des plus anciennes maladies infectieuses : quelles avancées récentes majeures ? Med Sci (Paris) 39, 203–204, http://doi.org/10.1051/medsci/2023054.
Masini, T., Furin, J., Udwadia, Z. and Guglielmetti, L. (2023). Optimal management of drug-resistant tuberculosis: Can India lead the way? Indian Journal of Medical Research 157, 220, http://doi.org/10.4103/ijmr.ijmr_300_23.
Domínguez, José, Boeree, M. J., Cambau, E., Chesov, D., Conradie, F., Cox, V., Dheda, K., Dudnyk, A., Farhat, M. R., Gagneux, S., Grobusch, M. P., Gröschel, M. I., Guglielmetti, L., Kontsevaya, I., Lange, B., van Leth, F., Lienhardt, C., Mandalakas, Anna M, Maurer, F. P., Merker, M., Miotto, P., Molina-Moya, B., Morel, F., Niemann, S., Veziris, N., Whitelaw, A., Horsburgh, Charles R, Lange, C., Domínguez, Jose, Boeree, M. J., Cambau, E., Chesov, D., Conradie, F., Cox, V., Dheda, K., Dudnyk, A., Farhat, M. R., Gagneux, S., Grobusch, M. P., Gröschel, M. I., Guglielmetti, L., Kontsevaya, I., Lange, B., van Leth, F., Lienhardt, C., Mandalakas, Anna Maria, Maurer, F., Merker, M., Miotto, P., Molina-Moya, B., Morel, F., Niemann, S., Veziris, N., Whitelaw, A., Horsburgh, Charles Robert and Lange, C. (2023). Clinical implications of molecular drug resistance testing for Mycobacterium tuberculosis: a 2023 TBnet/RESIST-TB consensus statement. The Lancet Infectious Diseases, http://doi.org/10.1016/S1473-3099(22)00875-1.
Barbier, E., Fouchet, T., Hartmann, A., Cambau, E., Mougari, F., Dubois, C., Lubetzki, M. and Rochelet, M. (2023). Rapid electrochemical detection of Mycobacterium tuberculosis in sputum by measuring Ag85 activity with disposable carbon sensors. Talanta 253, 123927, http://doi.org/10.1016/j.talanta.2022.123927.
Khan, U. and Guglielmetti, L. (2023). Tailored TPT for drug-resistant TB - promoting equity and access to optimal care. Int J Tuberc Lung Dis 27, 89b–890, http://doi.org/10.5588/ijtld.22.0538.
Günther, G., Guglielmetti, L., Leu, C., Lange, C., van Leth, F., Hasan Hafizi, Khachatryan, N., Aroyan, H., Kabasakalyan, E., Knappik, M., Skrahina, A., Klimuk, D., Nikolenka, A., Muylle, I., Milanov, V., Velkovska, D., Tarinska, N., Bachiyska, E., Jankovic, M., Pieridou, D., Adamide, T., Nicolaou, N., Vasakova, M., Sukholytka, M., Kopeckà, E., Folkvardsen, D. B., Svensson, E., Danilovits, M., Kummik, T., Vasankari, T., Fréchet-Jachym, M., Nahmiash, A., Togonidze, T., Avaliani, Z., Kinkladze, I., Aspindzelashvili, R., Bichashvili, T., Losaberidze, G., Merabishvili, T., Kalsdorf, B., Manika, K., Tsiakitzis, K., Bakos, A., Ægisdóttir, T. R., Michelsen, G. S., Karlsdóttir, K., McLaughlin, A.-M., Fitzgibbon, M., Chemtob, D., Codecasa, L. R., Ferrarese, M., Torri, S., Gjocaj, M., Kuksa, L., Davidaviciene, E., Wirtz, G., Perrin, M., Asciak, A. P., Chesov, D., de Lange, W., Akkerman, O., Poposka, B. I., Mack, U., Jensenius, M., Kvalvik, L., Mengshoel, A. T., Kruczak, K., Duarte, R., Ribeiro, N., Ibraim, E., Kaluzhenina, A., Barkanova, O., Pesut, D., Solovic, I., Svetina, P., Souza-Galvão, M.-L. de, Millet, J.-P., Casas, X., Vives, M., Bruchfeld, J., Dalemo, P., Jonsson, J., Aeschbacher, K., Keller, P., Özkara, S., Tiberi, S., Chen, C., Terleeva, Y. and Dudnyk, A. (2023). Availability and costs of medicines for the treatment of tuberculosis in Europe. Clinical Microbiology and Infection 29, 77–84, http://doi.org/10.1016/j.cmi.2022.07.026.
Senelle, G., Sahal, M. R., La, K., Billard-Pomares, T., Marin, J., Mougari, F., Bridier-Nahmias, A., Carbonnelle, E., Cambau, E., Refrégier, G., Guyeux, C. and Sola, C. (2023). Towards the reconstruction of a global TB history using a new pipeline “TB-Annotator". Tuberculosis 143, 102376, http://doi.org/10.1016/j.tube.2023.102376.
Motta, I., Boeree, M., Chesov, D., Dheda, K., Günther, G., Horsburgh, C. R., Kherabi, Y., Lange, C., Lienhardt, C., McIlleron, H. M., Paton, N. I., Stagg, H. R., Thwaites, G., Udwadia, Z., Van Crevel, R., Velásquez, G. E., Wilkinson, R. J., Guglielmetti, L., Motta, I., Kherabi, Y., Van Crevel, R. and Guglielmetti, L. (2023). Recent advances in the treatment of tuberculosis. Clinical Microbiology and Infection S1198743X23003397, http://doi.org/10.1016/j.cmi.2023.07.013.
Holmgaard, F. B., Guglielmetti, L., Lillebaek, T., Andersen, Å. B., Wejse, C. and Dahl, V. N. (2022). Efficacy and tolerability of concomitant use of bedaquiline and delamanid for multidrug- and extensively drug-resistant tuberculosis: a systematic review and meta-analysis. Clin Infect Dis ciac876, http://doi.org/10.1093/cid/ciac876.
Wetzstein, N., Drummer, A.-P., Bockey, A., Herrmann, E., Küpper-Tetzel, C. P., Graf, C., Koch, B., Goetsch, U., Vehreschild, M. J. G. T., Guglielmetti, L., Lange, B., Wichelhaus, T. A. and Stephan, C. (2022). Occurrence of extrapulmonary tuberculosis is associated with geographical origin: spatial characteristics of the Frankfurt TB cohort 2013–2018. Infection, http://doi.org/10.1007/s15010-022-01921-9.
Kherabi, Y., Tunesi, S., Kay, A. and Guglielmetti, L. (2022). Preventive Therapy for Contacts of Drug-Resistant Tuberculosis. Pathogens 11, 1189, http://doi.org/10.3390/pathogens11101189.
Khan, U. and Guglielmetti, L. (2022). Evidence and ethical considerations for the treatment of contacts exposed to drug-resistant TB. The International Journal of Tuberculosis and Lung Disease 26, 900–901, http://doi.org/10.5588/ijtld.22.0328.
Kherabi, Y., Fréchet-Jachym, M., Rioux, C., Yazdanpanah, Y., Méchaï, F., Pourcher, V., Robert, J. and Guglielmetti, L. (2022). Revised Definitions of Tuberculosis Resistance and Treatment Outcomes, France, 2006–2019. Emerg Infect Dis 28, 1796–1804, http://doi.org/10.3201/eid2809.220458.
De Castro, N., Mechaï, F., Bachelet, D., Canestri, A., Joly, V., Vandenhende, M., Boutoille, D., Kerjouan, M., Veziris, N., Molina, J. M., Grall, N., Tattevin, P., Laouénan, C., Yazdanpanah, Y. and for the FAST TB Study Group (2022). Treatment With a Three-Drug Regimen for Pulmonary Tuberculosis Based on Rapid Molecular Detection of Isoniazid Resistance: A Noninferiority Randomized Trial (FAST-TB). Open Forum Infectious Diseases 9, ofac353, http://doi.org/10.1093/ofid/ofac353.
Kraef, C., Lindquist, E., Svensson, E. and Cambau, E. (2022). Diagnostic toolkit for tuberculosis: should we include urine lipoarabinomannan (LAM) detection in the WHO European Region? Clinical Microbiology and Infection, http://doi.org/10.1016/j.cmi.2022.06.022.
Bachir, M., Guglielmetti, L., Tunesi, S., Billard-Pomares, T., Chiesi, S., Jaffré, J., Langris, H., Pourcher, V., Schramm, F., Lemaître, N. and Robert, J. (2022). Molecular detection of isoniazid monoresistance improves tuberculosis treatment: A retrospective cohort in France. Journal of Infection 85, 24–30, http://doi.org/10.1016/j.jinf.2022.05.017.
Maitre, T., Morel, F., Brossier, F., Sougakoff, W., Jaffre, J., Cheng, S., Veziris, N., Aubry, A. and on behalf of the NRC-MyRMA (2022). How a PCR Sequencing Strategy Can Bring New Data to Improve the Diagnosis of Ethionamide Resistance. Microorganisms 10, 1436, http://doi.org/10.3390/microorganisms10071436.
Eimer, J., Fréchet-Jachym, M., Le Dû, D., Caumes, E., El-Helali, N., Marigot-Outtandy, D., Mechai, F., Peytavin, G., Pourcher, V., Rioux, C., Yazdanpanah, Y., Robert, J., Guglielmetti, L. and for the LZDM group (2022). Increased linezolid plasma concentrations are associated with the development of severe toxicity in MDR-TB treatment. Clinical Infectious Diseases ciac485, http://doi.org/10.1093/cid/ciac485.
Bonnet, I., Haddad, E., Guglielmetti, L., Bémer, P., Bernard, L., Bourgoin, A., Brault, R., Catho, G., Caumes, E., Escaut, L., Fourniols, E., Fréchet-Jachym, M., Gaudart, A., Guillot, H., Lafon-Desmurs, B., Lanoix, J.-P., Lanotte, P., Lemaignen, A., Lemaire, B., Lemaitre, N., Michau, C., Morand, P., Mougari, F., Marigot-Outtandy, D., Patrat-Delon, S., Perpoint, T., Piau, C., Pourcher, V., Zarrouk, V., Zeller, V., Veziris, N., Jauréguiberry, S. and Aubry, A. (2022). Clinical Features and Outcome of Multidrug-Resistant Osteoarticular Tuberculosis: A 12-Year Case Series from France. Microorganisms 10, 1215, http://doi.org/10.3390/microorganisms10061215.
Guglielmetti, L., Günther, G., Leu, C., Cirillo, D., Duarte, R., Garcia-Basteiro, A. L., Goletti, D., Jankovic, M., Kuksa, L., Maurer, F. P., Méchaï, F., Tiberi, S., Leth, F. van, Veziris, N. and Lange, C. (2022). Rifapentine access in Europe: growing concerns over key tuberculosis treatment component. European Respiratory Journal 59, http://doi.org/10.1183/13993003.00388-2022.
Le Ray, L. F., Aubry, A., Sougakoff, W., Revest, M., Robert, J., Bonnet, I., Veziris, N. and Morel, F. (2022). atpE Mutation in Mycobacterium tuberculosis Not Always Predictive of Bedaquiline Treatment Failure. Emerg Infect Dis 28, 1062–1064, http://doi.org/10.3201/eid2805.212517.
Group, A. S. T., Georghiou, S. B., Rodwell, T. C., Korobitsyn, A., Abbadi, S. H., Ajbani, K., Alffenaar, J.-W., Alland, D., Alvarez, N., Andres, S., Ardizzoni, E., Aubry, A., Baldan, R., Ballif, M., Barilar, I., Böttger, E. C., Chakravorty, S., Claxton, P. M., Cirillo, D. M., Comas, I., Coulter, C., Denkinger, C. M., Derendinger, B., Desmond, E. P., Steenwinkel, J. E. M. de, Dheda, K., Diacon, A. H., Dolinger, D. L., Dooley, K. E., Egger, M., Ehsani, S., Farhat, M. R., Fattorini, L., Finci, I., Ray, L. F. L., Furió, V., Groenheit, R., Gumbo, T., Heysell, S. K., Hillemann, D., Hoffmann, H., Hsueh, P.-R., Hu, Y., Huang, H., Hussain, A., Ismail, F., Izumi, K., Jagielski, T., Johnson, J. L., Kambli, P., Kaniga, K., Karunaratne, G. H. R. E., Sharma, M. K., Keller, P. M., Kelly, E. C., Kholina, M., Kohli, M., Kranzer, K., Laurenson, I. F., Limberis, J., Lin, S.-Y. G., Liu, Y., López-Gavín, A., Lyander, A., Machado, D., Martinez, E., Masood, F., Mitarai, S., Mvelase, N. R., Niemann, S., Nikolayevskyy, V., Maurer, F. P., Merker, M., Miotto, P., Omar, S. V., Otto-Knapp, R., Palaci, M., Gutiérrez, J. J. P., Peacock, S. J., Peloquin, C. A., Perera, J., Pierre-Audigier, C., Pholwat, S., Posey, J. E., Prammananan, T., Rigouts, L., Robledo, J., Rockwood, N., Rodrigues, C., Salfinger, M., Schechter, M. C., Seifert, M., Sengstake, S., Shinnick, T., Shubladze, N., Sintchenko, V., Sirgel, F., Somasundaram, S., Sterling, T. R., Spitaleri, A., Streicher, E., Supply, P., Svensson, E., Tagliani, E., Tahseen, S., Takaki, A., Theron, G., Torrea, G., Deun, A. V., Ingen, J. van, Rie, A. V., Soolingen, D. van, Jr, R. V., Venter, A., Veziris, N., Villellas, C., Viveiros, M., Warren, R., Wen, S., Werngren, J., Wilkinson, R. J., Yang, C., Yılmaz, F. F., Zhang, T., Zimenkov, D., Ismail, N., Köser, C. U. and Schön, T. (2022). Updating the approaches to define susceptibility and resistance to anti-tuberculosis agents: implications for diagnosis and treatment. European Respiratory Journal 59, http://doi.org/10.1183/13993003.00166-2022.
Tunesi, S., Dû, D. L., Gualano, G., Millet, J.-P., Skrahin, A., Bothamley, G., Casas, X., Goletti, D., Lange, C., Musso, M., Palmieri, F., Pourcher, V., Rioux, C., Skrahina, A., Veziris, N., Viatushka, D., Jachym-Fréchet, M. and Guglielmetti, L. (2022). Co-administration of treatment for rifampicin-resistant TB and chronic HCV infection: a TBnet and ESGMYC study. Journal of Infection, http://doi.org/10.1016/j.jinf.2022.03.004.
Migliori, G. B., Wu, S. J., Matteelli, A., Zenner, D., Goletti, D., Ahmedov, S., Al-Abri, S., Allen, D. M., Balcells, M. E., Garcia-Basteiro, A. L., Cambau, E., Chaisson, R. E., Chee, C. B. E., Dalcolmo, M. P., Denholm, J. T., Erkens, C., Esposito, S., Farnia, P., Friedland, J. S., Graham, S., Hamada, Y., Harries, A. D., Kay, A. W., Kritski, A., Manga, S., Marais, B. J., Menzies, D., Ng, D., Petrone, L., Rendon, A., Silva, D. R., Schaaf, H. S., Skrahina, A., Sotgiu, G., Thwaites, G., Tiberi, S., Tukvadze, N., Zellweger, J.-P., D’Ambrosio, L., Centis, R. and Ong, C. W. M. (2022). Clinical standards for the diagnosis, treatment and prevention of TB infection. Int J Tuberc Lung Dis 26, 190–205, http://doi.org/10.5588/ijtld.21.0753.
Guyeux, C., Senelle, G., Refrégier, G., Bretelle-Establet, F., Cambau, E. and Sola, C. (2022). Connection between two historical tuberculosis outbreak sites in Japan, Honshu, by a new ancestral Mycobacterium tuberculosis L2 sublineage. Epidemiology & Infection 150, http://doi.org/10.1017/S0950268822000048.
Nyang’wa, B. T., LaHood, A. N., Mitnick, C. D. and Guglielmetti, L. (2021). TB research requires strong protections, innovation, and increased funding in response to COVID-19. Trials 22, 1–3, http://doi.org/10.1186/s13063-021-05331-4.
Bonnet, I., Enouf, V., Morel, F., Ok, V., Jaffré, J., Jarlier, V., Aubry, A., Robert, J. and Sougakoff, W. (2021). A Comprehensive Evaluation of GeneLEAD VIII DNA Platform Combined to Deeplex Myc-TB® Assay to Detect in 8 Days Drug Resistance to 13 Antituberculous Drugs and Transmission of Mycobacterium tuberculosis Complex Directly From Clinical Samples. Front Cell Infect Microbiol 11, 707244, http://doi.org/10.3389/fcimb.2021.707244.
Guglielmetti, L., Ardizzoni, E., Atger, M., Baudin, E., Berikova, E., Bonnet, M., Chang, E., Cloez, S., Coit, J. M., Cox, V., de Jong, B. C., Delifer, C., Do, J. M., Tozzi, D. D. S., Ducher, V., Ferlazzo, G., Gouillou, M., Khan, A., Khan, U., Lachenal, N., LaHood, A. N., Lecca, L., Mazmanian, M., McIlleron, H., Moschioni, M., O’Brien, K., Okunbor, O., Oyewusi, L., Panda, S., Patil, S. B., Phillips, P. P. J., Pichon, L., Rupasinghe, P., Rich, M. L., Saluhuddin, N., Seung, K. J., Tamirat, M., Trippa, L., Cellamare, M., Velásquez, G. E., Wasserman, S., Zimetbaum, P. J., Varaine, F. and Mitnick, C. D. (2021). Evaluating newly approved drugs for multidrug-resistant tuberculosis (endTB): study protocol for an adaptive, multi-country randomized controlled trial. Trials 22, 651, http://doi.org/10.1186/s13063-021-05491-3.
Roelens, M., Battista Migliori, G., Rozanova, L., Estill, J., Campbell, J. R., Cegielski, J. P., Tiberi, S., Palmero, D., Fox, G. J., Guglielmetti, L., Sotgiu, G., Brust, J. C. M., Bang, D., Lienhardt, C., Lange, C., Menzies, D., Keiser, O. and Raviglione, M. (2021). Evidence-based Definition for Extensively Drug-Resistant Tuberculosis. Am J Respir Crit Care Med 204, 713–722, http://doi.org/10.1164/rccm.202009-3527OC.
Veziris, N., Bonnet, I., Morel, F., Guglielmetti, L., Maitre, T., Ray, L. F. L., Sougakoff, W., Robert, J. and Aubry, A. (2021). Impact of the revised definition of extensively drug-resistant tuberculosis. European Respiratory Journal 58, http://doi.org/10.1183/13993003.00641-2021.
Starshinova, A., Guglielmetti, L., Rzhepishevska, O., Ekaterincheva, O., Zinchenko, Yu. and Kudlay, D. (2021). Diagnostics and management of tuberculosis and COVID-19 in a patient with pneumothorax (clinical case). J Clin Tuberc Other Mycobact Dis 24, 100259, http://doi.org/10.1016/j.jctube.2021.100259.
Ok, V., Aubry, A., Morel, F., Bonnet, I., Robert, J. and Sougakoff, W. (2021). Rapid Molecular Diagnosis of Tuberculosis and Its Resistance to Rifampicin and Isoniazid with Automated MDR/MTB ELITe MGB® Assay. Antibiotics 10, 797, http://doi.org/10.3390/antibiotics10070797.
Hewison, C. and Guglielmetti, L. (2021). Cardiac safety of multidrug-resistant tuberculosis treatment: moving towards individualised monitoring. Lancet Infect Dis 21, 894–895, http://doi.org/10.1016/S1473-3099(20)30836-7.
Guglielmetti, L. and Varaine, F. (2021). The coming-of-age of bedaquiline: a tale with an open ending. European Respiratory Journal 57, http://doi.org/10.1183/13993003.00066-2021.
World Health Organisation (2021). Technical Report on critical concentrations for drug susceptibility testing of isoniazid and the rifamycins (rifampicin, rifabutin and rifapentine), WHO, Geneva, URL: https://www.who.int/publications/i/item/technical-report-on-critical-concentrations-for-drugsusceptibility-testing-of-isoniazid-and-therifamycins-(rifampicin-rifabutin-and-rifapentine) [Accessed March 2022].
Maitre, T., Guglielmetti, L. and Veziris, N. (2021). Defining optimal fluoroquinolone exposure against Mycobacterium tuberculosis: contribution of murine studies. European Respiratory Journal 57, http://doi.org/10.1183/13993003.04315-2020.
Mohamed, S., Köser, C. U., Salfinger, M., Sougakoff, W. and Heysell, S. K. (2021). Targeted next-generation sequencing: a Swiss army knife for mycobacterial diagnostics? European Respiratory Journal 57, http://doi.org/10.1183/13993003.04077-2020.
Schön, T., Werngren, J., Machado, D., Borroni, E., Wijkander, M., Lina, G., Mouton, J., Matuschek, E., Kahlmeter, G., Giske, C., Santin, M., Cirillo, D. M., Viveiros, M. and Cambau, E. (2021). Multicentre testing of the EUCAST broth microdilution reference method for MIC determination on Mycobacterium tuberculosis. Clinical Microbiology and Infection 27, 288.e1-288.e4, http://doi.org/10.1016/j.cmi.2020.10.019.
Molina‐Moya, B., Guglielmetti, L., Bothamley, G., van Leth, F., Lange, C., Dominguez, J. and TBnet Study Group (2021). Use and impact of molecular methods for detecting drug‐resistant TB. The International Journal of Tuberculosis and Lung Disease 25, 157–159, http://doi.org/10.5588/ijtld.20.0527.
Calin, R., Belkacem, A., Caraux-Paz, P., Wagner, M., Guillot, H., Veziris, N., Jaureguiberry, S., Caumes, E., Patey, O. and Pourcher, V. (2021). Abdominal Tuberculosis: Experience from Two Tertiary-Care Hospitals in the Paris Region. The American Journal of Tropical Medicine and Hygiene 104, 223–228, http://doi.org/10.4269/ajtmh.20-0023.
1368488
2022
items
1
0
author
asc
year
1
241
https://cnrmyrma.fr/wp-content/plugins/zotpress/
%7B%22status%22%3A%22success%22%2C%22updateneeded%22%3Afalse%2C%22instance%22%3A%22zotpress-ac54947b1c2f29e6e5b723bc5ddb5cdd%22%2C%22meta%22%3A%7B%22request_last%22%3A0%2C%22request_next%22%3A0%2C%22used_cache%22%3Atrue%7D%2C%22data%22%3A%5B%7B%22key%22%3A%223996TQSC%22%2C%22library%22%3A%7B%22id%22%3A1368488%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Aubry%20et%20al.%22%2C%22parsedDate%22%3A%222022-08-01%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EAubry%2C%20A.%2C%20Sammarco%20Rosa%2C%20P.%2C%20Chauffour%2C%20A.%2C%20Fletcher%2C%20M.%20L.%2C%20Cambau%2C%20E.%20and%20Avanzi%2C%20C.%20%282022%29.%20%3Cb%3EDrug%20resistance%20in%20leprosy%3A%20An%20update%20following%2070years%20of%20chemotherapy%3C%5C%2Fb%3E.%20Infectious%20Diseases%20Now%20%3Ci%3E52%3C%5C%2Fi%3E%2C%20243%26%23x2013%3B251%2C%20%3Ca%20target%3D%27_blank%27%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.idnow.2022.04.001%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.idnow.2022.04.001%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Drug%20resistance%20in%20leprosy%3A%20An%20update%20following%2070years%20of%20chemotherapy%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Aubry%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P.%22%2C%22lastName%22%3A%22Sammarco%20Rosa%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Chauffour%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%20L.%22%2C%22lastName%22%3A%22Fletcher%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E.%22%2C%22lastName%22%3A%22Cambau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%22%2C%22lastName%22%3A%22Avanzi%22%7D%5D%2C%22abstractNote%22%3A%22Leprosy%20is%20one%20of%20the%20oldest%20infectious%20diseases%2C%20reported%20for%20more%20than%202000years.%20Leprosy%20elimination%20goal%20as%20a%20public%20health%20problem%20set%20by%20the%20World%20Health%20Organization%2C%20aiming%20for%20a%20global%20prevalence%20rate%3C1%20patient%20in%20a%20population%20of%2010%2C000%2C%20was%20achieved%20in%202000%20mainly%20thanks%20to%20the%20worldwide%20use%20of%20leprosy%20drugs%20starting%20in%20the%201980s%20and%20their%20access%20at%20no%20cost%20for%20patients%20since%201995.%20However%2C%20around%20200%2C000%20new%20cases%20are%20still%20reported%20each%20year%2C%20particularly%20in%20India%2C%20Brazil%2C%20and%20Indonesia.%20As%20with%20other%20bacteria%20of%20medical%20interest%2C%20antimicrobial%20resistance%20is%20observed%20in%20Mycobacterium%20leprae%20strains%20in%20several%20parts%20of%20the%20world%2C%20despite%20multidrug%20therapy%20being%20the%20recommended%20standard%20leprosy%20treatment%20to%20avoid%20resistance%20selection%20since%201982.%20Therefore%2C%20identifying%20and%20monitoring%20resistance%20is%20necessary.%20We%20provide%20an%20overview%20of%20the%20historical%20facts%20that%20led%20to%20the%20current%20drug%20resistance%20situation%2C%20the%20antibiotics%20effective%20against%20M.%5Cu00a0leprae%2C%20their%20mechanisms%20of%20action%20and%20resistance%2C%20and%20resistance%20detection%20methods.%20We%20also%20discuss%20therapeutic%20management%20of%20the%20resistant%20cases%2C%20new%20genes%20with%20potential%20roles%20in%20drug%20resistance%20and%20bacterial%20adaptation%2C%20new%20drugs%20under%20investigation%2C%20and%20the%20risk%20for%20resistance%20selection%20with%20the%20chemoprophylaxis%20measures.%22%2C%22date%22%3A%222022-08-01%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1016%5C%2Fj.idnow.2022.04.001%22%2C%22ISSN%22%3A%222666-9919%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fwww.sciencedirect.com%5C%2Fscience%5C%2Farticle%5C%2Fpii%5C%2FS2666991922000665%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222022-09-23T13%3A26%3A59Z%22%7D%7D%2C%7B%22key%22%3A%22PF5DMFLC%22%2C%22library%22%3A%7B%22id%22%3A1368488%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Bachir%20et%20al.%22%2C%22parsedDate%22%3A%222022-07-01%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EBachir%2C%20M.%2C%20Guglielmetti%2C%20L.%2C%20Tunesi%2C%20S.%2C%20Billard-Pomares%2C%20T.%2C%20Chiesi%2C%20S.%2C%20Jaffr%26%23xE9%3B%2C%20J.%2C%20Langris%2C%20H.%2C%20Pourcher%2C%20V.%2C%20Schramm%2C%20F.%2C%20Lema%26%23xEE%3Btre%2C%20N.%20and%20Robert%2C%20J.%20%282022%29.%20%3Cb%3EMolecular%20detection%20of%20isoniazid%20monoresistance%20improves%20tuberculosis%20treatment%3A%20A%20retrospective%20cohort%20in%20France%3C%5C%2Fb%3E.%20Journal%20of%20Infection%20%3Ci%3E85%3C%5C%2Fi%3E%2C%2024%26%23x2013%3B30%2C%20%3Ca%20target%3D%27_blank%27%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.jinf.2022.05.017%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.jinf.2022.05.017%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Molecular%20detection%20of%20isoniazid%20monoresistance%20improves%20tuberculosis%20treatment%3A%20A%20retrospective%20cohort%20in%20France%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marwa%22%2C%22lastName%22%3A%22Bachir%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lorenzo%22%2C%22lastName%22%3A%22Guglielmetti%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Simone%22%2C%22lastName%22%3A%22Tunesi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Typhaine%22%2C%22lastName%22%3A%22Billard-Pomares%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sheila%22%2C%22lastName%22%3A%22Chiesi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%5Cu00e9r%5Cu00e9my%22%2C%22lastName%22%3A%22Jaffr%5Cu00e9%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Hugo%22%2C%22lastName%22%3A%22Langris%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Val%5Cu00e9rie%22%2C%22lastName%22%3A%22Pourcher%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fr%5Cu00e9d%5Cu00e9ric%22%2C%22lastName%22%3A%22Schramm%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nadine%22%2C%22lastName%22%3A%22Lema%5Cu00eetre%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%5Cu00e9r%5Cu00f4me%22%2C%22lastName%22%3A%22Robert%22%7D%5D%2C%22abstractNote%22%3A%22Objectives%5CnIsoniazid-monoresistant%20tuberculosis%20%28HR-TB%29%20requires%20early%20diagnosis%20and%20adapted%20treatment%20to%20achieve%20optimal%20outcomes.%20The%20primary%20aim%20of%20the%20study%20was%20to%20assess%20the%20impact%20of%20the%20implementation%20of%20rapid%20diagnostic%20tests%20on%20HR-TB%20treatment%20in%20France.%5CnMethods%5CnWe%20designed%20a%20retrospective%20multicentre%20study%20including%20consecutive%20HR-TB%20patients%20diagnosed%20in%202016%20and%202017.%20Implementation%20of%20a%20molecular%20assay%20detecting%20isoniazid%20resistance%20directly%20on%20a%20clinical%20sample%20was%20recorded.%20The%20association%20between%20early%20implementation%20of%20such%20assays%20and%20adequate%20treatment%20was%20assessed%20by%20a%20multivariable%20Cox%20proportional%20hazards%20model.%5CnResults%5CnOverall%2C%2099%20HR-TB%20patients%20were%20included%20from%2020%20University%20Hospitals.%20Among%20all%20smear-positive%20HR-TB%20patients%2C%20only%2026%25%20beneficiated%20from%20early%20molecular%20HR%20detection.%20This%20detection%20was%20independently%20associated%20with%20shorter%20time%20to%20adequate%20treatment%20%28HR%5Cu00a0%3D%5Cu00a02.0%20%5B1.1%5Cu20133.8%5D%2C%20p%5Cu00a0%3D%5Cu00a00.03%29.%5CnConclusion%5CnIn%20our%20study%2C%20molecular%20detection%20of%20HR%20on%20an%20initial%20sample%20was%20independently%20associated%20with%20earlier%20treatment%20adaptation.%22%2C%22date%22%3A%222022-07-01%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1016%5C%2Fj.jinf.2022.05.017%22%2C%22ISSN%22%3A%220163-4453%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fwww.sciencedirect.com%5C%2Fscience%5C%2Farticle%5C%2Fpii%5C%2FS0163445322003061%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222022-07-06T13%3A19%3A23Z%22%7D%7D%2C%7B%22key%22%3A%22HUBVTWEL%22%2C%22library%22%3A%7B%22id%22%3A1368488%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Bonnet%20et%20al.%22%2C%22parsedDate%22%3A%222022-06-14%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EBonnet%2C%20I.%2C%20Haddad%2C%20E.%2C%20Guglielmetti%2C%20L.%2C%20B%26%23xE9%3Bmer%2C%20P.%2C%20Bernard%2C%20L.%2C%20Bourgoin%2C%20A.%2C%20Brault%2C%20R.%2C%20Catho%2C%20G.%2C%20Caumes%2C%20E.%2C%20Escaut%2C%20L.%2C%20Fourniols%2C%20E.%2C%20Fr%26%23xE9%3Bchet-Jachym%2C%20M.%2C%20Gaudart%2C%20A.%2C%20Guillot%2C%20H.%2C%20Lafon-Desmurs%2C%20B.%2C%20Lanoix%2C%20J.-P.%2C%20Lanotte%2C%20P.%2C%20Lemaignen%2C%20A.%2C%20Lemaire%2C%20B.%2C%20Lemaitre%2C%20N.%2C%20Michau%2C%20C.%2C%20Morand%2C%20P.%2C%20Mougari%2C%20F.%2C%20Marigot-Outtandy%2C%20D.%2C%20Patrat-Delon%2C%20S.%2C%20Perpoint%2C%20T.%2C%20Piau%2C%20C.%2C%20Pourcher%2C%20V.%2C%20Zarrouk%2C%20V.%2C%20Zeller%2C%20V.%2C%20Veziris%2C%20N.%2C%20Jaur%26%23xE9%3Bguiberry%2C%20S.%20and%20Aubry%2C%20A.%20%282022%29.%20%3Cb%3EClinical%20Features%20and%20Outcome%20of%20Multidrug-Resistant%20Osteoarticular%20Tuberculosis%3A%20A%2012-Year%20Case%20Series%20from%20France%3C%5C%2Fb%3E.%20Microorganisms%20%3Ci%3E10%3C%5C%2Fi%3E%2C%201215%2C%20%3Ca%20target%3D%27_blank%27%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.3390%5C%2Fmicroorganisms10061215%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.3390%5C%2Fmicroorganisms10061215%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Clinical%20Features%20and%20Outcome%20of%20Multidrug-Resistant%20Osteoarticular%20Tuberculosis%3A%20A%2012-Year%20Case%20Series%20from%20France%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Isabelle%22%2C%22lastName%22%3A%22Bonnet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Elie%22%2C%22lastName%22%3A%22Haddad%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lorenzo%22%2C%22lastName%22%3A%22Guglielmetti%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pascale%22%2C%22lastName%22%3A%22B%5Cu00e9mer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Louis%22%2C%22lastName%22%3A%22Bernard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anne%22%2C%22lastName%22%3A%22Bourgoin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Rachel%22%2C%22lastName%22%3A%22Brault%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gaud%22%2C%22lastName%22%3A%22Catho%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eric%22%2C%22lastName%22%3A%22Caumes%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L%5Cu00e9lia%22%2C%22lastName%22%3A%22Escaut%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eric%22%2C%22lastName%22%3A%22Fourniols%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mathilde%22%2C%22lastName%22%3A%22Fr%5Cu00e9chet-Jachym%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alice%22%2C%22lastName%22%3A%22Gaudart%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22H%5Cu00e9l%5Cu00e8ne%22%2C%22lastName%22%3A%22Guillot%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Barth%5Cu00e9l%5Cu00e9my%22%2C%22lastName%22%3A%22Lafon-Desmurs%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Philippe%22%2C%22lastName%22%3A%22Lanoix%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Philippe%22%2C%22lastName%22%3A%22Lanotte%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Adrien%22%2C%22lastName%22%3A%22Lemaignen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22B%5Cu00e9n%5Cu00e9dicte%22%2C%22lastName%22%3A%22Lemaire%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nadine%22%2C%22lastName%22%3A%22Lemaitre%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christophe%22%2C%22lastName%22%3A%22Michau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Philippe%22%2C%22lastName%22%3A%22Morand%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Faiza%22%2C%22lastName%22%3A%22Mougari%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Dhiba%22%2C%22lastName%22%3A%22Marigot-Outtandy%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sol%5Cu00e8ne%22%2C%22lastName%22%3A%22Patrat-Delon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thomas%22%2C%22lastName%22%3A%22Perpoint%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Caroline%22%2C%22lastName%22%3A%22Piau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Val%5Cu00e9rie%22%2C%22lastName%22%3A%22Pourcher%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Virginie%22%2C%22lastName%22%3A%22Zarrouk%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Val%5Cu00e9rie%22%2C%22lastName%22%3A%22Zeller%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nicolas%22%2C%22lastName%22%3A%22Veziris%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22St%5Cu00e9phane%22%2C%22lastName%22%3A%22Jaur%5Cu00e9guiberry%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alexandra%22%2C%22lastName%22%3A%22Aubry%22%7D%5D%2C%22abstractNote%22%3A%22The%20optimal%20treatment%20for%20osteoarticular%20infection%20due%20to%20multidrug-resistant%20tuberculosis%20strains%20%28MDR-OATB%29%20remains%20unclear.%20This%20study%20aims%20to%20evaluate%20the%20diagnosis%2C%20management%20and%20outcome%20of%20MDR-OATB%20in%20France.%20We%20present%20a%20case%20series%20of%20MDR-OATB%20patients%20reviewed%20at%20the%20French%20National%20Reference%20Center%20for%20Mycobacteria%20between%202007%20and%202018.%20Medical%20history%20and%20clinical%2C%20microbiological%2C%20treatment%20and%20outcome%20data%20were%20collected.%20Twenty-three%20MDR-OATB%20cases%20were%20reported%2C%20representing%203%25%20of%20all%20concurrent%20MDR-TB%20cases%20in%20France.%20Overall%2C%2017%20were%20male%2C%20and%20the%20median%20age%20was%2032%20years.%20Six%20patients%20were%20previously%20treated%20for%20TB%2C%20including%20four%20with%20first-line%20drugs.%20The%20most%20frequently%20affected%20site%20was%20the%20spine%20%28n%20%3D%2016%29.%20Bone%20and%20joint%20surgery%20were%20required%20in%2012%20patients.%20Twenty-one%20patients%20%2891%25%29%20successfully%20completed%20the%20treatment%20with%20a%20regimen%20containing%20a%20mean%20of%20four%20drugs%20%28range%2C%202%5Cu20136%29%20for%20a%20mean%20duration%20of%2020%20months%20%28range%2C%2013%5Cu201327%29.%20Overall%2C%20high%20rates%20of%20treatment%20success%20were%20achieved%20following%20WHO%20MDR-TB%20treatment%20guidelines%20and%20individualized%20patient%20management%20recommendations%20by%20the%20French%20National%20TB%20Consilium.%20However%2C%20the%20optimal%20combination%20of%20drugs%2C%20duration%20of%20treatment%20and%20role%20of%20surgery%20in%20the%20management%20of%20MDR-OATB%20remains%20to%20be%20determined.%22%2C%22date%22%3A%222022-6-14%22%2C%22language%22%3A%22%22%2C%22DOI%22%3A%2210.3390%5C%2Fmicroorganisms10061215%22%2C%22ISSN%22%3A%222076-2607%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fwww.ncbi.nlm.nih.gov%5C%2Fpmc%5C%2Farticles%5C%2FPMC9229793%5C%2F%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222022-06-29T14%3A21%3A11Z%22%7D%7D%2C%7B%22key%22%3A%22AM4AMZDJ%22%2C%22library%22%3A%7B%22id%22%3A1368488%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Chaptal%20et%20al.%22%2C%22parsedDate%22%3A%222022-09-09%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EChaptal%2C%20M.%2C%20Andrejak%2C%20C.%2C%20Bonifay%2C%20T.%2C%20Beillard%2C%20E.%2C%20Guillot%2C%20G.%2C%20Guyomard-Rabenirina%2C%20S.%2C%20Demar%2C%20M.%2C%20Trombert-Paolantoni%2C%20S.%2C%20Jacomo%2C%20V.%2C%20Mosnier%2C%20E.%2C%20Veziris%2C%20N.%2C%20Djossou%2C%20F.%2C%20Epelboin%2C%20L.%20and%20Group%2C%20F.%20G.%20P.%20working%20%282022%29.%20%3Cb%3EEpidemiology%20of%20infection%20by%20pulmonary%20non-tuberculous%20mycobacteria%20in%20French%20Guiana%202008%26%23x2013%3B2018%3C%5C%2Fb%3E.%20PLOS%20Neglected%20Tropical%20Diseases%20%3Ci%3E16%3C%5C%2Fi%3E%2C%20e0010693%2C%20%3Ca%20target%3D%27_blank%27%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1371%5C%2Fjournal.pntd.0010693%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1371%5C%2Fjournal.pntd.0010693%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Epidemiology%20of%20infection%20by%20pulmonary%20non-tuberculous%20mycobacteria%20in%20French%20Guiana%202008%5Cu20132018%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mil%5Cu00e8ne%22%2C%22lastName%22%3A%22Chaptal%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Claire%22%2C%22lastName%22%3A%22Andrejak%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Timoth%5Cu00e9e%22%2C%22lastName%22%3A%22Bonifay%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Emmanuel%22%2C%22lastName%22%3A%22Beillard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Genevi%5Cu00e8ve%22%2C%22lastName%22%3A%22Guillot%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22St%5Cu00e9phanie%22%2C%22lastName%22%3A%22Guyomard-Rabenirina%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Magalie%22%2C%22lastName%22%3A%22Demar%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sabine%22%2C%22lastName%22%3A%22Trombert-Paolantoni%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Veronique%22%2C%22lastName%22%3A%22Jacomo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Emilie%22%2C%22lastName%22%3A%22Mosnier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nicolas%22%2C%22lastName%22%3A%22Veziris%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Felix%22%2C%22lastName%22%3A%22Djossou%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lo%5Cu00efc%22%2C%22lastName%22%3A%22Epelboin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22French%20Guiana%20PNTM%20working%22%2C%22lastName%22%3A%22Group%22%7D%5D%2C%22abstractNote%22%3A%22Introduction%20Unlike%20diseases%20caused%20by%20Mycobacterium%20tuberculosis%2C%20M.%20leprae%20and%20M.%20ulcerans%2C%20the%20epidemiology%20of%20pulmonary%20non-tuberculous%20mycobacteria%20%28PNTM%29%20has%20not%20received%20due%20attention%20in%20French%20Guiana.%20The%20main%20objective%20of%20the%20current%20study%20was%20to%20define%20the%20incidence%20of%20these%20PNTM%20infections%3A%20NTM%20pulmonary%20diseases%20%28NTM-PD%29%20and%20casual%20PNTM%20isolation%20%28responsible%20of%20latent%20infection%20or%20simple%20colonization%29.%20The%20secondary%20objectives%20were%20to%20determine%20species%20diversity%20and%20geographic%20distribution%20of%20these%20atypical%20mycobacteria.%20Methods%20A%20retrospective%20observational%20study%20%282008%5Cu20132018%29%20of%20French%20Guiana%20patients%20with%20at%20least%20one%20PNTM%20positive%20respiratory%20sample%20in%20culture%20was%20conducted.%20Patients%20were%20then%20classified%20into%20two%20groups%3A%20casual%20PNTM%20isolation%20or%20pulmonary%20disease%20%28NTM-PD%29%2C%20according%20to%20clinical%2C%20radiological%20and%20microbiological%20criteria%20defined%20by%20the%20American%20Thoracic%20Society%20%5C%2F%20Infectious%20Disease%20Society%20of%20America%20%28ATS%20%5C%2F%20IDSA%29%20in%202007.%20Results%20178%20patients%20were%20included%2C%20out%20of%20which%20147%20had%20casual%20PNTM%20isolation%20and%2031%20had%20NTM-PD.%20Estimated%20annual%20incidence%20rate%20of%20respiratory%20isolates%20was%206.17%20%5C%2F%20100%2C000%20inhabitants%20per%20year%20while%20that%20of%20NTM-PD%20was%201.07%20%5C%2F%20100%2C000%20inhabitants%20per%20year.%20Among%20the%20178%20patients%2C%20M.%20avium%20complex%20%28MAC%29%20was%20the%20most%20frequently%20isolated%20pathogen%20%2838%25%29%2C%20followed%20by%20M.%20fortuitum%20then%20M.%20abscessus%20%2819%25%20and%206%25%20of%20cases%20respectively%29%2C%20the%20latter%20two%20mycobacteria%20being%20mainly%20found%20in%20the%20coastal%20center%20region.%20Concerning%20NTM-PD%2C%20two%20species%20were%20mainly%20involved%3A%20MAC%20%2881%25%29%20and%20M.%20abscessus%20%2816%25%29.%20Discussion%5C%2FConclusion%20This%20is%20the%20first%20study%20on%20the%20epidemiology%20of%20PNTM%20infections%20in%20French%20Guiana.%20PNTM%5Cu2019s%20incidence%20looks%20similar%20to%20other%20contries%20and%20metropolitan%20France%20and%20NTM-PD%20is%20mostly%20due%20to%20MAC%20and%20M.abscessus.%20Although%20French%20Guiana%20is%20the%20French%20territory%20with%20the%20highest%20tuberculosis%20incidence%2C%20NTM%20should%20not%20be%20overlooked.%22%2C%22date%22%3A%229%20sept.%202022%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1371%5C%2Fjournal.pntd.0010693%22%2C%22ISSN%22%3A%221935-2735%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fjournals.plos.org%5C%2Fplosntds%5C%2Farticle%3Fid%3D10.1371%5C%2Fjournal.pntd.0010693%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222022-09-23T13%3A15%3A19Z%22%7D%7D%2C%7B%22key%22%3A%22THH9Q9E6%22%2C%22library%22%3A%7B%22id%22%3A1368488%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Chiron%20et%20al.%22%2C%22parsedDate%22%3A%222022-09-11%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EChiron%2C%20R.%2C%20Hoefsloot%2C%20W.%2C%20Van%20Ingen%2C%20J.%2C%20Marchandin%2C%20H.%2C%20Kremer%2C%20L.%2C%20Morisse-Pradier%2C%20H.%2C%20Charriot%2C%20J.%2C%20Mallet%2C%20J.-P.%2C%20Herrmann%2C%20J.-L.%2C%20Caimmi%2C%20D.%2C%20Moreau%2C%20J.%2C%20Dumont%2C%20Y.%2C%20Godreuil%2C%20S.%2C%20Bergeron%2C%20A.%2C%20Drevait%2C%20M.%2C%20Bouzat-Rossigneux%2C%20E.%2C%20Terrail%2C%20N.%2C%20Andrejak%2C%20C.%2C%20Veziris%2C%20N.%2C%20Grenet%2C%20D.%2C%20Coudrat%2C%20A.%20and%20Catherinot%2C%20E.%20%282022%29.%20%3Cb%3EAmikacin%20Liposomal%20Inhalation%20Suspension%20in%20the%20Treatment%20of%20Mycobacterium%20abscessus%20Lung%20Infection%3A%20A%20French%20Observational%20Experience%3C%5C%2Fb%3E.%20Open%20Forum%20Infect%20Dis%20%3Ci%3E9%3C%5C%2Fi%3E%2C%20ofac465%2C%20%3Ca%20target%3D%27_blank%27%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1093%5C%2Fofid%5C%2Fofac465%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1093%5C%2Fofid%5C%2Fofac465%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Amikacin%20Liposomal%20Inhalation%20Suspension%20in%20the%20Treatment%20of%20Mycobacterium%20abscessus%20Lung%20Infection%3A%20A%20French%20Observational%20Experience%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Raphael%22%2C%22lastName%22%3A%22Chiron%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Wouter%22%2C%22lastName%22%3A%22Hoefsloot%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jakko%22%2C%22lastName%22%3A%22Van%20Ingen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22H%5Cu00e9l%5Cu00e8ne%22%2C%22lastName%22%3A%22Marchandin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laurent%22%2C%22lastName%22%3A%22Kremer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22H%5Cu00e9l%5Cu00e8ne%22%2C%22lastName%22%3A%22Morisse-Pradier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jeremy%22%2C%22lastName%22%3A%22Charriot%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Pierre%22%2C%22lastName%22%3A%22Mallet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Louis%22%2C%22lastName%22%3A%22Herrmann%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Davide%22%2C%22lastName%22%3A%22Caimmi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Johan%22%2C%22lastName%22%3A%22Moreau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yann%22%2C%22lastName%22%3A%22Dumont%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sylvain%22%2C%22lastName%22%3A%22Godreuil%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anne%22%2C%22lastName%22%3A%22Bergeron%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Margot%22%2C%22lastName%22%3A%22Drevait%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Elodie%22%2C%22lastName%22%3A%22Bouzat-Rossigneux%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nicolas%22%2C%22lastName%22%3A%22Terrail%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Claire%22%2C%22lastName%22%3A%22Andrejak%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nicolas%22%2C%22lastName%22%3A%22Veziris%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Dominique%22%2C%22lastName%22%3A%22Grenet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alexandre%22%2C%22lastName%22%3A%22Coudrat%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Emilie%22%2C%22lastName%22%3A%22Catherinot%22%7D%5D%2C%22abstractNote%22%3A%22A%20French%20observational%20cohort%20study%20investigated%20amikacin%20liposome%20inhaled%20suspension%20as%20an%20adjunct%20to%20antibiotic%20regimen%20for%20M%20abscessus%20lung%20infection.%20Sputum%20culture%20conversion%20was%20achieved%20in%2054%25%20%2814%5C%2F26%29%20of%20patients%20with%20acceptable%20safety%20profile%20after%206%20months%20of%20treatment.%22%2C%22date%22%3A%222022-9-11%22%2C%22language%22%3A%22%22%2C%22DOI%22%3A%2210.1093%5C%2Fofid%5C%2Fofac465%22%2C%22ISSN%22%3A%222328-8957%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fwww.ncbi.nlm.nih.gov%5C%2Fpmc%5C%2Farticles%5C%2FPMC9578164%5C%2F%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222022-12-28T16%3A03%3A48Z%22%7D%7D%2C%7B%22key%22%3A%22EBWEL99Z%22%2C%22library%22%3A%7B%22id%22%3A1368488%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Daniau%20et%20al.%22%2C%22parsedDate%22%3A%222022-03%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EDaniau%2C%20C.%2C%20Lecorche%2C%20E.%2C%20Mougari%2C%20F.%2C%20Benmansour%2C%20H.%2C%20Bernet%2C%20C.%2C%20Blanchard%2C%20H.%2C%20Robert%2C%20J.%2C%20Berger-Carbonne%2C%20A.%20and%20Cambau%2C%20E.%20%282022%29.%20%3Cb%3EAssociation%20of%20Healthcare%20and%20Aesthetic%20Procedures%20with%20Infections%20Caused%20by%20Nontuberculous%20Mycobacteria%2C%20France%2C%202012%26%23x2012%3B2020%3C%5C%2Fb%3E.%20Emerg%20Infect%20Dis%20%3Ci%3E28%3C%5C%2Fi%3E%2C%20518%26%23x2013%3B526%2C%20%3Ca%20target%3D%27_blank%27%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.3201%5C%2Feid2803.211791%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.3201%5C%2Feid2803.211791%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Association%20of%20Healthcare%20and%20Aesthetic%20Procedures%20with%20Infections%20Caused%20by%20Nontuberculous%20Mycobacteria%2C%20France%2C%202012%5Cu20122020%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C%5Cu00f4me%22%2C%22lastName%22%3A%22Daniau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Emmanuel%22%2C%22lastName%22%3A%22Lecorche%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Faiza%22%2C%22lastName%22%3A%22Mougari%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Hanaa%22%2C%22lastName%22%3A%22Benmansour%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Claude%22%2C%22lastName%22%3A%22Bernet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Herv%5Cu00e9%22%2C%22lastName%22%3A%22Blanchard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%5Cu00e9r%5Cu00f4me%22%2C%22lastName%22%3A%22Robert%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anne%22%2C%22lastName%22%3A%22Berger-Carbonne%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Emmanuelle%22%2C%22lastName%22%3A%22Cambau%22%7D%5D%2C%22abstractNote%22%3A%22We%20describe%20nontuberculous%20mycobacteria%20%28NTM%29%20infections%20during%202012%5Cu20132020%20associated%20with%20health%20care%20and%20aesthetic%20procedures%20in%20France.%20We%20obtained%20epidemiologic%20data%20from%20the%20national%20early%20warning%20response%20system%20for%20healtcare-associated%20infections%20and%20data%20on%20NTM%20isolates%20from%20the%20National%20Reference%20Center%20for%20Mycobacteria.%20We%20compared%20clinical%20and%20environmental%20isolates%20by%20using%20whole-genome%20sequencing.%20The%2085%20original%20cases%20were%20reported%20after%20surgery%20%2848%2C%2056%25%29%2C%20other%20invasive%20procedures%20%2828%2C%2033%25%29%20and%20other%20procedures%20%289%2C%2011%25%29.%20NTM%20isolates%20belonged%20to%20rapidly%20growing%20%2873%2C%2086%25%29%20and%20slowly%20growing%20%2810%2C%2012%25%29%20species%3B%20in%202%20cases%2C%20the%20species%20was%20not%20identified.%20We%20performed%20environmental%20investigations%20for%2038%20%2845%25%29%20cases%3B%20results%20for%2012%20%2832%25%29%20were%20positive%20for%20the%20same%20NTM%20species%20as%20for%20the%20infection.%20In%2010%20cases%20that%20had%20environmental%20and%20clinical%20samples%20whose%20genomes%20were%20similar%2C%20the%20infection%20source%20was%20probably%20the%20water%20used%20in%20the%20procedures.%20NTM%20infections%20could%20be%20preventable%20by%20using%20sterile%20water%20in%20all%20invasive%20procedures.%22%2C%22date%22%3A%222022-3%22%2C%22language%22%3A%22%22%2C%22DOI%22%3A%2210.3201%5C%2Feid2803.211791%22%2C%22ISSN%22%3A%221080-6040%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fwww.ncbi.nlm.nih.gov%5C%2Fpmc%5C%2Farticles%5C%2FPMC8888244%5C%2F%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222022-03-10T21%3A35%3A04Z%22%7D%7D%2C%7B%22key%22%3A%22FXY3SR7C%22%2C%22library%22%3A%7B%22id%22%3A1368488%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Daniau%20et%20al.%22%2C%22parsedDate%22%3A%222022-06%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EDaniau%2C%20C.%2C%20Berger-Carbonne%2C%20A.%20and%20Cambau%2C%20E.%20%282022%29.%20%3Cb%3EAssociation%20of%20Healthcare%20and%20Aesthetic%20Procedures%20with%20Infections%20Caused%20by%20Nontuberculous%20Mycobacteria%2C%20France%2C%202012%26%23x2012%3B2020%20%28response%29%3C%5C%2Fb%3E.%20Emerg%20Infect%20Dis%20%3Ci%3E28%3C%5C%2Fi%3E%2C%201303%26%23x2013%3B1304%2C%20%3Ca%20target%3D%27_blank%27%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.3201%5C%2Feid2806.220686%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.3201%5C%2Feid2806.220686%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Association%20of%20Healthcare%20and%20Aesthetic%20Procedures%20with%20Infections%20Caused%20by%20Nontuberculous%20Mycobacteria%2C%20France%2C%202012%5Cu20122020%20%28response%29%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C%5Cu00f4me%22%2C%22lastName%22%3A%22Daniau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anne%22%2C%22lastName%22%3A%22Berger-Carbonne%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Emmanuelle%22%2C%22lastName%22%3A%22Cambau%22%7D%5D%2C%22abstractNote%22%3A%22%22%2C%22date%22%3A%222022-6%22%2C%22language%22%3A%22%22%2C%22DOI%22%3A%2210.3201%5C%2Feid2806.220686%22%2C%22ISSN%22%3A%221080-6040%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fwww.ncbi.nlm.nih.gov%5C%2Fpmc%5C%2Farticles%5C%2FPMC9155901%5C%2F%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222022-09-23T13%3A28%3A15Z%22%7D%7D%2C%7B%22key%22%3A%2232L5JEUW%22%2C%22library%22%3A%7B%22id%22%3A1368488%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22De%20Castro%20et%20al.%22%2C%22parsedDate%22%3A%222022-08-01%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EDe%20Castro%2C%20N.%2C%20Mecha%26%23xEF%3B%2C%20F.%2C%20Bachelet%2C%20D.%2C%20Canestri%2C%20A.%2C%20Joly%2C%20V.%2C%20Vandenhende%2C%20M.%2C%20Boutoille%2C%20D.%2C%20Kerjouan%2C%20M.%2C%20Veziris%2C%20N.%2C%20Molina%2C%20J.%20M.%2C%20Grall%2C%20N.%2C%20Tattevin%2C%20P.%2C%20Laou%26%23xE9%3Bnan%2C%20C.%2C%20Yazdanpanah%2C%20Y.%20and%20for%20the%20FAST%20TB%20Study%20Group%20%282022%29.%20%3Cb%3ETreatment%20With%20a%20Three-Drug%20Regimen%20for%20Pulmonary%20Tuberculosis%20Based%20on%20Rapid%20Molecular%20Detection%20of%20Isoniazid%20Resistance%3A%20A%20Noninferiority%20Randomized%20Trial%20%28FAST-TB%29%3C%5C%2Fb%3E.%20Open%20Forum%20Infectious%20Diseases%20%3Ci%3E9%3C%5C%2Fi%3E%2C%20ofac353%2C%20%3Ca%20target%3D%27_blank%27%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1093%5C%2Fofid%5C%2Fofac353%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1093%5C%2Fofid%5C%2Fofac353%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Treatment%20With%20a%20Three-Drug%20Regimen%20for%20Pulmonary%20Tuberculosis%20Based%20on%20Rapid%20Molecular%20Detection%20of%20Isoniazid%20Resistance%3A%20A%20Noninferiority%20Randomized%20Trial%20%28FAST-TB%29%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22N%22%2C%22lastName%22%3A%22De%20Castro%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22F%22%2C%22lastName%22%3A%22Mecha%5Cu00ef%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22D%22%2C%22lastName%22%3A%22Bachelet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A%22%2C%22lastName%22%3A%22Canestri%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22V%22%2C%22lastName%22%3A%22Joly%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M%22%2C%22lastName%22%3A%22Vandenhende%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22D%22%2C%22lastName%22%3A%22Boutoille%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M%22%2C%22lastName%22%3A%22Kerjouan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22N%22%2C%22lastName%22%3A%22Veziris%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%20M%22%2C%22lastName%22%3A%22Molina%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22N%22%2C%22lastName%22%3A%22Grall%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P%22%2C%22lastName%22%3A%22Tattevin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C%22%2C%22lastName%22%3A%22Laou%5Cu00e9nan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Y%22%2C%22lastName%22%3A%22Yazdanpanah%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22name%22%3A%22for%20the%20FAST%20TB%20Study%20Group%22%7D%5D%2C%22abstractNote%22%3A%22The%20rationale%20behind%20the%20use%20of%20ethambutol%20in%20the%20standard%20tuberculosis%20treatment%20is%20to%20prevent%20the%20emergence%20of%20resistance%20to%20rifampicin%20in%20case%20of%20primary%20resistance%20to%20isoniazid.%20We%20evaluated%20whether%20early%20detection%20of%20isoniazid%20resistance%20using%20molecular%20testing%20allows%20the%20use%20an%20ethambutol-free%20regimen.FAST-TB%2C%20a%20phase%204%2C%20French%2C%20multicenter%2C%20open-label%2C%20non-inferiority%20trial%2C%20compared%202%20strategies%3A%20%281%29%20polymerase%20chain%20reaction%20%28PCR%29-based%20detection%20of%20isoniazid%20and%20rifampicin%20resistance%20at%20baseline%20using%20Genotype%20MTBDRplus%20version%202.0%20followed%20by%20ethambutol%20discontinuation%20if%20no%20resistance%20was%20detected%20%28PCR%20arm%29%20and%20%282%29%20a%20standard%204-drug%20combination%2C%20pending%20phenotypic%20drug-susceptibility%20results%20%28C%20arm%29.%20Adult%20patients%20with%20smear-positive%20pulmonary%20tuberculosis%20were%20enrolled.%20The%20primary%20endpoint%20was%20the%20proportion%20of%20patients%20with%20treatment%20success%20defined%20as%20bacteriological%20or%20clinical%20cure%20at%20the%20end%20of%20treatment.%20A%20non-inferiority%20margin%20of%2010%25%20was%20used.Two%20hundred%20three%20patients%20were%20randomized%2C%20104%20in%20the%20PCR%20arm%20and%2099%20in%20the%20C%20arm%3A%2026.6%25%20were%20female%2C%20median%20age%20was%2037%20%28interquartile%20range%2C%2028%5Cu201351%29%20years%2C%2072.4%25%20were%20born%20in%20Africa%2C%20and%205.4%25%20were%20infected%20with%20human%20immunodeficiency%20virus.%20Chest%20x-ray%20showed%20cavities%20in%2064.5%25%20of%20the%20cases.%20Overall%2C%20169%20patients%20met%20criteria%20of%20treatment%20success%3A%2087%20of%20104%20%2883.7%25%29%20in%20the%20PCR%20arm%20and%2082%20of%2099%20%2882.8%25%29%20in%20the%20C%20arm%20with%20a%20difference%20of%20%2B0.8%25%20%2890%25%20confidence%20interval%2C%20%5Cu22127.9%20to%209.6%29%2C%20meeting%20the%20noninferiority%20criteria%20in%20the%20intention-to-treat%20population%20%28P%5Cu2009%3D%5Cu2009.02%29.In%20a%20setting%20with%20low%20prevalence%20of%20primary%20isoniazid%20resistance%2C%20a%203-drug%20combination%20with%20isoniazid%2C%20rifampicin%2C%20and%20pyrazinamide%2C%20based%20on%20rapid%20detection%20of%20isoniazid%20resistance%20using%20molecular%20testing%2C%20was%20noninferior%20to%20starting%20the%20recommended%204-drug%20regimen.%22%2C%22date%22%3A%222022-08-01%22%2C%22language%22%3A%22%22%2C%22DOI%22%3A%2210.1093%5C%2Fofid%5C%2Fofac353%22%2C%22ISSN%22%3A%222328-8957%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1093%5C%2Fofid%5C%2Fofac353%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222022-09-23T13%3A20%3A00Z%22%7D%7D%2C%7B%22key%22%3A%22S6JQ4XIX%22%2C%22library%22%3A%7B%22id%22%3A1368488%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Eimer%20et%20al.%22%2C%22parsedDate%22%3A%222022-06-19%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EEimer%2C%20J.%2C%20Fr%26%23xE9%3Bchet-Jachym%2C%20M.%2C%20Le%20D%26%23xFB%3B%2C%20D.%2C%20Caumes%2C%20E.%2C%20El-Helali%2C%20N.%2C%20Marigot-Outtandy%2C%20D.%2C%20Mechai%2C%20F.%2C%20Peytavin%2C%20G.%2C%20Pourcher%2C%20V.%2C%20Rioux%2C%20C.%2C%20Yazdanpanah%2C%20Y.%2C%20Robert%2C%20J.%2C%20Guglielmetti%2C%20L.%20and%20for%20the%20LZDM%20group%20%282022%29.%20%3Cb%3EIncreased%20linezolid%20plasma%20concentrations%20are%20associated%20with%20the%20development%20of%20severe%20toxicity%20in%20MDR-TB%20treatment.%3C%5C%2Fb%3E%20Clinical%20Infectious%20Diseases%20ciac485%2C%20%3Ca%20target%3D%27_blank%27%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1093%5C%2Fcid%5C%2Fciac485%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1093%5C%2Fcid%5C%2Fciac485%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Increased%20linezolid%20plasma%20concentrations%20are%20associated%20with%20the%20development%20of%20severe%20toxicity%20in%20MDR-TB%20treatment.%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Johannes%22%2C%22lastName%22%3A%22Eimer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mathilde%22%2C%22lastName%22%3A%22Fr%5Cu00e9chet-Jachym%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Damien%22%2C%22lastName%22%3A%22Le%20D%5Cu00fb%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eric%22%2C%22lastName%22%3A%22Caumes%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Najoua%22%2C%22lastName%22%3A%22El-Helali%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Dhiba%22%2C%22lastName%22%3A%22Marigot-Outtandy%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fr%5Cu00e9d%5Cu00e9ric%22%2C%22lastName%22%3A%22Mechai%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gilles%22%2C%22lastName%22%3A%22Peytavin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Val%5Cu00e9rie%22%2C%22lastName%22%3A%22Pourcher%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christophe%22%2C%22lastName%22%3A%22Rioux%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yazdan%22%2C%22lastName%22%3A%22Yazdanpanah%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%5Cu00e9r%5Cu00f4me%22%2C%22lastName%22%3A%22Robert%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lorenzo%22%2C%22lastName%22%3A%22Guglielmetti%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22name%22%3A%22for%20the%20LZDM%20group%22%7D%5D%2C%22abstractNote%22%3A%22Treatment%20of%20multidrug-resistant%20tuberculosis%20%28MDR-TB%29%20with%20linezolid%20is%20characterized%20by%20high%20rates%20of%20adverse%20events.%20Evidence%20on%20therapeutic%20drug%20monitoring%20to%20predict%20drug%20toxicity%20is%20scarce.%20This%20study%20aimed%20to%20evaluate%20the%20association%20of%20linezolid%20trough%20concentrations%20with%20severe%20toxicity.We%20retrospectively%20assessed%20consecutive%20patients%20started%20on%20linezolid%20for%20MDR-TB%20between%202011%20and%202017.%20The%20primary%20outcome%20was%20severe%20mitochondrial%20toxicity%20%28SMT%29%20due%20to%20linezolid%2C%20defined%20as%20neurotoxicity%20or%20myelotoxicity%20leading%20to%20drug%20discontinuation.%20The%20impact%20of%20plasma%20linezolid%20trough%20concentrations%20%26gt%3B2%5Cu2005mg%5C%2FL%20was%20assessed%20in%20multivariate%20Cox%20proportional%20hazards%20models%20including%20time-varying%20covariates.SMT%20occurred%20in%2057%20of%20146%20included%20patients%20%2839%25%29%20at%20an%20incidence%20rate%20of%200.38%20per%20person-year%20%2895%25CI%200.30-0.49%29.%20A%20maximum%20linezolid%20trough%20concentration%20%26gt%3B2%5Cu2005mg%5C%2FL%20was%20detected%20in%2052%20patients%20%2835.6%25%29%2C%20while%20the%20mean%20trough%20concentration%20was%20%26gt%3B2%5Cu2005mg%5C%2FL%20in%2022%20%2815%25%29.%20The%20adjusted%20hazard%20ratio%20for%20SMT%20was%202.35%20%2895%25CI%201.26%5Cu20134.38%2C%20p%5Cu2009%3D%5Cu20090.01%29%20in%20patients%20with%20a%20mean%20trough%20concentration%20%26gt%3B2%5Cu2005mg%5C%2FL%20and%202.63%20%2895%25CI%201.55%5Cu20134.47%2C%20p%5Cu2009%26lt%3B%5Cu20090.01%29%20for%20SMT%20after%20the%20first%20detection%20of%20a%20trough%20concentration%20%26gt%3B2%5Cu2005mg%5C%2FL.%20In%20an%20exploratory%20analysis%2C%20higher%20maximum%20trough%20concentrations%20were%20dose-dependently%20associated%20with%20toxicity%2C%20while%20lowering%20of%20elevated%20trough%20concentrations%20did%20not%20restore%20baseline%20risk.Linezolid%20trough%20concentrations%20%26gt%3B2%5Cu2005mg%5C%2FL%20are%20strongly%20associated%20with%20the%20development%20of%20severe%20treatment-emergent%20toxicity%20in%20patients%20treated%20for%20MDR-TB.%20Pending%20further%20prospective%20evidence%2C%20an%20individual%20risk-benefit%20assessment%20on%20the%20continuation%20of%20linezolid%20treatment%20is%20warranted%20in%20any%20patient%20with%20trough%20concentrations%20above%202%5Cu2005mg%5C%2FL.%22%2C%22date%22%3A%222022-06-19%22%2C%22language%22%3A%22%22%2C%22DOI%22%3A%2210.1093%5C%2Fcid%5C%2Fciac485%22%2C%22ISSN%22%3A%221058-4838%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1093%5C%2Fcid%5C%2Fciac485%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222022-07-08T13%3A02%3A02Z%22%7D%7D%2C%7B%22key%22%3A%22QDAG4PLL%22%2C%22library%22%3A%7B%22id%22%3A1368488%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Group%20et%20al.%22%2C%22parsedDate%22%3A%222022-04-01%22%2C%22numChildren%22%3A3%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EGroup%2C%20A.%20S.%20T.%2C%20Georghiou%2C%20S.%20B.%2C%20Rodwell%2C%20T.%20C.%2C%20Korobitsyn%2C%20A.%2C%20Abbadi%2C%20S.%20H.%2C%20Ajbani%2C%20K.%2C%20Alffenaar%2C%20J.-W.%2C%20Alland%2C%20D.%2C%20Alvarez%2C%20N.%2C%20Andres%2C%20S.%2C%20Ardizzoni%2C%20E.%2C%20Aubry%2C%20A.%2C%20Baldan%2C%20R.%2C%20Ballif%2C%20M.%2C%20Barilar%2C%20I.%2C%20B%26%23xF6%3Bttger%2C%20E.%20C.%2C%20Chakravorty%2C%20S.%2C%20Claxton%2C%20P.%20M.%2C%20Cirillo%2C%20D.%20M.%2C%20Comas%2C%20I.%2C%20Coulter%2C%20C.%2C%20Denkinger%2C%20C.%20M.%2C%20Derendinger%2C%20B.%2C%20Desmond%2C%20E.%20P.%2C%20Steenwinkel%2C%20J.%20E.%20M.%20de%2C%20Dheda%2C%20K.%2C%20Diacon%2C%20A.%20H.%2C%20Dolinger%2C%20D.%20L.%2C%20Dooley%2C%20K.%20E.%2C%20Egger%2C%20M.%2C%20Ehsani%2C%20S.%2C%20Farhat%2C%20M.%20R.%2C%20Fattorini%2C%20L.%2C%20Finci%2C%20I.%2C%20Ray%2C%20L.%20F.%20L.%2C%20Furi%26%23xF3%3B%2C%20V.%2C%20Groenheit%2C%20R.%2C%20Gumbo%2C%20T.%2C%20Heysell%2C%20S.%20K.%2C%20Hillemann%2C%20D.%2C%20Hoffmann%2C%20H.%2C%20Hsueh%2C%20P.-R.%2C%20Hu%2C%20Y.%2C%20Huang%2C%20H.%2C%20Hussain%2C%20A.%2C%20Ismail%2C%20F.%2C%20Izumi%2C%20K.%2C%20Jagielski%2C%20T.%2C%20Johnson%2C%20J.%20L.%2C%20Kambli%2C%20P.%2C%20Kaniga%2C%20K.%2C%20Karunaratne%2C%20G.%20H.%20R.%20E.%2C%20Sharma%2C%20M.%20K.%2C%20Keller%2C%20P.%20M.%2C%20Kelly%2C%20E.%20C.%2C%20Kholina%2C%20M.%2C%20Kohli%2C%20M.%2C%20Kranzer%2C%20K.%2C%20Laurenson%2C%20I.%20F.%2C%20Limberis%2C%20J.%2C%20Lin%2C%20S.-Y.%20G.%2C%20Liu%2C%20Y.%2C%20L%26%23xF3%3Bpez-Gav%26%23xED%3Bn%2C%20A.%2C%20Lyander%2C%20A.%2C%20Machado%2C%20D.%2C%20Martinez%2C%20E.%2C%20Masood%2C%20F.%2C%20Mitarai%2C%20S.%2C%20Mvelase%2C%20N.%20R.%2C%20Niemann%2C%20S.%2C%20Nikolayevskyy%2C%20V.%2C%20Maurer%2C%20F.%20P.%2C%20Merker%2C%20M.%2C%20Miotto%2C%20P.%2C%20Omar%2C%20S.%20V.%2C%20Otto-Knapp%2C%20R.%2C%20Palaci%2C%20M.%2C%20Guti%26%23xE9%3Brrez%2C%20J.%20J.%20P.%2C%20Peacock%2C%20S.%20J.%2C%20Peloquin%2C%20C.%20A.%2C%20Perera%2C%20J.%2C%20Pierre-Audigier%2C%20C.%2C%20Pholwat%2C%20S.%2C%20Posey%2C%20J.%20E.%2C%20Prammananan%2C%20T.%2C%20Rigouts%2C%20L.%2C%20Robledo%2C%20J.%2C%20Rockwood%2C%20N.%2C%20Rodrigues%2C%20C.%2C%20Salfinger%2C%20M.%2C%20Schechter%2C%20M.%20C.%2C%20Seifert%2C%20M.%2C%20Sengstake%2C%20S.%2C%20Shinnick%2C%20T.%2C%20Shubladze%2C%20N.%2C%20Sintchenko%2C%20V.%2C%20Sirgel%2C%20F.%2C%20Somasundaram%2C%20S.%2C%20Sterling%2C%20T.%20R.%2C%20Spitaleri%2C%20A.%2C%20Streicher%2C%20E.%2C%20Supply%2C%20P.%2C%20Svensson%2C%20E.%2C%20Tagliani%2C%20E.%2C%20Tahseen%2C%20S.%2C%20Takaki%2C%20A.%2C%20Theron%2C%20G.%2C%20Torrea%2C%20G.%2C%20Deun%2C%20A.%20V.%2C%20Ingen%2C%20J.%20van%2C%20Rie%2C%20A.%20V.%2C%20Soolingen%2C%20D.%20van%2C%20Jr%2C%20R.%20V.%2C%20Venter%2C%20A.%2C%20Veziris%2C%20N.%2C%20Villellas%2C%20C.%2C%20Viveiros%2C%20M.%2C%20Warren%2C%20R.%2C%20Wen%2C%20S.%2C%20Werngren%2C%20J.%2C%20Wilkinson%2C%20R.%20J.%2C%20Yang%2C%20C.%2C%20Y%26%23x131%3Blmaz%2C%20F.%20F.%2C%20Zhang%2C%20T.%2C%20Zimenkov%2C%20D.%2C%20Ismail%2C%20N.%2C%20K%26%23xF6%3Bser%2C%20C.%20U.%20and%20Sch%26%23xF6%3Bn%2C%20T.%20%282022%29.%20%3Cb%3EUpdating%20the%20approaches%20to%20define%20susceptibility%20and%20resistance%20to%20anti-tuberculosis%20agents%3A%20implications%20for%20diagnosis%20and%20treatment%3C%5C%2Fb%3E.%20European%20Respiratory%20Journal%20%3Ci%3E59%3C%5C%2Fi%3E%2C%20%3Ca%20target%3D%27_blank%27%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1183%5C%2F13993003.00166-2022%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1183%5C%2F13993003.00166-2022%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Updating%20the%20approaches%20to%20define%20susceptibility%20and%20resistance%20to%20anti-tuberculosis%20agents%3A%20implications%20for%20diagnosis%20and%20treatment%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Antimycobacterial%20Susceptibility%20Testing%22%2C%22lastName%22%3A%22Group%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sophia%20B.%22%2C%22lastName%22%3A%22Georghiou%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Timothy%20C.%22%2C%22lastName%22%3A%22Rodwell%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alexei%22%2C%22lastName%22%3A%22Korobitsyn%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Said%20H.%22%2C%22lastName%22%3A%22Abbadi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kanchan%22%2C%22lastName%22%3A%22Ajbani%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jan-Willem%22%2C%22lastName%22%3A%22Alffenaar%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22David%22%2C%22lastName%22%3A%22Alland%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nataly%22%2C%22lastName%22%3A%22Alvarez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S%5Cu00f6nke%22%2C%22lastName%22%3A%22Andres%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Elisa%22%2C%22lastName%22%3A%22Ardizzoni%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alexandra%22%2C%22lastName%22%3A%22Aubry%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Rossella%22%2C%22lastName%22%3A%22Baldan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marie%22%2C%22lastName%22%3A%22Ballif%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ivan%22%2C%22lastName%22%3A%22Barilar%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Erik%20C.%22%2C%22lastName%22%3A%22B%5Cu00f6ttger%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Soumitesh%22%2C%22lastName%22%3A%22Chakravorty%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pauline%20M.%22%2C%22lastName%22%3A%22Claxton%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Daniela%20M.%22%2C%22lastName%22%3A%22Cirillo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22I%5Cu00f1aki%22%2C%22lastName%22%3A%22Comas%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Chris%22%2C%22lastName%22%3A%22Coulter%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Claudia%20M.%22%2C%22lastName%22%3A%22Denkinger%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Brigitta%22%2C%22lastName%22%3A%22Derendinger%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Edward%20P.%22%2C%22lastName%22%3A%22Desmond%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jurriaan%20E.%20M.%20de%22%2C%22lastName%22%3A%22Steenwinkel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Keertan%22%2C%22lastName%22%3A%22Dheda%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Andreas%20H.%22%2C%22lastName%22%3A%22Diacon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22David%20L.%22%2C%22lastName%22%3A%22Dolinger%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kelly%20E.%22%2C%22lastName%22%3A%22Dooley%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Matthias%22%2C%22lastName%22%3A%22Egger%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Soudeh%22%2C%22lastName%22%3A%22Ehsani%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Maha%20R.%22%2C%22lastName%22%3A%22Farhat%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lanfranco%22%2C%22lastName%22%3A%22Fattorini%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Iris%22%2C%22lastName%22%3A%22Finci%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laure%20Fournier%20Le%22%2C%22lastName%22%3A%22Ray%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Victoria%22%2C%22lastName%22%3A%22Furi%5Cu00f3%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ramona%22%2C%22lastName%22%3A%22Groenheit%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Tawanda%22%2C%22lastName%22%3A%22Gumbo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Scott%20K.%22%2C%22lastName%22%3A%22Heysell%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Doris%22%2C%22lastName%22%3A%22Hillemann%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Harald%22%2C%22lastName%22%3A%22Hoffmann%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Po-Ren%22%2C%22lastName%22%3A%22Hsueh%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yi%22%2C%22lastName%22%3A%22Hu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Hairong%22%2C%22lastName%22%3A%22Huang%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alamdar%22%2C%22lastName%22%3A%22Hussain%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Farzana%22%2C%22lastName%22%3A%22Ismail%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kiyohiko%22%2C%22lastName%22%3A%22Izumi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Tomasz%22%2C%22lastName%22%3A%22Jagielski%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22John%20L.%22%2C%22lastName%22%3A%22Johnson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Priti%22%2C%22lastName%22%3A%22Kambli%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kon%5Cu00e9%22%2C%22lastName%22%3A%22Kaniga%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22G.%20H.%20R.%20Eranga%22%2C%22lastName%22%3A%22Karunaratne%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Meenu%20Kaushal%22%2C%22lastName%22%3A%22Sharma%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Peter%20M.%22%2C%22lastName%22%3A%22Keller%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ellis%20C.%22%2C%22lastName%22%3A%22Kelly%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Margarita%22%2C%22lastName%22%3A%22Kholina%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mikashmi%22%2C%22lastName%22%3A%22Kohli%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Katharina%22%2C%22lastName%22%3A%22Kranzer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ian%20F.%22%2C%22lastName%22%3A%22Laurenson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jason%22%2C%22lastName%22%3A%22Limberis%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.-Y.%20Grace%22%2C%22lastName%22%3A%22Lin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yongge%22%2C%22lastName%22%3A%22Liu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alexandre%22%2C%22lastName%22%3A%22L%5Cu00f3pez-Gav%5Cu00edn%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anna%22%2C%22lastName%22%3A%22Lyander%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Diana%22%2C%22lastName%22%3A%22Machado%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Elena%22%2C%22lastName%22%3A%22Martinez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Faisal%22%2C%22lastName%22%3A%22Masood%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Satoshi%22%2C%22lastName%22%3A%22Mitarai%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nomonde%20R.%22%2C%22lastName%22%3A%22Mvelase%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Stefan%22%2C%22lastName%22%3A%22Niemann%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Vladyslav%22%2C%22lastName%22%3A%22Nikolayevskyy%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Florian%20P.%22%2C%22lastName%22%3A%22Maurer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Matthias%22%2C%22lastName%22%3A%22Merker%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Paolo%22%2C%22lastName%22%3A%22Miotto%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Shaheed%20V.%22%2C%22lastName%22%3A%22Omar%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ralf%22%2C%22lastName%22%3A%22Otto-Knapp%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mois%5Cu00e9s%22%2C%22lastName%22%3A%22Palaci%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Juan%20Jos%5Cu00e9%20Palacios%22%2C%22lastName%22%3A%22Guti%5Cu00e9rrez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sharon%20J.%22%2C%22lastName%22%3A%22Peacock%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Charles%20A.%22%2C%22lastName%22%3A%22Peloquin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jennifer%22%2C%22lastName%22%3A%22Perera%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Catherine%22%2C%22lastName%22%3A%22Pierre-Audigier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Suporn%22%2C%22lastName%22%3A%22Pholwat%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22James%20E.%22%2C%22lastName%22%3A%22Posey%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Therdsak%22%2C%22lastName%22%3A%22Prammananan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Leen%22%2C%22lastName%22%3A%22Rigouts%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jaime%22%2C%22lastName%22%3A%22Robledo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Neesha%22%2C%22lastName%22%3A%22Rockwood%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Camilla%22%2C%22lastName%22%3A%22Rodrigues%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Max%22%2C%22lastName%22%3A%22Salfinger%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marcos%20C.%22%2C%22lastName%22%3A%22Schechter%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marva%22%2C%22lastName%22%3A%22Seifert%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sarah%22%2C%22lastName%22%3A%22Sengstake%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thomas%22%2C%22lastName%22%3A%22Shinnick%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Natalia%22%2C%22lastName%22%3A%22Shubladze%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Vitali%22%2C%22lastName%22%3A%22Sintchenko%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Frederick%22%2C%22lastName%22%3A%22Sirgel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sulochana%22%2C%22lastName%22%3A%22Somasundaram%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Timothy%20R.%22%2C%22lastName%22%3A%22Sterling%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Andrea%22%2C%22lastName%22%3A%22Spitaleri%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Elizabeth%22%2C%22lastName%22%3A%22Streicher%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Philip%22%2C%22lastName%22%3A%22Supply%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Erik%22%2C%22lastName%22%3A%22Svensson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Elisa%22%2C%22lastName%22%3A%22Tagliani%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sabira%22%2C%22lastName%22%3A%22Tahseen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Akiko%22%2C%22lastName%22%3A%22Takaki%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Grant%22%2C%22lastName%22%3A%22Theron%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gabriela%22%2C%22lastName%22%3A%22Torrea%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Armand%20Van%22%2C%22lastName%22%3A%22Deun%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jakko%20van%22%2C%22lastName%22%3A%22Ingen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Annelies%20Van%22%2C%22lastName%22%3A%22Rie%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Dick%20van%22%2C%22lastName%22%3A%22Soolingen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Roger%20Vargas%22%2C%22lastName%22%3A%22Jr%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Amour%22%2C%22lastName%22%3A%22Venter%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nicolas%22%2C%22lastName%22%3A%22Veziris%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Cristina%22%2C%22lastName%22%3A%22Villellas%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Miguel%22%2C%22lastName%22%3A%22Viveiros%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Robin%22%2C%22lastName%22%3A%22Warren%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Shu%27an%22%2C%22lastName%22%3A%22Wen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jim%22%2C%22lastName%22%3A%22Werngren%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Robert%20J.%22%2C%22lastName%22%3A%22Wilkinson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Caie%22%2C%22lastName%22%3A%22Yang%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22F.%20Ferda%22%2C%22lastName%22%3A%22Y%5Cu0131lmaz%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Tingting%22%2C%22lastName%22%3A%22Zhang%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Danila%22%2C%22lastName%22%3A%22Zimenkov%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nazir%22%2C%22lastName%22%3A%22Ismail%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Claudio%20U.%22%2C%22lastName%22%3A%22K%5Cu00f6ser%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thomas%22%2C%22lastName%22%3A%22Sch%5Cu00f6n%22%7D%5D%2C%22abstractNote%22%3A%22Tweetable%20abstract%20%40ERSpublications%5Cnclick%20to%20tweetInappropriately%20high%20breakpoints%20have%20resulted%20in%20systematic%20false-susceptible%20AST%20results%20to%20anti-TB%20drugs.%20MIC%2C%20PK%5C%2FPD%20and%20clinical%20outcome%20data%20should%20be%20combined%20when%20setting%20breakpoints%20to%20minimise%20the%20emergence%20and%20spread%20of%20antimicrobial%20resistance.%20https%3A%5C%2F%5C%2Fbit.ly%5C%2F3i43wb6%22%2C%22date%22%3A%222022%5C%2F04%5C%2F01%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1183%5C%2F13993003.00166-2022%22%2C%22ISSN%22%3A%220903-1936%2C%201399-3003%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Ferj.ersjournals.com%5C%2Fcontent%5C%2F59%5C%2F4%5C%2F2200166%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222022-06-29T14%3A23%3A32Z%22%7D%7D%2C%7B%22key%22%3A%22NH7XCKNV%22%2C%22library%22%3A%7B%22id%22%3A1368488%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Guglielmetti%20et%20al.%22%2C%22parsedDate%22%3A%222022-05-01%22%2C%22numChildren%22%3A3%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EGuglielmetti%2C%20L.%2C%20G%26%23xFC%3Bnther%2C%20G.%2C%20Leu%2C%20C.%2C%20Cirillo%2C%20D.%2C%20Duarte%2C%20R.%2C%20Garcia-Basteiro%2C%20A.%20L.%2C%20Goletti%2C%20D.%2C%20Jankovic%2C%20M.%2C%20Kuksa%2C%20L.%2C%20Maurer%2C%20F.%20P.%2C%20M%26%23xE9%3Bcha%26%23xEF%3B%2C%20F.%2C%20Tiberi%2C%20S.%2C%20Leth%2C%20F.%20van%2C%20Veziris%2C%20N.%20and%20Lange%2C%20C.%20%282022%29.%20%3Cb%3ERifapentine%20access%20in%20Europe%3A%20growing%20concerns%20over%20key%20tuberculosis%20treatment%20component%3C%5C%2Fb%3E.%20European%20Respiratory%20Journal%20%3Ci%3E59%3C%5C%2Fi%3E%2C%20%3Ca%20target%3D%27_blank%27%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1183%5C%2F13993003.00388-2022%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1183%5C%2F13993003.00388-2022%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Rifapentine%20access%20in%20Europe%3A%20growing%20concerns%20over%20key%20tuberculosis%20treatment%20component%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lorenzo%22%2C%22lastName%22%3A%22Guglielmetti%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gunar%22%2C%22lastName%22%3A%22G%5Cu00fcnther%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Claude%22%2C%22lastName%22%3A%22Leu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Daniela%22%2C%22lastName%22%3A%22Cirillo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Raquel%22%2C%22lastName%22%3A%22Duarte%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alberto%20L.%22%2C%22lastName%22%3A%22Garcia-Basteiro%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Delia%22%2C%22lastName%22%3A%22Goletti%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mateja%22%2C%22lastName%22%3A%22Jankovic%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Liga%22%2C%22lastName%22%3A%22Kuksa%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Florian%20P.%22%2C%22lastName%22%3A%22Maurer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fr%5Cu00e9d%5Cu00e9ric%22%2C%22lastName%22%3A%22M%5Cu00e9cha%5Cu00ef%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Simon%22%2C%22lastName%22%3A%22Tiberi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Frank%20van%22%2C%22lastName%22%3A%22Leth%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nicolas%22%2C%22lastName%22%3A%22Veziris%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christoph%22%2C%22lastName%22%3A%22Lange%22%7D%5D%2C%22abstractNote%22%3A%22Tweetable%20abstract%20%40ERSpublications%5Cnclick%20to%20tweetLack%20of%20access%20to%20rifapentine%20in%20Europe%20denies%20patients%20optimal%20care%20for%20active%20tuberculosis%20and%20latent%20tuberculosis%20infection%2C%20and%20deprives%20healthcare%20providers%20of%20adequate%20tools%20to%20pursue%20tuberculosis%20control%20and%20elimination%20https%3A%5C%2F%5C%2Fbit.ly%5C%2F3jz85eh%22%2C%22date%22%3A%222022%5C%2F05%5C%2F01%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1183%5C%2F13993003.00388-2022%22%2C%22ISSN%22%3A%220903-1936%2C%201399-3003%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Ferj.ersjournals.com%5C%2Fcontent%5C%2F59%5C%2F5%5C%2F2200388%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222022-06-29T14%3A23%3A00Z%22%7D%7D%2C%7B%22key%22%3A%22MY9BQ8HY%22%2C%22library%22%3A%7B%22id%22%3A1368488%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Guyeux%20et%20al.%22%2C%22parsedDate%22%3A%222022%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EGuyeux%2C%20C.%2C%20Senelle%2C%20G.%2C%20Refr%26%23xE9%3Bgier%2C%20G.%2C%20Bretelle-Establet%2C%20F.%2C%20Cambau%2C%20E.%20and%20Sola%2C%20C.%20%282022%29.%20%3Cb%3EConnection%20between%20two%20historical%20tuberculosis%20outbreak%20sites%20in%20Japan%2C%20Honshu%2C%20by%20a%20new%20ancestral%20Mycobacterium%20tuberculosis%20L2%20sublineage%3C%5C%2Fb%3E.%20Epidemiology%20%26amp%3B%20Infection%20%3Ci%3E150%3C%5C%2Fi%3E%2C%20%3Ca%20target%3D%27_blank%27%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1017%5C%2FS0950268822000048%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1017%5C%2FS0950268822000048%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Connection%20between%20two%20historical%20tuberculosis%20outbreak%20sites%20in%20Japan%2C%20Honshu%2C%20by%20a%20new%20ancestral%20Mycobacterium%20tuberculosis%20L2%20sublineage%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christophe%22%2C%22lastName%22%3A%22Guyeux%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gaetan%22%2C%22lastName%22%3A%22Senelle%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Guislaine%22%2C%22lastName%22%3A%22Refr%5Cu00e9gier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Florence%22%2C%22lastName%22%3A%22Bretelle-Establet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Emmanuelle%22%2C%22lastName%22%3A%22Cambau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christophe%22%2C%22lastName%22%3A%22Sola%22%7D%5D%2C%22abstractNote%22%3A%22By%20gathering%20680%20publicly%20available%20Sequence%20Read%20Archives%20from%20isolates%20of%20Mycobacterium%20tuberculosis%20complex%20%28MTBC%29%20including%20190%20belonging%20to%20the%20lineage%202%20Beijing%2C%20and%20using%20an%20in-house%20bioinformatical%20pipeline%2C%20the%20TB-Annotator%2C%20that%20analyses%20more%20than%2050%20000%20characters%2C%20we%20describe%20herein%20a%20new%20L2%20sublineage%20from%2020%20isolates%20found%20in%20the%20Tochigi%20province%2C%20%28Japan%29%2C%20that%20we%20designate%20as%20asia%20ancestral%205%20%28AAnc5%29.%20These%20isolates%20harbour%20a%20number%20of%20specific%20criteria%20%2842%20SNPs%29%20and%20their%20intra-cluster%20pairwise%20distance%20suggests%20historical%20and%20not%20epidemiological%20transmission.%20These%20isolates%20harbour%20a%20mutation%20in%20rpoC%2C%20and%20do%20not%20fulfil%2C%20any%20of%20the%20modern%20Beijing%20lineage%20criteria%2C%20nor%20any%20of%20the%20other%20ancestral%20Beijing%20lineages%20described%20so%20far.%20Asia%20ancestral%205%20isolates%20do%20not%20possess%20mutT2%2058%20and%20ogt%2012%20characteristics%20of%20modern%20Beijing%2C%20but%20possess%20ancestral%20Beijing%20SNPs%20characteristics.%20By%20looking%20into%20the%20literature%2C%20we%20found%20a%20reference%20isolate%20ID381%2C%20described%20in%20Kobe%20and%20Osaka%20belonging%20to%20the%20%5Cu2018G3%5Cu2019%20group%2C%20sharing%2036%20out%20of%20the%2042%20specific%20SNPs%20found%20in%20AAnc5.%20We%20also%20assessed%20the%20intermediate%20position%20of%20the%20asia%20ancestral%204%20%28AAnc4%29%20sublineage%20recently%20described%20in%20Thailand%20and%20propose%20an%20improved%20classification%20of%20the%20L2%20that%20now%20includes%20AAnc4%20and%20AAnc5.%20By%20increasing%20the%20recruitment%20into%20TB-Annotator%20to%20around%203000%20genomes%20%28including%20642%20belonging%20to%20L2%29%2C%20we%20confirmed%20our%20results%20and%20discovered%20additional%20historical%20ancestral%20L2%20branches%20that%20remain%20to%20be%20investigated%20in%20more%20detail.%20We%20also%20present%2C%20in%20addition%2C%20some%20anthropological%20and%20historical%20data%20from%20Chinese%20and%20Japan%20history%20of%20tuberculosis%2C%20as%20well%20as%20from%20Korea%2C%20that%20could%20support%20our%20results%20on%20L2%20evolution.%20This%20study%20shows%20that%20the%20reconstruction%20of%20the%20early%20history%20of%20tuberculosis%20in%20Asia%20is%20likely%20to%20reveal%20complex%20patterns%20since%20its%20emergence.%22%2C%22date%22%3A%222022%5C%2Fed%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1017%5C%2FS0950268822000048%22%2C%22ISSN%22%3A%220950-2688%2C%201469-4409%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fwww.cambridge.org%5C%2Fcore%5C%2Fjournals%5C%2Fepidemiology-and-infection%5C%2Farticle%5C%2Fconnection-between-two-historical-tuberculosis-outbreak-sites-in-japan-honshu-by-a-new-ancestral-mycobacterium-tuberculosis-l2-sublineage%5C%2F79482A3DD638BB99618B2CCDAA4EBC56%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222022-05-26T21%3A18%3A03Z%22%7D%7D%2C%7B%22key%22%3A%22A2TD2VUD%22%2C%22library%22%3A%7B%22id%22%3A1368488%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Holmgaard%20et%20al.%22%2C%22parsedDate%22%3A%222022-11-04%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EHolmgaard%2C%20F.%20B.%2C%20Guglielmetti%2C%20L.%2C%20Lillebaek%2C%20T.%2C%20Andersen%2C%20%26%23xC5%3B.%20B.%2C%20Wejse%2C%20C.%20and%20Dahl%2C%20V.%20N.%20%282022%29.%20%3Cb%3EEfficacy%20and%20tolerability%20of%20concomitant%20use%20of%20bedaquiline%20and%20delamanid%20for%20multidrug-%20and%20extensively%20drug-resistant%20tuberculosis%3A%20a%20systematic%20review%20and%20meta-analysis%3C%5C%2Fb%3E.%20Clin%20Infect%20Dis%20ciac876%2C%20%3Ca%20target%3D%27_blank%27%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1093%5C%2Fcid%5C%2Fciac876%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1093%5C%2Fcid%5C%2Fciac876%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Efficacy%20and%20tolerability%20of%20concomitant%20use%20of%20bedaquiline%20and%20delamanid%20for%20multidrug-%20and%20extensively%20drug-resistant%20tuberculosis%3A%20a%20systematic%20review%20and%20meta-analysis%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Freja%20Breth%22%2C%22lastName%22%3A%22Holmgaard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lorenzo%22%2C%22lastName%22%3A%22Guglielmetti%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Troels%22%2C%22lastName%22%3A%22Lillebaek%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22%5Cu00c5se%20Bengaard%22%2C%22lastName%22%3A%22Andersen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christian%22%2C%22lastName%22%3A%22Wejse%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Victor%20Naestholt%22%2C%22lastName%22%3A%22Dahl%22%7D%5D%2C%22abstractNote%22%3A%22The%20introduction%20of%20two%20novel%20drugs%2C%20bedaquiline%20and%20delamanid%2C%20has%20given%20hope%20for%20better%20and%20shorter%20treatments%20of%20drug-resistant%20tuberculosis.%20A%20systematic%20review%20was%20conducted%20to%20evaluate%20the%20efficacy%20and%20safety%20of%20concomitant%20bedaquiline%20and%20delamanid%20administration.%20Pooled%20estimates%20of%20WHO-defined%20favorable%20treatment%20outcome%20and%20significant%20QTc-interval%20prolongation%20%28QTc%20%5Cu2265500%5Cu2005ms%20or%20%5Cu226560%5Cu2005ms%20increase%20from%20baseline%29%20were%20calculated%20using%20a%20random%20effects%20model.%20Thirteen%20studies%20including%20a%20total%20of%201031%20individuals%20with%20multidrug-resistant%5C%2Frifampicin-resistant%20tuberculosis%20who%20received%20bedaquiline%20and%20delamanid%20were%20included.%20The%20pooled%20estimate%20of%20favorable%20treatment%20outcome%20was%2073.1%25%20%2895%25CI%3A%2064.3-81.8%29.%20Sputum%20culture%20conversion%20at%20six%20months%20ranged%20from%2061-95%25.%20Overall%2C%20the%20pooled%20proportion%20of%20QTc-prolongation%20was%207.8%25%20%2895%25CI%3A%204.1-11.6%29%20and%20few%20cardiac%20events%20were%20reported%20%280.8%25%2C%20n%5Cu2009%3D%5Cu20096%5C%2F798%29.%20Rates%20of%20sputum%20culture%20conversion%20and%20favorable%20treatment%20outcome%20were%20high%20in%20patients%20treated%20concomitantly%20with%20bedaquiline%20and%20delamanid%2C%20and%20the%20treatment%20seemed%20tolerable%20with%20low%20rates%20of%20clinically%20significant%20cardiac%20toxicity.%22%2C%22date%22%3A%222022-11-04%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1093%5C%2Fcid%5C%2Fciac876%22%2C%22ISSN%22%3A%221537-6591%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222023-03-10T14%3A59%3A47Z%22%7D%7D%2C%7B%22key%22%3A%224ND3DBVZ%22%2C%22library%22%3A%7B%22id%22%3A1368488%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Khan%20and%20Guglielmetti%22%2C%22parsedDate%22%3A%222022-09-01%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EKhan%2C%20U.%20and%20Guglielmetti%2C%20L.%20%282022%29.%20%3Cb%3EEvidence%20and%20ethical%20considerations%20for%20the%20treatment%20of%20contacts%20exposed%20to%20drug-resistant%20TB%3C%5C%2Fb%3E.%20The%20International%20Journal%20of%20Tuberculosis%20and%20Lung%20Disease%20%3Ci%3E26%3C%5C%2Fi%3E%2C%20900%26%23x2013%3B901%2C%20%3Ca%20target%3D%27_blank%27%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.5588%5C%2Fijtld.22.0328%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.5588%5C%2Fijtld.22.0328%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Evidence%20and%20ethical%20considerations%20for%20the%20treatment%20of%20contacts%20exposed%20to%20drug-resistant%20TB%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22U.%22%2C%22lastName%22%3A%22Khan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L.%22%2C%22lastName%22%3A%22Guglielmetti%22%7D%5D%2C%22abstractNote%22%3A%22%22%2C%22date%22%3A%222022-09-01%22%2C%22language%22%3A%22%22%2C%22DOI%22%3A%2210.5588%5C%2Fijtld.22.0328%22%2C%22ISSN%22%3A%22%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222023-04-26T13%3A17%3A52Z%22%7D%7D%2C%7B%22key%22%3A%22YKWPDBTM%22%2C%22library%22%3A%7B%22id%22%3A1368488%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Kherabi%20et%20al.%22%2C%22parsedDate%22%3A%222022-09%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EKherabi%2C%20Y.%2C%20Fr%26%23xE9%3Bchet-Jachym%2C%20M.%2C%20Rioux%2C%20C.%2C%20Yazdanpanah%2C%20Y.%2C%20M%26%23xE9%3Bcha%26%23xEF%3B%2C%20F.%2C%20Pourcher%2C%20V.%2C%20Robert%2C%20J.%20and%20Guglielmetti%2C%20L.%20%282022%29.%20%3Cb%3ERevised%20Definitions%20of%20Tuberculosis%20Resistance%20and%20Treatment%20Outcomes%2C%20France%2C%202006%26%23x2013%3B2019%3C%5C%2Fb%3E.%20Emerg%20Infect%20Dis%20%3Ci%3E28%3C%5C%2Fi%3E%2C%201796%26%23x2013%3B1804%2C%20%3Ca%20target%3D%27_blank%27%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.3201%5C%2Feid2809.220458%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.3201%5C%2Feid2809.220458%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Revised%20Definitions%20of%20Tuberculosis%20Resistance%20and%20Treatment%20Outcomes%2C%20France%2C%202006%5Cu20132019%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yousra%22%2C%22lastName%22%3A%22Kherabi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mathilde%22%2C%22lastName%22%3A%22Fr%5Cu00e9chet-Jachym%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christophe%22%2C%22lastName%22%3A%22Rioux%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yazdan%22%2C%22lastName%22%3A%22Yazdanpanah%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fr%5Cu00e9d%5Cu00e9ric%22%2C%22lastName%22%3A%22M%5Cu00e9cha%5Cu00ef%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Val%5Cu00e9rie%22%2C%22lastName%22%3A%22Pourcher%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%5Cu00e9r%5Cu00f4me%22%2C%22lastName%22%3A%22Robert%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lorenzo%22%2C%22lastName%22%3A%22Guglielmetti%22%7D%5D%2C%22abstractNote%22%3A%22Definitions%20of%20resistance%20in%20multidrug-resistant%20tuberculosis%20%28MDR%20TB%29%20and%20extensively%20drug-resistant%20tuberculosis%20%28XDR%20TB%29%20have%20been%20updated.%20Pre%5Cu2013XDR%20TB%2C%20defined%20as%20MDR%20TB%20with%20additional%20resistance%20to%20fluoroquinolones%2C%20and%20XDR%20TB%2C%20with%20additional%20resistance%20to%20bedaquiline%20or%20linezolid%2C%20are%20frequently%20associated%20with%20treatment%20failure%20and%20toxicity.%20We%20retrospectively%20determined%20the%20effects%20of%20pre-XDR%5C%2FXDR%20TB%20resistance%20on%20outcomes%20and%20safety%20of%20MDR%20TB%20treatment%20in%20France.%20The%20study%20included%20298%20patients%20treated%20for%20MDR%20TB%20at%203%20reference%20centers%20during%202006%5Cu20132019.%20Of%20those%2C%20205%20%2868.8%25%29%20cases%20were%20fluoroquinolone-susceptible%20MDR%20TB%20and%2093%20%2831.2%25%29%20were%20pre-XDR%5C%2FXDR%20TB.%20Compared%20with%20fluoroquinolone-susceptible%20MDR%20TB%2C%20pre-XDR%5C%2FXDR%20TB%20was%20associated%20with%20more%20cavitary%20lung%20lesions%20and%20bilateral%20disease%20and%20required%20longer%20treatment.%20Overall%2C%20202%20patients%20%2867.8%25%29%20had%20favorable%20treatment%20outcomes%2C%20with%20no%20significant%20difference%20between%20pre-XDR%5C%2FXDR%20TB%20%2867.7%25%29%20and%20fluoroquinolone-susceptible%20MDR%20TB%20%2867.8%25%3B%20p%20%3D%200.99%29.%20Pre-XDR%5C%2FXDR%20TB%20was%20not%20associated%20with%20higher%20risk%20for%20serious%20adverse%20events.%22%2C%22date%22%3A%222022-9%22%2C%22language%22%3A%22%22%2C%22DOI%22%3A%2210.3201%5C%2Feid2809.220458%22%2C%22ISSN%22%3A%221080-6040%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fwww.ncbi.nlm.nih.gov%5C%2Fpmc%5C%2Farticles%5C%2FPMC9423894%5C%2F%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222022-09-23T13%3A14%3A59Z%22%7D%7D%2C%7B%22key%22%3A%22JXJYY2QR%22%2C%22library%22%3A%7B%22id%22%3A1368488%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Kherabi%20et%20al.%22%2C%22parsedDate%22%3A%222022-10%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EKherabi%2C%20Y.%2C%20Tunesi%2C%20S.%2C%20Kay%2C%20A.%20and%20Guglielmetti%2C%20L.%20%282022%29.%20%3Cb%3EPreventive%20Therapy%20for%20Contacts%20of%20Drug-Resistant%20Tuberculosis%3C%5C%2Fb%3E.%20Pathogens%20%3Ci%3E11%3C%5C%2Fi%3E%2C%201189%2C%20%3Ca%20target%3D%27_blank%27%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.3390%5C%2Fpathogens11101189%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.3390%5C%2Fpathogens11101189%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Preventive%20Therapy%20for%20Contacts%20of%20Drug-Resistant%20Tuberculosis%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yousra%22%2C%22lastName%22%3A%22Kherabi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Simone%22%2C%22lastName%22%3A%22Tunesi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alexander%22%2C%22lastName%22%3A%22Kay%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lorenzo%22%2C%22lastName%22%3A%22Guglielmetti%22%7D%5D%2C%22abstractNote%22%3A%22Preventing%20the%20progression%20of%20a%20drug-resistant%20tuberculosis%20%28DR-TB%29%20infection%20to%20disease%20is%20an%20important%20pillar%20of%20the%20DR-TB%20elimination%20strategy.%20International%20guidelines%20have%20recently%20proposed%20fluoroquinolones%20for%20tuberculosis%20preventive%20therapy%20%28TPT%29%20in%20DR-TB%20contacts%2C%20although%20the%20available%20evidence%20is%20low%20quality.%20The%20pooled%20data%20from%20small%20observational%20studies%20suggest%20that%20a%20fluoroquinolone-based%20TPT%20is%20safe%2C%20effective%20and%20cost-effective%20as%20a%20preventive%20treatment%20in%20DR-TB%20contacts.%20Three%20clinical%20trials%20are%20currently%20ongoing%20to%20generate%20higher%20quality%20evidence%20on%20the%20efficacy%20of%20levofloxacin%20and%20delamanid%20as%20a%20DR-TB%20preventive%20therapy.%20Additional%20evidence%20is%20also%20needed%2C%20regarding%20TPT%20treatment%20in%20fluoroquinolone-resistant-TB%20contacts%2C%20patient%20and%20health%20care%20worker%20perceptions%20on%20DR-TB%20preventive%20therapy%20for%20contacts%2C%20and%20the%20service%20delivery%20models%20to%20increase%20DR-TPT%20access.%20This%20state-of-the-art%20review%20presents%20the%20current%20literature%20on%20TPT%20for%20contacts%20of%20DR-TB%20cases%2C%20focusing%20on%20the%20available%20evidence%20and%20international%20guidelines.%22%2C%22date%22%3A%222022%5C%2F10%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.3390%5C%2Fpathogens11101189%22%2C%22ISSN%22%3A%222076-0817%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fwww.mdpi.com%5C%2F2076-0817%5C%2F11%5C%2F10%5C%2F1189%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222022-12-28T16%3A07%3A55Z%22%7D%7D%2C%7B%22key%22%3A%223SA6SQXF%22%2C%22library%22%3A%7B%22id%22%3A1368488%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Kilin%5Cu00e7%20et%20al.%22%2C%22parsedDate%22%3A%222022-06-24%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EKilin%26%23xE7%3B%2C%20G.%2C%20Walburg%2C%20K.%20V.%2C%20Franken%2C%20K.%20L.%20M.%20C.%2C%20Valkenburg%2C%20M.%20L.%2C%20Aubry%2C%20A.%2C%20Haks%2C%20M.%20C.%2C%20Saris%2C%20A.%20and%20Ottenhoff%2C%20T.%20H.%20M.%20%282022%29.%20%3Cb%3EDevelopment%20of%20Human%20Cell-Based%20In%20Vitro%20Infection%20Models%20to%20Determine%20the%20Intracellular%20Survival%20of%20Mycobacterium%20avium%3C%5C%2Fb%3E.%20Front%20Cell%20Infect%20Microbiol%20%3Ci%3E12%3C%5C%2Fi%3E%2C%20872361%2C%20%3Ca%20target%3D%27_blank%27%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.3389%5C%2Ffcimb.2022.872361%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.3389%5C%2Ffcimb.2022.872361%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Development%20of%20Human%20Cell-Based%20In%20Vitro%20Infection%20Models%20to%20Determine%20the%20Intracellular%20Survival%20of%20Mycobacterium%20avium%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22G%5Cu00fcl%22%2C%22lastName%22%3A%22Kilin%5Cu00e7%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kimberley%20V.%22%2C%22lastName%22%3A%22Walburg%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kees%20L.%20M.%20C.%22%2C%22lastName%22%3A%22Franken%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Merel%20L.%22%2C%22lastName%22%3A%22Valkenburg%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alexandra%22%2C%22lastName%22%3A%22Aubry%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mari%5Cu00eblle%20C.%22%2C%22lastName%22%3A%22Haks%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anno%22%2C%22lastName%22%3A%22Saris%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Tom%20H.%20M.%22%2C%22lastName%22%3A%22Ottenhoff%22%7D%5D%2C%22abstractNote%22%3A%22The%20Mycobacterium%20avium%20%28Mav%29%20complex%20accounts%20for%20more%20than%2080%25%20of%20all%20pulmonary%20diseases%20caused%20by%20non-tuberculous%20mycobacteria%20%28NTM%29%20infections%2C%20which%20have%20an%20alarming%20increase%20in%20prevalence%20and%20vary%20in%20different%20regions%2C%20currently%20reaching%200.3%5Cu20139.8%20per%20100%2C000%20individuals.%20Poor%20clinical%20outcomes%2C%20as%20a%20result%20of%20increasing%20microbial%20drug%20resistance%20and%20low%20treatment%20adherence%20due%20to%20drug-toxicities%2C%20emphasize%20the%20need%20for%20more%20effective%20treatments.%20Identification%20of%20more%20effective%20treatments%2C%20however%2C%20appears%20to%20be%20difficult%2C%20which%20may%20be%20due%20to%20the%20intracellular%20life%20of%20NTM%20and%20concomitant%20altered%20drug%20sensitivity%20that%20is%20not%20taken%20into%20account%20using%20traditional%20drug%20susceptibility%20testing%20screenings.%20We%20therefore%20developed%20human%20cell-based%20in%20vitro%20Mav%20infection%20models%20using%20the%20human%20MelJuSo%20cell%20line%20as%20well%20as%20primary%20human%20macrophages%20and%20a%20fluorescently%20labeled%20Mav%20strain.%20By%20testing%20a%20range%20of%20multiplicity%20of%20infection%20%28MOI%29%20and%20using%20flow%20cytometry%20and%20colony-forming%20unit%20%28CFU%29%20analysis%2C%20we%20found%20that%20an%20MOI%20of%2010%20was%20the%20most%20suitable%20for%20Mav%20infection%20in%20primary%20human%20macrophages%2C%20whereas%20an%20MOI%20of%2050%20was%20required%20to%20achieve%20similar%20results%20in%20MelJuSo%20cells.%20Moreover%2C%20by%20monitoring%20intracellular%20bacterial%20loads%20over%20time%2C%20the%20macrophages%20were%20shown%20to%20be%20capable%20of%20controlling%20the%20infection%2C%20while%20MelJuSo%20cells%20failed%20to%20do%20so.%20When%20comparing%20the%20MGIT%20system%20with%20the%20classical%20CFU%20counting%20assay%20to%20determine%20intracellular%20bacterial%20loads%2C%20MGIT%20appeared%20as%20a%20less%20labor-intensive%2C%20more%20precise%2C%20and%20more%20objective%20alternative.%20Next%2C%20using%20our%20macrophage%20Mav%20infection%20models%2C%20the%20drug%20efficacy%20of%20the%20first-line%20drug%20rifampicin%20and%20the%20more%20recently%20discovered%20bedaquiline%20on%20intracellular%20bacteria%20was%20compared%20to%20the%20activity%20on%20extracellular%20bacteria.%20The%20efficacy%20of%20the%20antibiotics%20inhibiting%20bacterial%20growth%20was%20significantly%20lower%20against%20intracellular%20bacteria%20compared%20to%20extracellular%20bacteria.%20This%20finding%20emphasizes%20the%20crucial%20role%20of%20the%20host%20cell%20during%20infection%20and%20drug%20susceptibility%20and%20highlights%20the%20usefulness%20of%20the%20models.%20Taken%20together%2C%20the%20human%20cell-based%20Mav%20infection%20models%20are%20reliable%20tools%20to%20determine%20the%20intracellular%20loads%20of%20Mav%2C%20which%20will%20enable%20researchers%20to%20investigate%20host%5Cu2013pathogen%20interactions%20and%20to%20evaluate%20the%20efficacy%20of%20%28host-directed%29%20therapeutic%20strategies%20against%20Mav.%22%2C%22date%22%3A%222022-6-24%22%2C%22language%22%3A%22%22%2C%22DOI%22%3A%2210.3389%5C%2Ffcimb.2022.872361%22%2C%22ISSN%22%3A%222235-2988%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fwww.ncbi.nlm.nih.gov%5C%2Fpmc%5C%2Farticles%5C%2FPMC9263196%5C%2F%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222022-09-23T13%3A31%3A19Z%22%7D%7D%2C%7B%22key%22%3A%224KRX87K9%22%2C%22library%22%3A%7B%22id%22%3A1368488%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Kraef%20et%20al.%22%2C%22parsedDate%22%3A%222022-07-05%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EKraef%2C%20C.%2C%20Lindquist%2C%20E.%2C%20Svensson%2C%20E.%20and%20Cambau%2C%20E.%20%282022%29.%20%3Cb%3EDiagnostic%20toolkit%20for%20tuberculosis%3A%20should%20we%20include%20urine%20lipoarabinomannan%20%28LAM%29%20detection%20in%20the%20WHO%20European%20Region%3F%3C%5C%2Fb%3E%20Clinical%20Microbiology%20and%20Infection%2C%20%3Ca%20target%3D%27_blank%27%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.cmi.2022.06.022%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.cmi.2022.06.022%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Diagnostic%20toolkit%20for%20tuberculosis%3A%20should%20we%20include%20urine%20lipoarabinomannan%20%28LAM%29%20detection%20in%20the%20WHO%20European%20Region%3F%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christian%22%2C%22lastName%22%3A%22Kraef%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Emilia%22%2C%22lastName%22%3A%22Lindquist%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Erik%22%2C%22lastName%22%3A%22Svensson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Emmanuelle%22%2C%22lastName%22%3A%22Cambau%22%7D%5D%2C%22abstractNote%22%3A%22%22%2C%22date%22%3A%222022-07-05%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1016%5C%2Fj.cmi.2022.06.022%22%2C%22ISSN%22%3A%221198-743X%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fwww.sciencedirect.com%5C%2Fscience%5C%2Farticle%5C%2Fpii%5C%2FS1198743X22003366%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222022-09-23T13%3A28%3A42Z%22%7D%7D%2C%7B%22key%22%3A%22WWYPJGM4%22%2C%22library%22%3A%7B%22id%22%3A1368488%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Lange%20et%20al.%22%2C%22parsedDate%22%3A%222022-01-25%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3ELange%2C%20C.%2C%20B%26%23xF6%3Bttger%2C%20E.%20C.%2C%20Cambau%2C%20E.%2C%20Griffith%2C%20D.%20E.%2C%20Guglielmetti%2C%20L.%2C%20van%20Ingen%2C%20J.%2C%20Knight%2C%20S.%20L.%2C%20Marras%2C%20T.%20K.%2C%20Olivier%2C%20K.%20N.%2C%20Santin%2C%20M.%2C%20Stout%2C%20J.%20E.%2C%20Tortoli%2C%20E.%2C%20Wagner%2C%20D.%2C%20Winthrop%2C%20K.%2C%20Daley%2C%20C.%20L.%2C%20Lange%2C%20C.%2C%20Andrejak%2C%20C.%2C%20B%26%23xF6%3Bttger%2C%20E.%2C%20Cambau%2C%20E.%2C%20Griffith%2C%20D.%2C%20Guglielmetti%2C%20L.%2C%20van%20Ingen%2C%20J.%2C%20Knight%2C%20S.%2C%20Leitman%2C%20P.%2C%20Marras%2C%20T.%20K.%2C%20Olivier%2C%20K.%20N.%2C%20Santin%2C%20M.%2C%20Stout%2C%20J.%20E.%2C%20Tortoli%2C%20E.%2C%20Wagner%2C%20D.%2C%20Wallace%2C%20R.%20J.%2C%20Winthrop%2C%20K.%20and%20Daley%2C%20C.%20%282022%29.%20%3Cb%3EConsensus%20management%20recommendations%20for%20less%20common%20non-tuberculous%20mycobacterial%20pulmonary%20diseases%3C%5C%2Fb%3E.%20The%20Lancet%20Infectious%20Diseases%2C%20%3Ca%20target%3D%27_blank%27%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2FS1473-3099%2821%2900586-7%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2FS1473-3099%2821%2900586-7%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Consensus%20management%20recommendations%20for%20less%20common%20non-tuberculous%20mycobacterial%20pulmonary%20diseases%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christoph%22%2C%22lastName%22%3A%22Lange%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Erik%20C%22%2C%22lastName%22%3A%22B%5Cu00f6ttger%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Emmanuelle%22%2C%22lastName%22%3A%22Cambau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22David%20E%22%2C%22lastName%22%3A%22Griffith%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lorenzo%22%2C%22lastName%22%3A%22Guglielmetti%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jakko%22%2C%22lastName%22%3A%22van%20Ingen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Shandra%20L%22%2C%22lastName%22%3A%22Knight%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Theodore%20K%22%2C%22lastName%22%3A%22Marras%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kenneth%20N%22%2C%22lastName%22%3A%22Olivier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Miguel%22%2C%22lastName%22%3A%22Santin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jason%20E%22%2C%22lastName%22%3A%22Stout%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Enrico%22%2C%22lastName%22%3A%22Tortoli%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Dirk%22%2C%22lastName%22%3A%22Wagner%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kevin%22%2C%22lastName%22%3A%22Winthrop%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Charles%20L%22%2C%22lastName%22%3A%22Daley%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christoph%22%2C%22lastName%22%3A%22Lange%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Claire%22%2C%22lastName%22%3A%22Andrejak%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Erik%22%2C%22lastName%22%3A%22B%5Cu00f6ttger%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Emmanuelle%22%2C%22lastName%22%3A%22Cambau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22David%22%2C%22lastName%22%3A%22Griffith%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lorenzo%22%2C%22lastName%22%3A%22Guglielmetti%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jakko%22%2C%22lastName%22%3A%22van%20Ingen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Shandra%22%2C%22lastName%22%3A%22Knight%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Philip%22%2C%22lastName%22%3A%22Leitman%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Theodore%20K.%22%2C%22lastName%22%3A%22Marras%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kenneth%20N.%22%2C%22lastName%22%3A%22Olivier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Miguel%22%2C%22lastName%22%3A%22Santin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jason%20E.%22%2C%22lastName%22%3A%22Stout%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Enrico%22%2C%22lastName%22%3A%22Tortoli%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Dirk%22%2C%22lastName%22%3A%22Wagner%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Richard%20J.%22%2C%22lastName%22%3A%22Wallace%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kevin%22%2C%22lastName%22%3A%22Winthrop%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Charles%22%2C%22lastName%22%3A%22Daley%22%7D%5D%2C%22abstractNote%22%3A%22The%202020%20clinical%20practice%20guideline%20for%20the%20treatment%20of%20non-tuberculous%20mycobacterial%20pulmonary%20disease%20%28NTM-PD%29%20by%20the%20American%20Thoracic%20Society%2C%20European%20Respiratory%20Society%2C%20European%20Society%20of%20Clinical%20Microbiology%20and%20Infectious%20Diseases%2C%20and%20Infectious%20Diseases%20Society%20of%20America%3B%20and%20the%202017%20management%20guideline%20by%20the%20British%20Thoracic%20Society%20covered%20pulmonary%20diseases%20in%20adults%20caused%20by%20Mycobacterium%20avium%20complex%2C%20Mycobacterium%20kansasii%2C%20Mycobacterium%20xenopi%2C%20and%20Mycobacterium%20abscessus.%20In%20order%20to%20provide%20evidence-based%20recommendations%20for%20the%20treatment%20of%20less%20common%20non-tuberculous%20mycobacterial%20%28NTM%29%20species%20in%20adult%20patients%20without%20cystic%20fibrosis%20or%20HIV%20infection%2C%20our%20expert%20panel%20group%20performed%20systematic%20literature%20searches%20to%20provide%20management%20guidance%20for%20pulmonary%20diseases%20caused%20by%20seven%20additional%20organisms%3A%20Mycobacterium%20chelonae%2C%20Mycobacterium%20fortuitum%2C%20Mycobacterium%20genavense%2C%20Mycobacterium%20gordonae%2C%20Mycobacterium%20malmoense%2C%20Mycobacterium%20simiae%2C%20and%20Mycobacterium%20szulgai.%20Treatment%20recommendations%20were%20developed%20by%20a%20structured%20consensus%20process.%20The%20evidence%20from%20the%20scientific%20literature%20published%20in%20English%20for%20treatment%20recommendations%20for%20pulmonary%20diseases%20caused%20by%20other%20NTM%20species%20was%20of%20very%20low%20quality%2C%20with%20the%20exception%20of%20M%20malmoense%2C%20and%20based%20on%20the%20evaluation%20of%20case%20reports%20and%20case%20series.%20For%20M%20malmoense%2C%20results%20from%20two%20randomised%20controlled%20trials%20and%20three%20retrospective%20cohort%20studies%20provided%20a%20better%20evidence%20base%20for%20treatment%20recommendations%2C%20although%20the%20evidence%20was%20still%20of%20low%20quality.%22%2C%22date%22%3A%222022-01-25%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1016%5C%2FS1473-3099%2821%2900586-7%22%2C%22ISSN%22%3A%221473-3099%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fwww.sciencedirect.com%5C%2Fscience%5C%2Farticle%5C%2Fpii%5C%2FS1473309921005867%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222022-03-16T14%3A15%3A16Z%22%7D%7D%2C%7B%22key%22%3A%22DP27S3F7%22%2C%22library%22%3A%7B%22id%22%3A1368488%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Le%20Ray%20et%20al.%22%2C%22parsedDate%22%3A%222022-05%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3ELe%20Ray%2C%20L.%20F.%2C%20Aubry%2C%20A.%2C%20Sougakoff%2C%20W.%2C%20Revest%2C%20M.%2C%20Robert%2C%20J.%2C%20Bonnet%2C%20I.%2C%20Veziris%2C%20N.%20and%20Morel%2C%20F.%20%282022%29.%20%3Cb%3EatpE%20Mutation%20in%20Mycobacterium%20tuberculosis%20Not%20Always%20Predictive%20of%20Bedaquiline%20Treatment%20Failure%3C%5C%2Fb%3E.%20Emerg%20Infect%20Dis%20%3Ci%3E28%3C%5C%2Fi%3E%2C%201062%26%23x2013%3B1064%2C%20%3Ca%20target%3D%27_blank%27%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.3201%5C%2Feid2805.212517%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.3201%5C%2Feid2805.212517%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22atpE%20Mutation%20in%20Mycobacterium%20tuberculosis%20Not%20Always%20Predictive%20of%20Bedaquiline%20Treatment%20Failure%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laure%20Fournier%22%2C%22lastName%22%3A%22Le%20Ray%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alexandra%22%2C%22lastName%22%3A%22Aubry%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Wladimir%22%2C%22lastName%22%3A%22Sougakoff%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Matthieu%22%2C%22lastName%22%3A%22Revest%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%5Cu00e9r%5Cu00f4me%22%2C%22lastName%22%3A%22Robert%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Isabelle%22%2C%22lastName%22%3A%22Bonnet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nicolas%22%2C%22lastName%22%3A%22Veziris%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Florence%22%2C%22lastName%22%3A%22Morel%22%7D%5D%2C%22abstractNote%22%3A%22We%20report%20the%20emergence%20of%20an%20atpE%20mutation%20in%20a%20clinical%20Mycobacterium%20tuberculosis%20strain.%20Genotypic%20and%20phenotypic%20bedaquiline%20susceptibility%20testing%20displayed%20variable%20results%20over%20time%20and%20ultimately%20were%20not%20predictive%20of%20treatment%20outcome.%20This%20observation%20highlights%20the%20limits%20of%20current%20genotypic%20and%20phenotypic%20methods%20for%20detection%20of%20bedaquiline%20resistance.%22%2C%22date%22%3A%222022-5%22%2C%22language%22%3A%22%22%2C%22DOI%22%3A%2210.3201%5C%2Feid2805.212517%22%2C%22ISSN%22%3A%221080-6040%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fwww.ncbi.nlm.nih.gov%5C%2Fpmc%5C%2Farticles%5C%2FPMC9045433%5C%2F%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222022-07-06T13%3A29%3A33Z%22%7D%7D%2C%7B%22key%22%3A%22VG5PNGPC%22%2C%22library%22%3A%7B%22id%22%3A1368488%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Maitre%20et%20al.%22%2C%22parsedDate%22%3A%222022-07%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EMaitre%2C%20T.%2C%20Morel%2C%20F.%2C%20Brossier%2C%20F.%2C%20Sougakoff%2C%20W.%2C%20Jaffre%2C%20J.%2C%20Cheng%2C%20S.%2C%20Veziris%2C%20N.%2C%20Aubry%2C%20A.%20and%20on%20behalf%20of%20the%20NRC-MyRMA%20%282022%29.%20%3Cb%3EHow%20a%20PCR%20Sequencing%20Strategy%20Can%20Bring%20New%20Data%20to%20Improve%20the%20Diagnosis%20of%20Ethionamide%20Resistance%3C%5C%2Fb%3E.%20Microorganisms%20%3Ci%3E10%3C%5C%2Fi%3E%2C%201436%2C%20%3Ca%20target%3D%27_blank%27%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.3390%5C%2Fmicroorganisms10071436%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.3390%5C%2Fmicroorganisms10071436%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22How%20a%20PCR%20Sequencing%20Strategy%20Can%20Bring%20New%20Data%20to%20Improve%20the%20Diagnosis%20of%20Ethionamide%20Resistance%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thomas%22%2C%22lastName%22%3A%22Maitre%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Florence%22%2C%22lastName%22%3A%22Morel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Florence%22%2C%22lastName%22%3A%22Brossier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Wladimir%22%2C%22lastName%22%3A%22Sougakoff%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%5Cu00e9remy%22%2C%22lastName%22%3A%22Jaffre%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sokleaph%22%2C%22lastName%22%3A%22Cheng%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nicolas%22%2C%22lastName%22%3A%22Veziris%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alexandra%22%2C%22lastName%22%3A%22Aubry%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22name%22%3A%22on%20behalf%20of%20the%20NRC-MyRMA%22%7D%5D%2C%22abstractNote%22%3A%22Ethionamide%20%28ETH%29%20is%20a%20second-line%20antituberculosis%20drug.%20ETH%20resistance%20%28ETH-R%29%20is%20mainly%20related%20to%20the%20mutations%20of%20the%20monooxygenase-activating%20ETH%20%28EthA%29%2C%20the%20ETH%20target%20%28InhA%29%2C%20and%20the%20inhA%20promoter.%20Nonetheless%2C%20diagnosing%20ETH-R%20is%20still%20challenging.%20We%20assessed%20the%20strategy%20used%20for%20detecting%20ETH-R%20at%20the%20French%20National%20Reference%20Center%20for%20Mycobacteria%20in%20497%20MDR-TB%20isolates%20received%20from%202008%20to%202016.%20The%20genotypic%20ETH%5Cu2019s%20resistance%20detection%20was%20performed%20by%20sequencing%20ethA%2C%20ethR%2C%20the%20ethA-ethR%20intergenic%20region%2C%20and%20the%20inhA%20promoter%20in%20the%20497%20multidrug-resistant%20isolates%2C%20whereas%20the%20phenotypic%20ETH%20susceptibility%20testing%20%28PST%29%20was%20performed%20using%20the%20reference%20proportion%20method.%20Mutations%20were%20found%20in%20up%20to%2076%25%20of%20the%20387%20resistant%20isolates%20and%20in%20up%20to%2028%25%20of%20the%20110%20susceptible%20isolates.%20Our%20results%20do%20not%20support%20the%20role%20of%20ethR%20mutations%20in%20ETH%20resistance.%20Altogether%2C%20the%20positive%20predictive%20value%20of%20our%20genotypic%20strategy%20to%20diagnose%20ETH-R%20was%20improved%20when%20only%20considering%20the%20variants%20included%20in%20the%20WHO%20catalogue%20and%20in%20other%20databases%2C%20such%20as%20TB-Profiler.%20Therefore%2C%20our%20work%20will%20help%20to%20update%20the%20list%20of%20mutations%20that%20could%20be%20graded%20as%20being%20associated%20with%20resistance%20to%20improve%20ETH-R%20diagnosis.%22%2C%22date%22%3A%222022%5C%2F7%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.3390%5C%2Fmicroorganisms10071436%22%2C%22ISSN%22%3A%222076-2607%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fwww.mdpi.com%5C%2F2076-2607%5C%2F10%5C%2F7%5C%2F1436%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222022-09-23T13%3A18%3A47Z%22%7D%7D%2C%7B%22key%22%3A%222V395TDR%22%2C%22library%22%3A%7B%22id%22%3A1368488%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Marijke%20Braet%20et%20al.%22%2C%22parsedDate%22%3A%222022-09-01%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EMarijke%20Braet%2C%20S.%2C%20Jouet%2C%20A.%2C%20Aubry%2C%20A.%2C%20Van%20Dyck-Lippens%2C%20M.%2C%20Lenoir%2C%20E.%2C%20Assoumani%2C%20Y.%2C%20Baco%2C%20A.%2C%20Mzembaba%2C%20A.%2C%20Cambau%2C%20E.%2C%20Vasconcellos%2C%20S.%20E.%20G.%2C%20Rigouts%2C%20L.%2C%20Suffys%2C%20P.%20N.%2C%20Hasker%2C%20E.%2C%20Supply%2C%20P.%20and%20de%20Jong%2C%20B.%20C.%20%282022%29.%20%3Cb%3EInvestigating%20drug%20resistance%20of%20Mycobacterium%20leprae%20in%20the%20Comoros%3A%20an%20observational%20deep-sequencing%20study%3C%5C%2Fb%3E.%20The%20Lancet%20Microbe%20%3Ci%3E3%3C%5C%2Fi%3E%2C%20e693%26%23x2013%3Be700%2C%20%3Ca%20target%3D%27_blank%27%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2FS2666-5247%2822%2900117-3%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2FS2666-5247%2822%2900117-3%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Investigating%20drug%20resistance%20of%20Mycobacterium%20leprae%20in%20the%20Comoros%3A%20an%20observational%20deep-sequencing%20study%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sofie%22%2C%22lastName%22%3A%22Marijke%20Braet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Agathe%22%2C%22lastName%22%3A%22Jouet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alexandra%22%2C%22lastName%22%3A%22Aubry%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Magalie%22%2C%22lastName%22%3A%22Van%20Dyck-Lippens%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Esteban%22%2C%22lastName%22%3A%22Lenoir%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Younoussa%22%2C%22lastName%22%3A%22Assoumani%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Abdallah%22%2C%22lastName%22%3A%22Baco%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Aboubacar%22%2C%22lastName%22%3A%22Mzembaba%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Emmanuelle%22%2C%22lastName%22%3A%22Cambau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sidra%20Ezidio%20Gon%5Cu00e7alves%22%2C%22lastName%22%3A%22Vasconcellos%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Leen%22%2C%22lastName%22%3A%22Rigouts%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Philip%20Noel%22%2C%22lastName%22%3A%22Suffys%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Epco%22%2C%22lastName%22%3A%22Hasker%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Philip%22%2C%22lastName%22%3A%22Supply%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bouke%20Catherine%22%2C%22lastName%22%3A%22de%20Jong%22%7D%5D%2C%22abstractNote%22%3A%22Background%5CnDespite%20strong%20leprosy%20control%20measures%2C%20including%20effective%20treatment%2C%20leprosy%20persists%20in%20the%20Comoros.%20As%20of%20May%2C%202022%2C%20no%20resistance%20to%20anti-leprosy%20drugs%20had%20been%20reported%2C%20but%20there%20are%20no%20nationally%20representative%20data.%20Post-exposure%20prophylaxis%20%28PEP%29%20with%20rifampicin%20is%20offered%20to%20contacts%20of%20patients%20with%20leprosy.%20We%20aimed%20to%20conduct%20a%20countrywide%20drug%20resistance%20survey%20and%20investigate%20whether%20PEP%20led%20to%20the%20emergence%20of%20drug%20resistance%20in%20patients%20with%20leprosy.%5CnMethods%5CnIn%20this%20observational%2C%20deep-sequencing%20analysis%20we%20assessed%20Mycobacterium%20leprae%20genomes%20from%20skin%20biopsies%20of%20patients%20in%20Anjouan%20and%20Moh%5Cu00e9li%2C%20Comoros%2C%20collected%20as%20part%20of%20the%20ComLep%20%28NCT03526718%29%20and%20PEOPLE%20%28NCT03662022%29%20studies.%20Skin%20biopsies%20that%20had%20sufficient%20M%20leprae%20DNA%20%28%3E2000%20bacilli%20in%202%20%5Cu03bcl%20of%20DNA%20extract%29%20were%20assessed%20for%20the%20presence%20of%20seven%20drug%20resistance-associated%20genes%20%28ie%2C%20rpoB%2C%20ctpC%2C%20ctpI%2C%20folP1%2C%20gyrA%2C%20gyrB%2C%20and%20nth%29%20using%20Deeplex%20Myc-Lep%20%28targeted%20next%20generation%20deep%20sequencing%29%2C%20with%20a%20limit%20of%20detection%20of%2010%25%20for%20minority%20M%20leprae%20bacterial%20populations%20bearing%20a%20polymorphism%20in%20these%20genes.%20All%20newly%20registered%20patients%20with%20leprosy%20for%20whom%20written%20informed%20consent%20was%20obtained%20were%20eligible%20for%20inclusion%20in%20the%20survey.%20Patients%20younger%20than%202%20years%20or%20with%20a%20single%20lesion%20on%20the%20face%20did%20not%20have%20biopsies%20taken.%20The%20primary%20outcome%20of%20our%20study%20was%20the%20proportion%20of%20patients%20with%20leprosy%20%28ie%2C%20new%20cases%2C%20patients%20with%20relapses%20or%20reinfections%2C%20patients%20who%20received%20single%20%28double%29%20dose%20rifampicin-PEP%2C%20or%20patients%20who%20lived%20in%20villages%20where%20PEP%20was%20distributed%29%20who%20were%20infected%20with%20M%20leprae%20with%20a%20drug-resistant%20mutation%20for%20rifampicin%2C%20fluoroquinolone%2C%20or%20dapsone%20in%20the%20Comoros.%5CnFindings%5CnBetween%20July%201%2C%202017%2C%20and%20Dec%2031%2C%202020%2C%201199%20patients%20with%20leprosy%20were%20identified%20on%20the%20basis%20of%20clinical%20criteria%2C%20of%20whom%201030%20provided%20a%20skin%20biopsy.%20Of%20these%201030%20patients%2C%20755%20%2873%5Cu00b73%25%29%20tested%20positive%20for%20the%20M%20leprae-specific%20repetitive%20element-quantitative%20PCR%20%28qPCR%29%20assay.%20Of%20these%20755%20patients%2C%20260%20%2834%5Cu00b74%25%29%20were%20eligible%20to%20be%20analysed%20using%20Deeplex%20Myc-Lep.%20251%20%2896%5Cu00b75%25%29%20were%20newly%20diagnosed%20with%20leprosy%2C%20whereas%20nine%20%283%5Cu00b74%25%29%20patients%20had%20previously%20received%20multidrug%20therapy.%2045%20%2817%5Cu00b73%25%29%20patients%20resided%20in%20villages%20where%20PEP%20had%20been%20administered%20in%202015%20or%202019%2C%20two%20%284%5Cu00b74%25%29%20of%20whom%20received%20PEP.%20All%20seven%20drug%20resistance-associated%20targets%20were%20successfully%20sequenced%20in%20216%20samples%2C%2039%20samples%20had%20incomplete%20results%2C%20and%20five%20had%20no%20results.%20No%20mutations%20were%20detected%20in%20any%20of%20the%20seven%20drug%20resistance-related%20genes%20for%20any%20patient%20with%20successfully%20sequenced%20results.%5CnInterpretation%5CnThis%20drug%20resistance%20survey%20provides%20evidence%20to%20show%20that%20M%20leprae%20is%20fully%20susceptible%20to%20rifampicin%2C%20fluoroquinolones%2C%20and%20dapsone%20in%20the%20Comoros.%20Our%20results%20also%20show%2C%20for%20the%20first%20time%2C%20the%20applicability%20of%20targeted%20sequencing%20directly%20on%20skin%20biopsies%20from%20patients%20with%20either%20paucibacillary%20or%20multibacillary%20leprosy.%20These%20data%20suggest%20that%20PEP%20had%20not%20selected%20rifampicin-resistant%20strains%2C%20although%20further%20support%20for%20this%20finding%20should%20be%20confirmed%20with%20a%20larger%20sample%20size.%5CnFunding%5CnEffect%3AHope%2C%20The%20Mission%20To%20End%20Leprosy%2C%20the%20Fonds%20Wetenschappelijk%20Onderzoek%2C%20the%20EU.%22%2C%22date%22%3A%222022-09-01%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1016%5C%2FS2666-5247%2822%2900117-3%22%2C%22ISSN%22%3A%222666-5247%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fwww.sciencedirect.com%5C%2Fscience%5C%2Farticle%5C%2Fpii%5C%2FS2666524722001173%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222022-09-23T13%3A29%3A27Z%22%7D%7D%2C%7B%22key%22%3A%22M3NEXJYZ%22%2C%22library%22%3A%7B%22id%22%3A1368488%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Migliori%20et%20al.%22%2C%22parsedDate%22%3A%222022-03%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EMigliori%2C%20G.%20B.%2C%20Wu%2C%20S.%20J.%2C%20Matteelli%2C%20A.%2C%20Zenner%2C%20D.%2C%20Goletti%2C%20D.%2C%20Ahmedov%2C%20S.%2C%20Al-Abri%2C%20S.%2C%20Allen%2C%20D.%20M.%2C%20Balcells%2C%20M.%20E.%2C%20Garcia-Basteiro%2C%20A.%20L.%2C%20Cambau%2C%20E.%2C%20Chaisson%2C%20R.%20E.%2C%20Chee%2C%20C.%20B.%20E.%2C%20Dalcolmo%2C%20M.%20P.%2C%20Denholm%2C%20J.%20T.%2C%20Erkens%2C%20C.%2C%20Esposito%2C%20S.%2C%20Farnia%2C%20P.%2C%20Friedland%2C%20J.%20S.%2C%20Graham%2C%20S.%2C%20Hamada%2C%20Y.%2C%20Harries%2C%20A.%20D.%2C%20Kay%2C%20A.%20W.%2C%20Kritski%2C%20A.%2C%20Manga%2C%20S.%2C%20Marais%2C%20B.%20J.%2C%20Menzies%2C%20D.%2C%20Ng%2C%20D.%2C%20Petrone%2C%20L.%2C%20Rendon%2C%20A.%2C%20Silva%2C%20D.%20R.%2C%20Schaaf%2C%20H.%20S.%2C%20Skrahina%2C%20A.%2C%20Sotgiu%2C%20G.%2C%20Thwaites%2C%20G.%2C%20Tiberi%2C%20S.%2C%20Tukvadze%2C%20N.%2C%20Zellweger%2C%20J.-P.%2C%20D%26%23x2019%3BAmbrosio%2C%20L.%2C%20Centis%2C%20R.%20and%20Ong%2C%20C.%20W.%20M.%20%282022%29.%20%3Cb%3EClinical%20standards%20for%20the%20diagnosis%2C%20treatment%20and%20prevention%20of%20TB%20infection%3C%5C%2Fb%3E.%20Int%20J%20Tuberc%20Lung%20Dis%20%3Ci%3E26%3C%5C%2Fi%3E%2C%20190%26%23x2013%3B205%2C%20%3Ca%20target%3D%27_blank%27%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.5588%5C%2Fijtld.21.0753%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.5588%5C%2Fijtld.21.0753%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Clinical%20standards%20for%20the%20diagnosis%2C%20treatment%20and%20prevention%20of%20TB%20infection%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22G.%20B.%22%2C%22lastName%22%3A%22Migliori%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%20J.%22%2C%22lastName%22%3A%22Wu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Matteelli%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22D.%22%2C%22lastName%22%3A%22Zenner%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22D.%22%2C%22lastName%22%3A%22Goletti%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%22%2C%22lastName%22%3A%22Ahmedov%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%22%2C%22lastName%22%3A%22Al-Abri%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22D.%20M.%22%2C%22lastName%22%3A%22Allen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%20E.%22%2C%22lastName%22%3A%22Balcells%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%20L.%22%2C%22lastName%22%3A%22Garcia-Basteiro%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E.%22%2C%22lastName%22%3A%22Cambau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R.%20E.%22%2C%22lastName%22%3A%22Chaisson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%20B.%20E.%22%2C%22lastName%22%3A%22Chee%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%20P.%22%2C%22lastName%22%3A%22Dalcolmo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%20T.%22%2C%22lastName%22%3A%22Denholm%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%22%2C%22lastName%22%3A%22Erkens%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%22%2C%22lastName%22%3A%22Esposito%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P.%22%2C%22lastName%22%3A%22Farnia%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%20S.%22%2C%22lastName%22%3A%22Friedland%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%22%2C%22lastName%22%3A%22Graham%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Y.%22%2C%22lastName%22%3A%22Hamada%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%20D.%22%2C%22lastName%22%3A%22Harries%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%20W.%22%2C%22lastName%22%3A%22Kay%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Kritski%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%22%2C%22lastName%22%3A%22Manga%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22B.%20J.%22%2C%22lastName%22%3A%22Marais%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22D.%22%2C%22lastName%22%3A%22Menzies%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22D.%22%2C%22lastName%22%3A%22Ng%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L.%22%2C%22lastName%22%3A%22Petrone%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Rendon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22D.%20R.%22%2C%22lastName%22%3A%22Silva%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22H.%20S.%22%2C%22lastName%22%3A%22Schaaf%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Skrahina%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22G.%22%2C%22lastName%22%3A%22Sotgiu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22G.%22%2C%22lastName%22%3A%22Thwaites%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%22%2C%22lastName%22%3A%22Tiberi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22N.%22%2C%22lastName%22%3A%22Tukvadze%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.-P.%22%2C%22lastName%22%3A%22Zellweger%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L.%22%2C%22lastName%22%3A%22D%5Cu2019Ambrosio%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R.%22%2C%22lastName%22%3A%22Centis%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%20W.%20M.%22%2C%22lastName%22%3A%22Ong%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%3A%5CnTuberculosis%20%28TB%29%20preventive%20therapy%20%28TPT%29%20decreases%20the%20risk%20of%20developing%20TB%20disease%20and%20its%20associated%20morbidity%20and%20mortality.%20The%20aim%20of%20these%20clinical%20standards%20is%20to%20guide%20the%20assessment%2C%20management%20of%20TB%20infection%20%28TBI%29%20and%20implementation%20of%20TPT.%5Cn%5CnMETHODS%3A%5CnA%20panel%20of%20global%20experts%20in%20the%20field%20of%20TB%20care%20was%20identified%3B%2041%20participated%20in%20a%20Delphi%20process.%20A%205-point%20Likert%20scale%20was%20used%20to%20score%20the%20initial%20standards.%20After%20rounds%20of%20revision%2C%20the%20document%20was%20approved%20with%20100%25%20agreement.%5Cn%5CnRESULTS%3A%5CnEight%20clinical%20standards%20were%20defined%3A%20Standard%201%2C%20all%20individuals%20belonging%20to%20at-risk%20groups%20for%20TB%20should%20undergo%20testing%20for%20TBI%3B%20Standard%202%2C%20all%20individual%20candidates%20for%20TPT%20%28including%20caregivers%20of%20children%29%20should%20undergo%20a%20counselling%5C%2Fhealth%20education%20session%3B%20Standard%203%2C%20testing%20for%20TBI%3A%20timing%20and%20test%20of%20choice%20should%20be%20optimised%3B%20Standard%204%2C%20TB%20disease%20should%20be%20excluded%20prior%20to%20initiation%20of%20TPT%3B%20Standard%205%2C%20all%20candidates%20for%20TPT%20should%20undergo%20a%20set%20of%20baseline%20examinations%3B%20Standard%206%2C%20all%20individuals%20initiating%20TPT%20should%20receive%20one%20of%20the%20recommended%20regimens%3B%20Standard%207%2C%20all%20individuals%20who%20have%20started%20TPT%20should%20be%20monitored%3B%20Standard%208%2C%20a%20TBI%20screening%20and%20testing%20register%20should%20be%20kept%20to%20inform%20the%20cascade%20of%20care.%5Cn%5CnCONCLUSION%3A%5CnThis%20is%20the%20first%20consensus-based%20set%20of%20Clinical%20Standards%20for%20TBI.%20This%20document%20guides%20clinicians%2C%20programme%20managers%20and%20public%20health%20officers%20in%20planning%20and%20implementing%20adequate%20measures%20to%20assess%20and%20manage%20TBI.%22%2C%22date%22%3A%222022-3%22%2C%22language%22%3A%22%22%2C%22DOI%22%3A%2210.5588%5C%2Fijtld.21.0753%22%2C%22ISSN%22%3A%221027-3719%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fwww.ncbi.nlm.nih.gov%5C%2Fpmc%5C%2Farticles%5C%2FPMC8886963%5C%2F%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222022-05-26T21%3A18%3A54Z%22%7D%7D%2C%7B%22key%22%3A%22EDWVUW7S%22%2C%22library%22%3A%7B%22id%22%3A1368488%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Tunesi%20et%20al.%22%2C%22parsedDate%22%3A%222022-03-07%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3ETunesi%2C%20S.%2C%20D%26%23xFB%3B%2C%20D.%20L.%2C%20Gualano%2C%20G.%2C%20Millet%2C%20J.-P.%2C%20Skrahin%2C%20A.%2C%20Bothamley%2C%20G.%2C%20Casas%2C%20X.%2C%20Goletti%2C%20D.%2C%20Lange%2C%20C.%2C%20Musso%2C%20M.%2C%20Palmieri%2C%20F.%2C%20Pourcher%2C%20V.%2C%20Rioux%2C%20C.%2C%20Skrahina%2C%20A.%2C%20Veziris%2C%20N.%2C%20Viatushka%2C%20D.%2C%20Jachym-Fr%26%23xE9%3Bchet%2C%20M.%20and%20Guglielmetti%2C%20L.%20%282022%29.%20%3Cb%3ECo-administration%20of%20treatment%20for%20rifampicin-resistant%20TB%20and%20chronic%20HCV%20infection%3A%20a%20TBnet%20and%20ESGMYC%20study%3C%5C%2Fb%3E.%20Journal%20of%20Infection%2C%20%3Ca%20target%3D%27_blank%27%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.jinf.2022.03.004%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.jinf.2022.03.004%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Co-administration%20of%20treatment%20for%20rifampicin-resistant%20TB%20and%20chronic%20HCV%20infection%3A%20a%20TBnet%20and%20ESGMYC%20study%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Simone%22%2C%22lastName%22%3A%22Tunesi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Damien%20Le%22%2C%22lastName%22%3A%22D%5Cu00fb%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gina%22%2C%22lastName%22%3A%22Gualano%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Joan-Pau%22%2C%22lastName%22%3A%22Millet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Aliaksandr%22%2C%22lastName%22%3A%22Skrahin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Graham%22%2C%22lastName%22%3A%22Bothamley%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Xavier%22%2C%22lastName%22%3A%22Casas%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Delia%22%2C%22lastName%22%3A%22Goletti%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christoph%22%2C%22lastName%22%3A%22Lange%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Maria%22%2C%22lastName%22%3A%22Musso%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fabrizio%22%2C%22lastName%22%3A%22Palmieri%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Val%5Cu00e9rie%22%2C%22lastName%22%3A%22Pourcher%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christophe%22%2C%22lastName%22%3A%22Rioux%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alena%22%2C%22lastName%22%3A%22Skrahina%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nicolas%22%2C%22lastName%22%3A%22Veziris%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Dzmitry%22%2C%22lastName%22%3A%22Viatushka%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mathilde%22%2C%22lastName%22%3A%22Jachym-Fr%5Cu00e9chet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lorenzo%22%2C%22lastName%22%3A%22Guglielmetti%22%7D%5D%2C%22abstractNote%22%3A%22%22%2C%22date%22%3A%222022-03-07%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1016%5C%2Fj.jinf.2022.03.004%22%2C%22ISSN%22%3A%220163-4453%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fwww.sciencedirect.com%5C%2Fscience%5C%2Farticle%5C%2Fpii%5C%2FS016344532200130X%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222022-03-16T14%3A21%3A35Z%22%7D%7D%2C%7B%22key%22%3A%22JTCH47MP%22%2C%22library%22%3A%7B%22id%22%3A1368488%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Vongthilath-Moeung%20et%20al.%22%2C%22parsedDate%22%3A%222022%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EVongthilath-Moeung%2C%20R.%2C%20Plojoux%2C%20J.%2C%20Poncet%2C%20A.%2C%20Renzi%2C%20G.%2C%20Veziris%2C%20N.%2C%20Schrenzel%2C%20J.%20and%20Janssens%2C%20J.-P.%20%282022%29.%20%3Cb%3ENontuberculous%20Mycobacteria%20under%20Scrutiny%20in%20the%20Geneva%20Area%20%282015%26%23x2013%3B2020%29%3C%5C%2Fb%3E.%20RES%20%3Ci%3E101%3C%5C%2Fi%3E%2C%20367%26%23x2013%3B375%2C%20%3Ca%20target%3D%27_blank%27%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1159%5C%2F000520033%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1159%5C%2F000520033%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Nontuberculous%20Mycobacteria%20under%20Scrutiny%20in%20the%20Geneva%20Area%20%282015%5Cu20132020%29%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Rechana%22%2C%22lastName%22%3A%22Vongthilath-Moeung%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%5Cu00e9r%5Cu00f4me%22%2C%22lastName%22%3A%22Plojoux%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Antoine%22%2C%22lastName%22%3A%22Poncet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gesuele%22%2C%22lastName%22%3A%22Renzi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nicolas%22%2C%22lastName%22%3A%22Veziris%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jacques%22%2C%22lastName%22%3A%22Schrenzel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Paul%22%2C%22lastName%22%3A%22Janssens%22%7D%5D%2C%22abstractNote%22%3A%22%3Cb%3E%3Ci%3EBackground%3A%3C%5C%2Fi%3E%3C%5C%2Fb%3E%20Nontuberculous%20mycobacteria%20%28NTM%29%20are%20increasingly%20identified%20in%20industrialized%20countries%2C%20and%20their%20role%20as%20pathogens%20is%20more%20frequently%20recognized.%20The%20relative%20prevalence%20of%20NTM%20strains%20shows%20an%20important%20geographical%20variability.%20Thus%2C%20establishing%20the%20local%20relative%20prevalence%20of%20NTM%20strains%20is%20relevant%20and%20useful%20for%20clinicians.%20%3Cb%3E%3Ci%3EMethods%3A%3C%5C%2Fi%3E%3C%5C%2Fb%3E%20Retrospective%20analysis%20%282015%5Cu20132020%29%20of%20a%20comprehensive%20database%20was%20conducted%20including%20all%20results%20of%20cultures%20for%20mycobacteria%20in%20a%20University%20Hospital%20%28Geneva%2C%20Switzerland%29%2C%20covering%20a%20population%20of%20approximately%20500%2C000%20inhabitants.%20All%20NTM%20culture-positive%20patients%20were%20included%20in%20the%20analyses.%20Patients%5Cu2019%20characteristics%2C%20NTM%20strains%2C%20and%20time%20to%20culture%20positivity%20were%20reported.%20%3Cb%3E%3Ci%3EResults%3A%3C%5C%2Fi%3E%3C%5C%2Fb%3E%20Among%2038%2C065%20samples%20analyzed%20during%20the%20study%20period%2C%20411%20were%20culture-positive%20for%20NTM%2C%20representing%20236%20strains%2C%20and%20231%20episodes%20of%20care%20which%20occurred%20in%20222%20patients.%20Patients%20in%20whom%20NTM%20were%20identified%20were%20predominantly%20female%20%2855%25%29%2C%20with%20a%20median%20age%20of%2062%20years%2C%20and%20a%20low%20BMI%20%28median%3A%2022.6%20kg%5C%2Fm%3Csup%3E2%3C%5C%2Fsup%3E%29.%20The%20%3Ci%3EMycobacterium%20avium%3C%5C%2Fi%3E%20complex%20%28MAC%29%20was%20the%20most%20frequently%20identified%20group%20%2837%25%20of%20strains%29%20followed%20by%20%3Ci%3EMycobacterium%20gordonae%3C%5C%2Fi%3E%20%2825%25%29%20and%20%3Ci%3EMycobacterium%20xenopi%3C%5C%2Fi%3E%20%2812%25%29%20among%20the%20slowly%20growing%20mycobacteria%20%28SGM%29%2C%20while%20the%20%3Ci%3EMycobacterium%20chelonae%5C%2Fabscessus%3C%5C%2Fi%3E%20group%20%2811%25%29%20were%20the%20most%20frequently%20identified%20rapidly%20growing%20mycobacteria%20%28RGM%29.%20Only%2019%25%20of%20all%20patients%20were%20treated%2C%20mostly%20for%20pulmonary%20infections%3A%20the%20MAC%20was%20the%20most%20frequently%20treated%20NTM%20%28%3Ci%3En%3C%5C%2Fi%3E%20%3D%2019%2C%2043%25%20of%20cases%20in%20patients%20treated%29%20followed%20by%20RGM%20%28%3Ci%3En%3C%5C%2Fi%3E%20%3D%2015%2C%2034%25%29%20and%20%3Ci%3EM.%20xenopi%3C%5C%2Fi%3E%20%28%3Ci%3En%3C%5C%2Fi%3E%20%3D%206%2C%2014%25%29.%20Among%20those%20treated%2C%2023%25%20were%20immunosuppressed%2C%2012%25%20had%20pulmonary%20comorbidities%2C%20and%205%25%20systemic%20comorbidities.%20Cultures%20became%20positive%20after%20a%20median%20of%2041%20days%20%28IQR%3A%2023%3B%2068%29%20for%20SGM%20and%2028%20days%20%2814%3B%2035%29%20for%20RGM.%20%3Cb%3E%3Ci%3EConclusions%3A%3C%5C%2Fi%3E%3C%5C%2Fb%3E%20In%20Western%20Switzerland%2C%20%3Ci%3EM.%20avium%3C%5C%2Fi%3E%20and%20%3Ci%3EM.%20gordonae%3C%5C%2Fi%3E%20were%20the%20most%20prevalent%20NTM%20identified.%20Positive%20cultures%20for%20NTM%20led%20to%20a%20specific%20treatment%20in%2019%25%20of%20subjects.%20Patients%20with%20a%20positive%20culture%20for%20NTM%20were%20mostly%20female%2C%20with%20a%20median%20age%20of%2062%20years%2C%20a%20low%20BMI%2C%20and%20a%20low%20prevalence%20of%20immunosuppression%20or%20associated%20severe%20comorbidities.%22%2C%22date%22%3A%222022%22%2C%22language%22%3A%22english%22%2C%22DOI%22%3A%2210.1159%5C%2F000520033%22%2C%22ISSN%22%3A%220025-7931%2C%201423-0356%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fwww.karger.com%5C%2FArticle%5C%2FFullText%5C%2F520033%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222022-03-10T21%3A33%3A36Z%22%7D%7D%2C%7B%22key%22%3A%228NJBYM8Z%22%2C%22library%22%3A%7B%22id%22%3A1368488%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Wetzstein%20et%20al.%22%2C%22parsedDate%22%3A%222022-10-01%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EWetzstein%2C%20N.%2C%20Drummer%2C%20A.-P.%2C%20Bockey%2C%20A.%2C%20Herrmann%2C%20E.%2C%20K%26%23xFC%3Bpper-Tetzel%2C%20C.%20P.%2C%20Graf%2C%20C.%2C%20Koch%2C%20B.%2C%20Goetsch%2C%20U.%2C%20Vehreschild%2C%20M.%20J.%20G.%20T.%2C%20Guglielmetti%2C%20L.%2C%20Lange%2C%20B.%2C%20Wichelhaus%2C%20T.%20A.%20and%20Stephan%2C%20C.%20%282022%29.%20%3Cb%3EOccurrence%20of%20extrapulmonary%20tuberculosis%20is%20associated%20with%20geographical%20origin%3A%20spatial%20characteristics%20of%20the%20Frankfurt%20TB%20cohort%202013%26%23x2013%3B2018%3C%5C%2Fb%3E.%20Infection%2C%20%3Ca%20target%3D%27_blank%27%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1007%5C%2Fs15010-022-01921-9%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1007%5C%2Fs15010-022-01921-9%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Occurrence%20of%20extrapulmonary%20tuberculosis%20is%20associated%20with%20geographical%20origin%3A%20spatial%20characteristics%20of%20the%20Frankfurt%20TB%20cohort%202013%5Cu20132018%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nils%22%2C%22lastName%22%3A%22Wetzstein%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alena-Pauline%22%2C%22lastName%22%3A%22Drummer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Annabelle%22%2C%22lastName%22%3A%22Bockey%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eva%22%2C%22lastName%22%3A%22Herrmann%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Claus%20Philippe%22%2C%22lastName%22%3A%22K%5Cu00fcpper-Tetzel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christiana%22%2C%22lastName%22%3A%22Graf%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Benjamin%22%2C%22lastName%22%3A%22Koch%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Udo%22%2C%22lastName%22%3A%22Goetsch%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Maria%20J.%20G.%20T.%22%2C%22lastName%22%3A%22Vehreschild%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lorenzo%22%2C%22lastName%22%3A%22Guglielmetti%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Berit%22%2C%22lastName%22%3A%22Lange%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thomas%20A.%22%2C%22lastName%22%3A%22Wichelhaus%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christoph%22%2C%22lastName%22%3A%22Stephan%22%7D%5D%2C%22abstractNote%22%3A%22Tuberculosis%20%28TB%29%20is%20caused%20by%20M.%20tuberculosis%20complex%20%28MTB%29%20and%20pulmonary%20tuberculosis%20%28PTB%29%20is%20its%20classical%20manifestation.%20However%2C%20in%20some%20regions%20of%20the%20world%2C%20extrapulmonary%20TB%20%28EPTB%29%20seems%20to%20be%20more%20frequent.%22%2C%22date%22%3A%222022-10-01%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1007%5C%2Fs15010-022-01921-9%22%2C%22ISSN%22%3A%221439-0973%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1007%5C%2Fs15010-022-01921-9%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222022-12-28T16%3A07%3A36Z%22%7D%7D%5D%7D
Aubry, A., Sammarco Rosa, P., Chauffour, A., Fletcher, M. L., Cambau, E. and Avanzi, C. (2022). Drug resistance in leprosy: An update following 70years of chemotherapy. Infectious Diseases Now 52, 243–251, http://doi.org/10.1016/j.idnow.2022.04.001.
Bachir, M., Guglielmetti, L., Tunesi, S., Billard-Pomares, T., Chiesi, S., Jaffré, J., Langris, H., Pourcher, V., Schramm, F., Lemaître, N. and Robert, J. (2022). Molecular detection of isoniazid monoresistance improves tuberculosis treatment: A retrospective cohort in France. Journal of Infection 85, 24–30, http://doi.org/10.1016/j.jinf.2022.05.017.
Bonnet, I., Haddad, E., Guglielmetti, L., Bémer, P., Bernard, L., Bourgoin, A., Brault, R., Catho, G., Caumes, E., Escaut, L., Fourniols, E., Fréchet-Jachym, M., Gaudart, A., Guillot, H., Lafon-Desmurs, B., Lanoix, J.-P., Lanotte, P., Lemaignen, A., Lemaire, B., Lemaitre, N., Michau, C., Morand, P., Mougari, F., Marigot-Outtandy, D., Patrat-Delon, S., Perpoint, T., Piau, C., Pourcher, V., Zarrouk, V., Zeller, V., Veziris, N., Jauréguiberry, S. and Aubry, A. (2022). Clinical Features and Outcome of Multidrug-Resistant Osteoarticular Tuberculosis: A 12-Year Case Series from France. Microorganisms 10, 1215, http://doi.org/10.3390/microorganisms10061215.
Chaptal, M., Andrejak, C., Bonifay, T., Beillard, E., Guillot, G., Guyomard-Rabenirina, S., Demar, M., Trombert-Paolantoni, S., Jacomo, V., Mosnier, E., Veziris, N., Djossou, F., Epelboin, L. and Group, F. G. P. working (2022). Epidemiology of infection by pulmonary non-tuberculous mycobacteria in French Guiana 2008–2018. PLOS Neglected Tropical Diseases 16, e0010693, http://doi.org/10.1371/journal.pntd.0010693.
Chiron, R., Hoefsloot, W., Van Ingen, J., Marchandin, H., Kremer, L., Morisse-Pradier, H., Charriot, J., Mallet, J.-P., Herrmann, J.-L., Caimmi, D., Moreau, J., Dumont, Y., Godreuil, S., Bergeron, A., Drevait, M., Bouzat-Rossigneux, E., Terrail, N., Andrejak, C., Veziris, N., Grenet, D., Coudrat, A. and Catherinot, E. (2022). Amikacin Liposomal Inhalation Suspension in the Treatment of Mycobacterium abscessus Lung Infection: A French Observational Experience. Open Forum Infect Dis 9, ofac465, http://doi.org/10.1093/ofid/ofac465.
Daniau, C., Lecorche, E., Mougari, F., Benmansour, H., Bernet, C., Blanchard, H., Robert, J., Berger-Carbonne, A. and Cambau, E. (2022). Association of Healthcare and Aesthetic Procedures with Infections Caused by Nontuberculous Mycobacteria, France, 2012‒2020. Emerg Infect Dis 28, 518–526, http://doi.org/10.3201/eid2803.211791.
Daniau, C., Berger-Carbonne, A. and Cambau, E. (2022). Association of Healthcare and Aesthetic Procedures with Infections Caused by Nontuberculous Mycobacteria, France, 2012‒2020 (response). Emerg Infect Dis 28, 1303–1304, http://doi.org/10.3201/eid2806.220686.
De Castro, N., Mechaï, F., Bachelet, D., Canestri, A., Joly, V., Vandenhende, M., Boutoille, D., Kerjouan, M., Veziris, N., Molina, J. M., Grall, N., Tattevin, P., Laouénan, C., Yazdanpanah, Y. and for the FAST TB Study Group (2022). Treatment With a Three-Drug Regimen for Pulmonary Tuberculosis Based on Rapid Molecular Detection of Isoniazid Resistance: A Noninferiority Randomized Trial (FAST-TB). Open Forum Infectious Diseases 9, ofac353, http://doi.org/10.1093/ofid/ofac353.
Eimer, J., Fréchet-Jachym, M., Le Dû, D., Caumes, E., El-Helali, N., Marigot-Outtandy, D., Mechai, F., Peytavin, G., Pourcher, V., Rioux, C., Yazdanpanah, Y., Robert, J., Guglielmetti, L. and for the LZDM group (2022). Increased linezolid plasma concentrations are associated with the development of severe toxicity in MDR-TB treatment. Clinical Infectious Diseases ciac485, http://doi.org/10.1093/cid/ciac485.
Group, A. S. T., Georghiou, S. B., Rodwell, T. C., Korobitsyn, A., Abbadi, S. H., Ajbani, K., Alffenaar, J.-W., Alland, D., Alvarez, N., Andres, S., Ardizzoni, E., Aubry, A., Baldan, R., Ballif, M., Barilar, I., Böttger, E. C., Chakravorty, S., Claxton, P. M., Cirillo, D. M., Comas, I., Coulter, C., Denkinger, C. M., Derendinger, B., Desmond, E. P., Steenwinkel, J. E. M. de, Dheda, K., Diacon, A. H., Dolinger, D. L., Dooley, K. E., Egger, M., Ehsani, S., Farhat, M. R., Fattorini, L., Finci, I., Ray, L. F. L., Furió, V., Groenheit, R., Gumbo, T., Heysell, S. K., Hillemann, D., Hoffmann, H., Hsueh, P.-R., Hu, Y., Huang, H., Hussain, A., Ismail, F., Izumi, K., Jagielski, T., Johnson, J. L., Kambli, P., Kaniga, K., Karunaratne, G. H. R. E., Sharma, M. K., Keller, P. M., Kelly, E. C., Kholina, M., Kohli, M., Kranzer, K., Laurenson, I. F., Limberis, J., Lin, S.-Y. G., Liu, Y., López-Gavín, A., Lyander, A., Machado, D., Martinez, E., Masood, F., Mitarai, S., Mvelase, N. R., Niemann, S., Nikolayevskyy, V., Maurer, F. P., Merker, M., Miotto, P., Omar, S. V., Otto-Knapp, R., Palaci, M., Gutiérrez, J. J. P., Peacock, S. J., Peloquin, C. A., Perera, J., Pierre-Audigier, C., Pholwat, S., Posey, J. E., Prammananan, T., Rigouts, L., Robledo, J., Rockwood, N., Rodrigues, C., Salfinger, M., Schechter, M. C., Seifert, M., Sengstake, S., Shinnick, T., Shubladze, N., Sintchenko, V., Sirgel, F., Somasundaram, S., Sterling, T. R., Spitaleri, A., Streicher, E., Supply, P., Svensson, E., Tagliani, E., Tahseen, S., Takaki, A., Theron, G., Torrea, G., Deun, A. V., Ingen, J. van, Rie, A. V., Soolingen, D. van, Jr, R. V., Venter, A., Veziris, N., Villellas, C., Viveiros, M., Warren, R., Wen, S., Werngren, J., Wilkinson, R. J., Yang, C., Yılmaz, F. F., Zhang, T., Zimenkov, D., Ismail, N., Köser, C. U. and Schön, T. (2022). Updating the approaches to define susceptibility and resistance to anti-tuberculosis agents: implications for diagnosis and treatment. European Respiratory Journal 59, http://doi.org/10.1183/13993003.00166-2022.
Guglielmetti, L., Günther, G., Leu, C., Cirillo, D., Duarte, R., Garcia-Basteiro, A. L., Goletti, D., Jankovic, M., Kuksa, L., Maurer, F. P., Méchaï, F., Tiberi, S., Leth, F. van, Veziris, N. and Lange, C. (2022). Rifapentine access in Europe: growing concerns over key tuberculosis treatment component. European Respiratory Journal 59, http://doi.org/10.1183/13993003.00388-2022.
Guyeux, C., Senelle, G., Refrégier, G., Bretelle-Establet, F., Cambau, E. and Sola, C. (2022). Connection between two historical tuberculosis outbreak sites in Japan, Honshu, by a new ancestral Mycobacterium tuberculosis L2 sublineage. Epidemiology & Infection 150, http://doi.org/10.1017/S0950268822000048.
Holmgaard, F. B., Guglielmetti, L., Lillebaek, T., Andersen, Å. B., Wejse, C. and Dahl, V. N. (2022). Efficacy and tolerability of concomitant use of bedaquiline and delamanid for multidrug- and extensively drug-resistant tuberculosis: a systematic review and meta-analysis. Clin Infect Dis ciac876, http://doi.org/10.1093/cid/ciac876.
Khan, U. and Guglielmetti, L. (2022). Evidence and ethical considerations for the treatment of contacts exposed to drug-resistant TB. The International Journal of Tuberculosis and Lung Disease 26, 900–901, http://doi.org/10.5588/ijtld.22.0328.
Kherabi, Y., Fréchet-Jachym, M., Rioux, C., Yazdanpanah, Y., Méchaï, F., Pourcher, V., Robert, J. and Guglielmetti, L. (2022). Revised Definitions of Tuberculosis Resistance and Treatment Outcomes, France, 2006–2019. Emerg Infect Dis 28, 1796–1804, http://doi.org/10.3201/eid2809.220458.
Kherabi, Y., Tunesi, S., Kay, A. and Guglielmetti, L. (2022). Preventive Therapy for Contacts of Drug-Resistant Tuberculosis. Pathogens 11, 1189, http://doi.org/10.3390/pathogens11101189.
Kilinç, G., Walburg, K. V., Franken, K. L. M. C., Valkenburg, M. L., Aubry, A., Haks, M. C., Saris, A. and Ottenhoff, T. H. M. (2022). Development of Human Cell-Based In Vitro Infection Models to Determine the Intracellular Survival of Mycobacterium avium. Front Cell Infect Microbiol 12, 872361, http://doi.org/10.3389/fcimb.2022.872361.
Kraef, C., Lindquist, E., Svensson, E. and Cambau, E. (2022). Diagnostic toolkit for tuberculosis: should we include urine lipoarabinomannan (LAM) detection in the WHO European Region? Clinical Microbiology and Infection, http://doi.org/10.1016/j.cmi.2022.06.022.
Lange, C., Böttger, E. C., Cambau, E., Griffith, D. E., Guglielmetti, L., van Ingen, J., Knight, S. L., Marras, T. K., Olivier, K. N., Santin, M., Stout, J. E., Tortoli, E., Wagner, D., Winthrop, K., Daley, C. L., Lange, C., Andrejak, C., Böttger, E., Cambau, E., Griffith, D., Guglielmetti, L., van Ingen, J., Knight, S., Leitman, P., Marras, T. K., Olivier, K. N., Santin, M., Stout, J. E., Tortoli, E., Wagner, D., Wallace, R. J., Winthrop, K. and Daley, C. (2022). Consensus management recommendations for less common non-tuberculous mycobacterial pulmonary diseases. The Lancet Infectious Diseases, http://doi.org/10.1016/S1473-3099(21)00586-7.
Le Ray, L. F., Aubry, A., Sougakoff, W., Revest, M., Robert, J., Bonnet, I., Veziris, N. and Morel, F. (2022). atpE Mutation in Mycobacterium tuberculosis Not Always Predictive of Bedaquiline Treatment Failure. Emerg Infect Dis 28, 1062–1064, http://doi.org/10.3201/eid2805.212517.
Maitre, T., Morel, F., Brossier, F., Sougakoff, W., Jaffre, J., Cheng, S., Veziris, N., Aubry, A. and on behalf of the NRC-MyRMA (2022). How a PCR Sequencing Strategy Can Bring New Data to Improve the Diagnosis of Ethionamide Resistance. Microorganisms 10, 1436, http://doi.org/10.3390/microorganisms10071436.
Marijke Braet, S., Jouet, A., Aubry, A., Van Dyck-Lippens, M., Lenoir, E., Assoumani, Y., Baco, A., Mzembaba, A., Cambau, E., Vasconcellos, S. E. G., Rigouts, L., Suffys, P. N., Hasker, E., Supply, P. and de Jong, B. C. (2022). Investigating drug resistance of Mycobacterium leprae in the Comoros: an observational deep-sequencing study. The Lancet Microbe 3, e693–e700, http://doi.org/10.1016/S2666-5247(22)00117-3.
Migliori, G. B., Wu, S. J., Matteelli, A., Zenner, D., Goletti, D., Ahmedov, S., Al-Abri, S., Allen, D. M., Balcells, M. E., Garcia-Basteiro, A. L., Cambau, E., Chaisson, R. E., Chee, C. B. E., Dalcolmo, M. P., Denholm, J. T., Erkens, C., Esposito, S., Farnia, P., Friedland, J. S., Graham, S., Hamada, Y., Harries, A. D., Kay, A. W., Kritski, A., Manga, S., Marais, B. J., Menzies, D., Ng, D., Petrone, L., Rendon, A., Silva, D. R., Schaaf, H. S., Skrahina, A., Sotgiu, G., Thwaites, G., Tiberi, S., Tukvadze, N., Zellweger, J.-P., D’Ambrosio, L., Centis, R. and Ong, C. W. M. (2022). Clinical standards for the diagnosis, treatment and prevention of TB infection. Int J Tuberc Lung Dis 26, 190–205, http://doi.org/10.5588/ijtld.21.0753.
Tunesi, S., Dû, D. L., Gualano, G., Millet, J.-P., Skrahin, A., Bothamley, G., Casas, X., Goletti, D., Lange, C., Musso, M., Palmieri, F., Pourcher, V., Rioux, C., Skrahina, A., Veziris, N., Viatushka, D., Jachym-Fréchet, M. and Guglielmetti, L. (2022). Co-administration of treatment for rifampicin-resistant TB and chronic HCV infection: a TBnet and ESGMYC study. Journal of Infection, http://doi.org/10.1016/j.jinf.2022.03.004.
Vongthilath-Moeung, R., Plojoux, J., Poncet, A., Renzi, G., Veziris, N., Schrenzel, J. and Janssens, J.-P. (2022). Nontuberculous Mycobacteria under Scrutiny in the Geneva Area (2015–2020). RES 101, 367–375, http://doi.org/10.1159/000520033.
Wetzstein, N., Drummer, A.-P., Bockey, A., Herrmann, E., Küpper-Tetzel, C. P., Graf, C., Koch, B., Goetsch, U., Vehreschild, M. J. G. T., Guglielmetti, L., Lange, B., Wichelhaus, T. A. and Stephan, C. (2022). Occurrence of extrapulmonary tuberculosis is associated with geographical origin: spatial characteristics of the Frankfurt TB cohort 2013–2018. Infection, http://doi.org/10.1007/s15010-022-01921-9.